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Abstract 
Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disease 
affecting motor neurons (MNs). It is primarily sporadic, however a proportion of cases 
are inherited and of these ~20 % are caused by mutations in the superoxide dismutase 
1 (SOD1) gene. The work described in this thesis has focused on the characterisation 
of the role that the SOD1 protein plays in ALS, investigating the human and the 
mouse variants in vivo and in vitro. 
SOD1 mutations result in ALS by an unknown gain of function mechanism, although 
mouse models suggest that complete loss of SOD1 is also detrimental to MN function. 
To investigate a possible role of SOD1 loss of function in SOD1-ALS, a meta-analysis 
was carried out on the literature reviewing measures of SOD1 activity from patients 
carrying SOD1 familial ALS mutations and the phenotype of Sod1 knockout mice. 
The first set of experiments aimed to phenotypically characterise a novel mouse model, 
Sod1D83G, carrying a pathological mutation in the mouse Sod1 gene. Sod1D83G/D83G mice 
have no SOD1 activity, low levels of SOD1 protein, develop central MN degeneration 
and a distal peripheral neuropathy. Further the Sod1D83G mice were crossed with Sod1 
knockout mice and mice overexpressing the human wild-type SOD1 to determine if it 
was possible to dissect elements of a loss of function (the peripheral axonopathy) and 
aspects of a gain of function (the central body degeneration). 
ALS mutations generally cause SOD1 to become more aggregate-prone, but it is 
unclear whether the human and the mouse SOD1 proteins co-aggregate in mouse 
models of SOD1 familial ALS. To investigate possible interactions between human and 
mouse SOD1 variants, recombinant proteins were produced, characterised and their 
spontaneous aggregation propensity was assessed in vitro. 
Finally a sensitised screen focused on the effect of unknown mutations on the life-span 
of a low copy SOD1G93A transgenic model of ALS, identified one mouse line with 
reduced survival, named Galahad. The phenotype of the Galahad mouse progeny was 
examined and a quantitative trait loci analysis was carried out to try to identify possible 
modifying locus/loci interacting with the SOD1 G93A mutation. 
The present work aims to shed light on the interaction between human and mouse 
SOD1 proteins and increase our understanding on the mechanism affecting central and 
peripheral degeneration of MNs in the context of SOD1 familial ALS mutations. 
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Chapter 1 Introduction 
1.1 Amyotrophic lateral sclerosis (ALS)  
Amyotrophic lateral sclerosis (ALS) is the most common adult onset motor neuron 
disease, characterised by the degeneration and death of upper and lower motor 
neurons (MNs). This relentless and fatal neurodegenerative disorder has a progressive 
clinical course typically starting with a focal onset of motor weakness which spreads 
through the body leading to paralysis and death within 3 to 5 years after diagnosis 
(Hirtz et al., 2007; Valdmanis and Rouleau, 2008). 
1.1.1 Epidemiology 
A meta-analysis study of global data provided a median incidence rate of ALS of 1.90 
per 100,000 and a prevalence of 4.48 per 100,000 of total population. In considering 
this figure it is important to note that the great majority of research on ALS 
epidemiology has been conducted in Europe and that there is wide variability in the 
incidence and prevalence reported in literature (Chiò et al., 2013). Investigation of ALS 
sex ratios showed that men are 1.2-1.5 times more likely to develop ALS compared to 
women, and this difference decreases with age (Manjaly et al., 2010). The average age 
of onset is 65.2 for men and 67.0 for women, while the peak incidence is between the 
ages of 70-74 for men and 65-69 for women (Logroscino et al., 2010; Strong and 
Rosenfeld, 2003). 
1.1.2 ALS clinical course 
ALS affects both the upper and lower motor neurons. Upper motor neuron (UMN) 
degeneration presents itself clinically as weakness of the voluntary muscles, spasticity, 
and brisk reflexes. While symptoms of lower motor neuron (LMN) impairment are 
muscular atrophy, weakness of the skeletal muscles, cramping, fasciculation, twitching 
and flaccidity (Traynor et al., 2000). 
1.1.2.1 Motor neuron degeneration 
About 70 % of ALS patients develop a primary lumbar onset, which usually starts with 
asymmetric focal weakness of the extremities. In 25 % of the cases the onset is bulbar 
causing pronunciation problems (dysarthria) and swallowing difficulties (dysphagia) 
(Piao et al., 2003). While in the remaining 5 % of affected individuals the onset occurs 
in the trunk muscles, affecting the respiratory system (Kiernan et al., 2011). In most of 
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the cases, during the course of the disease symptoms become progressively more 
severe, developing from muscle weakness to paralysis and they also spread from a focal 
site of onset through the rest of body (Fujimura-Kiyono et al., 2011). Patients usually 
have preserved oculomotor muscles and voluntary sphincters of bowel and bladder 
functions (Eisen et al., 1992; Kiernan et al., 2011). Of note the majority of patients die 
from respiratory failure arising from paralysis of intercostal muscles, or related 
complications (Haverkamp et al., 1995; Mitchell and Borasio, 2007; Valdmanis and 
Rouleau, 2008). 
Although ALS causes both upper and lower motor neuron degeneration, symptoms 
often have a wide clinical spectrum with cases showing predominantly UMN or LMN 
signs (Burrell et al., 2011). The age of onset ranges extensively from about 14 to 90 
years of age (Andersen et al., 1996; Gouveia and de Carvalho, 2007). Also disease 
duration is heterogeneous, indeed even though the majority of patients die within 2.5 
years of onset there are about 15-20 % who survive past 5 years (Talbot, 2009) and rare 
cases exhibiting survival of over 40 years (Grohme et al., 2001). Interestingly a shorter 
disease progression has been found to correlate with advanced age and body mass at 
onset, bulbar onset, respiratory dysfunctions, and fast spread from the initial site of 
onset (Fujimura-Kiyono et al., 2011; Magnus et al., 2002; Traxinger et al., 2013). 
1.1.2.2 Cognitive dysfunctions 
ALS was initially considered a pure motor system disorder (Strong et al., 1996), but a 
component of cognitive impairment gradually became apparent. Recent studies 
confirmed that 51 % of ALS patients develop significant cognitive dysfunction 
presenting symptoms such as impaired memory and alteration in behaviour, abstract 
reasoning, problem solving and language comprehension (Zimmerman et al., 2007). 
Histological evidence and neuroimaging studies support clinical findings showing 
degeneration of neurons in extra-motor neuron areas (Neumann et al., 2006) and 
regional atrophy of the frontal and temporal lobes of the brain (Chang et al., 2005) 
Indeed about 15 % of ALS patients also present frontotemporal dementia (FTD), 
(Ringholz et al., 2005). These two disorders share pathological and genetic features, see 
section 1.1.7 (Giordana et al., 2011; Orr, 2011). 
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1.1.3 Diagnosis 
To date there is no specific diagnostic laboratory test or clinical procedure to recognise 
ALS. Physicians establish the presence of the disease through a standard diagnostic 
protocol involving positive inclusion and negative exclusion criteria: The Revised El 
Escorial Criteria (Brooks et al., 2000). Inclusion criteria are evidence of signs of 
impairment of LMNs or UMNs confirmed by clinical examination, electrophysiological 
or neuropathological changes. Exclusion criteria are employed to reject the presence of 
pathological characteristics of other diseases that explain the degeneration of motor 
neurons (Table 1.1). Despite the establishment of these diagnostic criteria, incorrect 
diagnoses are still frequent. In addition, the combination of UMN and LMN 
symptoms may not be evident until a late point in the disease meaning that there is 
often a latency period between onset of symptoms and diagnosis. 
Diagnostic level  Description 
Clinically definite Either UMN signs with LMN signs in the bulbar region 
plus two other signs, or UMN and LMN signs in 3 or 
more spinal regions 
Clinically probable UMN and LMN sings in 2 spinal cord regions with some 
UMN signs rostral to LMN signs 
Clinically probable 
Laboratory supported 
Either UMN and LMN signs in 1 region, or UMN signs 
with EMG defined LMN signs in 2 regions 
Clinically possible Either UMN and LMN signs in 1or UMN signs in 2 or 
more regions, or LMN signs rostral to UMN signs 
UMN signs for diagnosis Spasticity, increased muscle tone and clonus, bilateral 
facial weakness affecting lower face and dysarthria 
LMN signs for diagnosis Muscle weakness, atrophy, fasciculation and flaccid 
dysarthria 
Table 1.1 El Escorial diagnostic criteria for ALS. (EMG) electromyography. (Brooks et al., 2000; 
Economides et al., 2013; Kiernan et al., 2011; Ravits et al., 2007a; Wijesekera and Leigh, 2009). 
1.1.4 Treatments 
ALS is an incurable disease, despite the large number of clinical trials testing the effect 
of over 50 different compounds only one drug is available for the treatment of this 
neurodegenerative disorder, Riluzole, which can increase survival by 2-3 months 
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(Miller et al., 2012a; Turner, 2001). Thus to date the main method in the care of ALS 
patients consists of symptomatic treatment via a multidisciplinary approach covering 
physiotherapy, nutrition, respiration and pain management to help improve life quality 
(Kiernan et al., 2011; Miller et al., 2009a, 2009b, 2012b). 
1.1.5  Environmental risk factors  
Environmental factors such as exposure to toxins, solvents, pesticides, formaldehyde, 
smoking, exercise, infectious agents, and physical trauma have been associated with 
increased risk of developing ALS.  
For example, the elevated rate of ALS reported for the indigenous population of Guam 
was postulated to be the consequence of exposure to the neurotoxic non-protein 
amino acid β-N-methylamino-L-alanine (BMAA). This neurotoxin present in the cycad 
seeds was assumed by people in Guam through the consumption of home-grown 
plants and animals (Khabazian et al., 2002; Lee, 2011; Shaw and Wilson, 2003). 
Although it was clear that the etiologic agent could be an environmental neurotoxin an 
eventual genetic contribution to disease could not be excluded. Also intense physical 
activity has been suspected of being an environmental factor in ALS. For instance, 
increased risk of ALS has been reported in Italian professional soccer players actively 
engaged between 1970 and 2001. However, the absence of ALS cases in professional 
road cyclists and basketball players suggests that ALS is not related to physical activity 
in general (Chio et al., 2009). 
Despite many studies none has produced consistent and convincing evidence that 
environmental factors can cause ALS; therefore to date other than age, gender and 
family history no other non-genetic risk factor is associated with the disease (Al-
Chalabi and Hardiman, 2013; Ingre et al., 2015). 
1.1.6 ALS pathological features 
1.1.6.1 Degeneration of motor neurons 
The main neuropathological feature of ALS is the degeneration of both upper and 
lower motor neurons causing the denervation of skeletal muscles, see Figure 1.1 
(Mendonça et al., 2005; Miki et al., 2010; Ota et al., 2005; Ravits et al., 2007b).  
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Figure 1.1 Impairment of the neuromuscular system in ALS. (a) Upper motor neurons (UMNs) are 
located in the motor cortex and their axons project down to the spinal cord where they form synapses 
with lower motor neurons (LMNs). The axons of LMNs project to the muscles forming synapses at the 
level of the neuromuscular junctions (NMJs). (b) In healthy individuals the motor cortex connects with 
the muscles through the MNs. At the muscle level each LMN axon branch innervates a single muscle 
fibre. The neurotransmitter acetylcholine (red dots) is released from the foot plate of the axon and 
received by nicotinic acetylcholine receptors located on end plate of the muscle fibre. In this case the 
NMJ, the foot plate and the end plate are closely aligned to ensure efficient signal transduction. (c) In a 
degenerating NMJ the foot plate and the axon degenerate progressively retracting and reducing the 
efficiency of signal between the axon terminal and the muscle, eventually losing contact. 
The selective vulnerability of MNs to neurodegeneration might be explained by their 
structural and metabolic specialization. In humans MNs are typically large cells, with a 
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central body of approximately 50-60 μm and an axon of 1 m. To maintain such a large 
structure mitochondria have to meet high energy demands, consequentially increasing 
the production of reactive oxygen species (ROS) and therefore leaving the cell more 
prone to oxidative stress damages (Barber and Shaw, 2010). Moreover MNs have low 
levels of cytosolic calcium-binding proteins (CaBP) compared to other neuronal 
populations. The lack of CaBP, forces mitochondria to sequester calcium ions, 
triggering further an increase in ROS. In addition, MNs have low expression of the 
glutamate receptor 2 (GluR2) subunit of the Alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) glutamate receptors, which imparts a high calcium 
permeability contributing once again to generate more ROS and ultimately to 
selectively damage MNs (Barber and Shaw, 2010; Jaiswal, 2014). Degeneration mostly 
takes place in the anterior and lateral columns of the spinal cord, but is evident also in 
the motor cortex and brain stem. Investigation of brain and spinal cord of ALS 
patients using magnetic resonance imaging (MRI) and diffusion tensor tomography 
techniques have shown an in vivo correlation between the severity of the atrophy and 
the clinical symptoms of the disease (Branco et al., 2014; Cohen-Adad et al., 2013; 
Schuster et al., 2013; Thorns et al., 2013). Furthermore post mortem LMN 
investigation has suggested that MNs loss is a contiguous process that progresses in 
parallel with the disease symptoms, with an average loss at end stage of 55 %, ranging 
from 8 % to 90 % (Ravits et al., 2007b).  
1.1.6.2 Gliosis 
Astrogliosis and microgliosis are hallmarks of ALS and they occur in the dorsal and 
ventral horns of the spinal cord (McGeer and McGeer, 2002; O’Reilly et al., 1995; Ota 
et al., 2005; Schiffer et al., 1996) and in motor and non-motor regions of the cortical 
grey matter (Kushner et al., 1991; Nagy et al., 1994; Sugiyama et al., 2013). The 
impairment within astrocytes and microglia has been suggested to accelerate disease 
progression, while intensity of microglial activation has been shown to correlate with 
the severity of MN damage (Lasiene and Yamanaka, 2011). 
1.1.6.3 Inclusion bodies  
A major pathological feature of ALS is the presence of cytoplasmic inclusions or 
aggregates in degenerating MNs and adjacent oligodendrocytes. Inclusions are present 
in the spinal cord, in the frontotemporal cortices, hippocampus and cerebellum of ALS 
patients (Al-Chalabi et al., 2012). The predominant inclusions found are ubiquitinated 
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aggregates that are classified either as Lewy body-like hyaline inclusions or skein-like 
inclusions, the first characterised by a round shape and the second characterised by 
bundles of filaments with granules. TDP-43 protein has been shown to be the major 
component of these ubiquitinated inclusions (Mackenzie et al., 2007; Nishihira et al., 
2008), but also p62 immunoreactivity is present in these aggregates (Blokhuis et al., 
2013; Leigh et al., 1991; Mizuno et al., 2006; Ota et al., 2005). Other neuropathological 
inclusions are: neurofilament heavy chain accumulations in spinal cord MN cell bodies 
and axons (Mendonça et al., 2005), phosphorylated neurofilament inclusions, often co-
localising with ubiquitin (Takahashi et al., 1997; Troost et al., 1992), astrocytic hyaline-
inclusions, similar to lewy-body-like hyaline but present in astrocytes (Kato et al., 1997) 
and Bunina bodies, small eosinophilic granules occasionally co-localising with TDP-43 
(Miki et al., 2010; Ota et al., 2005). Of note hyaline inclusions containing SOD1 
protein are found in ALS patients with SOD1 mutations (Shibata et al., 1996a), and 
present a fibrillar morphology reminiscent of the amyloid formation observed in many 
neurodegenerative diseases (Ross and Poirier, 2004). 
1.1.6.4 Muscle atrophy 
Atrophy of the muscles, due to loss of innervation of motor neurons is another 
important feature of ALS. In healthy individuals when motor neurons innervating a 
muscle bundle die the adjacent axons tend to re-innervate those muscle fibers 
exhibiting a non-random regrouping of muscle fiber type. However, it has been 
suggested that sprouting axons in ALS are unable to change fiber types of re-
innervated muscle. In fact, ALS patients characteristically have an atrophic group 
containing mixed fiber types rather than a non-random regrouping muscle fiber type 
pattern (Baloh et al., 2007a; Daube et al., 2000). 
1.1.7 Genetics of ALS 
The majority of ALS cases are sporadic (sALS) since they lack a clear genetic 
component, however, a significant percentage are caused by inherited genetic 
mutations, termed familial ALS (fALS). The percentage of ALS patients with a family 
history has been apprised from a low 0.8 % up to 23 % of the ALS population; this 
might still be an underestimation since many cases labelled as sporadic might indeed be 
familial with a reduced disease penetrance (Andersen and Al-Chalabi, 2011). All genes 
found to be causative of fALS have also been found mutated in sALS patients. 
Moreover sALS and fALS are clinically indistinguishable in terms of disease 
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progression and neuropathology; but the average age of onset of fALS is approximately 
10 years earlier than sALS (Andersen and Al-Chalabi, 2011; Siddique and Ajroud-Driss, 
2011).  
The first major breakthrough in understanding the genetic basis of ALS occurred in 
1993, when Rosen and colleagues found that mutations in the superoxide dismutase 1 
(SOD1) gene were causative of fALS (Rosen et al., 1993). To date over 160 SOD1 
mutations have been associated with ALS, variations in this gene account for about 12-
24 % of fALS and for 2-7 % of sALS cases (Pasinelli and Brown, 2006; Renton et al., 
2014; Valdmanis and Rouleau, 2008). Since the identification of SOD1 other genes 
have been discovered to be causative of ALS; with varying levels of prevalence. The 
percentage of ALS explained by each gene in populations of European ancestry are 
reported in Table 1.2 and Figure 1.2 (Renton et al., 2014). Additionally several risk loci 
have been identified mainly on the basis of genome wide association studies (GWAS), 
and they have been predicted to be responsible for 60 % of the risk of developing ALS 
with the reaming 40 % being environmental (Al-Chalabi et al., 2010). 
Of note the identification of an expanded hexanucleotide repeat in an intronic region 
of the uncharacterized gene C9ORF72 strengthened the link between ALS and FTD. 
Normal individuals have at most 23 repeats while ALS or FTD patients can have up to 
several thousand of repeats (Rohrer et al., 2015). This pathogenic expansion repeats 
account for about 40 % of fALS cases, 7 % sALS cases, 25 % of familial FTD cases 
and 4 % of sporadic FTD cases (Andersen and Al-Chalabi, 2011; DeJesus-Hernandez 
et al., 2011; Gijselinck et al., 2012; Renton et al., 2011). Indeed many of the ALS 
causative genes are mutated also in FTD, see Table 1.2. Moreover in some families 
individuals carrying these mutations may develop ALS or FTD or a combination of 
both diseases, reinforcing the hypothesis of a common genetic behind ALS and FTD 
(Orr, 2011).  
In many cases mutations in a specific ALS causative gene can cause specific 
pathologies in patients. For example, SOD1 protein aggregates are present in mutant 
SOD1 cases (Kato et al., 2000). In a similar way mutation in TDP-43 and FUS genes 
cause TDP-43 and FUS protein to mislocalise into the cytoplasm (Blokhuis et al., 
2013). While C9orf72 repeat expansions are characterised by RNA aggregates and 
protein aggregates containing atypical products (Mackenzie et al., 2014). 
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Figure 1.2 Percentage of sALS and fALS explained by each gene. (a) Percentage of fALS cases 
explained by the different genes: C9orf72 = 40 %; FUS = 4 %; SOD1 = 12 %; TDP-43 = 4 %; VCP = 
1 %; SQSTM1 = 1 %; OPTN, PFN1 and UBQLN2 < 1 %. (b) Percentage of sALS cases explained by 
the different genes: C9orf72 = 7 %; FUS = 1 %; SOD1 = 1-2 %; TDP-43 = 1%; VCP = 1 %; SQSTM1, 
OPTN, PFN1 and UBQLN2 < 1 %. Data according to Renton 2014, values are referred to populations 
of European ancestry (Renton et al., 2014). 
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Gene 
symbol 
Gene name Location Inheritance Frequency Link to 
FTD 
Putative function  References 
 Not identified (ALS3) 18q21 AD Rare no Unknown  (Hand et al., 2002) 
 Not identified (ALS7) 20p13 AD Rare no Unknown  (Sapp et al., 2003) 
ALS2 Alsin 2q33.2 AR Rare, juvenile  no Endosomal trafficking and 
cell signalling 
(Hadano et al., 2001) 
ANG Angiogenin 14q11.2 AD Rare yes RNA processing (Greenway et al., 
2006) 
ATXN2 Ataxin 2 12q24.12 AD Rare no Endocytosis, RNA 
translation 
(Elden et al., 2010) 
C9orf72 Chromosome 9 reading 
frame 72 
9p21-q22 AD 22.5-46 % 
fALS, 21 % 
sALS 
yes Homologue to guanine 
nucleotide exchange factor  
(DeJesus-Hernandez 
et al., 2011; Levine et 
al., 2013)  
CHMP2B Chromatin modifying 
protein 2B 
3p11 AD Rare yes Vesicle trafficking (Parkinson et al., 
2006) 
DAO d-amino acid oxidase 12q24.11 AD Rare no Glutamate excitotoxicity (Mitchell et al., 2010) 
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Gene 
symbol 
Gene name Location Inheritance Frequency Link to 
FTD 
Putative function  References 
FIG4 Polyphospoinositide 
phospate 
6q21 AD Rare 1-2 % 
fALS 
no Endosomal trafficking and 
cell signalling 
(Chow et al., 2009) 
FUS Fused in sarcoma 16q11.2 AD, AR, de 
novo mutation 
4-5 % fALS 
juvenile  
yes RNA processing (Kwiatkowski et al., 
2009; Vance et al., 
2009) 
hnRNPA1 Heterogenous nuclear 
ribonucleoprotein A1 
12q13.3 AD Rare no RNA processing (Kim et al., 2013) 
OPTN Optineurin 10p15-p14 AD and AR Rare no Endosomal trafficking and 
cell signalling 
(Maruyama et al., 
2010) 
PFN1 Profilin 1 17p13.2 AD Rare no Cytoskeleton / transport (Wu et al., 2012) 
SETX Senataxin 9q34 AD Rare, juvenile no RNA processing (Chen et al., 2004) 
SIGMAR1 σ Non opioid receptor 1 9p13.3 AD and AR Rare adult 
and juvenile 
yes Unknown  (Al-Saif et al., 2011; 
Luty et al., 2010) 
SOD1  Superoxide dismutase 1 21q22.1 AD, AR, de 
novo mutation 
20 % fALS 
7 % sALS 
no Superoxide metabolism (Rosen et al., 1993) 
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Gene 
symbol 
Gene name Location Inheritance Frequency Link to 
FTD 
Putative function  References 
SPG11 Spatacsin 15q15-q21 AR Rare, juvenile no  (Orlacchio et al., 
2010) 
SQSTM1 Sequestosome 1 5q35 AD 1 % fALS yes Ubiquitinantion / autophagy (Shimizu et al., 2013) 
TDP-43 TAR DNA-binding 
protein 43 (TDP-43) 
1p36.2 AD AR(rare) 5 % fALS yes RNA processing (Sreedharan et al., 
2008) 
UBQLN2 Ubiquilin 2 Xp11 X-linked  yes  (Deng et al., 2011) 
VAPB Vescicle-associated 
membrane protein-associated 
protein B 
20q13.3 AD Rare  no Endosomal trafficking and 
cell signalling 
(Nishimura et al., 
2004) 
VCP Valosin-containing protein 9p13-p12 AD 1 % fALS yes Ubiquitin / protein 
degradation 
(Johnson et al., 2010) 
Table 1.2 ALS associated genes. Autosomal dominant (AD); Autosomal recessive (AR). 
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1.2 SOD1-fALS 
In 1993 Rosen and colleagues identified for the first time 11 missense mutations in the 
SOD1 gene in 13 different fALS families (Rosen et al., 1993; Saccon et al., 2013). Since 
then over 160 SOD1 variants have been associated with ALS although pathogenicity 
has been confirmed only for 75 of them (Bunton-Stasyshyn et al., 2014)(ALS online 
Database (ALSoD) http://alsod.iop.kcl.ac.uk/).  
1.2.1 Clinical course and pathogenicity of SOD1-fALS 
The clinical course of SOD1-fALS is very similar to the one of SOD1-sALS regarding 
site of onset, progression and duration of the disease (Synofzik et al., 2010). 
Interestingly SOD1-fALS patients have been suggested to be less likely to develop 
cognitive deficits, nevertheless a low proportion SOD1-fALS families have been 
reported with cases of ALS-FTD (Battistini et al., 2005; Katz et al., 2012; Masè et al., 
2001; Wicks et al., 2009). Of note the clinical phenotype deriving from the SOD1-
fALS mutations can be very heterogeneous among patients, sometimes even between 
siblings of a single family (Ito et al., 2002). 
Although mostly similar, the neuropathology of SOD1-fALS presents some differences 
compared to the one of non-SOD1-fALS and sALS. TDP-43 inclusions for example 
were thought to be absent in SOD1-fALS and have been used for a long time to 
discriminate between sporadic and familial SOD1-ALS cases (Mackenzie et al., 2007; 
Tan et al., 2007). However, recent studies reported TDP-43 pathology also in SOD1-
fALS cases (Maekawa et al., 2009; Okamoto et al., 2011; Sumi et al., 2009). Bunina 
bodies are also thought to be absent in fALS (Nakamura et al., 2014; Shibata et al., 
1996a; Tan et al., 2007) while neuronal and astrocytic SOD1 inclusions are ubiquitously 
expressed in SOD1-fALS but often absent in sALS and non-SOD1-fALS (Bruijn et al., 
1998; Hineno et al., 2012; Kato et al., 1996, 2000, 2001; Shibata et al., 1996a, 1996b). 
1.2.2 SOD1 gene and inheritance pattern 
The SOD1 gene, which encodes Cu/Zn superoxide dismutase 1, is located on human 
chromosome 21q22.11 and is 9,310 base pairs (bp) long (Wang et al., 2006; Wulfsberg 
et al., 1983). The gene is composed of 5 exons and is transcribed into 966 bp mRNA 
transcript (Figure 1.3) which encodes a 154 amino acid metalloenzyme, (described in 
section 1.3, Figure 1.4) (Wang et al., 2006). 
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Mutations in SOD1 are scattered throughout the coding sequence of the gene and they 
are mainly missense substitutions. However there are also deletions, insertions, 
mutations in the non-coding areas of the gene and silent point mutations (Birve et al., 
2010; Hu et al., 2012; Turner and Talbot, 2008; Valdmanis et al., 2009; Zinman et al., 
2009; Zu et al., 1997). All SOD1 mutations are associated with a dominant inheritance 
pattern with few exceptions such as N86S and D90A, which also behave as recessive 
traits (Andersen and Al-Chalabi, 2011; Turner and Talbot, 2008). The D90A mutation 
has also been found in association with D96N in recessive fALS (Hand et al., 2001), 
and as a neutral polymorphism in unaffected Scandinavian people (Turner and Talbot, 
2008). Some mutations are found more frequently in populations than others for 
example, the D90A mutation is the most common worldwide, the A4V is the most 
common in the USA (Turner and Talbot, 2008), while I113T is the most common in 
the UK (Orrell et al., 1999). Mutations in the SOD1 gene are thought to cause ALS 
through a still unknown toxic gain of function, even though the majority of the SOD1-
fALS mutations reduce the activity of the SOD1 protein in patients, see section 3.3.1 
(Saccon et al., 2013). The effect of these mutations on the biological function of the 
SOD1 protein will be discussed later in section 1.5. 
A range of transcription factor binding sites have been identified for the SOD1 gene, 
located between -1,200 and +1 bp from the transcriptional start site (Miao and St Clair, 
2009; Park and Rho, 2002; Romanuik et al., 2009; Yoo et al., 1999a, 1999b). Further 2 
functional transcripts with a different 3’ untranslated region (UTR) have also been 
describe (Kilk et al., 1995; Sherman et al., 1983).  
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Figure 1.3 Human SOD1 gene chromosomal location, DNA and mRNA structure. (a) Location 
of the human SOD1 gene on chromosome 21. (b) SOD1 gene structure. The gene is 9,310 bp long, 
including a 1.2 kb upstream encompassing the promoter region. Exons are labelled in red, introns in 
black and UTRs in yellow. (c) SOD1 mRNA is 966 bp. Coding regions are labelled in red and UTRs in 
yellow. 
1.3 SOD1 protein  
SOD1 is an abundant copper and zinc containing protein ubiquitously expressed in all 
cell types, particularly abundant in the motor neurons of the spinal cord (Bordo et al., 
1994; Lindenau et al., 2000). Protein expression levels in vivo are stable within tissues 
and across time independently from environmental factors (Miao and St Clair, 2009; 
Radyuk et al., 2004). This metalloenzyme is highly conserved across species (Fridovich, 
1995), indeed 73 % of the amino acid sequence is shared across mammals (Wang et al., 
2006). Within the cell, SOD1 localises in the cytoplasm, nucleus, lysosomes and inter-
membrane space of mitochondria (Chang et al., 1988; Crapo et al., 1992; Kawamata 
and Manfredi, 2010; Keller et al., 1991; Sturtz et al., 2001). 
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1.3.1 Biological function 
SOD1 is an antioxidant enzyme and its main canonical function consists in the catalysis 
and conversion of toxic superoxide anions (O2-) to molecular oxygen (O2) and 
hydrogen peroxide (H2O2), thus providing a defence against oxygen toxicity (Zelko et 
al., 2002). 
The dismutase of O2- is a two-step process. First one molecule of O2- reduces the 
cupric ion (Cu2+ZnSOD) to form O2, then a second molecule of O2- reoxidise the 
reduced cupric ion (Cu+ZnSOD) to form H2O2. This two-step reaction has been 
shown to work in a pH range of 5.0 to 9.5 (Valentine et al., 2005). 
Step 1 O2- + Cu2+ZnSOD → O2 + Cu+ZnSOD 
Step 2 O2- + 2H+ + Cu+ZnSOD → H2O2 + Cu2+ZnSOD 
Another role for SOD1 in cellular metabolism has been recently identified by Reddi 
and Culotta, using yeast and human cell lines. In the mechanism proposed SOD1 is 
thought to act as an O2 and glucose dependent regulator of respiration through 
stabilisation of casein kinase 1-gamma (CK1γ), via hydrogen peroxide (Bunton-
Stasyshyn et al., 2014; Reddi and Culotta, 2013). SOD1 has also been suggested to 
work as a molecular switch that initiate endoplasmic reticulum (ER) stress in 
conditions of zinc deficiency. In particular the dissociation of zinc form wild-type 
SOD1 during zinc depletion induces a mutant-like conformation change that exposes 
the binding site for Derlin-1, a component of the ER-associated degradation 
machinery. The SOD1-Derlin-1 interaction has been proposed to activate homeostatic 
ER stress by triggering the unfolded protein response (UPR) and consequently 
preventing the accumulation of misfolded proteins (Homma et al., 2013). Furthermore 
mutant SOD1 has been proposed to activate ER stress by disrupting ER-Golgi 
trafficking through binding to the coatomer coat protein II (COPII) (Atkin et al., 2008; 
Bunton-Stasyshyn et al., 2014). Recent studies have suggested a potential role for 
SOD1 in nucleic acid metabolism; SOD1 might be able to control transcription by 
binding to nuclear promoters to regulate oxidative resistance genes (Hu et al., 2012; 
Tsang et al., 2014).  
The SOD1 protein is produced at high levels and represents about 1 % of all 
cytoplasmic proteins in the cell. The functions described above do not account for 
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such a big quantity of SOD1, therefore it is likely that this protein plays other roles in 
the cellular metabolism that have not yet been identified (Bunton-Stasyshyn et al., 
2014; Milani et al., 2013). 
1.3.2 Structural features and protein stability 
The human SOD1 protein functions as a 32 kDa homodimer, and as mentioned before 
has a highly conserved structure. Each monomer contains an intrasubunit disulphide 
bond (S-S), one copper (Cu2+) and one zinc (Zn2+). When the protein is metal loaded 
the copper and the zinc ions are located in close proximity and share an imidazole 
ligand, histidine 63 (His63) (Figure 1.4); their bond is further stabilised by a network of 
hydrogen bonds. Each subunit is made of an 8-stranded β-barrel connected by loops, 
and 1 helical structure in residues 134-137 (Figure 1.4 (b)). The two largest loops are 
particularly important for the correct function of the enzyme: the metal binding loop 
(residues 49-84) and the electrostatic loop (residues 122-143) (Rakhit et al., 2007). The 
disulphide bond is linked between two cysteine residues: cysteine 57 (Cys57) and 
cysteine 146 (Cys146) (Figure 1.4). The two monomers are connected by hydrophobic 
interactions, water mediated hydrogen bonding and main chain to main chain hydrogen 
bonding between the monomers (Elam et al., 2003). 
Metallated SOD1 has been reported to be one of the most stable proteins in nature 
(Rakhit et al., 2007), in particular the intrasubunit S-S bond and the zinc ion act as a 
monodentate ligand contributing to protein stability. SOD1 when fully metallated has a 
melting temperature of 85-95 °C, and does not lose its enzymatically active in 8 M urea 
or in 1 % SDS or 4 M guanidine HCl (Rakhit and Chakrabartty, 2006; Rodriguez et al., 
2002). However, SOD1 loses its stability and becomes intrinsically disordered when in 
the apo- and disulfide reduced forms (Rodriguez et al., 2005). Evidence from in vitro 
and in vivo experiments using non-metallated forms of SOD1 have suggested that a 
mixture of SOD1 species with varying degrees of metallation exists in cells and that 
instability caused by metal-deficiency can be a mechanism through which SOD1 
mutations cause the disease (Hilton et al., 2015). 
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Figure 1.4 Human SOD1 protein structure. (a) 3-dimensional structure of dimeric SOD1. Residue 
His63 is involved both in copper and zinc binding (red); His71, His80 and Asp83 are involved in zinc 
binding (purple); His46, His48 and His120 are involved in copper binding (blue). Cysteine 57 and 146 
form the disulfide bond (green). (b) Secondary structure elements of SOD1. The 8 β-strands are 
represented as arrows and numbered, the α-helix (α1) that forms copper and zinc binding is shown in 
yellow. His63 is labelled in red, residues involved in zinc binding in purple and residues involved in 
copper binding in blue. The disulphide bond is highlighted as a green dotted line. 
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1.3.3 Properties of mutant SOD1 proteins 
1.3.3.1 Effect of mutations on protein function 
Since their first discovery in 1993 mutations in the SOD1 gene are known to reduce the 
dismutase activity of the SOD1 protein. Initially it was hypothesised that this reduction 
in enzymatic activity was the mechanism through which SOD1 mutations were causing 
the disease. Subsequent findings carried out on mouse models soon dismissed that 
theory, and suggested that the disease is caused by a toxic gain of function (reviewed in 
chapter 3). 
A study carried out in HEK cells transfected with 132 flag-SOD1 variants showed that 
124 SOD1-ALS mutations have an exposed Derlin-1 binding site that is blocked in the 
wild-type protein (Fujisawa et al., 2012), suggesting that pathogenic SOD1 mutations 
may induce a common conformational change in SOD1 that leads to motor neuron 
toxicity though ER-stress activation (Fujisawa et al., 2012; Homma et al., 2013). 
Primary spinal MN culture experiments reinforced this hypothesis (Nishitoh et al., 
2008). However, even though a Derlin-1 and mutant SOD1 CNS specific interaction 
have been shown in a transgenic SOD1-fALS mouse models, to date the functional 
consequence of this interaction has not yet been demonstrated outside of cell culture 
(Nishitoh et al., 2008). Further Derlin-1 has never been identified in screens for SOD1 
interactors in SOD1-fALS mice (Watanabe et al., 2008; Zetterström et al., 2011). 
Mutations of specific residues in the copper binding region have been shown to block 
SOD1 activity, and they might influence the role of SOD1 in respiration repression 
described by Reddi and Culotta (Reddi and Culotta, 2013). 
1.3.3.2 Effect of mutations on SOD1 biochemical properties  
Biophysical studies of mutant SOD1 investigating protein activity, metal content and 
spectroscopy, allowed the classification of these mutants into 2 main groups depending 
on their similarity with the wild-type SOD1 protein (Rodriguez et al., 2002). Mutants 
SOD1 with reduced activity and reduced protein stability are classified as metal-
binding-region (MBR) since typically their mutations are located in the region close to 
zinc and copper ions. Variants that are shown to behave similarly to wild-type SOD1 
are defined as wild-type-like (WTL) and typically their mutations are located away from 
the metal binding site (Rodriguez et al., 2002; Valentine et al., 2005). Table 1.3 shows 
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the classification of fALS mutant SOD1 proteins investigated in the present work, 
according to Valentine (2005). 
WTL MBR 
G93A D83G 
D101G  
I113T  
Table 1.3 Classification of mutant SOD1 proteins to WTL and MBR categories. Mutant proteins 
employed in this thesis, are listed under one of the two groups WTL (wild-type-like) or MBR (metal-
binding-region), (Valentine et al., 2005). 
In vivo and in vitro studies trying to correlate disease severity with activity of enzyme, 
half-life, proteolysis resistance, mutation position, protein charge and aggregation 
propensity have not produce convincing results (Lindberg et al., 2002; Prudencio et al., 
2009a; Ratovitski et al., 1999; Vassall et al., 2011). However some biophysical and 
biochemical properties of SOD1 mutations that have been shown to differ significantly 
from wild-type SOD1 are listed below: 
 Resistance to proteinase K digestion: MBR mutants are more easily digested 
than WTL mutants (Ratovitski et al., 1999). 
 Thermal stability: generally all SOD1 mutants show a reduction in thermal 
stability, but there is only a slight reduction in WTL mutants compared to a 
significant reduction in MBR mutants (Rodriguez et al., 2002). Furthermore a 
correlation between decreased disease duration and decreased thermal stability 
has been shown for a small number of MBR mutants (Kitamura et al., 2011; 
Lindberg et al., 2002). 
 Sensitivity to disulfide reduction: MBR mutants are more susceptible to S-S 
reduction compared to WTL mutants and wild-type SOD1 (Rodriguez et al., 
2005). 
 Protein half-life: protein half-life did not correlate to whether mutations were 
MBR or WTL type, although generally SOD1 mutants had shorter half-lives 
than wild-type SOD1, correlating with protein stability (Sato et al., 2005). 
Further cell studies have shown that some MBR mutants with markedly 
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reduced stability have a comparable half-life to wild-type SOD1 (Borchelt et al., 
1994; Ratovitski et al., 1999; Reaume et al., 1996). 
 Degree of hydrophobic exposure: SOD1 mutants have a greater exposure of 
hydrophobic areas than wild-type SOD1 (Rakhit et al., 2002; Rodriguez et al., 
2005). 
 Net charge of protein: net charge of protein at physiological pH varies in 
different SOD1 mutants, independently of whether mutations are MBR or 
WTL type. A reduction in net charge of SOD1 mutants is likely to increase 
their propensity to aggregate especially in cellular environment of low and 
fluctuating pH, as would be found in the lysosomes and in the intermembrane 
space of the mitochondria (Lindberg et al., 2005). 
 Dimer dissociation: SOD1 monomers have been identified as a common 
misfolding intermediate both in sporadic and familial SOD1-ALS (Rakhit et al., 
2004). SOD1 dimer dissociation is a key step in aggregation and occurs due to 
mutations, glutathionylation and cellular stress. In particular SOD1 mutations 
located in the inter-subunit cleft are able to disrupt the dimer interface leading 
to more facile dissociation. Recently a link between the propensity of mutant 
SOD1 to monomerise and disease severity has been suggested specifically, 
when glutathionylation of SOD1 is taken into consideration (McAlary et al., 
2013). 
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Figure 1.5 Human SOD1 secondary structure and mutations responsible for fALS. The 8 β-
strands are represented as arrows, the α-helix that forms copper and zinc binding is in blue. His63 is 
labelled in red, residues involved in zinc binding in purple and residues involved in copper binding in 
blue. The disulphide bond is highlighted as a green dotted line. Mutations known to be causative of 
fALS are reported along the secondary structure of the protein. In the nomenclature, for amino acid 
substitutions the first letter indicates the residue in the wild-type form of the protein, the number 
indicates the amino acid positon and the second letter the new residue. For example, D83G is a 
substitution of an asparagine for a glycine in position 83. Point mutations, deletions and insertions are 
indicated with a line, while mutations that cause a C-terminal truncation are illustrated with a scissor. 
Modified from (Valentine et al., 2005). 
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1.4 SOD1 mouse models 
1.4.1  Why we use mouse models in ALS research  
Mice are one of the most widely used model organisms in research. Indeed it is 
currently the most genetically tractable and cheap mammalian model (Huang et al., 
2011; Niu et al., 2014). The mouse genome has been sequenced and it is 14 % smaller 
compared to humans; at the nucleotide level approximately 40 % of the human 
genome can be aligned to the mouse genome (Waterston et al., 2002). Mice were the 
first species in which an exogenous genetic sequence was introduced (Jaenisch and 
Mintz, 1974) and also the first species with embryonic stem cells (ESC) cultured in vitro 
(Evans and Kaufman, 1981; Martin, 1981). Both these techniques and many others 
lead to the creation of important mouse models and currently over 2,252 human 
diseases have at least one mouse model available (www.informatics.jax.org September 
2015). 
In the study of the nervous system mice are preferentially employed compared to other 
models such as the fruit fly or zebrafish, because they are genetically and 
physiologically more similar to humans. ALS research makes no exception and mice 
are the most widely employed model organism (Gurney et al., 1994). However, also 
rats (Howland et al., 2002), zebrafish (Lemmens et al., 2007), fruit flies (Mizielinska et 
al., 2014; Phillips et al., 1995), and nematodes (Oeda et al., 2001) are used to investigate 
this disease. A small amount of research has also been carried out in horses and dogs 
specifically regarding the SOD1 mutation (Coates and Wininger, 2010; de la Rúa-
Domènech et al., 1996; Zeng et al., 2014). 
1.4.1.1 Mouse models of SOD1-ALS 
Since the identification of SOD1 as a causative gene of fALS (Rosen et al., 1993), 
several different types of mouse model have been generated to investigate SOD1 
mutations. From transgenic mouse models overexpressing either the human mutant or 
the wild-type SOD1 protein, to Sod1 knockout models and also mice overexpressing 
the mouse SOD1 protein. Several experimental crosses have also been carried out 
using these animals to further elucidate the role of SOD1 in ALS. Some of these 
mouse models relevant to the present work are described below, details of other 
important lines are reported in the relevant chapters. 
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1.4.2 SOD1 transgenic mice 
The first mouse expressing the human mutant SOD1 transgene was presented in 1994 
by Gurney and colleagues. Since then a great number of transgenic SOD1 mice have 
been produced, including mice expressing tagged proteins, experimental mutations, 
conditional/inducible lines, and one model overexpressing the mouse SOD1 (Deng et 
al., 2008; Pramatarova et al., 2001; Ripps et al., 1995; Wang, 2003; Watanabe et al., 
2005). A comprehensive list of all these transgenic animals is reported in Table 8.1 of 
Appendix 8.1.  
Almost all these transgenic SOD1 mouse lines, share similar behavioural phenotypes, 
disease progression patterns and neuropathological characteristics resembling of the 
pathology seen in ALS patients. However, they have different ages of onset and 
survival times which often correlate with the level of transgene expression or with the 
number of copies in the transgene array (Gurney et al., 1994; Tu et al., 1996; Watanabe 
et al., 2005; Wong et al., 1995). 
Three SOD1 transgenic mouse lines have been employed in the present work: two 
overexpressing the mutant SOD1 G93A mutation at different levels, referred to as 
transgenic SOD1 G93A high copy (TgSOD1G93A(H)) (Chiu et al., 1995) and low copy 
(TgSOD1G93A(L)) (Zhang et al., 1997) and one overexpressing the human wild-type 
SOD1 protein (TgSOD1WT) (Gurney et al., 1994). TgSOD1G93A(H) and TgSOD1WT lines 
have been used through the whole thesis and are described here, while the 
TgSOD1G93A(L) line has been specifically employed for one project and is described in 
section 6.1.3. 
1.4.2.1 Transgenic SOD1G93A high copy mice 
In 1994 Gurney and colleagues established for the first time four transgenic SOD1 
mouse lines carrying the G93A mutation (Gurney et al., 1994). The mouse line 
employed in the present work, Tg(SOD1*G93A)1Gur, referred in the text as 
TgSOD1G93A(H), derives from one of these original lines but has 40 % expansion 
resulting in 25 copies in the transgene array (Chiu et al., 1995). The transgene 
integration site has been mapped to band E of mouse chromosome 12 (Achilli et al., 
2005).  
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The TgSOD1G93A(H) line was originally maintained and described in a C57BL6-SJL 
background (Chiu et al., 1995). TgSOD1G93A(H) mice are characterised by a gradual loss 
of body weight starting at approximately 10 week of age. Signs of motor disturbance 
typically starts at 13 weeks usually in the form of tremors in one or more limbs. 
Similarly to ALS patients these animals develop muscle weakness and atrophy along 
with symptoms such as spasticity, limb-grasping and clonus. With the progressive loss 
of strength in the hind limbs mice display a dropped pelvis and typically drag the body 
using the forelimbs. According to Chiu and colleagues (1995) mice reached the humane 
end point at 136 days of age, which was defined as 10 % loss of body weight or 
inability to right themselves within 30 seconds when placed on their side.  
Electrophysiological studies confirmed the behavioural data describe above showing a 
loss of muscle strength from 40 days of age, compatible with a pattern of preferential 
loss of larger MNs innervating faster muscle fibres (Hegedus et al., 2007, 2008). 
Further pathological studies revealed that, as occurs in ALS patients, these mice have a 
progressive loss of MNs starting at 100 days of age. In particular by end stage a 50 % 
loss of MNs is detected in the spinal cord (Chiu et al., 1995; Fischer et al., 2004; Gould 
et al., 2006). Vacuolation has been observed in the MNs of the spinal cord from 80 
days of age and also in the mitochondria, which appear abnormal (Dal Canto and 
Gurney, 1994; Fischer et al., 2004). Events of denervation and reinnervation of skeletal 
muscles are detected from 47 days of age, moreover evidence of axonal degeneration is 
present in ventral roots from 80 days of age (Chiu et al., 1995; Fischer et al., 2004). 
Astrocytosis is also apparent in the spinal cord from 82 days of age (Tu et al., 1996). 
Several types of inclusion are detectable from an early stage for example spheroid 
neurofilament inclusions are visible in swollen axons of the ventral spinal cord from 82 
days of age, (Gurney et al., 1994; Tu et al., 1996). There are also SOD1 inclusions, 
particularly in the MNs’ ventral horn (Gurney et al., 1994) and p62 and ubiquitin 
aggregates, which have all been shown to co-localise by 120 days (Gal et al., 2007). 
Typically TDP-43 pathology is absent in this mouse line (Robertson et al., 2007), 
however TDP-43 mislocalisation has been reported once at end stage (Shan et al., 
2009). 
50 
 
1.4.2.2 Transgenic SOD1WT mice 
Three wild-type SOD1 transgenic lines were generated together with the first G93A 
mutant SOD1 transgenic line by Gurney and colleagues in 1994 and one of them is 
employed in the present work: Tg(SOD1)2Gur, referred in text as TgSOD1WT. This 
line is thought to carry 7 copies of the SOD1 human wild-type transgene, and is 
typically used as control of the TgSOD1G93A(H) line since it has comparable levels of 
SOD1 protein expression and activity (Tu et al., 1996), even though not all studies 
agree (Jaarsma et al., 2000). 
Initially the TgSOD1WT line was thought to be free from motor deficits (Chiu et al., 
1995; Tu et al., 1996), but further phenotypic investigation reviled mild deficits form 58 
week of age (Jaarsma et al., 2000). 
Histological studies showed abundant SOD1 staining in the lateral ventral horn and 
throughout the spinal cord of the TgSOD1WT mice (Gurney et al., 1994). In particular 
at an early stage SOD1 staining is homogeneously distributed but from 30 weeks of age 
it appears enriched within the MNs’ axons (Jaarsma et al., 2000). Further SOD1 
inclusions are detected in MNs from 86 week of age (Jonsson et al., 2006a), and axonal 
degeneration and vacuolation are seen from 30-35 weeks of age, however, denervation 
or reinnervation events are never detected at this stage (Chiu et al., 1995; Dal Canto 
and Gurney, 1995; Jaarsma et al., 2000). Several other pathologies similar to those seen 
in TgSOD1G93A(H) mice, have been reported, but with milder characteristics and at a 
later point in life. Neurofilament and mitochondrial pathology are present and occur at 
a later age, for example neurofilament pathology is seen at 18.6 weeks rather than 11.7 
(Dal Canto and Gurney, 1995; Jaarsma et al., 2000; Tu et al., 1996). The same happens 
for gliosis, MN vacuolation and MN degeneration (Jaarsma et al., 2000; Tu et al., 1996). 
Of note, Graffmo and colleagues have recently investigated homozygous TgSOD1WT 
mice on a different background, due to failure to produce homozygotes in the original 
C57BL/6J background. Interestingly the same phenotype described for the 
TgSOD1G93A(H) mice has been reported but with a longer time scale. These mice show 
hind limb paralysis from 36 weeks, end stage at 52 weeks, presence of misfolded SOD1 
and astrocytosis in the spinal cord and 40 % MNs loss at end stage (Graffmo et al., 
2013). 
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1.4.3 Sod1 knock out mice 
Sod1 knockout mice are not considered a model of ALS since they do not develop 
typical disease phenotypes such as paralysis, loss of motor neuron or premature death 
(Saccon et al., 2013). Nonetheless these mice develop a series of ALS-like phenotypes 
and they have been extensively employed in the study of ALS. Furthermore they have 
been extremely helpful in the investigation of the role that a SOD1 loss of function 
might play in the disease. The Sod1 knockout mice are described in Chapter 3 section 
3.3.2. 
Of note the mouse Sod1 gene is located in mouse chromosome 16, is composed of 5 
exons and is 5581 bp long. The mouse Sod1 mRNA is 116 bp. Despite some difference 
in the gene compared to the human SOD1 gene, the mouse Sod1 encodes for a protein 
of 154 amino acid, very similar to the human homologues. 
1.4.4 Effect of background on mouse phenotypes 
Inbred mouse strain are often employed in research to isolate the effects of a particular 
mutation since they allow the minimisation of background genetic heterogeneity.  
Several inbred strains have been employed in ALS research and since the phenotypes 
of a specific mutation can change depending on the background in which mice are 
bred, it is important to consider it when comparing results. Further, since genetic 
variability can result in phenotypic variations it is important to conduct characterisation 
studies using pure inbred or congenic lines. Congenic lines are obtained by 
backcrossing a donor line to a recipient inbred line for 10 generations. The result of 
such backcross is a ~99.8 % homozygous loci for the recipient allele (Acevedo-
Arozena et al., 2008).  
An example of a phenotypic change modulated by the background strain comes from 
TgSOD1G93A(H) mice. Indeed the time of end stage of these animals was found to be 
significantly different between mice kept on a C57BL/6J or on a C57B6-SJL 
background (Mead et al., 2011). Variance among background strains of TgSOD1G93A(H) 
mice was observed also for other factors, such as onset, disease progression and 
response to drugs (Mancuso et al., 2012; Nardo et al., 2013; Pan et al., 2012; 
Pizzasegola et al., 2009; Wooley et al., 2005). It is also important to note that variability 
among publications might be also due to different humane end points or inconsistency 
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of transgene copy number. Survival variability of TgSOD1G93A(H) mice in different 
backgrounds is reported in Figure 1.6. 
Specific background strains have also been documented to increase gender differences 
in survival, onset and also behavioural tests such as grip-strength, both in 
TgSOD1G93A(H) and TgSOD1G93A(L) mice (Acevedo-Arozena et al., 2011; Heiman-
Patterson et al., 2005; Mancuso et al., 2012; Pan et al., 2012). The same pattern has also 
been reported for other SOD1 transgenes (Kunst et al., 2000; Pan et al., 2012). 
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Figure 1.6 Genetic background effect on TgSOD1G93A(H) mouse survival. Survival time expressed in 
days for TgSOD1G93A(H) mice maintained in different background strains. Data come from different 
publications reporting results from two or more background strains (Heiman-Patterson et al., 2005, 
2011; Mancuso et al., 2012; Pan et al., 2012; Pizzasegola et al., 2009; Wooley et al., 2005). Where survival 
was measured separately for each gender the average is plotted. 
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1.4.5  Limitations of current SOD1-ALS mouse models 
Transgenic mouse models of SOD1-fALS and Sod1 knock out models have been very 
useful in furthering our understanding of motor neuron disease, but as all model 
organisms they have some limitations. 
The majority of the SOD1 transgenic mice, develop ALS symptoms and pathology but 
they are not a perfect genetic representation of the human disease since they 
overexpress the mutant SOD1 gene in addition to the mouse endogenous Sod1. 
TgSOD1G93A(H) mice for example overexpress the human SOD1 protein up to 17 times 
the level of the endogenous mouse SOD1 in some studies and up to 25 times in some 
others, and such high levels of mutant protein have been proven to affect various 
aspect of the disease phenotype and pathology from onset to survival (Jaarsma et al., 
2000; Jonsson et al., 2006b). Sod1 knockout animals have also been crucial for 
investigating the effects of a 50 % reduction of SOD1 dismutase activity as seen in 
patients (Saccon et al., 2013). However, the absence of the Sod1 gene does not mimic 
the human situation, since these animals do not develop motor neuron loss and 
premature death (Saccon et al., 2013). Further, as explained above different factors can 
influence animal pathology and phenotype such as background strain, transgene copy 
number and gender; therefore it is important to take them into consideration in 
interpreting existing results and designing new experiments (Perrin, 2014). 
Despite these limitations to date SOD1 transgenic mice are the most commonly used 
and the most accurate models of ALS. Indeed, the majority of SOD1 transgenic mice 
available recapitulate the keys histopathological and biochemical features of the human 
disease and their onset and survival correlates with the level of the mutant protein 
expressed (Jucker, 2010). Moreover, SOD1 transgenic mice have been extensively 
employed as preclinical models and a substantial number of compounds that modulate 
their pathology have been identified, but only few have been successfully translated in 
clinical trial. Nevertheless there are examples of treatments developed in SOD1 mouse 
models, such as riluzole, the only approved drug for ALS, where the effects seen in 
transgenic SOD1 mice match the clinical experience, demonstrating that these animals 
are an invaluable tool in the study of ALS (Gurney et al., 1996; Ittner et al., 2015; 
Turner and Talbot, 2008). 
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1.5 How mutant SOD1 causes disease  
1.5.1 SOD1-fALS proposed mechanisms of pathogenicity  
Studies carried out in SOD-fALS and sALS patients and SOD1-fALS mouse models 
lead to the conclusion that SOD1-ALS is caused by one or more toxic functions of the 
mutant SOD1 protein, rather than a reduction of superoxide dismutase activity. A 
plethora of molecular mechanisms of pathogenesis have been proposed (Ilieva et al., 
2009). However, to date it is still unknown which of these mechanisms are the cause of 
motor neuron degeneration and which are consequences of the disease. The most 
important of these proposed mechanisms relevant to SOD1-fALS are summarised 
below. 
1.5.1.1 Glutamate toxicity and calcium homeostasis  
High levels of glutamate have been observed in the central nervous system (CNS) of 
sporadic and familial ALS patients (Arundine and Tymianski, 2003; Foran and Trotti, 
2009), and SOD1 mutant mouse models (Ilieva et al., 2009). Elevated concentrations 
of this excitatory neurotransmitter, that triggers motor neurons to fire, can initiate a 
cascade of toxic events in the motor neurons. Taking together these two observations 
it has been proposed that glutamate excitotoxicity can cause motor neuron death in 
ALS. In particular excess of glutamate provokes activation of the glutamate receptors 
which causes a prolonged opening of associated ion channels in mitochondria, 
resulting in increased levels of intracellular calcium and production of ROS (Mattson, 
2003; Rothstein, 1995; Shaw and Ince, 1997). These findings are confirmed by data 
coming from mouse models of SOD1-fALS, where glutamate release and glutamate 
sensitivity are increased (Milanese et al., 2010; Tortarolo et al., 2006). 
Moreover deficiency of the glutamate transporter excitatory amino-acid transporter 2 
(EAAT2) has been reported in astrocytes of sALS and fALS patients and SOD1 mouse 
models, causing glutamate accumulation in the synapses (Howland et al., 2002; 
Rothstein, 1995; Yang et al., 2009, 2010). 
Of note Riluzole which is the only drug used in the treatment of ALS is an anti-
glutaminergic agent which regulates glutamate release (Foran and Trotti, 2009). 
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1.5.1.2 Endoplasmic reticulum (ER) stress and unfolded protein response 
(UPR) 
Pathogenic mutants of SOD1 are involved in the activation of the ER stress (Fujisawa 
et al., 2012; Homma et al., 2013; Nishitoh et al., 2008). When perturbed the ER 
typically activates two stress responses: the UPR and the ER-associated degradation 
(ERAD) (Bunton-Stasyshyn et al., 2014). Indeed markers of UPR response and ERAD 
have been found in ALS patient tissues (Atkin et al., 2008; Ito et al., 2009; Walker and 
Atkin, 2011) and SOD1-fALS mice (Ito et al., 2009; Kikuchi et al., 2006; Saxena et al., 
2009). In particular, as described above, the mechanisms through which SOD1 
mutations have been proposed to cause ER stress are the interaction between SOD1 
and COPII that disrupt the ER-Golgi trafficking (Atkin et al., 2014), and binding of 
SOD1 with Derlin-1 in situations of zinc deficiency (Homma et al., 2013).  
Genetic and pharmacological manipulation of the UPR have been proven to affect 
degeneration in SOD1-fALS mice, presumably because the mice had a reduced 
capacity to turn down synthesis of misfolded SOD1 (Kalmar et al., 2008; Wang et al., 
2011a). In interpreting these findings it is import to consider that in transgenic mouse 
models of SOD1-fALS the SOD1 protein is greatly overexpressed and the ER stress 
response seen might, at least in part, be caused by the presence of an abnormal amount 
of protein. Of note Kiskinis and colleagues showed that motor neurons are more 
susceptible to ER stress than other cell types, and this might be the reason why motor 
neurons are more vulnerable in ALS (Kiskinis et al., 2014). 
1.5.1.3 Mitochondrial dysfunction  
Ultrastructural studies revealed mitochondrial abnormalities in motor neurons of sALS 
patients. The same pathology is present also in transgenic SOD1 G93A mice (Gurney 
et al., 1994) and other SOD1-fALS mouse models (Dal Canto and Gurney, 1994, 1995; 
Kong and Xu, 1998; Martin et al., 2007; Wong et al., 1995).  
Furthermore energy metabolism dysfunctions have been observed in mitochondria 
from CNS (central nervous system), blood and muscle of patients and also in motor 
neurons from SOD1-fALS mouse models (Crugnola et al., 2010; Martin et al., 2007; 
Mattiazzi et al., 2002; Swerdlow et al., 1998; Wiedemann et al., 1998). In particular it 
has been observed: an alteration of the mitochondrial electron transfer chain activity 
(Borthwick et al., 1999; Bowling et al., 1993), aberrant calcium homeostasis (Curti et al., 
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1996; Siklós et al., 1996) and abnormal localization of SOD1 to the inner membrane 
space (IMS) (Mattiazzi et al., 2002). In mice mutant SOD1 specifically targeted to the 
mitochondria IMS has been shown to impair the mitochondria respiratory chain and 
cause ALS like phenotypes such as loss of motor neurons and muscle weakness but 
not muscle denervation (Igoudjil et al., 2011). Therefore, there is evidence that in mice 
mutant SOD1 can cause mitochondrial dysfunction that results in some ALS features, 
but other mechanisms may be necessary to recapitulate all aspects of the ALS 
phenotype (Igoudjil et al., 2011).  
1.5.1.4 Oxidative stress 
Even though it is known that SOD1-ALS is caused by a toxic gain of function, the idea 
that the lack of SOD1 activity provoking oxidative stress might play a role in the 
disease has not yet been dismissed. Indeed SOD1-fALS patients show on average 
approximately 50 % reduced dismutase activity, see section 3.3.1 (Saccon et al., 2013). 
Moreover there are also other indications, independent from the loss of SOD1 
enzymatic function suggesting a role for oxidative stress in ALS. 
For example signs of increased oxidative damage of protein, lipids, DNA and mRNA 
together with other indicators of oxidative stress have been observed in spinal cord but 
also in urine, blood and cerebrospinal fluid of SOD1-fALS and sALS patients (Barber 
and Shaw, 2010; D’Amico et al., 2013). Moreover increased 3-nitrotyrosine levels, an 
oxidative stress marker have been detected in motor neurons of SOD1-fALS patients 
(Beal et al., 1997). Of note in a small number of cases oxidative stress damage has been 
also shown to correlate with disease measures (Abe et al., 1995; Babu et al., 2008; Beal 
et al., 1997; Bogdanov et al., 2000; Bowling et al., 1993; Chang et al., 2008; Cova et al., 
2010; Ferrante et al., 1997a; Murata et al., 2008; Sasaki et al., 2000; Shaw et al., 1995; 
Shibata et al., 2001, 2004; Simpson et al., 2004; Smith et al., 1998; Tohgi et al., 1999).  
Interestingly similar oxidative stress markers have been detected in SOD1-fALS mouse 
models providing further evidence that oxidative damage is implicated in motor neuron 
degeneration (Andrus et al., 1998; Casoni et al., 2005; Cha et al., 2000; Ferrante et al., 
1997b; Lee et al., 2009; Liu et al., 2007, 1998; Poon et al., 2005). In mice SOD1 has 
been found to be oxidised, oxidation has indeed been implicated in the 
monomerisation and aggregation of wild-type and mutant SOD1 (Ezzi et al., 2007; 
Rakhit et al., 2002; Wilcox et al., 2009). Evidence that mRNA oxidation contributes to 
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motor neuron degeneration also comes from SOD1-fALS mouse models, and the 
majority of oxidised mRNA species identified in the spinal cord of the mice are 
implicated with ALS (Chang et al., 2008). 
Recent findings underlined the central role of oxidative stress in SOD1-fALS showing 
that overexpression of oxidation resistance 1 (OXR1), a gene protective against 
oxidative stress, induced damage in neurons of transgenic SOD1 G93A mice, delays 
spinal cord and muscle pathology, extends survival and delays the non-cell-
autonomous inflammatory response (Liu et al., 2015). Moreover, alterations in 
peroxiredoxin (PRDX) 1, 3 and 6, the enzymes responsible for reducing hydrogen 
peroxide levels, and reduction in several isoforms of glutathione S-transferase (GST) 
mu1, 2 and 5 have been demonstrated in SOD1 G93A ALS mouse and cell models, 
suggesting a crucial role of oxidative stress in disease (Allen et al., 2003; Jain et al., 
2008; Strey et al., 2004). 
From all these studies is possible to conclude that even if the role of oxidative stress is 
still unclear, the fact that it is involved in several pathogenic mechanisms of the disease 
suggests that it is an important factor in ALS (Barber and Shaw, 2010).  
1.5.1.5 Axonal transport impairment 
Disruption of axonal transport has been demonstrated in several SOD1-fALS mouse 
models and in primary MNs expressing mutant SOD1. In particular in several SOD1-
fALS mice both slow anterograde and fast retrograde axonal transport system defects 
are present (Bilsland et al., 2010; Warita et al., 1999; Williamson and Cleveland, 1999; 
Zhang et al., 1997). While in primary MNs fast anterograde and retrograde transport 
are disrupted triggering mitochondrial reduction in the axon (De Vos et al., 2007). Also 
in human spinal cords the axonal anterograde transport has been suggested to be 
impaired causing mislocalisation of mitochondria (Sasaki and Iwata, 1996). 
SOD1 has been shown to interact with a driver of retrograde transport, the dynein 
complex, in cell, mouse and rat models (Zhang et al., 2007). Interestingly in cell models 
it has been shown that perturbation of SOD1-dynein complex interaction correlates 
with reduction of SOD1 toxicity and aggregation (Ström et al., 2008).  
In mice SOD1 aggregation together with a progressive motor phenotype are triggered 
by deficits in the axonal retrograde transport caused by a mutation in the cytoplasmic 
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dynein heavy chain 1 (Dync1h1) gene (Hafezparast et al., 2003). Further mutant and 
oxidised wild-type SOD1 can inhibit dynein based fast anterograde transport (Rotunno 
and Bosco, 2013). 
A damaged axonal transport might cause problems with cytoskeletal structure, energy 
metabolism and seriously impair the transport of crucial proteins and organelles (De 
Vos et al., 2007) creating a process in which all these components are mislocalised and 
the cell is unable to recycle them. MNs have been suggested to be more sensitive to 
this type of axonal impairment than other neuronal cells, due to their morphology 
(Chevalier-Larsen and Holzbaur, 2006). 
1.5.1.6 Non-cell autonomous mechanism 
Motor neuron degeneration is a hallmark of ALS but several other cell types are known 
to be involved in disease pathogenesis. Indeed studies carried out in SOD1-fALS 
mouse models have shown that the selective expression of mutant SOD1 in motor 
neurons or in astrocytes, fails to cause an ALS phenotype, suggesting a non-cell 
autonomous nature of the disease (Gong et al., 2000; Pramatarova et al., 2001). 
However, other experiments have found that the selective expression of mutant SOD1 
in MNs, can give MN loss but no behavioural motor phenotype (Wang et al., 2008) or 
MN loss and behavioural phenotype (Jaarsma et al., 2008). 
Subsequent studies carried out on chimeric mice and on mice in which the transgenes 
were excised from particular cell types, have provided more consistent results. 
Expression of mutant SOD1 in motor neurons determines diseases onset and 
influences progression (Boillée et al., 2006; Wang et al., 2009b; Yamanaka et al., 2008a, 
2008b). While mutant SOD1 expressed in astrocytes and microglia has been proposed 
to be the main key for determining the progression of degeneration (Beers et al., 2006; 
Boillée et al., 2006; Gong et al., 2000; Wang et al., 2009b, 2011b; Yamanaka et al., 
2008b). Transgenic mice with mutant SOD1 expressed in skeletal muscle have shown 
muscle atrophy and reduced strength, but it is still unclear whether this can cause 
degeneration of MNs (Dobrowolny et al., 2008; Wong and Martin, 2010).  
Co-culture experiments have revealed that astrocytes expressing mutant SOD1 are 
toxic to neurons (Fritz et al., 2013; Di Giorgio et al., 2008; Kunze et al., 2013; 
Marchetto et al., 2008; Nagai et al., 2007). Also mutant SOD1 microglial toxicity seems 
likely although the effect may be indirect (Thonhoff et al., 2012; Zhao et al., 2010). 
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All these results taken together suggest that the expression of mutant SOD1 in 
astrocytes and microglia is crucial for disease progression, but the expression of the 
mutant protein in motor neurons is necessary for the disease onset (Boillée et al., 
2006).  
Barber and Shaw proposed a mechanism in which damaged motor neurons activate 
glial cells through the release of ROS, which in turn activate other glial cells leading to 
further motor neuron damage (Barber and Shaw, 2010). The mechanism of this 
communication is still unknown however, a recent publication hypostasised that OXR1 
could act as mediator of the cross-talk between motor neurons and toxic mutant 
SOD1 microglia and astrocytes, extending MN survival (Liu et al., 2015).  
1.5.1.7 SOD1 involvement in RNA metabolism  
TDP-43 and FUS are RNA binding proteins, and are both causative of fALS when 
mutated; their discovery highlighted the possibility that RNA metabolism might play a 
crucial role in the pathogenesis of ALS (Ling et al., 2013). SOD1 has been also shown 
to be involved in RNA metabolism by binding and stabilising mRNAs. 
For example mutant SOD1 may down regulate vascular endothelial growth factor 
(VEGF) expression by directly binding its mRNA transcript. Indeed VEGF mRNA 
expression is downregulated in the spinal cords of transgenic SOD1 G93A mice, and a 
luciferase reporter assay carried out in an in vitro culture model of glia cells expressing 
mutant SOD1, showed that mutant SOD1 protein has a high binding affinity for 
VEGF adenine/uridine-rich elements (ARE) (Lu et al., 2007; Miao and St Clair, 2009). 
Furthermore, in vitro mutant SOD1 has been shown to directly compete with HuR and 
neuronal HuC embryonic lethal abnormal visual (ELAV) RNA stabilizer proteins, 
specifically for VEGF mRNA binding. This gain of function of mutant SOD1 may 
disrupt ELAV protein function leading to loss of expression of VEGF that is essential 
for motor neuron survival (Li et al., 2009). Indeed VEGF increased expression has 
been shown to attenuate the phenotype of SOD1-fALS mice (Bunton-Stasyshyn et al., 
2014; Keifer et al., 2014). Furthermore a polymorphism in the VEGF promoter has 
been related to increased risk of ALS and lower age of onset (Su et al., 2014) and a 
deletion in the promoter of the mouse gene has resulted in a MN degenerative 
phenotype characterised by late onset (Oosthuyse et al., 2001).  
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In a similar way mutant SOD1 also binds the 3’ UTR of low molecular weight 
neurofilament (NFL) mRNA negatively affecting its stability (Bunton-Stasyshyn et al., 
2014; Chen et al., 2014; Ge et al., 2005; Volkening et al., 2009). Experiments carried 
out in NSC34 cells showed that mutant SOD1 but not wild-type SOD1 interacts 
directly with hNFL mRNA and functions as a trans-acting hNFL mRNA stability 
determinant acting within the 3′-UTR (Ge et al., 2005). Further studies showed that a 
reduction in NFL mRNA mediate by mutant SOD1 induces axonal degeneration in 
sALS, SOD1-fALS mouse models and also in MNs differentiated from induced 
pluripotent stem cells (iPSC) derived from SOD1-fALS patients (Chen et al., 2014; 
Julien, 1999; Menzies et al., 2002). However in a SOD1-fALS mouse model the 
knockout of NFL resulted in a significant delay of disease onset (Williamson et al., 
1998), therefore the reduction of the NFL mRNA is probably not the main pathogenic 
mechanism of SOD1-fALS. 
1.5.2 Protein misfolding and aggregation 
1.5.2.1 SOD1 protein aggregates  
The presence of specific protein aggregates is a hallmark of several neurodegenerative 
diseases. In SOD1-fALS the presence of non-amyloid SOD1 aggregates in the MNs 
has been extensively reported (Kato et al., 1996, 1997; Kerman et al., 2010; Okamoto 
et al., 1991; Wang et al., 2002a). Nevertheless the role of such aggregates is still 
unknown. In particular it is unclear whether they are toxic pathogenic species or if they 
are the result of a coping mechanism used to protect the organism against other 
misfolded protein species like monomers and oligomers. (Mulligan and Chakrabartty, 
2013; Ross and Poirier, 2005).  
Investigation of SOD1-fALS mice suggested a link between SOD1 aggregation and the 
disease phenotype. Indeed SOD1 aggregates are preferentially located in the ALS 
affected tissues, and their level has a positive correlation with disease progression 
(Cheroni et al., 2005; Turner et al., 2003; Wang et al., 2002a, 2002b). Moreover Wang 
and colleagues suggested that SOD1 expression levels should reach a certain threshold 
to cause aggregation in order for ALS like symptoms to arise (Wang et al., 2002a).  
Experiments carried out using double transgenic mice expressing both mutant and 
wild-type SOD1 showed increased aggregation and co-localization of the mutant 
SOD1 protein with the wild-type form. In general these animals have a reduced 
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survival compared to single transgenic mice and develop an early onset of ALS 
symptoms (Deng et al., 2006; Fukada et al., 2001; Jaarsma et al., 2000, 2008; Prudencio 
et al., 2010; Wang et al., 2009c). However how the presence of wild-type SOD1 
modulate the aggressiveness of the phenotype and the quantity and nature of the 
aggregates might depend on the expression level of the wild-type SOD1 protein. A 
cross between the L126Z mutant SOD-fALS mouse and 2 lines of transgenic wild-type 
mice showed that higher levels of wild-type SOD1 increase toxicity leaving aggregation 
of mutant SOD1 unchanged; while lower levels of wild-type SOD1 do not affect the 
phenotype but higher levels of aggregation are observed (Prudencio et al., 2010).  
Of note SOD1 aggregate inclusions are detected in mice always after the denervation 
of the muscles (Bruijn et al., 1997; Gould et al., 2006; Johnston et al., 2000; Koyama et 
al., 2006). 
Cell culture model experiments confirmed findings from double transgenic mice 
showing that increased levels of soluble SOD1 correlates with increased toxicity, while 
increased levels of insoluble SOD1 correlates with reduced toxicity. Moreover when 
mutant and wild-type SOD1 are co-expressed aggregation is lessened while toxicity is 
increased (Brotherton et al., 2013; Prudencio et al., 2010; Weisberg et al., 2012; Witan 
et al., 2008, 2009). 
Of note in SOD1-fALS mice high levels of misfolded SOD1 can overload the 
ubiquitin proteasome system (UPS) causing it to become dysfunctional and therefore 
increase aggregation of SOD1 (Bendotti et al., 2012; Urushitani et al., 2002). However, 
this mechanism is always detected after disease onset (Lee et al., 2002). UPS 
dysfunction is observed in SOD1-fALS mice, but not until after onset (Cheroni et al., 
2009) and SOD1 aggregation caused by UPS inhibition is not necessarily toxic (Lee et 
al., 2002), suggesting that this is not a primary cause of mutant SOD1 toxicity. 
The fact that aggregated SOD1 is mainly detected in symptomatic animals suggests that 
aggregates are not the primary cause of ALS, however pre-aggregated SOD1 forms 
present before disease onset might be toxic species (Karch et al., 2009). This does not 
exclude that SOD1 aggregates can cause secondary toxicity by sequestration of other 
important proteins (Bergemalm et al., 2010; Pasinelli et al., 2004; Weisberg et al., 2012), 
or by disrupting axonal transport (Sau et al., 2011). 
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1.5.2.2 SOD1 pre-aggregate species  
Several SOD1 species are detected in the spinal cord of affected SOD1-fALS animals, 
such as: soluble, insoluble and detergent resistant monomers, soluble and insoluble 
dimers, oligomers and other high molecular weight SOD1 species (Koyama et al., 
2006). 
SOD1 mutants typically show an increased propensity of the SOD1 dimers to 
monomerise, together with defects in folding and dimerization of the protein (Bruns 
and Kopito, 2007; Khare et al., 2006; Rakhit et al., 2004). Since monomerisation is a 
crucial step for the formation of oligomers and aggregates (Rakhit et al., 2004; Ray et 
al., 2004) this propensity could accelerate the aggregation process of the SOD1 
mutants. For instance, spinal cords from four different SOD1-fALS mouse mutant 
lines have been shown to be enriched in soluble hydrophobic disordered monomers 
compared to mice overexpressing the human wild-type SOD1 transgenic protein. The 
level of these monomers correlates with survival in the 4 mutant lines, associating 
monomeric SOD1 with disease (Zetterström et al., 2007, 2013). 
Not only monomers but also other oligomeric soluble and insoluble SOD1 species 
have been identified in pre-symptomatic SOD1-fALS mice and they have been 
suggested to correlate with progression of the phenotype (Johnston et al., 2000; Wang 
et al., 2009a). Indeed staining of the MNs of SOD1-fALS mice using antibodies that 
specifically label misfolded forms of SOD1, revealed the presence of non-native 
dimeric species in pre-symptomatic mice and inclusions after disease onset (Liu et al., 
2012; Rakhit et al., 2007). 
The mechanisms through which these monomeric or oligomeric species of SOD1 
might cause toxicity are still unknown, however, some assumptions have been made. 
Monomerisation could for example expose the SOD1 binding site for derlin-1 
triggering ER stress (Fujisawa et al., 2012; Nishitoh et al., 2008), or could impair the 
copper binding causing oxidative stress (Kishigami et al., 2010). Oligomerisation has 
instead been proposed to disrupt retrograde axonal transport by competing with other 
transport targets overwhelming the system (Johnston et al., 2000). 
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1.5.2.3 Prion-like protein misfolding mechanism  
Prion diseases are fatal neurodegenerative diseases characterised by misfolding of the 
prion protein (PrP). They can be sporadic, caused by mutation in the prion protein 
(PRNP) gene or caused by infection with misfolded PrP (PrPsc). In particular the PrPsc 
protein can induce the correctly folded cellular PrP (PrPc) to misfold and take the 
characteristics of the infectious PrPsc. The disease can be transmitted cell to cell, but 
also among animals via oral uptake, blood, or other sources of direct contact 
(Acquatella-Tran Van Ba et al., 2013; Grad et al., 2015; Lee and Kim, 2015). 
There are several lines of evidence suggesting that ALS is a propagating process similar 
to prion diseases. First of all both SOD1 and TDP-43 are known to self-propagate 
within and between neuronal cells (Münch et al., 2011; Nonaka et al., 2013). Moreover 
ALS patients have aggregates of misfolded protein in their motor neurons and post 
mortem studies showed that the loss of motor neurons is more prominent in the 
region of onset and gradually decreases in the other affected areas, with distance from 
the focal onset (Ravits et al., 2007b; Verma, 2013). ALS might be therefore considered 
a prion-like disease. The term prion-like is used to describe two main features: one is 
the ability of a misfolded protein of seeding aggregation and misfold a correctly folded 
protein, and the other is the capacity of spreading this process between cells, see 
section 5.1.1 (Lee and Kim, 2015). 
Even though amyloid features have never been detected in SOD1-fALS and sALS 
patients, the SOD1 protein has been shown to display prion-like mechanism in vitro 
showing both seeding and cell to cell transmission (Chia et al., 2010; Grad et al., 2014; 
Münch et al., 2011). Moreover recent findings suggest a cell to cell transmissibility of 
the SOD1 protein also in mice (Ayers et al., 2014). The SOD1 prion-like mechanism is 
discussed in detail in 5.1.1. It is import to note that the majority of SOD1-fALS studies 
are conducted in mouse models where beside the overexpression of the mutant forms 
of the human SOD1 protein also the endogenous mouse SOD1 protein is present. 
Investigating the possible interactions between the human and the mouse SOD1 
variants will be extremely helpful to better understand and interpret the results from 
the many studies carried out in ALS research. 
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1.5.3 Role of wild-type SOD1 in the pathogenesis of ALS  
As mentioned above SOD1 aggregates are present both in sporadic and familial ALS 
and typically wild-type SOD1 protein is detected in aggregates of SOD1-fALS patients 
in addition to mutant SOD1 (Bruijn et al., 1998; Matsumoto et al.; Shibata et al., 1994, 
1996b; Watanabe et al., 2001). The advent of antibodies able to distinguish between 
misfolded and correctly folded SOD1 revealed the presence of misfolded SOD1 also in 
some sALS and non-SOD1-fALS cases (Bosco et al., 2010; Forsberg et al., 2010, 2011; 
Gruzman et al., 2007; Pokrishevsky et al., 2012). 
Interestingly wild-type SOD1 can misfold and acquire characteristics of the SOD1 
mutant proteins, becoming toxic to the motor neurons. This transformation of the 
wild-type SOD1 protein has been proposed to happen as consequence of a prion-like 
mechanism, initiated by mutant SOD1 proteins, by oxidative damage or demetalation 
(Ezzi et al., 2007; Lindberg et al., 2004; Rakhit et al., 2004; Redler et al., 2011; 
Urushitani et al., 2006). Further in cell models oxidation and misfolding of wild-type 
SOD1 has been reported after expression of wild-type TDP-43 and wild-type FUS 
(Pokrishevsky et al., 2012). 
Transgenic mice expressing human wild-type SOD1, have been extensively 
investigated. Interestingly these animals show ALS-like phenotypes late in life (Dal 
Canto and Gurney, 1995). In particular when the wild-type SOD1 protein is greatly 
overexpressed mice develop motor neuron loss and misfolded SOD1 is detected 
(Graffmo et al., 2013; Jaarsma et al., 2000). Misfolded-oxidised wild-type SOD1 
behaves as mutant SOD1 also in cellular and in vitro models, impairing anterograde 
axonal transport, activating ER-stress and causing mitochondrial damage (Bosco et al., 
2010; Guareschi et al., 2012; Pasinelli et al., 2004; Sundaramoorthy et al., 2013). 
Wild-type SOD1 has been proposed to increase mutant SOD1 toxicity in several ways. 
SOD1-fALS mouse model data showed, for example, that the presence of wild-type 
SOD1 can increase solubility of the mutant protein (Fukada et al., 2001). Also 
misfolded wild-type SOD1 lacking zinc has been observed to become more toxic in 
the presence of correctly folded wild-type SOD1 (Sahawneh et al., 2010). Further wild-
type SOD1 has been suggested to increase the toxicity of mutant or misfolded SOD1 
by forming homodimers with pre-aggregated toxic species, stabilizing them and 
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consequently slowing aggregation as reported in cellular models (Brotherton et al., 
2013; Prudencio et al., 2010; Weisberg et al., 2012; Witan et al., 2008, 2009) . 
Although all mechanisms have not yet been elucidated it is clear that overexpression of 
the wild-type SOD1 protein can cause toxicity. 
1.6 Research aim and current questions in SOD1-fALS 
1.6.1 Does SOD1 loss of function play a role in the disease? 
Mutations in the SOD1 gene were the first to be identified as causative of fALS (Rosen 
et al., 1993). Initially, two mechanisms have been suggested to cause motor neuron 
death in mutant SOD1-induced fALS: a toxic gain of function and a loss of function. 
Data from Sod1 knock out and transgenic mice overexpressing mutant SOD1 provided 
evidence of a neuromuscular phenotype. However, it was soon clear that transgenic 
SOD1 mutant mice better mimicked the MN loss phenotype seen in patients. In 1998, 
a seminal paper showed that the SOD1 loss of function did not influence the survival 
of the gain of function disease models excluding a role of loss of function in SOD1 
fALS (Bruijn et al., 1998). 
Since then several groups further investigated the phenotype of Sod1 knockout mice 
characterising and examining the specific neuromuscular involvement. These studies 
taken together with recent findings on mice overexpressing SOD1 (Ezzi et al., 2007; 
Khare et al., 2004; Rakhit et al., 2004; Wilcox et al., 2009) suggested a possible 
modifying role played by loss of SOD1 activity on the fALS disease course. 
Furthermore loss of function and gain of function mechanisms have been proposed to 
contribute to pathogenesis of TDP-43-ALS and FUS-ALS (Guo et al., 2011; Lagier-
Tourenne and Cleveland, 2009). The contribution of both these mechanism to 
neurodegeneration has been reported also in other disease such as Huntington’s 
disease (HD) (Zuccato et al., 2010), Parkinson’s disease (Winklhofer et al., 2008) and 
spinocerebellar ataxia 1 (Crespo-Barreto et al., 2010; Lim et al., 2008). 
In Chapter 3 papers reporting SOD1 activity data from SOD1-fALS patients and 
publications on Sod1 knockout mice are reviewed to investigate if a possible role for 
SOD1 loss of function in SOD1-fALS pathogenesis exists and what can be done to 
definitively address this issue. 
67 
 
1.6.2 Can we dissect the central and the peripheral effects of mutant SOD1 
toxicity using a new mouse model of motor neuron disease? 
Many SOD1 transgenic mice have been generated in the last twenty years, and as 
explained above they have been implicated in many potential ALS pathological 
mechanisms (McGoldrick et al., 2013). However, these animals overexpress the mutant 
or the wild-type SOD1 protein and it is difficult to determine whether the phenotype 
and pathology that they exhibit are the cause of the disease or an effect of the large 
amount of SOD1 protein (Acevedo-Arozena et al., 2011; Chang et al., 2008; Deng et 
al., 2006; Graffmo et al., 2013; Prudencio et al., 2010). Sod1 knock out mice have also 
been crucial in ALS research and develop a distal axonopathy, but the absence of the 
SOD1 protein is not capable of causing MN degeneration (Fischer et al., 2011, 2012). 
Recently we described a new mouse model carrying a point mutation (D83G) in the 
mouse Sod1 gene, identical to an ALS-causing SOD1 mutation in humans (Joyce et al., 
2014; Millecamps et al., 2010). Animals homozygous for this mutation (Sod1D83G/D83G) 
develop MN loss and also a distal neuropathy, due respectively to gain of function and 
loss of function  effects (Joyce et al., 2014). In the work presented in Chapter 4 the 
morphological innervation patterns of endplate NMJs, SOD1 protein level and SOD1 
activity of Sod1D83G animals are investigated. Moreover to characterise further the gain 
of function and loss of function phenotypes, by dissecting the MN loss and the 
peripheral neuropathy of the Sod1D83G mouse, Sod1D83G mice were crossed with 
TgSOD1WT animals to see if the overexpression of the human wild-type SOD1 could 
rescue the disease phenotype of Sod1D83G/D83G mice. Further, Sod1D83G were crossed with 
Sod1 knockout out mice to see if only once copy of the D83G allele was sufficient to 
cause both motor neuron loss and distal neuropathy. 
1.6.3 Is there an interaction between human and mouse SOD1 proteins, and 
how does this change our interpretation of SOD1 mouse models? 
In several transgenic mouse models of neurodegenerative disease overexpressing a 
mutant human protein, it has been shown that the presence of the homologous mouse 
protein affects the phenotype. For example, in mouse models of human prion disease 
the presence of both mouse and human PrP delays the disease onset and the 
phenotypes detected are more variable than when the mouse gene is knocked-out 
(Collinge et al., 1995; Telling et al., 1995). In mice expressing wild-type human tau no 
disease pathology is detected when the endogenous mouse Mapt gene is functional 
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(Duff et al., 2000). However, when the mouse Mapt is knocked-out, animals develop a 
pattern of pathology similar to that seen in Alzheimer disease (AD), including neuronal 
death (Andorfer et al., 2003, 2005). 
A transgenic SOD1-fALS mutant line carrying the G85R mutation investigated both in 
presence and absence of the endogenous Sod1 gene showed no difference in survival 
and phenotype (Bruijn et al., 1998). However, in a more recent study carried out on a 
similar cross with a G93A mutant SOD1 transgenic, a delay in disease onset and longer 
survival has been observed in absence of the mouse Sod1 gene. Data from double 
transgenic animals have shown that the interaction between wild-type and mutant 
human SOD1 exacerbates the disease. Nevertheless, when wild-type human SOD1 has 
been expressed in a mouse carrying the mouse SOD1 G86R mutation no difference in 
the phenotype has been detected (Audet et al., 2010). 
Cell studies have shown that both human and mouse wild-type SOD1 can slow the 
aggregation of mutant human SOD1, but the mouse and the human SOD1 protein 
have never been shown to co-aggregate (Grad et al., 2011; Prudencio et al., 2009b; 
Qualls et al., 2013). 
In order to interpret results from SOD1 transgenic models it is important to 
understand if there is an interaction between the human and the mouse SOD1 protein, 
and if there is, how it influences the disease phenotype. The mouse SOD1 dimer is 
more stable compared to the human one and therefore predicted to form less 
aggregates (Jonsson et al., 2006b).  
As described in Chapter 5, to investigate human and mouse aggregation propensity 
several human and mouse SOD1 recombinant proteins have been produced, purified 
and biochemically characterised and preliminary experiments have been carried out to 
assess their propensity to spontaneously aggregate. 
1.6.4 Can we identify new genes involved in SOD1-ALS by creating new 
modifier mouse models?  
Mouse models of SOD1-fALS have been used in the investigation of modifier genes 
that might positively or negatively influence the ALS phenotype. To do so the main 
approach that has been employed consists in crossing SOD1-fALS mouse models with 
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other mice that transgenically express or lack genes that are considered of interest (Liu 
et al., 2015; Riboldi et al., 2011; Turner and Talbot, 2008). 
In order to investigate new modifiers of the SOD1 gene a sensitized screen was carried 
out at MRC Harwell, in which N-ethyl-N-nitrosourea (ENU) mutagenized mice were 
crossed with animals carrying the transgenic SOD1 G93A low copy mutation. As result 
of this screen one mouse with a reduced survival was identified as a phenodeviant of 
the TgSOD1G93A(L) line, named Galahad. 
A phenotypic investigation of the Galahad mouse progeny and a quantitative trait loci 
(QTL) analysis to try to identify possible modifying locus/loci interacting with the 
SOD1 G93A mutation are reported in Chapter 6. 
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Chapter 2 Materials and methods 
2.1 Materials 
2.1.1 Equipment 
1 l polypropylene centrifuge bottle Nalgene 
2 l erlenmeyer flask Nalgene 
5 l beaker  Nalgene 
96-well black microtiter plate Griener 
96-well PCR microplate VWR 
Balance  Mettler-Toledo 
Beads Hybaid Ribolyser 
Bench top refrigerated microfuge Heraeus Fresco 17 Thermo Fisher 
Bio-Rad Bio-Logic chromatography system Bio-Rad  
Centrifuge 5402 or 5424 Eppendorf  
Centrifuge 6K15 rotor number: 12500; 12166 Sigma Laboratory 
Centrifuge tube 50 ml Oakridge 
Chromatographic glass column Bio-Rad  
Confocal microscope LSM 710 Zeiss 
Coverslips VWR 
Cryostat BrightTM 
Dialysis cassette Pierce 
Dialysis membrane tubing (8 ml/cm, 8 kDa) Spectra pro 
Dissection tools Dumont 
Electrophoresis power pack Bio-Rad  
Epifluorescence microscope Leica DMR 
Filter unit Sartolab 
Fluorimeter plate reader Infinite M1000 PRO Tecan 
Gel cast for agarose gel Scie-plas 
Gel scanner Hewlett-Packard (hp) 
Gel tank submarine Mupi 
Gilson pipettes Anachem Ltd 
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Grip-strength meter bio-GS3 BioSeb 
Heat block Grant Instruments 
Homogeniser TissueRuptor  Qiagen 
Incubator shaker Orbital 
Jasco J-715 Circular Dichroism Spectropolarimeter Jasco  
Magnetic flea stirrer BIBBY 
Microscope slides VWR 
Microwave Sharp 
Odyssey Classic imaging system Licor 
PAP pen VWR 
Pasteur pipette VWR 
Peltier Thermal Cyclers PTC-225 Bio-Rad  
pH meter Mettler-Toledo 
Photo-film Kodak 
Plastic cuvettes Starstedt 
Plate incubator shaker GrantBio 
Poly-lysine coated slides VWR 
Polyvinylidene difluoride (PVDF) membrane Millipore 
Protein machine ÄKTA pure GE Healthcare Life Sciences  
qPCR machine  Applied Biosystems 
Sonicator Philip Harris Scientific 
Sonicator Probe MS73 Sigma-Aldrich 
Spectrophotometer NanoDrop® ND-1000  NanoDrop Technologies 
Spectrophotometer Sunrise Tecan 
UV illuminator ChemiDoc XRS+ BioRad  
UV/VIS disposable cuvettes Kartell 
Vacusafe pump Integra Biosciences 
XCell SureLock Mini-Cell Electrophoresis System Life Technologies 
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2.1.2 Chemicals and reagents 
16 % Tris-Glycine precast gel Life Technologies 
2-mercaptoethanol Sigma-Aldrich 
3-12 % NativePAGE Bis-Tris precast gels Life Technologies 
4-12 % NuPAGE Bis-Tris precast gels Life Technologies 
Acetic acid VWR 
Benzonase VWR 
Bovine Serum Albumins (BSA) Sigma-Aldrich 
Calcium chloride (CaCl2) Sigma-Aldrich 
Coomassie Brilliant Blue R Sigma-Aldrich 
Copper sulphate (CuSO4) Sigma-Aldrich 
EDTA free protease inhibitor cocktail Roche 
Ethanol (CH3CH2OH) VWR 
Ethidium bromide Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Extraction Solution  Sigma-Aldrich 
Florescent mounting media DAKO 
Glutathione Sigma-Aldrich 
Glycerol Sigma-Aldrich 
Guanidine hydrochloride (GuHCl) Sigma-Aldrich 
HyperLadder IV Bioline 
Imidazole Sigma-Aldrich 
Isopropanol VWR 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Melford 
Kanamycin Sigma-Aldrich 
Luria Broth (LB) Sigma-Aldrich 
Lysozyme Sigma-Aldrich 
MES SDS Running buffer 20X Life Technologies 
Methanol (CH3OH) VWR 
N,N,N´,N´-tetramethylethylenediamine (TEMED) Sigma-Aldrich 
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NativeMark unstained protein standard Life Technologies 
NativePAGE Cathode buffer additive 20X Life Technologies 
NativePAGE Running buffer 20X Life Technologies 
NativePAGE Sample buffer 4X Life Technologies 
Neutralisation Solution B Sigma-Aldrich 
Nitro blue tetrazolium  Sigma-Aldrich 
NuPAGE LDS Sample buffer 4X Life Technologies 
NuPAGE Transfer buffer 20X Life Technologies 
OCT  Sakura Finetek 
Odyssey blocking buffer (PBS)  Licor 
Paraformaldehyde Sigma-Aldrich 
Phosphate Buffered Saline (PBS) Sigma-Aldrich 
Potassium phosphate  Sigma-Aldrich 
Proteinase K Invitrogen 
Riboflavin Sigma-Aldrich 
Seeblue plus2 protein standard Life Technologies 
Sodium acetate Sigma-Aldrich 
Sodium azide Sigma-Aldrich 
Sodium chloride (NaCl) Sigma-Aldrich 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich 
Sodium pentobarbital Euthatal 
Sodium phosphate (Na3PO4) Sigma-Aldrich 
Sucrose Sigma-Aldrich 
Taq polymerase REDTaq ReadyMix Sigma-Aldrich 
TaqMan Universal PCR Master Mix Applied Biosystems 
TBS Sigma-Aldrich 
Thioflavin-T (ThT) Sigma-Aldrich 
Thrombin  Sigma-Aldrich 
Tissue Prep Solution Sigma-Aldrich 
Tris acetate  Sigma-Aldrich 
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2.1.3 Commercial kits  
2.1.4 Antibodies  
2.1.4.1 Primary antibodies 
 
2.1.4.2 Secondary antibodies  
Tris borate  Sigma-Aldrich 
Tris hydrochloride (Tris-HCl) Sigma-Aldrich 
Tris-Glycine Electroblotting Buffer 10X National Diagnostic 
Tris-Glycine SDS Buffer 10X National Diagnostic 
Tris-Glycine SDS sample buffer 2X Life Technologies 
Triton X-100 Sigma-Aldrich 
Trizma base (Tris) Sigma-Aldrich 
Tween-20 Sigma-Aldrich 
UltraPure agarose Invitrogen 
Zinc sulphate (ZnSO4) Sigma-Aldrich 
DCTM Protein Assay  Bio-Rad 
ECL Enhanced chemiluminescent substrate Pierce 
M.O.M. Immunodetection basic kit Vector Labs 
Quick Start™ Bradford Protein Assay Bio-Rad  
4',6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich 
Anti-β-actin Sigma-Aldrich 
Mouse monoclonal anti-neurofilament (165 k Da) (2H3) Developmental Studies 
Hybridoma Bank 
Mouse monoclonal anti-synaptic vesicle (SV2) Developmental Studies 
Hybridoma Bank 
SEDI (SOD1 exposed dimer interface) (Rakhit et al., 2007) 
SOD-100 rabbit pan-anti SOD1 Enzo 
USOD (Unfolded SOD1) (Kerman et al., 2010) 
IRDye Licor anti-mouse Licor 
IRDye Licor anti-rabbit Licor 
Polyclonal goat anti-mouse IgG-HRP DAKO 
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2.1.5 Software  
Applied Biosystems 7500 software v2.0.1 
Carl Zeiss software ZEN 
GraphPad Prism 6 
IBM SPSS Statistics 19 
i-controlTM 
ImageJ v1.47 for Windows  
Jasco Standard Analysis software  
Odyssey v2.1 from Licor 
R (programming language) 
2.2 Mice 
All animals were maintained and animal experiments were executed in accordance with 
the Animals (Scientific Procedures) Act 1986 and Home Office Project licence 
No. 30/2290. 
Humane end points were defined as loss of 20 % maximum body weight, presence of 
hind limb paralysis or loss of righting reflex. Animals were assessed daily and weighed 
at least twice a month. 
In the present work an abbreviated nomenclature will be used to describe mouse 
genotypes, defined in Table 2.1. 
Polyclonal goat anti-rabbit IgG-HRP DAKO 
Streptavidin Alexa Fluor 488 Invitrogen 
α-bungarotoxin-rhodamine Sigma-Aldrich 
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Genotypes   Short nomenclature 
Sod1 wild-type Sod1+/+ 
Sod1 knockout heterozygous Sod1+/- 
Sod1 knockout homozygous  Sod1-/-   
Human wild-type SOD1 hemizygous transgenic  TgSOD1WT  
Human SOD1G93A hemizygous high copy transgenic  TgSOD1G93A(H) 
Human SOD1G93A hemizygous low copy transgenic  TgSOD1G93A(L) 
Sod1D83G heterozygous Sod1+/D83G 
Sod1D83G homozygous  Sod1D83G/D83G 
Sod1D83G compound heterozygous knockout Sod1-/D83G 
Human wild-type SOD1 hemizygous transgenic; Sod1D83G 
heterozygous Tg
WTSod1+/D83G 
Human wild-type SOD1 hemizygous transgenic; Sod1D83G 
homozygous Tg
WTSod1D83G/D83G 
Galahad without human SOD1G93A hemizygous low copy 
transgenic  NTgGalahad 
Galahad with human SOD1G93A hemizygous low copy 
transgenic  Tg
G93A(L)Galahad 
Galahad with human SOD1G93A hemizygous high copy 
transgenic  Tg
G93A(H)Galahad 
Galahad with human SOD1G93A hemizygous low copy 
transgenic; possibly carrying ENU mutation/s mTg
G93A(L)Galahad 
Table 2.1 Mouse genotypes nomenclature. 
2.2.1 Housing and husbandry of mice 
Mice were housed in two different facilities under constant conditions: 19-23 °C 
temperature, 55±10 % humidity, 12 hours light:dark cycle. All animals were kept in 
individually ventilated cages (IVCs) with constant access to food and water, and grade 
five dust-free autoclaved wood bedding. If mice became unable to move freely or 
experienced a weight loss between 10 and 15 %, paper was removed and hydrogel was 
placed in the cage at ground level. 
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2.2.2 C57BL/6J mice 
C57BL/6J mice (Jax stock number: 000664) were purchased from the Jackson 
Laboratory, and maintained by animal technicians. These animals have been used as 
the background strain for all the mice employed in the present work. 
2.2.3 Sod1 knockout mice 
B6;129S-Sod1tm1Leb/J mice (Matzuk et al., 1998) (Jax stock number: 002972) were 
purchased from the Jackson Laboratory on a C57BL/6J X 129S hybrid background. 
These animals were backcrossed to C57BL/6J for at least 5 generations before use, and 
maintained by animal technicians.  
Within the present work this strain will be referred to as Sod1 knockout (Sod1 KO), 
while the three genotypes produced from it will be named: Sod1+/+ (homozygous for 
the Sod1 wild-type allele); Sod1+/- (heterozygous for the Sod1 KO allele) and Sod1-/- 
(homozygous for the Sod1 KO allele).  
Genotyping was carried out as described in section 2.5.2.2. 
2.2.4 Human wild-type SOD1 transgenic mice 
B6JL-Tg(SOD1)2Gur/J mice (Gurney et al., 1994) (Jax stock code number: 002297) 
were purchased from the Jackson Laboratory on a C57BL/6J X SJL/J hybrid 
background. These animals were backcrossed to C57BL/6J for at least 5 generations 
before use, and maintained by animal technicians.  
In the present work only hemizygous transgenic littermates coming from this strain 
have been employed in experiments and they will be referred to as TgSOD1WT. 
Genotyping was carried out as described in section 2.5.2.1. 
2.2.5 Human SOD1G93A transgenic high copy mice 
B6.Cg-Tg(SOD1*G93A)1Gur/J (Chiu et al., 1995; Gurney et al., 1994) (Jax stock code 
number: 004435) were purchased from the Jackson Laboratory, already congenic to 
C57BL/6J and maintained by animal technicians. Animals employed for breeding 
purposes were culled at 120 days of age, before development of symptoms. 
In the present work only transgenic littermates coming from this strain have been 
employed in experiments and they will be referred as TgSOD1G93A(H). 
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Genotyping was carried out as described in section 2.5.2.1. 
2.2.6 Sod1D83G mice 
Sod1D83G mice have been identified by screening genomic DNA from the MRC Harwell 
ENU mutagenesis archive for mutations in Sod1 (Joyce et al., 2014). Sod1D83G mice were 
originally on a C57BL/6J-C3H background and they have been backcrossed to 
C57BL/6J for at least 5 generations before use. 
I maintained my own Sod1D83G colony in collaboration with Dr Philip Mcgoldrick. All 
three genotypes generated from this mouse line have been employed in experiments: 
Sod1+/+ (homozygous for the Sod1 wild-type allele); Sod1+/D83G (heterozygous for the 
Sod1D83G allele) and Sod1D83G/D83G (homozygous for the Sod1D83G allele).  
Genotyping was carried out by Dr Abraham Acevedo using pyrosequencing at MRC 
Harwell. 
2.2.7 Galahad mice 
Galahad mice were identified by an ENU mutagenesis modifier screen carried out by 
Dr Abraham Acevedo in collaboration with Prof Elizabeth Fisher see section 6.1.1. 
The colony founder mouse was on a C57BL/6J-BALB/c hybrid background, the line 
produced from it was then maintained on congenic C57BL/6J. 
Two genotypes were generated form this line: TgG93A(L)Galahad (carrying the human 
transgene SOD1G93A low copy) and NTgGalahad (mice non transgenic for the human 
SOD1G93A low copy).  
Genotyping was carried out as described in section 2.5.2.1. 
2.2.8 Sod1D83G X Sod1 knockout cross  
To produce this line Sod1D83G mice were crossed to Sod1 knockout mice in a two-step 
cross. In the first step Sod1+/D83G males were mated with Sod1+/- females, producing 
four possible genotypes: Sod1+/D83G, Sod1+/-, Sod1-/D83G and Sod1+/+ as illustrated in 
Figure 2.1 (a). In the second step Sod1-/D83G males were mated with Sod1+/- and 
Sod1+/D83G females, producing six possible genotypes: Sod1+/D83G, Sod1+/-, Sod1-/D83G, 
Sod1-/- and Sod1D83G/D83G see Figure 2.1 (b). 
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Genotyping for the presence of the Sod1 knockout allele was carried out as described in 
section 2.5.2.2, while genotyping for the presence of the Sod1D83G allele was carried out 
by Dr Abraham Acevedo using pyrosequencing at MRC Harwell. 
 
Figure 2.1 Breeding scheme for Sod1D83G X Sod1 KO. 
2.2.9 Sod1D83G X Human wild-type SOD1 transgenic cross  
To produce this line Sod1D83G mice were crossed to TgSOD1WT mice in a two-step 
cross. In the first step hemizygous TgSOD1WT males were mated with Sod1+/D83G 
females, producing four possible genotypes: TgSOD1WT, Sod1+/D83G, Sod1+/+, and 
TgWTSod1+/D83G see Figure 2.2 (a). In the second step TgWTSod1+/D83G males were mated 
with Sod1+/D83G females, producing six possible genotypes: TgSOD1WT, TgWTSod1+/D83G, 
TgWTSod1D83G/D83G, Sod1+/+, Sod1+/D83G and Sod1D83G/D83G as illustrated in Figure 2.2 (b).  
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Genotyping for the presence of the transgene allele was carried out as described in 
section 2.5.2.1 while genotyping for the presence of the Sod1D83G allele was carried out 
by Dr Abraham Acevedo using pyrosequencing at MRC Harwell. 
 
Figure 2.2 Breeding scheme for Sod1D83G X TgSOD1WT . 
2.2.10 Galahad X Human SOD1G93A transgenic high copy cross  
To produce this line NTgGalahad females were crossed with hemizygous 
TgSOD1G93A(H) males, producing two genotypes: NTgGalahad and TgG93A(H)Galahad. The 
line was maintained by crossing the TgG93A(H)Galahad males with wild-type C57BL/6J 
females, and NTgGalahad female with TgSOD1G93A(H) males. 
Genotyping was carried out as described in section 2.5.2.1. 
2.3 Mouse experimental procedures  
2.3.1 General mouse experimental procedures  
2.3.1.1 Perfusion with paraformaldehyde  
Mice were terminally anaesthetised by intraperitoneal injections with 200 µl of 
200 mg/ml sodium pentobarbital (Euthatal). Surgical plane of anaesthesia was 
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evaluated by blink reflex and paw pinch. Once unresponsive, the animal was pinned on 
its back, and the sternum was exposed by opening the abdominal cavity. An incision 
was made on the diaphragm along the entire length of the rib cage, which was 
subsequently cut on each side up to the collarbone. The sternum was lifted back to 
expose the heart and the pericardium was removed. A 27 gauge needle connected to a 
perfusion pump was carefully inserted into the left ventricle. The right atrium was cut 
and ice cold sterile 0.9 % NaCl (Sigma-Aldrich) was pumped into the heart for 
4 minutes at 3 ml/min flow rate. The buffer was then changed and the animal was 
perfused with ice cold 4 % paraformaldehyde (PFA) (Sigma-Aldrich) in phosphate 
buffer saline (PBS) (Sigma-Aldrich) for 8 minutes at a flow rate of 3 ml/min flow rate.  
2.3.2 Mouse experimental procedures specific for Galahad mice 
2.3.2.1 Neurological checks  
Galahad mice carrying a transgene were checked weekly by animal technicians for 
indications of neurological onset starting at 90 days of age for TgG93A(H)Galahad and at 
150 days of age for TgG93A(L)Galahad. Animals were lifted by the tail and observed for 
the presence of the following symptoms: tremors, rear limbs moving towards the 
middle and paralysis. 
2.3.2.2 Weekly weight 
All Galahad mice were weighed weekly on a set day by technical staff starting at 90 days 
of age for TgG93A(H)Galahad and at 150 days of age for TgG93A(L)Galahad and NTgGalahad. 
When animals reached 10 % weight loss compared to their maximum body weight they 
were weighed daily. Weights have been analysed by ANOVA. 
2.3.2.3 Grip-strength 
Grip-strength of TgG93A(L)Galahad and NTgGalahad animals was evaluated once a week 
starting at 150 days of age. Measures were taken by technicians using Grip-strength 
meter bio-GS3 (BioSeb). 
Each animal was lifted by the base of the tail and placed with all four feet on the mesh 
of the grip-strength meter. Once the mouse settled on a grip it was drawn back along 
the mesh in one single movement. Three individual measurements were taken for each 
time point, values were averaged and divided for the weight of the mouse of the 
correspondent week. Data were analysed by ANOVA. 
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2.3.2.4 Survival 
Humane end points defined in section 2.2 have been used for Galahad mice. On 
reaching the human end points animals were perfused as described in section 2.3.1.1, 
and tissues were harvested as described below in section 2.4.2. Control mice that did 
not display ALS symptoms were kept until 315 days of age and then culled by exposure 
to rising concentration of CO2.  
Kaplan-Meier estimator was used for survival data analysis. 
2.4 Histology  
2.4.1 Harvesting of fresh tissues  
For molecular biology experiments the following tissues were harvested fresh from 
each animal: brain, spinal cord, liver, sciatic nerves, tibialis anterior (TA) muscle, 
extensor digitorum longus (EDL) muscle and tail.  
When collecting fresh samples animals were culled by cervical dislocation one at a time. 
The mouse was placed supine to dissect TA, EDL muscles and sciatic nerves. The skin 
on the leg was peeled off and the distal TA tendon was exposed. The ligament of the 
TA was cut and muscle was gently removed, the same was done for the EDL muscle. 
A deep cut was performed from the lumbar region of the vertebral column to the 
gluteal muscles to expose both sciatic nerves, which were then harvested. The mouse 
was turned on its back, a sample of the tail was taken and an incision on the abdomen 
was made to collect the liver. The head was then detached from the body and the brain 
was separated from the skull. Finally the whole column was removed from the body 
and the spinal cord was carefully pinned and dissected.  
Immediately after dissection tissues were placed in cryotubes, snap frozen in liquid 
nitrogen and stored at -80 °C.  
2.4.2 Harvesting and embedding of fixed tissues  
Following perfusion fixed tissues were harvested from mice: brain, spinal cord, TA and 
EDL muscles. 
TA and EDL muscles were dissected with the same technique used for fresh tissues 
described in section 2.4.1. They were then arranged on supports, post fixed for 3 hours 
in 4 % PFA at 4 °C and placed overnight in 40 % sucrose (Sigma-Aldrich), 0.001 % 
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sodium azide (Sigma-Aldrich) in PBS at 4 °C. The following day muscles were 
embedded in OCT freezing medium (Sakura) using aluminium foil moulds. Muscles 
were stored at -20 °C. Brain was dissected as described in section 2.4.1 and post fixed 
overnight in 4 % PFA at 4 °C. The following day it was placed in 40 % sucrose, 
0.001 % sodium azide in PBS and stored at 4 °C. The column was removed from the 
body and post fixed overnight in 4 % PFA at 4 °C. The following day the spinal cord 
was dissected and stored in 40 % sucrose, 0.001 % sodium azide in PBS at 4 °C.  
2.4.3 Neuromuscular junction (NMJ) 
2.4.3.1 Sectioning of the extensor digitorum longus (EDL) muscle  
A BrightTM cryostat was used to cut two series of 20 µm longitudinal sections of frozen 
EDL muscles. Muscles were cut through their entire length and since NMJs are 
approximately 40 µm in size all NMJs present in a muscle should be captured in each 
series. One of the two series cut per muscle was stained and analysed. Sections were 
collected onto poly-lysine coated slides (VWR), air dried at room temperature for 1 
hour and stored at -20 °C. 
2.4.3.2 Immunostaining 
Muscle sections were defrosted, circled with a PAP pen (VWR) and air dried for 
30 minutes. Slices were then placed in a humidified chamber at room temperature and 
kept there for the duration of the staining process.  
Sections were washed 3 times for 5 minutes with TBS (Sigma-Aldrich) to remove OCT 
and then blocked for 1 hour with 3.5 % M.O.M. blocking reagent (Vector Labs) in 
TBS with 0.2 % Triton X-100 (Sigma-Aldrich) (referred to as TBS+). Slices were 
washed twice in TBS+ for 2 minutes and incubated for 30 minutes with 1:10 dilution 
of primary antibodies prepared in 7.5 % M.O.M. diluent (Vector Labs) in TBS+. The 
two primary antibodies used were mouse monoclonal anti-synaptic vesicle (SV2) 
(Developmental Studies Hybridoma Bank) and mouse monoclonal anti-neurofilament 
(2H3) (165 kDa) (Developmental Studies Hybridoma Bank). Sections were washed 
again in TBS+ and incubated for 10 minutes with M.O.M. biotinylated anti-mouse 
secondary antibody (Vector Labs) diluted 1:250 in M.O.M. diluent. Another TBS+ 
washing was applied to the section before incubation with fluorescent labelling 
performed as followed: 1:200 of streptavidin Alexa Fluor 488 (Invitrogen), 1:500 of α-
bungarotoxin-rhodamine (Sigma-Aldrich) 1:500 of DAPI (Sigma-Aldrich) in TBS+ for 
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30 minutes in the dark. Sections were rinsed with TBS and cover slipped using 
florescent mounting media (DAKO), dried overnight at room temperature and stored 
at -20 °C. 
2.4.3.3 Analysis  
NMJs were manually counted using a Leica DMR epifluorescent microscope. The total 
number of NMJs in each muscle was assessed by identification of the end plates on the 
red florescence channel (stained by α-bungarotoxin-rhodamine). The innervation status 
of each NMJ, defined in Table 2.2, was evaluated by determining the co-localisation 
level between the muscle fibre end plate (red) and the foot plate of the motor neuron 
(green, stained by SV2 antibody). All analysis was carried out blind to genotype. Images 
were acquired on a laser scanner confocal microscope Zeiss LSM 710 using proprietary 
software (Carl Zeiss Ltd, Hertfordshire, UK). 
Innervation status Morphology 
Innervated Complete overlap between nerve terminal and endplate 
Intermediate Partial overlap between nerve terminal and endplate 
Denervated Absent overlap between nerve terminal and endplate 
En-passant Synapses that occur at a non-terminal region of an axon 
Table 2.2 Classification of NMJs innervation status. 
2.5 General DNA protocols 
2.5.1 Nucleic acids extraction and purification from mouse tissue  
DNA was extracted from 2 mm ear notches or from 0.5 mm tail biopsies. Two 
different extraction techniques have been employed: a fast DNA extraction for 
genotyping polymerase chain reaction (PCR), and a proteinase K DNA extraction for 
quantity real time polymerase chain reaction (qPCR) and pyrosequencing genotyping. 
2.5.1.1 Fast DNA extraction 
Tissues were incubated in 50 μl Extraction Solution (Sigma-Aldrich) and 12.5 μl Tissue 
Prep Solution (Sigma-Aldrich) for 20 minutes at room temperature then transferred at 
95 °C for 4 minutes. Samples were centrifuged for 30 seconds at maximum speed in a 
bench top microfuge (Heraeus Fresco 17, Thermo Fisher). 50 μl of Neutralisation 
Solution B (Sigma-Aldrich) were added and mixed by vortexing. Samples were then 
85 
 
centrifuged for 7 minutes at maximum speed. For genotyping PCR, 1 μl of a 1:10 
dilution in ddH2O was used as template. 
2.5.1.2 Proteinase K DNA extraction 
Tissues were digested at 55 °C overnight in 210 μl filtered lysis buffer: 20 mg/ml 
proteinase K (Invitrogen), 100 mM Tris (pH 8.0) (Sigma-Aldrich), 5 mM 
ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich), 200 mM NaCl, 0.2 % sodium 
dodecyl sulphate (SDS) (Sigma-Aldrich). Once digested, the mixtures were centrifuged 
for 5 minutes, at 20817 x g at 4 °C to pellet non-digested tissues. Supernatants were 
transferred to clean 1.5 ml Eppendorf tubes. DNAs were precipitated by adding 200 μl 
isopropanol (VWR) and pelleted by 10 minutes centrifugation at 20817 x g at 4° C. The 
supernatants were then removed by pipetting, and the pellets were air-dried overnight 
at room temperature. DNA pellets were resuspended in 50 μl TE buffer: 10 mM Tris-
HCl (Sigma-Aldrich), 1 mM EDTA. One μl of DNA diluted 1:10 in TE buffer was 
used as template for genotyping pyrosequencing and qPCR. 
2.5.2 Polymerase chain reaction (PCR) 
Primers were either supplied by collaborators ready to be used or purchased as desalted 
lyophilised pellets (Sigma-Aldrich). Purchased primers stocks were reconstituted to 
100 μM in ddH2O and stored at -20 °C. Working dilutions were made to 5 μM with 
ddH2O and stored at -20 °C.  
For genotyping PCR a 2X REDTaq ReadyMix (REDTaq) Taq polymerase from Sigma-
Aldrich was used. Mega mix contained gel loading dye and buffer thus PCR products 
were loaded directly onto agarose gels. 
2.5.2.1 SOD1 transgene genotyping PCR 
This PCR protocol has been employed for genotyping all mouse lines with human 
SOD1 wild-type or human SOD1 G93A transgene: TgSOD1WT, TgSOD1G93A(H), 
Sod1D83G X TgSOD1WT, Galahad and Galahad X TgSOD1G93A(H) mice.  
A 10 μl master mix was used per sample, containing: 2X REDTaq, four primers 
defined in Table 2.3 at a concentration of 0.5 μM, a template of 1 μl of genomic DNA 
diluted 1:10 in ddH2O or TE and appropriate quantity of ddH2O to reach final volume. 
PCR was carried out using Peltier Thermal Cycler PTC-225 (Bio-Rad), cycling 
conditions are reported in Table 2.4. Products from PCR were resolved on a 2 % 
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agarose (Invitrogen), 45 mM Tris-borate (Sigma-Aldrich), 0.1 mM EDTA gel, (see 
below 2.5.2.3) running at 100 V for 30 minutes.  
The success of the PCR was confirmed by the presence in all samples of a 324 bp 
fragment. This band amplifies across an intron 3/exon 3 boundary from the gene 
Interleukin 2 (Il2) on chromosome 3. While the presence of the transgene was 
established by a band of 236 bp which amplifies across exon 4 of the SOD1 transgene, 
from intron 3 to intron 4 see Figure 2.3. 
 Forward Reverse 
Control CTAGGCCACAGAATTGAAAGATCT GTAGGTGGAAATTCTAGCATCATC 
Transgene CATCAGCCCTAATCCATCTGA CGCGACTAACAATCAAAGTGA 
Table 2.3 SOD1 transgene genotyping primers. 
Step Condition  Temperature 
(°C) 
Time 
(min) 
1 denaturation 95 03:00 
2 denaturation 95 00:30 
3 annealing 60 00:30 
4 extension  72 00:45 
Cycle 35 times from step 2 
5 final extension  72 02:00 
6 storing 4 forever 
Table 2.4 PCR cycling conditions for SOD1 transgene genotyping. 
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Figure 2.3 Example of transgene genotyping PCR. (L) Ladder, (ntc) no template control, (Tg) 
transgenic control, (NTg) non-transgenic control; non-transgenic and transgenic samples. 
2.5.2.2 Sod1 knockout genotyping PCR 
This PCR protocol has been employed for genotyping all mouse lines with Sod1 
knockout allele: Sod1 KO and Sod1D83G X Sod1 KO mice.  
A 10 μl master mix was used per sample, containing: 2X REDTaq, four primers 
defined in Table 2.5 at a concentration of 0.5 μM, a template of 1 μl of genomic DNA 
diluted 1:10 in ddH2O or TE and appropriate quantity of ddH2O to reach final volume. 
PCR was carried out using the cycling conditions defined in Table 2.6. 
Products from PCR were resolved on a 2 % agarose, 45 mM Tris-borate, 0.1 mM 
EDTA gel, (see below 2.5.2.3) running at 100 V for 30 minutes.  
The presence of a wild-type allele was revealed by a 123 bp band amplified from exon 
2 to intron 2 of Sod1 on chromosome 16. While the presence of the knockout allele 
was established by a band of 240 bp which presumably amplifies from the selection 
cassette used to replace exon 1 and exon 2, however the sequence was not published 
by (Matzuk et al., 1998) and details are not given on the Jax website. 
 Forward Reverse 
Control TGAACCAGTTGTGTTGTCAGG TCCATCACTGGTCACTAGCC 
KO TGTTCTCCTCTTCCTCATCTCC ACCCTTTCCAAATCCTCAGC 
Table 2.5 Sod1 knockout genotyping primers. 
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Step Condition  Temperature 
(°C) 
Time 
(min) 
1 denaturation   95 03:00 
2 denaturation 95 00:20 
3 annealing 61 01:00 
4 extension  72 01:00 
Cycle 35 times from step 2 
5 final extension  72 05:00 
6 storing   4 forever 
Table 2.6 PCR cycling conditions for Sod1 knockout genotyping. 
2.5.2.3 Agarose gel electrophoresis (AGE) 
For electrophoresis of PCR products 6 mm gels were prepared by dissolving 2 % 
Invitrogen UltraPure agarose in 100 ml 4.5 mM Tris-borate, 0.1 mM EDTA (TBE 
buffer). The solution was heated in a microwave for 1-2 minutes, allowed to cool 
slightly before adding 0.05 μg/ml of ethidium bromide (Sigma-Aldrich) and poured 
into gel casts (Scie-plas). Gels were left at room temperature to solidify for about 30-40 
minutes.  
Electrophoresis was carried out at 100 V at room temperature for 30 minutes in TBE 
buffer using horizontal submarine gel tanks (Mupi). Gels were visualized and imaged 
using a UV illuminator and digital imaging system (ChemiDoc XRS+ Bio-Rad). A 
quantitative DNA ladder was used to assed the size of the DNA bands: 
HyperLadder IV (Bioline). 
2.5.3 Galahad chromosome single-nucleotide polymorphism PCR 
This PCR protocol has been used to amplify DNA for pyrosequencing assays (carried 
out by collaborators at MRC Harwell) for Galahad and Galahad X TgSOD1G93A(H) mice. 
Six PCRs were run per samples with different primers pairs defined in Table 2.7. A 
10 μl master mix was used for each sample, containing: 2X REDTaq, a forward and a 
reverse primer both at a concentration of 0.2 μM, a template of 2 μl of genomic DNA 
diluted 1:10 in TE and appropriate quantity of ddH2O to reach final volume. PCR was 
carried out using Peltier Thermal Cycler PTC-225, for cycling conditions see Table 2.8.  
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Chr1 166 Mb 
Forward GTTTTACGATGTTGCATT 
Reverse AAAATTCTGGTTTTACGATGTTGCAT 
Biotinylated TCCTTAGACATAGGCAATTTACAGC 
Chr1 181 Mb 
Forward GCGTGTTAAGCCCAA 
Reverse TGCTGGGTGTGTTGAGGTTTG 
Biotinylated CCTCTGCCCAGTTCACAATGG 
Chr1 191 Mb 
Forward CTGGCAGCTGGATG 
Reverse TGAAATACTGGCAGCTGGATG 
Biotinylated GGGAAGATTTTTGCATCCTGTGAG 
Chr7 40 Mb 
Forward ACGTACCAGGTCCAGT 
Reverse AGGGTCTGCGGCTAATAG 
Biotinylated ATATACACACCTCGACCTACCAC 
Chr7 60 Mb 
Forward GAGCACATATTCAGGGT 
Reverse AATGGGAAAAATCTGTGTTGT 
Biotinylated TTGGCAGAAGCTTGACTTA 
Chr7 90 Mb 
Forward ACAACCAACCCTCTTC 
Reverse AAACAACCAACCCTCTTCA 
Biotinylated CAGTGCCAAGATGACCAG 
Table 2.7 Galahad genotyping primers. 
Step Condition  Temperature 
(°C) 
Time 
(min) 
1 denaturation   95 05:00 
2 denaturation 95 00:15 
3 annealing 60 00:30 
4 extension  72 00:15 
Cycle 44 times from step 2 
5 final extension  72 05:00 
6 storing   4 forever 
Table 2.8 Galahad PCR cycling conditions. 
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2.5.4 Quantitative real time PCR (qPCR) for SOD1 transgene copy number 
The qPCR protocol to determine transgene copy number was developed by Dr Rosie 
Bunton-Stasyshyn from the procedure published on Jackson Laboratory website: 
http://jaxmice.jax.org. Assays and the analysis were carried out by technical staff and 
used to asses copy number for the following mouse lines: TgSOD1G93A(H), Galahad and 
Galahad X TgSOD1G93A(H). 
The assay used TaqMan (Applied Biosystems) reagents and relative standard curve 
quantitation of multiplex reactions, containing one measure of the transgene (Tg) and 
one internal endogenous control (EC). 
Primers and probes defined in Table 2.9 have been purchased from Sigma-Aldrich as 
lyophilised pellets and resuspended to 100 μM. The endogenous control primers 
amplified 74 bp from exon 24 of the Apob gene on mouse chromosome 12. The 
transgene primers amplified 88 bp from intron 4 of the human SOD1 transgene. 
A 10 μl master mix was used for each sample, containing: 2X TaqMan Universal PCR 
Master Mix, 0.8 μM of EC forward and EC reverse primers, 0.1 μM of Tg forward and 
Tg reverse primers, 0.1 μM of EC and Tg probes, a template of 1 μl of genomic DNA 
diluted 1:20 and appropriate quantity of ddH2O to reach final volume. For each assay 
plate a five point standard curve was created using a known copy number DNA by 
Jackson Laboratory at the following concentrations: 100, 20, 4, 0.8 and 0.16 ng/μl. 
Each point on the standard curve was replicate six times. Three replicates were 
measured for the SOD1 Tg standard curve and three were measured for the EC 
standard curve. On each plate experimental DNA samples and two control DNAs (a 
Jackson Laboratory control and a known reduced copy number sample) were assayed 
over four replicate reactions. Applied Biosystems 7500 Software v2.0.1 was used to set 
up a standard run, using default baseline and threshold settings and the cycling 
conditions describe in Table 2.10. The delta threshold cycle (Ct) was calculated by 
subtracting the mean SOD1 Tg Ct from the mean EC Ct for each replicate group. The 
delta-delta Ct was then calculated by subtracting the replicate group delta Ct from the 
Jackson Laboratory control delta Ct. Relative quantity was then calculated as 2 to the 
power of the negative delta-delta Ct. 
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Primers and probes Sequence 5’ label 3’ label 
Endogenous control (EC) 
forward primer 
CACGTGGGCTCCAGCATT   
Endogenous control (EC) 
reverse primer 
TCACCAGTCATTTCTGCC
TTTG   
Transgene (Tg) forward 
primer 
GGGAAGCTGTTGTCCCA
AG   
Transgene (Tg) reverse 
primer 
CAAGGGGAGGTAAAAGA
GAGC   
EC probe 
CCAATGGTCGGGCACTG
CTCAA Cy5 
Black Hole 
Quencher 2 
Tg probe 
CTGCATCTGGTTCTTGCA
AAACACCA 6-FAM 
Black Hole   
Quencher 1 
Table 2.9 SOD1 transgene copy number qPCR primers and probes. 
Step Temperature 
(°C) 
Time 
(min) 
1 50 02:00 
2 95 10:00 
3 95 00:15 
4 60 01:00 
Cycle 39 times from step 3 
 
Table 2.10 SOD1 transgene copy number qPCR cycling conditions. 
2.6 SOD1 protein protocols 
2.6.1 Production and purification of wild-type and mutant SOD1 recombinant 
proteins 
Human and mouse SOD1 proteins were produced and purified from an E.coli 
expression system. All expression constructs have been generated and cloned into 
vectors by Dr Ruth Chia, Dr David Emery and Julian Pietrzyk see Appendix 8.1 for 
more details. Constructs were transformed into E.coli strain BL21 (DE3) (Novagen) by 
Dr Chia Ruth and Mark Bachelor. To confirm that constructs were successfully 
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transformed, Dr Chia Ruth and Mark Bachelor also performed a small scale protein 
expression screen on each colony. Plasmids were isolated for sequence verification to 
ensure the construct did not change during transformation. Cells were stored at -80 °C 
in 15 % glycerol (Sigma-Aldrich).  
2.6.1.1 Protein expression, cell harvesting and cell lysis  
Protein expression  
To produce a sufficient amount of proteins each construct was expressed in 9 l culture 
Figure 2.4 (a). A transformant colony was inoculated in 100 ml autoclaved 4 % Luria 
Broth in ddH2O (LB) (Sigma-Aldrich) with 50 μg/ml kanamycin (Sigma-Aldrich) and 
grown overnight at 37 °C in a shaking incubator (200 rpm) (Orbital). The following 
day nine erlenmeyer flasks (Nalgene) containing 1 l of autoclaved LB and 50 μg/ml 
kanamycin each, were inoculated with 11 ml of overnight growth. Cells were grown at 
37 °C in a shaking incubator (200 rpm) until the optical density at 600 nm (OD600) was 
between 0.6-1.0 (about 2.5 hours). Cells were then induced overnight at 37 °C in a 
shaking incubator (250 rpm) by addition of 1 ml of 1 M isopropyl-ß-D-
thiogalactopyranoside (IPTG) (Melford). 
Cell harvesting 
Harvesting of cells was performed by successive centrifugation and decantation of 
supernatant in 1 l polypropylene bottles (Nalgene) at 17000 x g for 5 minutes at 10 °C 
using a Sigma Laboratory Centrifuge 6K15 (rotor Nr. 12500) see Figure 2.4 (b). If not 
used immediately cell pellets were stored at -80 °C, otherwise they were carefully 
resuspended in 100 ml of extraction buffer: 50 mM Tris-HCl, 200 mM NaCl, 0.1 % 
Tween-20 (Sigma-Aldrich), 50 U/ml benzonase (VWR), 10 µg/ml lysozyme (Sigma-
Aldrich) at pH 8.0.  
Cell lysis 
Cells resuspended in extraction buffer were lysed by sonication (sonicator probe MS73, 
Sigma-Aldrich) with 2 minutes bursts at 45 % power repeated 3 times. The solution 
was clarified by centrifugation at 17000 x g for 30 minutes at 10 °C (rotor number: 
12166) the supernatant was discard and the pellet retained. The extraction step was 
repeated a second time using the same conditions to obtain a new pellet, Figure 2.4 (c). 
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Solubilisation  
Pellet was resuspended in 40 ml solubilisation buffer: 6 M GuHCl (Sigma-Aldrich), 
50 mM Tris-HCl, and 0.8 % 2-mercaptoethanol (Sigma-Aldrich) at pH 8.0. The 
solution was sonicated with 2 minutes bursts at 45 % power repeated 3 times and 
clarified by centrifugation at 21000 x g for 45 minutes at 10 °C. Supernatant was 
retained, pellet was resuspended again in 40 ml solubilisation buffer, and the process 
was repeated at the same conditions. The pellet was now discard and the supernatant 
was combined with the one obtained before and stored at -20 °C, see Figure 2.4 (d). 
 
Figure 2.4 SOD1 protein production. (a) Each construct was expressed in 9 l culture. (b) Bacterial 
growth was centrifuged and cell pellet retained. (c) Cell pellet was resuspended in extraction buffer. 
Suspension was sonicated centrifuged, and pellet retained. The process was repeated twice. (d) Pellet was 
resuspended in solubilisation buffer, sonicated and supernatant containing His-tagged SOD1 protein 
was retained. The process was repeated twice. 
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2.6.1.2 Affinity chromatography Ni-NTA 
Metal chelate affinity chromatography with nickel ions immobilised on a nitrilotriacetic 
acid sepharose matrix (Ni-NTA) was used to purify SOD1 proteins. A technique based 
on the high specificity bond between immobilised nickel ions and histidine residues in 
the His-tag fused to SOD1 proteins.  
Ni-NTA runs were performed at room temperature using an ÄKTA pure (GE 
Healthcare Life Sciences) chromatography system. Each purification process required 
two Ni-NTA column runs. The first run removed contaminated proteins from the cell 
lysate, the second removed the free His-tag after cleavage from SOD1. 
Column details 
A 65 ml glass column (BioRad) packed with 150 ml Ni-NTA resin (Qiagen) was used 
for protein purification. The column resin was recharged with metal ions every 6 runs, 
see protocol in section 8.3. The column was stored at room temperature in 20 % 
ethanol (VWR). 
First column 
A column was flushed with 120 ml ddH2O and equilibrated with 120 ml of filter 
sterilised buffer A: 6 M GuHCl, 10 mM Tris-HCl, 100 mM Na3PO4 (Sigma-Aldrich), 
10 mM glutathione (GSH) (Sigma-Aldrich) at pH 8.0. The column was then loaded 
with solubilised protein preparation previously defrosted and filtered, and flushed with 
120 ml of buffer A. Protein was refolded on-column overnight with a gradient of 0-
100 % filter sterilised buffer B (10 mM Tris-HCl, 100 mM Na3PO4 at pH 8.0) over 30 
column volumes. The following day protein was eluted with a gradient of 0-100 % 
filter sterilised buffer C (10 mM Tris-HCl, 100 mM Na3PO4, 2 M imidazole (Sigma-
Aldrich) at pH 7.0) over 2 column volumes. See Figure 2.5 (a). 
Dialysis and cleavage  
Protein was transferred within a dialysis membrane (Spectra pro) and dialysed at room 
temperature for 3 hours in 5 l of 25 mM Tris-HCl, 150 mM NaCl at pH 8.4 in ddH2O 
over 3 buffer changes. Concentration of the protein sample was measured using 
absorbance at OD280. His-tags were then cleaved from the protein by addition 0.1 U 
thrombin (VWR) per 1 mg of protein and CaCl2 (Sigma-Aldrich) at a final 
concentration of 2.5 mM see Figure 2.5 (b). The solution was left shaking overnight at 
room temperature to assure complete cleavage. 
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Second column 
A column was flushed with 120 ml ddH2O and equilibrated with 120 ml of filter 
sterilised buffer D: 20 mM Tris-HCl, 300 mM NaCl at pH 8.0. The protein solution 
was loaded into the column and eluted over 5 column volume of 0-100 % gradient of 
filter sterilised buffer E: 20 mM Tris-HCl, 300 mM NaCl, 2 M imidazole at pH 8.0 as 
illustrated in Figure 2.5 (c).  
After use column was cleaned with 150 ml of 6 M GuHCl, 2 M imidazole to remove 
flushed with 120 ml of ddH2O and stored in 20 % ethanol. 
Dialysis and Cu/Zn metal loading 
Protein obtained from the second column run was dialysed at room temperature for 3 
hours in 20 mM Tris-HCl, pH 8.0 over 3 buffer changes.  
Protein was then either stored at -80 °C in 15 % glycerol or metal loaded with copper 
and zinc by subsequent dialysis at room temperature. The first dialysis was carried out 
for 3 hours in 5 l of 100 mM Tris-HCl, 300 mM NaCl, 150 μM of CuSO4 (Sigma-
Aldrich) in ddH2O at pH 8.0; the second for 3 hours in 5 l of 100 mM Tris-HCl, 
300 mM NaCl, 150 μM of ZnSO4 (Sigma-Aldrich) in ddH2O at pH 8.0. Finally the 
protein was dialysed in storage buffer containing 20 mM Tris-HCl in ddH2O at pH 7.5, 
snap freeze and stored at -80 °C.  
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Figure 2.5 SOD1 protein purification. (a) Solubilised protein preparation was loaded to the column. 
Contaminates were removed and protein refolded overnight. His-tagged SOD1 protein was collected. 
(b) Overnight cleavage of the His-tags from SOD1 protein. (c) Cleaved solution was loaded to the 
column, only free His-tags attached to the resin and SOD1 protein was collected. 
2.6.2 Preparation of animal tissues for protein investigation 
2.6.2.1 Brains preparation specific for Sod1D83G experiments  
Frozen mouse brains collected as described in section 2.4.1 were rinsed in PBS and 
weighed. Brains were homogenised using a TissueRuptor (Qiagen) in ice cold lysis 
buffer 0.1 M Tris-HCl at pH 7.4, 0.5 % Triton X-100, 1 mM EDTA and complete 
EDTA-free protease inhibitors (Roche) to make a 10 % weight/volume solution. 
Crude homogenates were kept on ice for 20 minutes and centrifuged at 14000 x g for 
10 minutes at 4 °C. Supernatants were collected and stored at -80 °C. 
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2.6.2.2 Spinal cord preparation specific for transmission experiments  
Frozen mouse spinal cords collected as described in section 2.4.1 were homogenised 
using TissueRuptor in ice cold PBS to make a 10 % weight/volume solution. Crude 
homogenates were kept on ice for 20 minutes, filtered using a syringe with a 20 gauge 
needle and stored at -80 °C. 
2.6.3 Spectrophotometric protein concentration measurements  
2.6.3.1 Absorbance  
While performing affinity chromatography (2.6.1.2) protein concentration of samples 
was estimated using absorbance. One ml of protein sample diluted 5 times was 
measured for absorbance at 280 nm using NanoDrop® ND-1000 Spectrophotometer. 
The concentration for SOD1 was calculated using an experimentally determined 
extinction coefficient (εSOD1) at 280 nm of 10800 M-1cm-1 (Choi et al., 2005) 
calculated using the following formula: 
SOD1 concentration (M) = OD280 / εSOD1 
2.6.3.2 Colorimetric assays 
Two different type of colorimetric protein assay kits with different reactivity to 
detergents have been employed to measure protein concentration: Bradford assay (Bio-
Rad) and DC protein assay (Bio-Rad). 
Bradford assay 
This assay was used, according to manufacturer’s instructions, to determine the 
concentration of solubilised proteins towards the addition of an acidic dye. A 
differential colour change of the day occurred in response to different protein 
concentration. Absorbance measured at 595 nm with a 96 well microplate reader 
(Sunrise, Tecan) and comparison to a standard curve provided a relative quantification 
of protein concentration. 
DC protein assay 
The DC protein assay was used, according to manufacturer’s instructions, to measure 
the relative concentration of solubilized protein. The assay was based a reaction of the 
protein with alkaline copper tartrate solution followed by the reduction of the folin 
reagents with the copper treated-protein which produce several reduced species with a 
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characteristic blue colour. Measurement of the absorbance at 750 nm using a 96 well 
microplate reader and comparison with a standard curve provided quantification of the 
relative protein concentration. 
2.6.4 Polyacrylamide gel electrophoresis  
Gel electrophoresis and blotting were carried out using XCell SureLock Mini-Cell 
Electrophoresis System from Life Technologies. All types of precast polyacrylamide 
gels, buffers and protein standards have been also purchased from Life Technologies 
unless specified differently. Gels and blots were quantified using ImageJ software.  
2.6.4.1 Coomassie blue staining  
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
For coomassie blue staining proteins were separated by polyacrylamide gels 
electrophoresis on 16 % Tris-glycine precast gels with 1X Tris-glycine SDS running 
buffer (National Diagnostic). Prior to running, samples were mixed with 1X Tris-
glycine SDS sample buffer, 2 % 2-mercaptoethanol, heated at 100 °C for 2 minutes and 
loaded onto the gel. Electrophoresis was performed at room temperature at 125 V for 
90 minutes. A BSA (Sigma-Aldrich) control of a known concentration and SeeBlue 
plus2 protein standard were include in all experiments.  
Proteins visualisation 
Proteins were visualised by soaking the gel for 1 hour in coomassie brilliant blue 
solution containing: 10 % acetic acid (VWR), 60 mg / l of Coomassie Blue R (Sigma-
Aldrich) in ddH2O. Gels were destained in ddH2O until they become colourless and 
only protein bands were visible. All gels were imaged using an hp scanner. For protein 
concentration analysis the proteins of interest were compared to the BSA control. 
2.6.4.2 Western blot 
SDS-polyacrylamide gel electrophoresis 
For reducing and denaturing western blots, proteins were separated by polyacrylamide 
gels electrophoresis on 4-12 % NuPAGE Bis-Tris precast gels with 1X MES running 
buffer. Prior to running, samples to a final concentration of 30 µg were mixed with 2X 
LDS sample buffer, 2 % 2-mercaptoethanol and heated at 70 °C for 10 minutes. 
Electrophoresis was performed at room temperature at 200 V for 35 minutes, SeeBlue 
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ladder was used in all experiments in order to identify the molecular weight of the 
proteins of interest. 
Transfer 
Proteins were transferred by electro-blotting from the gel to a polyvinylidene difluoride 
(PVDF) membranes (Millipore). Each PVDF membrane was pre-wet in methanol 
(VWR) at least for 2 minutes before use. Electro-blot was performed at room 
temperature at 35 V for 2 hours using a transfer buffer made up with 1X Tris-Glycine 
Electroblotting buffer (National Diagnostic), 10 % methanol. 
Blocking  
The membrane was blocked in blocking solution (Odyssey blocking buffer (PBS) 
Licor) for 1 hour at room temperature. 
Immunodetection of SOD1  
The membrane was incubated overnight at 4 °C with SOD-100 primary antibody 
(Enzo) (1:2000) and anti-β-actin (Sigma-Aldrich) (1:10000) in 50 % blocking solution, 
50 % PBS with 0.05 % Tween (PBS-T). The unbound antibodies were removed by 3 
washes of 5 minutes in PBS-T. Membrane was then exposed for 2 hours in the dark to 
infrared secondary antibodies: IRDye Licor anti-mouse (1:10000) and IRDye Licor 
anti-rabbit (1:10000) in 50 % blocking solution, 50 % PBS-T. The membrane was 
washed 2 times for 5 minutes with PBS-T and 1 time for 5 minutes with PBS prior 
imaging using Odyssey Classic from Licor. For quantification proteins were normalized 
for β-actin internal control. 
2.6.4.3 Native western blot 
Native-polyacrylamide gel electrophoresis 
For native western blots proteins were separated by polyacrylamide gels electrophoresis 
on 3-12 % NativePAGE Bis-Tris precast gels in non-denaturing and non-reducing 
conditions. Samples to a final concentration of 30 µg were mixed with 1X 
NativePAGE sample buffer and loaded onto the gel. Electrophoresis was performed at 
room temperature in two stages. In the first stage the outer chamber of the 
electrophoresis tank was filled with 600 ml of 1X NativePAGE running buffer and the 
inner chamber was filled with 200 ml of dark blue cathode buffer (1X NativePAGE 
running buffer, 1X NativePAGE cathode buffer additive). The gel was electrophoresed 
for 40 minutes at 120 V until the dye front migration was 1/3rd of the gel. For the 
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second stage the inner chamber buffer was substituted with 200 ml of light blue 
cathode buffer (1X NativePAGE running buffer, 0.1X NativePAGE cathode buffer 
additive). Proteins were resolved on the gel for another hour at 120 V. NativeMark 
unstained protein standard was used in all experiments. 
Transfer 
Proteins were transferred to a PVDF membrane by electro-blotting. The membrane 
was pre-wet in methanol at least for 2 minutes and the gel was soaked for 15 minutes 
in 50 ml of 0.1 % SDS in ddH2O. Electro-blotting was performed at room temperature 
at 35 V for 2 hours using 1X NuPAGE transfer buffer. 
Blocking  
To prevent diffusion of proteins, the membrane was soaked in 20 ml of 8 % acetic acid 
for 15 minutes, washed with ddH2O and air dried for at least 30 minutes. The 
membrane was then reactivated in methanol for 2 minutes rinsed in ddH2O and 
blocked in Odyssey blocking solution for 1 hour at room temperature. 
Immunodetection of SOD1  
Three different antibodies against SOD1 have been employed in native western blot 
experiments, concentrations and secondary antibodies details are given in Table 2.11. 
Membrane was incubated overnight at 4 °C with primary antibody diluted in 50 % 
blocking solution, 50 % PBS-T. The following day unbound antibodies were removed 
by 3 washes of 5 minutes in PBS-T. Membrane was incubate for 2 hours with 
horseradish peroxidase (HRP) conjugated secondary antibody diluted in 50 % blocking 
solution, 50 % PBS-T and was washed 2 time for 5 minutes with PBS-T and 1 time for 
5 minutes with PBS. Enhanced chemiluminescent substrate (ECL) (Pierce) was applied 
to each membrane for 5 minutes to detect HRP. In the dark room photo-films were 
exposed to a membrane and developed. Exposure time varied as needed for optimal 
detection.  
Primary antibody  Secondary antibody  
SOD-100 (Enzo) 1:1000 Goat anti-rabbit IgG-HRP (DAKO) 1:5000 
SEDI (Rakhit et al., 2007) 1:1000 Goat anti-rabbit IgG-HRP (DAKO) 1:5000 
USOD (Kerman et al., 2010) 1:100 Goat anti-rabbit IgG-HRP (DAKO) 1:5000 
 
Table 2.11 Primary and secondary antibodies for native blots. 
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2.6.4.4 SOD1 activity in-gel assay 
To perform an in-gel assay for SOD1 activity quantification, 30 μg of brain 
homogenates were resolved using 3-12 % NativePAGE Bis-Tris precast gels in 1X 
NativePAGE running buffer. Samples were mixed with 2X NativePAGE sample 
buffer and electrophoresed at 120 V for 50 minutes. The gel was then soaked for 45 
minutes in the dark with 50 mM potassium phosphate (Sigma-Aldrich) at pH 7.8, 
275 µg/ml nitro blue tetrazolium (Sigma-Aldrich), 65 µg/ml riboflavin (Sigma-
Aldrich), and 3.2 µl/ml TEMED (Sigma-Aldrich). The gel was rinsed with ddH2O and 
developed by exposure to light. 
2.6.5 Protein characterisation using circular dichroism (CD) 
Secondary structure of purified SOD1 proteins was determined by circular dichroism 
(CD) spectroscopy. Prior to analysis, SOD1 proteins were dialysed over 3 buffer 
change in 20 mM sodium phosphate (Sigma-Aldrich) at pH 7.5. CD spectra at far-UV 
250-190 nm was performed with a J-715 Circular Dichroism Spectropolarimeter 
(Jasco) using 0.1 mm path length circular cuvette. Data were collected at a stop 
resolution of 1 nm, a scan speed of 50 nm/minute, and 1 second response time. Each 
protein sample was measured over 10 accumulations and corrected against storage 
buffer. Protein concentrations were approximately 1.0 mg/ml, and CD measurements 
were converted to units of molar ellipticity ([θ]). Corrections and processing were 
performed using the Jasco Standard Analysis Software (Jasco). 
2.6.6 Conversion of SOD1 proteins into fibrils in vitro 
To form amyloid fibrils each recombinant protein was diluted to a final protein 
concentration of 10 µM in filtered 20 mM Tris acetate buffer (Sigma-Aldrich) with 
0.5 M GuHCl at pH 3.0, containing a final concentration of 10 µM Thioflavin-T (ThT) 
(Sigma-Aldrich). The assay was carried out on a 96 well plate with transparent flat 
bottom, prearranged with 4 Hybaid Ribolyser beads per well. For each sample 200 µl 
of reaction mixture was pipetted into 6 wells and the plate was covered with optically 
corrected adhesive film. The plates was incubated with continuous shaking at 830 rpm 
at 37 °C using GrantBio plate incubator shaker. The kinetics of fibril formation were 
monitored daily by measuring fluorescence emission at 485 nm when excited at 
450 nm using a fluorimeter plate reader (Infinite M1000 PRO, Tecan) with i-controlTM 
software.  
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The lag phase of amyloid formation was determined by fitting the time-dependent 
changes in the fluorescence of ThT (F) overtime of the reaction (t) to using the 
equation: 
F = A + B / (1 + exp [ k * (tm - t)]) 
In the equation above (A) is the base lave of florescence during the lag phase, (B) 
difference between final fluorescence level at plateau and the initial level during the lag 
phase, (k) is the rate constant of fibril growth (h-1), and (tm) is the observed time at 
transition midpoint. The lag time (tl) of fibril formation was calculated as: tl = tm – 2 / k 
(Chia et al., 2010) . 
2.7 Meta-analysis on SOD1 activity in SOD1-ALS affected patients 
Data for meta-analysis were collected by searching Pubmed, ALSoD and Medline 
electronic databases between 1993 and April 2015. Reference lists from relevant articles 
and from all papers obtained were also checked. The search terms used are listed below 
and they have been employed both alone and in combination with each other. 
Search terms: amyotrophic lateral sclerosis, SOD1 enzymatic activity, fALS, loss of 
function, red blood cells, fibroblasts, lymphoblast cells lines, in-gel activity assay. All 
names of SOD1 mutations have also been used as search terms in combination with 
the words “enzymatic activity” for example: “SOD1 G93A enzymatic activity”. 
Original papers but no abstracts or reports from meetings were considered. Studies 
were grouped according to the type of data presented and examined for sources and 
type of SOD1 enzymatic activity measurements taken. Only articles where SOD1 
activity was assessed from red blood cells, fibroblasts and lymphoblast cells lines of 
fALS patients were taken into consideration for analysis. 
2.8 Statistical analysis  
Statistical analysis was carried out using IBM SPSS, GraphPad Prism 6 and R with the 
exception of Chi Square test for calculation of inheritance ratios that was carried out 
using Graph Pad online http://graphpad.com/quickcalcs/chisquared1.cfm. 
103 
 
Chapter 3 SOD1 loss of function in SOD1-amyotrophic 
lateral sclerosis 
3.1 Introduction 
In 1993 Rosen and colleagues identified the first ALS causative mutations, 11 missense 
substitutions spread throughout the SOD1 gene. This result together with the finding 
of loss of dismutase activity in ALS patients, initially suggested a loss of function as a 
disease causative mechanism (Deng et al., 1993; Rosen et al., 1993). 
However, in 1994 analysis of a mutant SOD1 transgenic mouse model (TgSOD1G93A) 
gave the first indication for a gain of function mechanism as the cause of ALS (Gurney 
et al., 1994). TgSOD1G93A mice indeed exhibited an increased SOD1 activity together 
with a progressive adult onset motor phenotype with loss of lower MNs. 
Subsequent data from human and mouse studies supported the hypothesis that ALS 
arises from a gain of function mechanism. For example, in humans SOD1 dismutase 
activity did not correlate with aggressiveness of clinical features (Ratovitski et al., 1999). 
Mice lacking the Sod1 gene (Sod1-/-) had no SOD1 activity and did not display ALS-like 
phenotypes (Reaume et al., 1996). Moreover most of the transgenic mouse models 
overexpressing mutant human SOD1 (Joyce et al., 2011) showed an increased SOD1 
activity and loss of MNs.  
The idea that a loss of function played a role in the disease was abandoned without 
question in 1998, when Bruijn and colleagues compared the survival of a transgenic 
SOD1 mouse model (TgSOD1G85R) on a normal wild-type background and on a Sod1-/- 
background. The two mouse lines showed no change in survival, demonstrating that 
survival was influenced by a gain of function mechanism while was independent from 
mouse SOD1 loss of function (Bruijn et al., 1998).  
Further studies on SOD1-ALS together with the identification of other ALS causative 
genes confirmed the undeniable presence of a still unknown toxic gain of function as 
cause of this disease. Several mechanisms by which this gain of function might occur 
have been proposed and reviewed (Ilieva et al., 2009; Rothstein, 2009; Turner and 
Talbot, 2008). However, recently additional investigations on transgenic SOD1 mice 
and Sod1-/- mice pointed to the possibility that a loss of dismutase activity may 
contribute to SOD1-fALS. 
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3.2 Aim 
The aim of the work described in this chapter was to re-examine over twenty years of 
human and mouse research on SOD1 dismutase activity to see if SOD1 loss of 
function may play a modifying role in SOD1-ALS. 
In particular published data regarding SOD1 enzymatic activity of SOD1-ALS patients, 
and phenotypic data of Sod1 knockout mice were analysed and reviewed. 
3.3 Results 
3.3.1 SOD1 loss of function in SOD1-fALS patients 
Published papers about SOD1 enzymatic activity measured in SOD1-fALS patients 
were collected and reviewed as described in section 2.7. 
3.3.1.1 Methods of measuring SOD1 dismutase activity 
In mammals there are three unique and highly compartmentalized superoxide 
dismutases: SOD1 localised in the cytoplasm, SOD2 (Mn-SOD) localised in the 
mitochondrial matrix (Fridovich, 1986; Zelko et al., 2002) and SOD3 (Fe-SOD) which 
is mainly extracellular (Marklund et al., 1982). The presence of other two antioxidant 
enzymes similar to SOD1 complicates the measures of its activity. 
Two methods have been employed to assess SOD1 activity in patients: the “activity 
assay” and the “gel assay”. The activity assay (explained in Table 3.1) measures the total 
activity of the three dismutase enzymes and then subtracts SOD2 and SOD3 activity to 
obtain a measure of SOD1 activity alone. In the gel assay the three proteins are 
separated by electrophoresis and only the band corresponding to SOD1 is used to 
determine its activity. 
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Activity assay Xanthine-xanthine oxidase is added to samples to generate 
superoxide anions (O2-), and then a chromogen is used as an 
indicator of O2- production. In the presence of SOD, O2- 
concentration is reduced, resulting in a decreased colorimetric 
signal. However, all three SOD isoforms contribute to the 
measure of activity, therefore SOD1 activity is obtained indirectly 
by subtraction of SOD2 and SOD3 from total SOD activity. This 
is achieved by running a parallel assay with the addition of 
potassium cyanide which preferentially inhibits SOD1 (Roe et al., 
1988). 
Gel assay Proteins are separated by electrophoresis using a native gel. The 
gel is stained using a solution of NBT and riboflavin (a source of 
superoxide anions after exposure to light). When the gel is 
exposed to light the superoxide anions interact with NBT, 
reducing the yellow tetrazolium within the gel to a blue precipitate 
and staining the gel blue. However, SOD inhibits this reaction, 
resulting in colourless bands where SOD is present. 
Quantification of activity is inferred by measuring the intensity of 
the bands at the correct molecular weight using a digital software 
(Weydert and Cullen, 2010). 
Table 3.1 Methods of measuring SOD1 activity. 
3.3.1.2 Intrinsic and overall SOD1 activity 
In the literature SOD1 dismutase activity was measured either outside (intrinsic 
activity) or within a biological system (overall activity). 
The intrinsic activity of SOD1 was assessed using SOD1 recombinant proteins 
normalised for their quantity. This particular measure reflects only the enzymatic 
efficiency of the SOD1 protein. 
Conversely the overall activity was calculated within biological samples and normalised 
to the tissue quantity. This measure therefore reflects the amount of activity present in 
a biological contexts and takes into account known and unknown factors that affect 
the quantity, biological availability and functionality of SOD1. The intrinsic activity 
itself is one of these factors, others are: SOD1 mRNA half-life, SOD1 protein half-life, 
correct folding of SOD1, Cu++ loading of SOD1 and other post-translational 
modifications (Wilcox et al., 2009).  
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3.3.1.3 SOD1 dismutase activity is reduced in SOD1-fALS patients 
Data of SOD1 intrinsic activity were found only for eight mutant recombinant 
proteins, see Figure 3.1. Intrinsic activity values ranged between 0 % and 150 % of 
human wild-type SOD1 activity, and did not show any correlation with clinical aspects 
of the disease (Borchelt et al., 1994; Ratovitski et al., 1999). 
SOD1 overall activity instead was more frequently measured from patients’ red blood 
cells, fibroblasts and lymphoblast cell lines. Data from 48 different SOD1-fALS 
mutations were found in literature (Figure 3.1 and Table 3.2). The majority of them 
had a reduced overall SOD1 activity (Table 3.2), with a remarkable average loss of 
58 % (± 17, S.D.) of normal values (Figure 3.1). 
These results were consistent and more homogenous than measures of intrinsic activity 
considering that they were produced by different laboratories and that there is a 
naturally occurring variation in activity assessed in blood samples (Borchelt et al., 1994; 
de Lustig et al., 1993; Robberecht et al., 1994). Only in two of the 48 mutations SOD1 
overall activity was found to be normal or slightly reduced: D90A expressed both in 
heterozygosity and homozygosis and L117V when expressed in heterozygosity. Further 
literature investigation on these two mutations revealed some atypical characteristics 
(Table 3.3) and suggested that they might have a propensity to aggregate which is 
sufficient to start the disease process but not sufficient to determine misfolding and 
loss of SOD1 activity in the peripheral tissues.  
No correlation was found between intrinsic and overall SOD1 activity in the eight 
mutations where activity was assessed both from recombinant proteins and in patients. 
The G37R mutation was the most striking example having an overall activity of 40 % 
and an intrinsic activity of 150 % compared to wild-type. As mentioned the intrinsic 
activity is considered to be only one of the many factors that contribute to the overall 
activity, other determinants such as stability of mutant SOD1 proteins need to be 
investigated to account for this difference. Protein half-life for instance is variable 
among SOD1 mutants, but consistently reduced compared to the wild-type protein 
(Sato et al., 2005). A study that combined protein half-life and intrinsic SOD1 activity 
of six SOD1-fALS mutations predicted overall activity of 50 % of normal levels 
(Borchelt et al., 1994). This result is in accordance with Figure 3.1 and with other 
findings (Birve et al., 2010; Deng et al., 1993). Of note most of the data collected in 
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this meta-analysis are measures of SOD1 activity from patients’ red blood cells, which 
are a particularly reliable system for the detection of protein half-life changes due to 
their lack of active protein synthesis (Broom et al., 2008). 
SOD1 activity was found to be reduced to similar levels both in red blood cells and 
post mortem CNS tissues, the similarity was even more striking when compared within 
the same subset of patients (Bowling et al., 1993; Browne et al., 1998; Jonsson et al., 
2004; Rosen et al., 1994; Watanabe et al., 1997b). 
 
Figure 3.1 Diagram of human SOD1 mutations dismutase activity in the current literature. 
Measurements from patients carrying 48 SOD1 fALS mutations between 1993 and April 2015; original 
references are cited in Table 3.2. All intrinsic activity measures fall below 100% of controls activity. 
Three mutations found in homozygous individuals are shown on the right hand side of the figure. Red 
circles show measures of intrinsic activity where these are known. We note that all mutations shown 
here are familial, not sporadic, and have supporting data indicating they are causative of ALS (Table 3.2). 
Where more than one publication reports overall activity for an individual mutation the value from the 
report with the highest sample size has been plotted. Heterozygous (Het); homozygous (Hom) (Saccon 
et al., 2013). 
SOD1 mutation % of SOD1 activity Reference 
A4V 57.8 % (Bowling et al., 1993) 
A4V 45 % intrinsic activity (Borchelt et al., 1994) 
C6F 25.3 % (Morita et al., 1996) 
C6S 73.5 % (Brotherton et al., 2011) 
C6S 70 % intrinsic activity (Marin et al., 2012) 
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SOD1 mutation % of SOD1 activity Reference 
V7E 69.1 % (Hirano et al., 1994) 
G12R 80 % (Penco et al., 1999) 
V14G 57.2 % (Andersen et al., 1997) 
G37R 40 % (Borchelt et al., 1994) 
G37R 150 % intrinsic activity (Borchelt et al., 1994) 
L38V 35 % (Robberecht et al., 1994) 
G41D 47 % (Fujii et al., 1995) 
G41D 49 % intrinsic activity (Borchelt et al., 1994) 
G41S 73 % (Tsuda et al., 1994) 
H43R 42.7 % (Rosen et al., 1993) 
H46R 75.7 % (Abe et al., 1996) 
c.240-7T>G 46. % (Birve et al., 2010) 
G72C 54.7 % (Stewart et al., 2006) 
G72S 55 % (Orrell et al., 1997a) 
D76Y 50 % (Andersen et al., 1997) 
D76V 54.9 % (Segovia-Silvestre et al., 2002) 
L84F * 80.5 %; 69.8 % (Curti et al., 2002) 
L84V 74.8 % (Abe et al., 1996) 
G85R 39.5 % (Deng et al., 1993) 
G85R 0 % intrinsic activity (Borchelt et al., 1994) 
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SOD1 mutation % of SOD1 activity Reference 
A89V 83.5 % (Jacobsson et al., 2001) 
D90V 41 % (Morita et al., 1996) 
G93A 35.8 % (Deng et al., 1993) 
G93A 102 % intrinsic activity (Chia et al., 2010) 
G93D 63.2 % (Bowling et al., 1993) 
G93R 31.7 % (Orrell et al., 1997b) 
G93V 54.2 % (Orrell et al., 1997b) 
E100G 75 % (Calder et al., 1995) 
I104F 43.1 % (Abe et al., 1996) 
S105L 58.4 % (Jacobsson et al., 2001) 
G112T 66.6 % (Esteban et al., 1994) 
I112T 47.3 % (Bowling et al., 1993) 
I113T 50.6 % (Orrell et al., 1997b) 
I113T 65 % intrinsic activity (Borchelt et al., 1994) 
G114A 52.4 % (Jacobsson et al., 2001) 
D125H 52.8 % (Orrell et al., 1997b) 
L126delTT 35 % (Nakashima et al., 1995) 
L126delTT 0 % intrinsic activity  (Zu et al., 1997) 
G127insTGG 60 % (Andersen et al., 1997) 
E132insTT 46.3 % (Orrell et al., 1997b) 
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SOD1 mutation % of SOD1 activity Reference 
S134N 74.4 % (Watanabe et al., 1997a) 
N139H 60.8 % (Nogales-Gadea et al., 2004) 
N139K 53.5 % (Pramatarova et al., 1995) 
A140G 70 % (Naini et al., 2002) 
V148G 35.7 % (Deng et al., 1993) 
V148I 57.7 % (Abe et al., 1996) 
I149T 59.5 % (Pramatarova et al., 1995) 
G27delGGACCA 
heterozygous 
70 % (Zinman et al., 2009) 
G27delGGACCA 
homozygous 
50 % (Zinman et al., 2009) 
D90A heterozygous 82.5 % (Andersen et al., 1995) 
D90A homozygous 93 % (Andersen et al., 1995) 
L117V heterozygous 100 % (Synofzik et al., 2012) 
L117V homozygous 66.8 % (Synofzik et al., 2012) 
L126S heterozygous 75 % (Takehisa et al., 2001) 
L126S homozygous 25 % (Takehisa et al., 2001) 
Table 3.2 SOD1 overall and intrinsic activity of SOD1-fALS patients in the current literature. 
(Figure 3.1). SOD1 overall activities, unless intrinsic where shown. The overall and intrinsic activity of 
each SOD1 mutations is represented with its corresponding reference. In case where the activity of a 
given SOD1 mutant was determined by more than one study, the one with the greatest number of 
clinical samples was reported (Saccon et al., 2013). * 80.5 % is the mean of percentage activity compared 
to wild-type SOD1, as determined in 5 patients carrying the L84F mutation (one was asymptomatic). For 
3 of these patients the SOD1 activity has been measured 3 times at one year intervals and the average 
activity for these 3 measurements is 69.8 %. 
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 D90A L117V 
Presence of misfolded SOD1 
in cells derived from patients 
Not present Not present 
Frequency of homozygosis Majority of patients 1 in 4 patients 
Penetrance in heterozygosity Low Low 
Disease progression Slow Slow 
Table 3.3 Characteristic of D90A and L117V mutations. 
3.3.1.4 Dismutase activity reduction might be enhanced in motor neurons  
The level of SOD1 activity in patients’ motor neurons and other specific cell types, 
known to be affected in ALS, is unknown. This is mainly due to technical difficulties in 
the measurement and availability of post-mortem tissues. However, studies on SOD1 
mRNA, aggregation and oxidative stress suggests that dismutase activity may be 
reduced in motor neurons. 
In normal conditions the half-life of SOD1 mRNA in brain and spinal cord tissues was 
found to be prolonged after formation of complexes with ribonucleoproteins. Though, 
in the presence of SOD1 mutations this complex formation was impaired, reducing the 
half-life of mutant SOD1 mRNA preferentially in the central nervous system of 
SOD1-fALS patients (Ge et al., 2006). 
Other indirect evidence that SOD1 activity might be reduced in specific cells types 
comes from aggregation studies. For example a reduction of SOD1 activity was 
detected in cells where SOD1 G93A and amyloid-β were co-expressed, suggesting that 
aggregation triggers reduction of dismutase activity (Yoon et al., 2009). Moreover in 
mice overexpressing the human wild-type SOD1 protein, SOD1 aggregates were found 
in brain and spinal cord but not in liver and muscle samples. Interestingly the levels of 
the SOD1 protein were similarly increased among the four different tissues; but the 
dismutase activity was increased accordingly only in liver and muscle and not in brain 
and spinal cord, suggesting a link between aggregation and loss of SOD1 enzymatic 
activity (Graffmo et al., 2013). Even if the dismutase activity is retained in SOD1 
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aggregates, it is unknown whether they are able to accomplish the normal SOD1 
function when SOD1 dimer is correctly targeted to the appropriate cell compartments. 
Furthermore, misfolding and aggregation are a hallmark of SOD1-fALS (Jonsson et al., 
2008), and have been recently found also in SOD1-sALS patients (Bosco et al., 2010). 
All these findings from aggregation studies taken together make a dominant negative 
loss of function in SOD1-ALS feasible. 
Lastly oxidative stress it is known to induce monomerisation of SOD1 making it 
dismutase inactive (Ezzi et al., 2007; Khare et al., 2004; Rakhit et al., 2004; Wilcox et 
al., 2009). This mechanism might be particularly prominent in motor neurons since 
susceptibility to oxidative stress was proven to be more prominent in MNs than in 
other cells (Barber and Shaw, 2010). 
In conclusion these findings on tissue specific changes in SOD1 protein and SOD1 
mRNA suggest that dismutase activity might be lower in motor neurons and other 
affected cells compared to that assessed in patients’ red blood cells. Further, SOD1 
overall activity is consistently reduced in SOD1-fALS patients compared to wild-type 
controls. This is caused by changes in protein activity and protein half-life, and possibly 
there is also a tissue-specific dismutase reduction in affected neurons. 
3.3.2  SOD1 loss of function in Sod1 knockout mice 
Sod1 knockout mice have been extensively employed in SOD1-ALS research even if 
they do not model ALS disease. To get more insight on the role of SOD1 loss of 
function in SOD1-ALS, historical and more recent papers about these mice have been 
collected and reviewed using the criteria described in section 2.7. 
Up to now five Sod1 knockout mouse lines have been published (Table 3.4), all were 
generated by homologous recombination in mouse embryonic stem cells. In the five 
models, different regions of the Sod1 gene are deleted, ranging from a single exon to 
the entire genomic sequence. Despite the presence of different Sod1 gene regions, the 
five mouse lines present a strikingly similar phenotype and they have been compared in 
several papers (Huang et al., 1997; Kondo et al., 1997; Kostrominova, 2010). 
Importantly SOD1 protein is undetectable in all homozygous mice and SOD1 
dismutase activity is either absent or very low; detection of low activity levels may be 
caused by the presence of alternative scavenging enzyme or assay background (Reaume 
et al., 1996). Another example that confirms similarity among these mouse lines is the 
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development in three of them of an accelerated age-related muscle denervation 
(Kostrominova, 2010).   
Of note the majority of the studies collected for this meta-analysis have been 
conducted using Sod1 knockout mice on a congenic C57BL/6J background, making 
results from different laboratories comparable. 
Since the first studies on Sod1-/- mice it was clear that these animals do not develop MN 
degeneration. In 1996 Reaume and colleagues did not find a reduction in the number 
Sod1-/- MNs up until 4 months of age. However, they detected a higher number of 
small neurons and astrocytes from spinal cord tissues (Reaume et al., 1996). Later 
papers confirmed the absence of MN loss also at 6, 9 and 17 months of age and ruled 
out the presence of other hallmarks of ALS such as vacuolation and chromatolysis in 
mice of 4 and 18 months of age (Fischer et al., 2012; Flood et al., 1999). Also 
microgliosis and ubiquitinated protein accumulation in MNs were excluded, but mild 
astrocytosis was found at 4 and 18-months (Fischer et al., 2012).  
Even though Sod1-/- mice do not have motor neuron loss they develop a series of 
phenotypes, some of which relevant to ALS. Also Sod1+/- have been shown to have 
several neuronal dysfunction. Therefore investigating the phenotype of both Sod1 
knockout homozygous and heterozygous mice might be crucial to elucidate the role of 
SOD1 loss of function. 
Mouse line Reference 
Sod1tm1Cpe (Reaume et al., 1996) 
Sod1tm1Cje (Huang et al., 1997) 
Sod1tm1Lem (Matzuk et al., 1998) 
Sod1tm1Ysh (Ho et al., 1998) 
Sod1tm1Dkd (Yoshida et al., 2000) 
Table 3.4 Published Sod1 knockout mouse lines. 
3.3.2.1 Absence of Sod1 causes a progressive adult-onset motor 
axonopathy in Sod1-/- mice 
Several studies show that homozygous Sod1 knockout mice develop an adult onset 
motor axonopathy, and other phenotypes relevant to ALS disease. 
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Behavioural data 
Behavioural analysis from different laboratories showed that even if at birth Sod1-/- 
mice were indistinguishable from wild-type littermates, with age they developed several 
neuromuscular deficits. All behavioural data collected are gathered together in Table 
3.5. 
Age 
(months) 
Phenotype Reference 
3 Decrease in voluntary wheel running  (Muller et al., 2006) 
5 
Body weight reduced by 20 % compared to 
wild-type littermates * (Reaume et al., 1996) 
9 Progressive deficit in rotarod  (Flood et al., 1999) 
9 Progressive deficit in stride-length analysis  (Muller et al., 2006) 
12 Deficit in grip-strength  (Fischer and Glass, 2010) 
12 Presence of tremors  (Fischer and Glass, 2010) 
Table 3.5 Sod1-/- mice behavioural phenotypes. * The light body weight detected in these mice might 
be explained by an impairment in intestine lipid metabolism (Kurahashi et al., 2012) and by a reduction 
lipoprotein secretion in the liver (Uchiyama et al., 2006). 
Neurophysiological data 
Neurophysiological investigations also showed the presence of ALS related 
phenotypes, revealing a clear muscle denervation as well as deficits in motor axons and 
functional motor units. Firstly direct stimulation of muscles showed a reduction in 
muscle strength from 8 months of age. While, muscle strength generated by nerve 
stimulation became increasingly worse compared to measures from direct muscle 
stimulation suggesting a progressive deficit in innervation (Larkin et al., 2011). 
Secondly a progressive reduction in motor unit number was detected starting at 3-
months of age (Shefner et al., 1999). Finally at 6 months of age analysis of nerve 
conduction velocity and latency performed on sensory and mixed nerves, revealed a 
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reduction only where a motor component was present suggesting a deficit in the largest 
motor axons (Flood et al., 1999). 
Axonal damage and neuromuscular junctions denervation 
Investigating neuromuscular junctions (and early pathological disease target in SOD1-
fALS mouse models) revealed a progressive denervation of both fast and slow twitch 
muscles (Fischer et al., 2012; Flood et al., 1999; Larkin et al., 2011). The pattern was 
found to be more aggressive in fast twitch muscles with a reduction of TA muscle 
innervation to 70 % of endplates by 4 months of age, and to 34 % by 18 months of age 
(Fischer et al., 2012; Jang et al., 2010). These results highlighted that as occurs in ALS 
patients and mouse models of fALS, functional SOD1 is also crucial for maintenance 
of motor axons and their terminals in Sod1-/- mice. 
Muscle pathology is secondary to denervation  
Analysis of Sod1-/- muscles showed a progressive loss of muscle mass, and the presence 
of angular muscle fibres (an indicator of denervation). Specifically gastrocnemius mass 
was reduced by 20 % at 3 months of age and hind limb muscles were reduced by 40 % 
at 20 months of age (Jang et al., 2010; Larkin et al., 2011; Muller et al., 2006). No 
reduction was detected in other organs such as liver, heart and kidney (Muller et al., 
2006). Angular muscle fibres were found to be present starting at 2 months of age and 
increased overtime (Flood et al., 1999). Furthermore at 8 months massive reduction in 
fibre number was detected preferentially in fibres innervated by large motor neurons 
(Larkin et al., 2011; Reaume et al., 1996). The muscle profile of Sod1-/- mice was found 
to be similar to the one described for transgenic mouse models of SOD1-fALS (Frey et 
al., 2000; Kennel et al., 1996) and suggested that muscle pathology is secondary to 
axonal impairment. Confirmation of this hypothesis came from a study were Sod1-/- 
mice were crossed with transgenic mice expressing the Sod1 gene in the CNS but not in 
muscles. Although Sod1 was not present in muscles of double mutant mice, the muscle 
pathology was fully rescued in these animals (Flood et al., 1999). Other evidence 
proving that muscle denervation is secondary to axonal damage came from 
examination of the redox state of the tibial nerve and gastrocnemius muscle in 4 
months old Sod1-/- mice, showing a selective involvement of the nerve (Fischer et al., 
2012). These results taken together indicate that in Sod1-/- mice muscle changes are 
secondary to denervation. 
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3.3.2.2 Motor neurons of Sod1-/- mice have an increased vulnerability to 
stress 
The selective involvement of MNs and their susceptibility to stress are a hallmark of 
ALS. Even if Sod1-/- do not develop MN loss, lack of SOD1 activity was shown to 
induce phenotypes that preferentially affected these neuronal cells, such as 
susceptibility to damage, vulnerability after injuries and mitochondrial function 
impairments. 
Selective susceptibility to damage of the motor system 
Histopathological examination of L3 dorsal and ventral roots in 19 month old Sod1-/- 
mice revealed signs of degeneration and regeneration only in the ventral roots 
suggesting a preferential motor involvement (Flood et al., 1999). Also epidermal 
nerves, which are the most distal tracts of the sensory axons were unaffected while 
NMJs were impaired as described in section 3.3.2.1 (Fischer et al., 2012). 
Other insights on MNs susceptibility came from Sod1-/- primary embryonic MNs 
culture experiments. Firstly MNs from Sod1-/- animals did not survive more than 72 
hours in culture while wild-type mouse embryonic MNs lived for about 10 days (L. 
Greensmith, UCL, personal communication). Secondly analysis of initial stages of  
Sod1-/- MNs culture showed reduced mitochondrial density, a significant oxidation of 
thioredoxin 2 and reduced axonal length and outgrowth, that depend on the intrinsic 
levels of oxidative stress (Acevedo-Arozena et al., 2011; Fischer et al., 2012) Finally 
dorsal root ganglia (DRG) cultures from the same mice were normal for two days and 
then showed a significant reduction in axonal growth (Fischer and Glass, 2010; Fischer 
et al., 2011). 
Motor neuron vulnerability after injury 
SOD1 activity was shown to be important for motor neuron survival after injury. 
Facial axotomy conducted on 5 month old Sod1-/- mice and wild-type littermates 
showed that after 5 weeks there was a significant increase in MN loss in Sod1-/- animals 
compared to controls (Reaume et al., 1996). 
Mitochondrial function is affected by loss of SOD1  
ALS and mitochondrial dysfunction studies underlined the crucial role of mitochondria 
for preservation of functional distal axons (Baloh et al., 2007b; Cassereau et al., 2011; 
Faes and Callewaert, 2011). For example mitochondrial abnormalities were shown in 
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transgenic mouse models of ALS (De Vos et al., 2007), and abnormal mitochondrial 
accumulations were described in lower MNs and proximal axons from, ALS patients 
post-mortem (Sasaki et al., 2009). Interestingly investigation of Sod1-/- mice revealed a 
reduction in mitochondrial density in axons, which could be rescued together with the 
neuromuscular phenotype by replacing SOD1 selectively in the mitochondrial 
intermembrane space of these mice (Fischer et al., 2011). This may be explained by the 
fact that mitochondria of Sod1-/- animals release high levels of free radicals due to the 
absence of dismutase, consequently increasing oxidative stress (Jang et al., 2010). 
Thus, even if mice do not develop MNs degeneration, MNs are more vulnerable to 
damage. 
3.3.2.3 Sod1-/- develop other non-motor neuronal and extra neuronal 
phenotypes 
In addition to the neuronal phenotypes described above, Sod1-/- mice were found to 
develop other neuronal characteristics not directly related to ALS, listed in Table 3.6 
(more details are provided in Appendix 8.4). These animals also presented a series of 
extra-neuronal phenotypes described in Table 3.7 the most relevant of all was the 
susceptibility to hepatocellular carcinoma a feature known to be present in humans and 
in Sod1D83G mice (Elchuri et al., 2005; Joyce et al., 2014), more details are provided 
in Appendix 8.4. 
Phenotype  Reference 
Hearing deficit and ganglion neurons loss (Keithley et al., 2005) 
Progressive retinal degeneration  (Hashizume et al., 2008; Imamura et al., 2006) 
Blood brain barrier disruption and increased lethality after 
cerebral ischemia  
(Kim et al., 2003;  
Kondo et al., 1997) 
Increased damage after brain trauma (Lewén et al., 2000; Mikawa et al., 1996) 
Increased susceptibility to neurodegeneration (Bechara et al., 2009; Murakami et al., 2011) 
Table 3.6 Sod1-/- non-motor neuronal phenotypes. 
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Phenotype  Reference 
Decrease survival and hepatocellular carcinoma (Elchuri et al., 2005; Takahashi et al. 2002) 
Impaired endothelial-dependent relaxation (Didion et al., 2002) 
Skin thinning and osteoporosis (Murakami et al., 2009) 
Infertility 
(Ho et al., 1998; Matzuk 
et al., 1998; Tsunoda et 
al., 2012) 
Table 3.7 Sod1-/- extra-neuronal phenotypes. 
3.3.2.4 Sod1+/- mice have a 50% reduction of SOD1 activity and develop 
abnormal neuronal function  
Heterozygous Sod1 knockout mice retain 50 % of SOD1 dismutase activity (Reaume et 
al., 1996) mimicking the physiological levels described in SOD1-fALS patients (Figure 
3.1). Several papers have highlighted the presence of an abnormal range of phenotypes 
in Sod1+/- animals such as: progressive cellular damage and deficits in reaction to injury 
and toxic stimuli. Here the relevance of these phenotypes to ALS is investigated. 
Sod1+/- MNs are more susceptible to cell death after axon injury 
Following facial nerve axotomy Sod1+/- mice lost a significantly higher number of MNs 
compared to wild-type controls, but a significantly lower number compared to Sod1-/- 
mice. This intermediate situation suggests a dose-dependent effect, and shows that in 
mouse retaining 50 % SOD1 activity is not sufficient for normal MN function in 
response to injury (Reaume et al., 1996). 
Of note, facial nerve axotomy was also performed on copper chaperone for SOD1 
knockout mice (Ccs-/-). These animals retain only 20 % of SOD1 activity, due to the 
lack of this crucial protein for delivery of copper to SOD1. As happened for Sod1 
knockout mice, MN survival was significantly reduced in Ccs-/-mice (Subramaniam et 
al., 2002). Results from all these mice, are important in light of the potential role for 
injury and trauma as a trigger in ALS pathogenesis (Yip and Malaspina, 2012).  
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Spontaneous denervation, MN sensitivity and reduction in mitochondrial 
numbers, show trends but are not significant in Sod1+/-  
Neuromuscular junction analysis and other studies carried out in Sod1+/- mice failed to 
show a significant pattern of denervation. However, these results even if not 
statistically significant, highlighted a denervation trend. For example in 18 months of 
age Sod1+/- animals 20 % of TA muscle endplates (NMJs) were denervated compared 
to 8 % in controls (Fischer et al., 2011, 2012). 
Of note cultured Sod1+/- MNs (unlikely Sod1-/- MNs ) showed a non-significant trend in 
reduction of axon length and mitochondrial density, whereas axon length and surface 
area of DRGs was normal (Fischer and Glass, 2010). 
Enhanced Glutamate toxicity in Sod1+/- mice 
As mentioned glutamate toxicity is implicated in disease in ALS patients and in animal 
models (Ilieva et al., 2009). Importantly overexpression of SOD1 is known to be 
protective against glutamate toxicity (Cadet et al., 1994; Chan et al., 1990). When 
SOD1 neuronal sensitivity to glutamate toxicity was assessed in vivo by intrastriatal 
injection of and N-methyl-D-aspartic acid and kainite glutamate receptor agonist; 
Sod1+/- mice were susceptible to the neurotoxic effects while mice overexpressing 
SOD1 were not (Schwartz et al., 1998). Thus, SOD1 partial loss of function could play 
a role in facilitating damage from glutamate toxicity, which may have relevance to ALS. 
Increased susceptibility to cerebral ischemia in Sod1+/-mice 
After induced focal cerebral ischemia, Sod1+/- mice had decreased survival along with 
increased early blood brain barrier (BBB) disruption and increased infarct volume 
causing brain swelling (Kondo et al., 1997). Furthermore, augmented apoptotic 
neuronal death demonstrated enhanced ischemia-reperfusion injury (Kondo et al., 
1997). Interestingly, an important mechanism involved in ischemia-reperfusion injury is 
glutamate excitotoxicity (section 1.5.1.1) (Beal, 1992). Of note BBB disruption was 
seen also in transgenic SOD1-ALS mouse models and indirect indication of disruption, 
such as increased cerebrospinal fluid albumin/plasma albumin ratios, was documented 
in ALS patients (Apostolski et al., 1991; Leonardi et al., 1984). 
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Increased memory deficits and plaque formation in an AD model on a Sod1+/- 
background 
Overexpression of the amyloid precursor protein (APP) gene carrying the Swedish 
mutation on a Sod1+/- background, resulted in increased deficits in memory behavioural 
tests and in increased senile plaque formation. Thus, in contrast with what happened 
with a 100 % loss of SOD1 activity, a 50 % loss failed to increase the development of a 
neurodegenerative phenotype in vivo. 
Increased ganglion neuron loss with ageing in Sod1+/- mice 
Sod1+/- mice did not display hearing deficits or altered auditory brainstem response 
thresholds as observed in Sod1 homozygous knockout animals. However, ganglion cell 
density was significantly reduced at 15 months of age demonstrating that a 50 % 
reduction in SOD1 activity results in reduced neuronal survival in vivo (Keithley et al., 
2005). 
Reduction of DNA methylation in Sod1+/- mice 
DNA methylation in prostate tissue of 2 months old Sod1+/- mice was significantly 
reduced, suggesting once again that a reduction of SOD1 activity increases oxidative 
stress (Bhusari et al., 2010), Even though this study was not carried out on ALS-
affected tissues, it could be relevant to the disease since DNA methyltransferases, the 
enzymes involved in DNA methylation, and 5-methycytosine, the end-product of 
DNA methylation, were found to be upregulated in human ALS (Chestnut et al., 2011).  
Development of a contractile vascular phenotype with ageing in Sod1+/- mice  
Loss of 50 % of dismutase activity was sufficient to increase vascular superoxide levels 
and produced vascular contractile dysfunction with ageing in mice (Didion et al., 2006). 
In summary loss of SOD1 activity to 50 % of normal levels does not cause death of 
MNs. However, Sod1+/- animals are a valuable tool to investigate SOD1-ALS. Indeed, 
the increased loss of specific cell types and susceptibility to injury present in these mice 
are mechanisms postulated in human ALS pathogenesis. 
121 
 
3.3.3 SOD1 loss of function influence on SOD1-fALS mouse models 
3.3.3.1 Loss of function of mouse endogenous SOD1 does not affect 
lifespan of transgenic SOD1-fALS mouse models 
The role of SOD1 loss of function in ALS pathogenesis has been investigated by 
analysing the double mutant progeny of Sod1-/- or of Ccs-/- mice crossed to three 
transgenic SOD1-ALS lines overexpressing the human mutations: G93A, G37R and 
G85R.  
Experiments carried out by crossing G93A and G37R mutants were not informative 
regarding the role of SOD1 loss of function in ALS, for several reasons. Firstly both 
these mutants retained dismutase activity see Figure 3.1. Secondly they had an increase 
of over 6 fold of SOD1 activity, compared to non-transgenic control mice (Bruijn et 
al., 1997; Deng et al., 2006; Subramaniam et al., 2002) As a result of this, even on a Ccs-
/- background, these two transgenic lines still had SOD1 activity levels comparable to 
those of non-transgenic wild-type mice (Subramaniam et al., 2002).  
On the other hand data from G85R mutants were very informative since this mutation 
was known to have no detectable intrinsic activity (Borchelt et al., 1994; Bruijn et al., 
1997). SOD1 activity was predicted to be 0 % when TgSOD1G85R were crossed with     
Sod1-/- and 20% when crossed with Ccs-/- (Bruijn et al., 1998; Subramaniam et al., 2002). 
Furthermore TgSOD1G85R mice had a late disease onset (8-10 months of age) compared 
to other transgenic SOD1 mouse models of ALS making them ideal for evaluating 
potential modifying effects of lack of SOD1 (Bruijn et al., 1998). Double mutant mice 
coming from both crosses (Sod1-/- n=5 and Ccs-/- n=10) did not showed significant 
effects on lifespan, but unfortunately no analysis was done on age of disease onset and 
pathology (Bruijn et al., 1997; Subramaniam et al., 2002). Thus it is possible to 
conclude only that lack of SOD1 activity does not affect survival, but it is still unclear 
if it affects other features such as age of onset or disease progression. 
3.3.3.2 Influence of SOD1 overexpression on disease 
To investigate if overexpression of wild-type SOD1 had an effect on disease, 
transgenic SOD1-ALS animals were crossed with TgSOD1WT mice. The double mutant 
progeny showed an earlier age of onset and a reduced survival compared to single 
mutant transgenic SOD1-ALS animals (Bruijn et al., 1998; Deng et al., 2006; Fukada et 
al., 2001; Jaarsma et al., 2000; Prudencio et al., 2010; Wang et al., 2009b, 2009c). 
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However, it is important to consider that TgSOD1WT mice develop spontaneous MN 
and axon loss and have misfolded SOD1 accumulations (Jaarsma et al., 2000). 
3.3.3.3 Tissue specific expression and inactivation of mutant SOD1 
suggest a modifying role for dismutase activity 
Experiments using Cre-loxP (causes recombination - locus for crossing over x P1) 
technology were conducted to conditionally eliminate mutant SOD1 expression in 
different cell lineages or used specific promoters to overexpress mutant SOD1 in 
selected cell types. Cre-loxP is a type of site specific recombinase (SSR) widely 
employed to carry out deletions, insertions, translocations and inversions at specific 
sites in the DNA. Briefly Cre recombinase is an enzyme that when expressed can 
recognize and splice specific loxP sites; therefore, depending on the position of the loxP 
sequences specific genes can be activated or repressed in particular tissues and at 
particular developmental time points. The analysis of site specific mutagenized SOD1 
transgenic mice demonstrated a central role for neurons in the determination of age of 
onset and disease progression in SOD1-fALS, and pointed to a role for other cell 
types, such as astrocytes and microglia in influencing the course of the disease (Ilieva et 
al., 2009). Cre-loxP experiments were conducted using two mutant transgenic SOD1 
mouse lines: conditional TgSOD1G37R, which retained intrinsic dismutase activity, and 
conditional TgSOD1G85R, which lacked activity (data are gathered in Table 3.8). This 
data suggested a protective role of SOD1 dismutase activity, at least in some cell types, 
on non-cell-autonomous degeneration and disease in SOD1-ALS. 
Excision TgSOD1G37R TgSOD1G85R 
Neurons  Increased survival 
 Delay of disease onset 
 Increased survival 
 Delay of disease onset 
Microglia  No change in disease onset  Delay of disease onset 
Astrocytes  No change in disease onset  Delay of disease onset 
Shwann cells  Increased disease progression  Delay of disease onset 
 Increased survival 
 Pathology amelioration 
Table 3.8 Consequences of mutant SOD1 excision in TgSOD1G37R and TgSOD1G85R mice. 
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3.4 Conclusions 
3.4.1 Sod1 knockout models share commonalities with ALS and indicate 
specific cell-type sensitivities 
Sod1 homozygous knockout mice have been the most useful tool to investigate in vivo a 
possible modifying role for SOD1 loss of function in ALS. These animals do not 
develop motor neuron degeneration and therefore are not considered a model of the 
human disease. However, several studies pointed out striking features related to ALS. 
To begin with Sod1-/- mice develop a progressive distal motor axonopathy, as happens 
in early stages of ALS (Murray et al., 2010). The most affected motor units in these 
mice are fast-twitch, as observed in other ALS models (Frey et al., 2000). Even if MNs 
are not lost they have a great susceptibility to injury and they are preferentially affected 
compared to other neuronal cells, as seen in patients (Pupillo et al., 2012). Lack of 
SOD1 activity in the mitochondrial intermembrane and decrease in mitochondrial 
density in axons have been demonstrated to be causative of the neuronal phenotype of 
these mice (Fischer et al., 2011). This is not surprising since mitochondrial contribution 
has been proven not only in ALS but also in other motor neuronal diseases (Acsadi et 
al., 2009; Baloh et al., 2007a; Faes and Callewaert, 2011; Sasaki et al., 2009; De Vos et 
al., 2007; Wen et al., 2010). Finally as described above, homozygous Sod1 knockout 
mice present many other phenotypes related to the disease.  
3.4.2 SOD1 activity is reduced in human SOD1-fALS patients  
The meta-analysis conducted on SOD1-fALS patients clearly shows a reduction in 
SOD1 activity of approximately 50 % compared to normal levels Figure 3.1 (Saccon et 
al., 2013). Many papers suggest that this reduction could be even bigger in specific 
tissues and cell types mainly due to mutant SOD1 mRNA half-life decrease in the CNS 
or due to possible effects of SOD1 protein misfolding and aggregation on activity. 
Data from Sod1+/- mice support these hypothesis and match what is known from 
patients. In these animals decrease in SOD1 dismutase activity causes neuronal loss, 
susceptibility to injury, to MN axonal damage and to glutamate toxicity. Moreover 
Sod1+/- mice show spontaneous loss of spiral ganglion cells and increased vulnerability 
of the BBB after injury, as described both in patients and in mouse models of ALS. 
Finally exacerbation of neurodegeneration in an AD mouse model when on a Sod1+/- 
background indicates that 50 % loss of SOD1 activity affects neuronal survival. 
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3.4.3 Absence of loss of function phenotypes in humans 
In this meta-analysis both homozygous and heterozygous Sod1 knockout mice were 
found to have many phenotypes relevant to ALS, but as expected, no studies suggested 
that a loss of SOD1 activity in humans could cause the disease. Indeed, though over 
160 mutation have been reported to be causative of ALS none of them generates a null 
allele. Furthermore no patients with full loss of SOD1 activity were identified in the 
literature search. Even if to date there is no evidence of loss of function phenotypes in 
SOD1-fALS patients, the studies analysed here underlined the importance of 
investigating this aspect in humans. A modifying role for SOD1 loss of function could 
point to new directions in researching therapies for ALS. 
3.4.4 SOD1 gain and loss of function could both play a role in ALS 
pathogenesis 
The mouse data reviewed here show that a reduction in SOD1 dismutase activity is not 
causative for ALS, however, this leaves open the possibility that it may modify disease. 
This disease modification might happen through a direct or indirect increase in 
susceptibility to neurodegeneration, such as for example, effects on respiration in MNs. 
Indeed SOD1 was recently reported to be implicated in energy metabolism by 
repressing respiration, integrating O2, glucose and superoxide levels, through casein 
kinase signalling (Reddi and Culotta, 2013). Loss of SOD1 could therefore affect 
cellular metabolism, and many other patterns still unknown. 
In other neurodegenerative diseases like Huntington’s disease, Parkinson’s disease, 
spinocerebellar ataxia and myotonic dystrophy (DM) mechanisms of gain and loss of 
function coexist (Crespo-Barreto et al., 2010; Lim et al., 2008; Winklhofer et al., 2008; 
Zuccato et al., 2010). For example in DM type 1 the expansion of unstable CTG 
trinucleotide repeats in the 3’ UTR of the dystrophia myotonica protein kinase 
(DMPK) gene, leads to disease through the misregulation of two RNA binding 
proteins; specifically causing a gain of function of CUG-binding protein 1 (CUGBP1) 
and loss of function of muscleblind-like 1 (MBNL-1). Furthermore, the hypothesis that 
a loss of function mechanism might contribute to ALS has been formulated not only 
for SOD1-ALS but also for TDP43-ALS and FUS-ALS (Guo et al., 2011; Lagier-
Tourenne and Cleveland, 2009). SOD1 protein has a crucial role in superoxide 
clearance and its absence increases oxidative stress. SOD1 is also a major target of 
oxidisation in transgenic SOD1-ALS mouse models, (Andrus et al., 1998) and in the 
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presence of oxidative stress, its two monomers have been shown to dissociate after 
oxidation and glutathionylation (Ezzi et al., 2007; Khare et al., 2004; Rakhit et al., 2004; 
Wilcox et al., 2009). These findings reported by several groups point once more to the 
possibility of a co-occurrence of SOD1 loss and gain of function in ALS. Indeed, a 
vicious circle was hypothesized in which oxidized SOD1 has increased propensity to 
misfold, causing seeding and aggregation of SOD1 and a reduction of dismutase 
activity, which therefore feeds more potential oxidative stress to the beginning of the 
loop (Saccon et al., 2013) see Figure 3.2. 
 
Figure 3.2 The cycle of SOD1 loss of function, schematic representation of a potential co-
operation between SOD1 loss and gain of function in SOD1 pathogenesis. SOD1 loss of function 
(LOF) increases levels of oxidative stress, which through glutathionylation and oxidation, can facilitate 
the monomerisation of dimeric SOD1. Once monomerized, SOD1 is more prone to become misfolded, 
oligomerized and aggregated. The monomerization of previously active dimeric SOD1 and the 
recruitment of SOD1 into aggregates further enhance the loss of function, feeding back to the beginning 
of the loop. In this way the gain of function (GOF) effects of misfolded, oligomerized and aggregated 
SOD1, which are known to cause motor neuron degeneration, are amplified by the loss of function 
circle. Mutant SOD1 (mutSOD1) has both a direct effect on reduction of SOD1 activity and induces 
SOD1 misfolding and aggregation. Mislocalisation of both TDP-43 and FUS result in misfolding of 
SOD1. ER = endoplasmic reticulum; MN = motor neuron (Saccon et al., 2013). 
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3.4.5 SOD1 loss of function implications in ALS therapeutic approaches  
Therapies for dominant mutations diseases are being developed using knockdown of 
the mutant allele RNA (Kordasiewicz et al., 2012; Lu and Yang, 2012; Smith et al., 
2006), many of them, for example, against Huntington’s disease, seem very promising. 
Interestingly these approaches have been tested also for SOD1-ALS (Ralph et al., 2005; 
Raoul et al., 2005; Saito et al., 2005; Smith et al., 2006; Towne et al., 2011; Wang et al., 
2010; Wright et al., 2012). In particular a phase 1 clinical trial has been conducted 
(Fratta, 2013; Miller et al., 2013) employing antisense oligonucleotides that silence both 
mutant and wild-type SOD1, known to be effective in rats (Smith et al., 2006). The 
results of this preliminary study only assessed that the treatment was well-tolerated by 
patients for a short period of time. However, it is still unknown if downregulation of 
SOD1 triggers negative effects. Data on Sod1 knockout mouse models give insights for 
the development of these type of strategies (Elchuri et al., 2005). First of all the 
incidence of liver cancer in these animals suggests that it is necessary to monitor non-
neuronal effects also in patients and carefully optimise delivery routes and protein 
levels. Even if it is important to consider that Sod1-/- mice lack Sod1 from birth, and it 
will be more relevant to patients to investigate the case in which Sod1 is knocked down 
in adulthood. Secondly Sod1+/- mice findings raise the necessity to investigate other 
aspects of SOD1-ALS in patients such as: incidence of cardiovascular disease, stroke 
and liver cancer. Lastly, Sod1 knockout animals loss of dismutase activity associate with 
abnormal phenotypes suggest that SOD1-ALS patients should also be screened for 
other non-fatal characteristics for example, age-related macular degeneration, 
progressive hearing loss. 
3.5 Summary 
 SOD1 activity is reduced to approximately half of normal in SOD1-fALS 
patients  
 Sod1-/- mice develop and adult-onset progressive motor axonopathy  
 Sod1-/- mice do not develop MN loss but they have an increased susceptibility 
to MNs degeneration  
 Sod1-/- mice develop a wide range of other neuronal and extra-neuronal 
phenotypes  
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 Sod1+/- mice have 50 % reduction of SOD1 activity and develop abnormal 
phenotypes also within the motor system  
 Mutant SOD1 tissue specific expression and inactivation suggest a modifying 
role for dismutase activity  
 SOD1 loss of function by increasing oxidative stress could facilitate gain of 
function effects such as monomerisation, misfolding and aggregation of SOD1 
which in turn could feed more potential oxidative stress to the loss of function 
mechanism  
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Chapter 4 Sod1D83G a mouse model for motor neuron 
disease 
4.1 Introduction 
Transgenic mouse models overexpressing the SOD1 gene have been extremely useful 
tools in the study of ALS. To date there are number of different transgenic mouse lines 
overexpressing either the wild-type or mutant forms of the human SOD1 gene, and 
one overexpressing a mutant form of the mouse Sod1 gene, see Table 8.1 (Graffmo et 
al., 2013; Gurney et al., 1994; Joyce et al., 2011; McGoldrick et al., 2013; Ripps et al., 
1995; Turner and Talbot, 2008). The majority of these animals are considered models 
of SOD1-ALS since they develop the same features seen in patients: progressive motor 
deficits, hind limb paralysis, degeneration of motor neurons, and premature death 
(Joyce et al., 2011; McGoldrick et al., 2013; Turner and Talbot, 2008). However, these 
mice largely overexpress the mutant SOD1 protein and although they model the toxic 
gain of function that leads to motor neuron degeneration they are not a direct genetic 
representation of human ALS. Such raised expression levels might indeed affect 
aspects of the phenotype like disease onset or survival (Acevedo-Arozena et al., 2011; 
Joyce et al., 2014). For example, mice overexpressing the human SOD1 G93A mutant 
at different levels also present a different disease progression: the higher the number of 
copies of the mutant human SOD1 transgene, the more accelerated the disease 
(Acevedo-Arozena et al., 2011; Jonsson et al., 2006b), indicating that SOD1 dose is 
important in determining the phenotype. Moreover mice overexpressing the SOD1 
gene generally present an increased SOD1 activity thus they do not model the effects 
that a reduction in dismutase activity may have in the pathogenesis of the disease, as 
observed in SOD1-fALS patients (Saccon et al., 2013).  
To investigate the effects of SOD1 mutations at endogenous level and to create a 
model that is genetically more representative of human SOD1-ALS our group in 
collaboration with Linda Greensmith and Abraham Acevedo identified and 
characterised a new mutant line that carries an N-ethyl-N-nitrosourea (ENU)-induced 
point mutation in the mouse Sod1 gene (Joyce et al., 2014) (see Appendix 8.5). This 
mutation is an adenosine to guanidine change that results in a D83G substitution and is 
identical to a pathological change found in several ALS families, mainly characterised 
by early onset and slow disease progression (Millecamps et al., 2010). Of note this 
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mutation is predicted to disrupt SOD1 activity and protein stability since it lies in the 
zinc-binding residue (Krishnan et al., 2006). 
Characterisation of the Sod1D83G mice has revealed several interesting phenotypes 
especially in the homozygous animals. Sod1D83G/D83G mice indeed develop degeneration 
of both upper and lower motor neurons between 6 and 29 weeks of age, but differently 
from fALS patients and transgenic mouse models of SOD1-ALS, motor neuron cell 
death does not progress to paralysis and premature death (Joyce et al., 2014). A 
complete characterisation of Sod1D83G homozygous and heterozygous mice was 
published in 2014 (Joyce et al., 2014), the data I collected are presented in the results 
section of this chapter while other findings most relevant to this work are summarised 
below. 
Loss of upper and lower motor neurons 
To investigate loss of upper and lower motor neurons in the Sod1D83G model, the 
number of LMN in the sciatic motor pool of lumbar spinal cord and the survival of 
corticospinal motor neurons were assessed in Sod1D83G homozygous, heterozygous and 
wild-type littermates see Table 4.1. As mentioned Sod1D83G/D83G mice were found to 
develop loss of both upper and lower MNs that does not progress to paralysis, while 
Sod1+/D83G appeared to be normal. Furthermore astrogliosis and microgliosis were 
detected in lumbar spinal cords of 15 weeks old homozygous animals and were shown 
to aggravate with age (Joyce et al., 2014). 
Phenotype 
Age 
(weeks) 
Sod1+/D83G Sod1D83G/D83G 
% of LMNs compared 
to wild-type 
6 100 % 100 % 
 15 100 % 77 % 
 52 100 % 77 % 
% of UMNs compared 
to wild-type 
15 100 % 100 % 
 29 100 % 78 % 
Table 4.1 Sod1D83G mice upper and lower motor neurons characterisation. Sod1D83G/D83G animals 
develop lower MNs loss by 15 week of age and upper MNs loss by 29 week of age. Data from (Joyce et 
al., 2014). 
130 
 
Analysis of functional motor units 
The number of functional motor neurons that innervate the EDL muscle was 
determined by physiological analysis of motor unit survival in Sod1D83G homozygous, 
heterozygous and wild-type littermates at 15 and 52 weeks of age. Sod1+/D83G animals 
did not reveal any significant difference in the number of EDL motor units compared 
to wild-type littermates at both time points. However, Sod1D83G/D83G showed a 
significant reduction in the number of motor units in the EDL at 52 week of age, in 
accordance with the loss of MNs detected in these animals (Joyce et al., 2014). 
Behavioural deficits  
A series of behavioural tests were carried out to investigate Sod1D83G motor functions. 
Sod1D83G/D83G animals presented several behavioural deficits that progressively worsen 
with age, the most important results for homozygous and heterozygous mice are 
gathered in Table 4.2 (Joyce et al., 2014). 
Table 4.2 Sod1D83G mice behavioural tests. All data are compared to wild-type littermates 
(Joyce et al., 2014). 
Analysis of muscle force 
Physiological analysis of TA and EDL muscles of females Sod1D83G/D83G, Sod1+/D83G and 
wild-type mice revealed a progressive loss of muscle strength in homozygous animals 
between 15 and 52 weeks of age see Table 4.3. 
Test  Sod1+/D83G Sod1D83G/D83G 
Weight  Normal Weight loss, starting at 4 weeks 
Grip-strength  Normal Reduced from 6 weeks  
Accelerating 
rotarod 
No deficit Deficit at 23 weeks for females and at 67 weeks for males 
Wheel running  Not tested  Impaired from 44 weeks 
Tremors 
About 20 % mice develop 
tremors by 96 weeks of age 
100 % of mice develop tremors 
by 22 weeks of age 
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Genotype 
Age 
(weeks) 
 % of TA tetanic force 
compared to wild-type 
% of EDL tetanic force 
compared to wild-type 
Sod1+/D83G 15 100 % 100 % 
 52 100 % 100 % 
 96 100 % 100 % 
Sod1D83G/D83G 15 65 % 100 % 
 52 55 % 65 % 
Table 4.3 Sod1D83G mice EDL and TA muscle force. TA force of Sod1D83D83G animals is affected 
starting at 15 weeks of age, while EDL force is affected starting at 52 weeks of age. Data from (Joyce et 
al., 2014). 
Survival and incidence of hepatocellular carcinoma 
Survival of Sod1D83G homozygous mice was significantly reduced compared to 
heterozygous and wild-type littermates, with a higher incidence in males. Interestingly 
85 % of Sod1D83G/D83G animals develop hepatocellular carcinoma, a feature typical of 
Sod1 knockout models (section 3.3.2) (Elchuri et al., 2005). Of note Sod1D83G/D83G mice 
were not produced with a Mendelian ratio (Joyce et al., 2014). 
In conclusion, Sod1D83G is the first mouse model carrying a pathological point mutation 
in the Sod1 gene which is expressed at endogenous levels, and the presence of a non-
progressive motor neuron degeneration in homozygous Sod1D83G animals make them a 
good system for studying early stages of ALS. Of note another mouse model with a 
spontaneous point mutation in the mouse Sod1 gene has been previously described but 
the equivalent mutation in humans has not been identified as pathogenic (Joyce et al., 
2014; Luche et al., 1997). 
4.2 Aim 
This chapter aims to characterise further the Sod1D83G model and use it to investigate 
the gain of function mechanisms and a possible role of the loss of dismutase function 
in SOD1-ALS.  
To better understand this new model an immunohistochemical, biochemical and 
molecular analysis was carried out for Sod1D83G animals in comparison to wild-type 
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littermates. In particular the morphological innervation pattern of endplate NMJs of 
the EDL muscle was investigated at two different time points using an 
immunohistochemical approach. First to confirm the development of an axonopathy 
in Sod1D83G/D83G animals and second to examine whether in this model axonal 
impairment precedes neuronal body degeneration or if these are two separate events. 
Further, since the D83 residue is predicted to interfere with the correct folding of 
SOD1 and potentially affect its function (Krishnan et al., 2006), SOD1 protein levels 
were measured by western blot and SOD1 dismutase activity was assessed by in gel 
assay, in homozygous and heterozygous Sod1D83G animals compared to wild-type 
littermates at two different time points. 
Sod1D83G homozygous characterisation revealed that these mice present elements of 
both a gain of function and of a loss of function mechanism (Joyce et al., 2014). In 
order to try to dissect these two aspects Sod1D83G mice were crossed with Sod1 
knockout animals and with mice overexpressing the human wild-type SOD1 gene. In 
particular: 
 To investigate whether the Sod1D83G phenotype is dose-dependent, the protein 
levels and the SOD1 activity of the progeny generated by the cross between 
Sod1D83G mice and Sod1 knockout mice were analysed by western blot and in gel 
assay respectively. Specifically SOD1 activity and protein levels of the 
compound heterozygous animals Sod1-/D83G were compared with that of 
Sod1D83G/D83G mice. If the Sod1D83G phenotype is dose-dependent SOD1 protein 
activity levels of Sod1-/D83G mice are expected to be lower compared to those of 
Sod1D83G/D83G. 
 To investigate if the presence of human SOD1 protein rescues the MNs loss or 
if it exacerbates the ALS-like phenotypes described for Sod1D83G animals, SOD1 
protein levels and activity of the progeny generated by the cross between 
Sod1D83G mice and mice overexpressing the human wild-type SOD1 gene, were 
examined by western blot and in gel assay. Specifically the TgSod1D83G/D83G were 
compared to Sod1D83G/D83G mice, to confirm the overexpression of the human 
SOD1 protein. 
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4.3 Results 
4.3.1 Sod1D83G mice characterisation  
In the experiments described in this section female mice were employed to investigate 
NMJ morphology, and male mice were used to asses SOD1 protein level and activity in 
order to minimise gender variability.  
4.3.1.1 Neuromuscular junctions of the EDL 
Neuromuscular junction denervation is considered to be a hallmark of ALS; and 
several studies suggested that the distal degeneration of the skeletal muscle plays a role 
in disease progression (Fischer et al., 2004; Murray et al., 2010). Furthermore 
investigations carried out using SOD1 transgenic mouse models and Sod1 knockout 
mice demonstrated that NMJ degeneration occurs in the early disease stages, long 
before loss of MNs (Kanning et al., 2010).  
To examine the innervation pattern of the EDL muscle in the Sod1D83G line a 
morphological analysis of the endplate neuromuscular junctions was performed for 
Sod1D83G/D83G, Sod1+/D83G, and wild-type littermates at 15 and 52 weeks of age. For each 
muscle the total number of NMJs was counted and NMJs were classified in three 
groups depending on the level of innervation of the postsynaptic apparatus: innervated, 
intermediate and denervated (Table 2.2, Figure 4.1 and Figure 4.2). In particular the 
innervation status of each NMJ was evaluated by determining the co-localisation 
between synaptic vesicles of the axon terminal, and acetylcholine receptors present in 
the foot plate of the skeletal muscle see Figure 4.1 and Figure 4.2. The three genotypes 
were compared at both time points for the total number of NMJs and for each 
classification group using a one-way ANOVA. 
At 15 weeks no significant difference was detect in the number of denervated 
endplates NMJs, or in any of the other categories among the three genotypes (Figure 
4.3 (a) (d); Table 4.4). However, at 52 weeks of age significant denervation had taken 
place in the Sod1D83G/D83G mice compared to wild-type and Sod1+/D83G littermates (Figure 
4.3 (b) (d); Table 4.4). Furthermore the number of partially innervated endplates 
(intermediate) was higher in Sod1D83G/D83G animals compared to other genotypes but it 
was significantly different only to Sod1+/D83G littermates (Figure 4.3 (b); Table 4.4).  
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There was no difference in the total number of endplate NMJs counted among 
genotypes at 15 week, but at 52 weeks the number of NMJs counted was significantly 
reduce in Sod1D83G homozygous animals compared to heterozygous and wild-type 
littermates (Figure 4.3 (c); Table 4.5). 
This analysis confirmed the presence of a distal progressive denervation between 15 
and 52 weeks of age in Sod1D83G/D83G mice (Joyce et al., 2014).  
 
Figure 4.1 Representative image of innervated NMJs from EDL muscle of a 52 weeks old wild-
type mouse. Axon projections and axonal terminals are identified respectively by 2H3 antibody staining 
neurofilaments (green) and SV2 antibody staining synaptic vesicles (green). Motor endplates are 
identified by α-bungarotoxin staining of acetylcholine receptors (red). Nuclei are stained by DAPI (blue). 
Scale bar = 20 µm. 
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Figure 4.2 Representative images of innervated, intermediate and denervated NMJs of the three 
Sod1D83G genotypes at 52 weeks of age. (a; b; c) Wild-type (WT); (d; e; f) Sod1+/D83G; (g; h; i) 
Sod1D83G/D83G. The synaptic vesicles and the axon terminals were visualized with SV2 and 2H3 antibodies 
respectively (both in green), while the acetylcholine receptors in skeletal muscle were labelled with α-
bungarotoxin (red). Scale bar = 20 μm.  
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Figure 4.3 NMJs analysis from EDL muscle of Sod1D83G mice at 15 and 52 weeks. (a) Percentage 
of innervated, intermediate and denervated NMJs for the 3 Sod1D83G genotypes at 15 weeks, and (b) at 52 
weeks. (c) Total number of NMJs at 15 and 52 weeks for the 3 genotypes. (d) Percentage of denervated 
NMJs at 15 and 52 weeks for the 3 genotypes. For all measurements p < 0.001 = ***; p < 0.01 = **; 
p < 0.05 = * n=5 for all genotypes. 
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15 weeks 
Genotype 
Innervated 
(% of total) 
Intermediate 
(% of total) 
Denervated 
(% of total) 
Wild-type 99.0 % ± 0.6 % 0.2 % ± 0.1 % 0.7 % ± 0.6 % 
Sod1+/D83G 99.2 % ± 0.5 % 0.5 % ± 0.3 % 0.3 % ± 0.2 % 
Sod1D83G/D83G 91.0 % ± 7.5 % 8.5 % ± 7.6 % 0.5 % ± 0.3 % 
52 weeks 
Genotype 
Innervated 
(% of total) 
Intermediate 
(% of total) 
Denervated 
(% of total) 
Wild-type 90.5 % ± 3.3 % 6.0 % ± 2.7 % 2.5 % ± 1.0 % 
Sod1+/D83G 94.2 % ± 3.0 % 3.1 % ± 1.5 % 2.7 % ± 1.5 % 
Sod1D83G/D83G 74.0 % ± 6.1 % 16.8 % ± 4.0 % 14.1 % ± 1.0 % 
Table 4.4 Percentage of innervated intermediate and denervated NMJs at 15 and 52 weeks. 
Values represent the mean percentage ± SEM of the total number of NMJs calculate on an n = 5 per 
genotype. 
Genotype 
Total NMJs at  
15 weeks 
Total NMJs at  
52 weeks 
Wild-type 714 ± 33 742 ± 39 
Sod1+/D83G 705 ± 82.5 740 ± 36 
Sod1D83G/D83G 719 ± 100 463 ± 30 
Table 4.5 Total number of NMJs at 15 and 52 week. Values represent the mean of the total NMJs 
counted ± SEM, n = 5 per genotype. 
4.3.1.2 SOD1 protein levels of Sod1D83G mice 
In order to investigate protein stability SOD1 levels were assessed by western blot 
(section 2.6.4.2) from brain homogenates of Sod1D83G/D83G, Sod1+/D83G and wild-type 
mice at 15 and 60 weeks of age. To confirm experimental conditions accuracy SOD1 
levels were also measured for 15 weeks old control mice: Sod1-/-, Sod1+/-, wild-type and 
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TgSOD1G93A(H). Values from control genotypes at 15 weeks and from Sod1D83G animals 
at 15 and 60 weeks were compared using one-way ANOVA. 
As expected, Sod1-/- controls were significantly lacking the SOD1 protein 
(0.4 % ± 0.4 %) compared to wild-type animals (100 % ± 2.7 %) and Sod1+/- mice had 
a significant protein reduction of 53.6 % ± 8.1 % compared to normal. Further 
TgSOD1G93A(H) mice SOD1 protein levels were over six fold (627.1 % ± 2.6 %) of wild-
type, see Figure 4.4 (a) and Figure 4.5 (a). 
SOD1 protein levels of homozygous and heterozygous Sod1D83G mice were significantly 
reduced compared to wild-type littermates both at 15 and 60 week of age. In particular 
at 15 weeks SOD1 protein of Sod1D83G/D83G mice was reduced down to 11.8 % ± 0.4 % 
of wild-type littermates (100 % ± 9.4 %), while Sod1+/D83G mice retained 
70.4 % ± 5.3 % of SOD1 protein compared to wild-type (Figure 4.4 (c) and Figure 4.5 
(c)). Similarly at 60 weeks SOD1 protein levels were reduced to 14.6 % ± 0.4 % in 
homozygous Sod1D8G3 animals and to 57.0 % ± 0.7 % in heterozygous mice compared 
to wild-type littermates (100 % ± 4.3 %) see Figure 4.4 (e) and Figure 4.5 (e). 
4.3.1.3 SOD1 enzymatic activity of Sod1D83G mice 
To investigate SOD1 enzymatic activity gel assays were carried out using brain 
homogenate from Sod1D83G/D83G, Sod1+/D83G and wild-type mice at 15 and 60 week of 
age; and also from Sod1-/-, Sod1+/-, wild-type and TgSOD1G93A(H) animals at 15 weeks 
(section 2.6.4.4). Values from control genotypes at 15 weeks and from Sod1D83G animals 
at 15 and 60 weeks were compared using one-way ANOVA. 
Confirming published data Sod1-/- mice were completely lacking SOD1 activity 
(0.40 % ± 1.6 %) (Reaume et al., 1996), Sod1+/- animals retained 33.8 % ± 9.1 % of 
activity and TgSOD1G93A(H) mice presented a 291.3 % ± 5.3 % increase of dismutase 
activity compared to wild-type-littermates (100 % ± 6.4 %) see Figure 4.4 (b) and 
Figure 4.5 (b). 
As for SOD1 protein levels also SOD1 dismutase activity of homozygous and 
heterozygous Sod1D83G mice was significantly reduced compared to wild-type littermates 
at both time points. Specifically, at 15 weeks SOD1 activity of Sod1D83G/D83G mice was 
1.3 % ± 2.1 %, and SOD1 activity of Sod1+/D83G mice was 55.9 % ± 7.0 % of wild-type 
littermates (100 % ± 14.4 %), see Figure 4.4 (d) and Figure 4.5 (d). While at 60 weeks 
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SOD1 activity was reduce to 1.5 % ± 5.3 % in homozygous Sod1D8G3 animals and to 
34.2 % ± 5.3% in heterozygous Sod1D8G3 mice compared to wild-type littermates (100 
% ± 2.9 %), see Figure 4.4 (f) and Figure 4.5 (f).  
The SOD1 activity bands detected from brain homogenates of TgSOD1G93A(H) mice 
migrated faster in the gel compared to the SOD1 activity bands from brain 
homogenates of wild-type, Sod1+/- and Sod1D83G mice. Gel electrophoresis was carried 
out in non-denaturing and non-reducing conditions, therefore the electrophoretic 
mobility of the proteins depended only on their charge-to-mass ratio and physical 
shape. Of note in these assays it was not possible to use native ladder markers to detect 
the size of the SOD1 activity bands. 
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Figure 4.4 SOD1 western blots and activity gel assays of Sod1D83G mice and controls at 15 and 60 
weeks of age. (a) Western blot and (b) activity gel assay of Sod1-/-, Sod1+/-, wild-type (WT) and 
TgSOD1G93A(H) animals. (c) Western blot and (d) activity gel assay of Sod1D83G homozygous, heterozygous 
and wild-type (WT) littermates at 15 weeks. (e) Western blot and (f) activity gel assay of Sod1D83G 
homozygous, heterozygous and wild-type (WT) littermates at 60 weeks; n = 3 per genotype. 20 µg of 
protein for western blot and 30 µg of protein for activity assay were added per well. In activity gel assays 
SOD1 bands from TgSOD1G93A(H) mice migrate faster compared to SOD1 bands from wild-type, Sod1+/- 
and Sod1D83G mice. 
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Figure 4.5 Quantification of SOD1 protein levels and activity of Sod1D83G mice and controls at 15 
and 60 weeks of age. (a) SOD1 protein levels and (b) activity of Sod1-/-, Sod1+/-, wild-type (WT) and 
TgSOD1G93A(H) animals. (c) SOD1 protein levels and (d) activity of Sod1D83G homozygous, heterozygous 
and wild-type (WT) littermates at 15 weeks. (e) SOD1 protein levels and (f) activity of Sod1D83G 
homozygous, heterozygous and wild-type (WT) littermates at 60 weeks. Values represent the mean ± 
SEM from 3 independent experiments, expressed as % of wild-type, SOD1 protein levels are normalised 
for β-actin. For all measurements p < 0.001 = ***; p < 0.01 = **; p < 0.05 = *, n = 3 per genotype per 
experiment. 
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4.3.2 Sod1D83G X Sod1 knockout cross characterisation 
Characterisation of the Sod1D83G line showed that Sod1D83G/D83G phenocopy several 
aspects of Sod1-/- mice, such as reduced survival, development of hepatocellular 
carcinoma, NMJ denervation, development of axonopathy and lack of dismutase 
activity (Joyce et al., 2011; McGoldrick et al., 2013; Turner and Talbot, 2008). 
However, unlike Sod1-/- mice, Sod1D83G/D83G animals retain about 12 % of SOD1 protein 
and have an additional toxic gain of function that causes degeneration of motor 
neurons (Joyce et al., 2014). To investigate if the gain of function element seen in 
Sod1D83G mice is dose dependent and how it affects axonopathy and motor neuron loss, 
Sod1D83G animals were crossed with the Sod1 knockout line (see breeding scheme in 
section 2.2.8). In particular the phenotype of the compound heterozygous Sod1-/D83G 
was analysed in comparison with Sod1D83G/D83G and Sod1-/- animals. If the Sod1D83G line 
have a dose dependent gain of function mechanism, as expected, the compound 
animals should have a phenotype less severe than the Sod1D83G/D83G mice. 
Mice from this cross were maintained and sampled in collaboration with Dr. Philip 
McGoldrick. Here are present data of SOD1 protein levels and dismutase activity. 
Motor neuron counts, muscle force and EDL motor unit number from the same 
colony were measured by Dr. Philip McGoldrick (data not yet published). 
4.3.2.1 SOD1 protein levels of Sod1D83G X Sod1 knockout progeny at 15 
weeks 
SOD1 protein levels were assessed by western blot (section 2.6.4.2) from brain 
homogenate of 15 weeks Sod1+/D83G, Sod1-/D83G and Sod1D83G/D83G mice. Values were 
compared using one-way ANOVA. Control mice and Sod1+/D83G protein levels relative 
to wild-type are reported in Figure 4.5 (a) and (c). 
SOD1 protein levels of heterozygous Sod1D83G mice (100 % ± 4.7 %) were significantly 
higher compared to homozygous (20.5 % ± 1.6 %) and compound heterozygous 
knockout mice (7 % ± 0.5 %). Furthermore Sod1-/D83G protein levels were significantly 
reduced also compared to Sod1D83G/D83G animals, confirming that the absence of one 
D83G allele results in a reduction of SOD1 protein see Figure 4.6 (a) and Figure 4.7 
(a). 
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4.3.2.2 SOD1 enzymatic activity of Sod1D83G X Sod1 knockout progeny at 
15 weeks 
SOD1 enzymatic activity was measured by activity gel assays (section 2.6.4.4) using 
brain homogenate of 15 weeks Sod1+/D83G, Sod1-/D83G and Sod1D83G/D83G mice. Values 
were compared using one-way ANOVA. Controls and Sod1+/D83G measures relative to 
wild-type can be found in Figure 4.5 (b) and (d). 
SOD1 activity of heterozygous Sod1D83G mice (100 % ± 13.9 %) was significantly higher 
compared to both homozygous (1.2 % ± 0.6 %) and compound heterozygous 
knockout mice (0.4 % ± 0.2 %), where activity was absent as expected, see Figure 4.6 
(b) Figure 4.7 (b). 
 
Figure 4.6 SOD1 western blots and activity gel assays of Sod1D83G X Sod1 KO offspring and 
controls at 15 weeks. (a) Western blot and (b) activity gel assay of Sod1+/D83G, Sod1-/D83G and 
Sod1D83G/D83G mice; n = 3 per genotype. 20 µg of protein for western blot and 30 µg of protein for 
activity assay were added per well. 
 
Figure 4.7 Quantification of SOD1 protein levels and activity of Sod1D83G X Sod1 KO offspring at 
15 weeks. (a) SOD1 protein levels and (b) activity of Sod1+D83G, Sod1-/D83G and Sod1D83G/D83G animals at 15 
weeks. Values represent the mean ± SEM from 3 independent experiments, expressed as % of 
Sod1+/D83G, SOD1 protein levels are normalised for β-actin. For all measurements p < 0.001 = ***; p < 
0.01 = **; p < 0.05 = * n = 3 per genotype per experiment. 
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4.3.3 Sod1D83G X TgSOD1WT cross characterisation 
To see if it was possible to dissect elements of a loss of function and gain of function 
mechanism in the Sod1D83G mice, this line was crossed with mice overexpressing the 
human wild-type SOD1 protein, see breeding scheme in section 2.2.9. In particular the 
aim was to investigate the phenotype of TgSod1D83G/D83G mice to see if the presence of 
the human SOD1 protein can rescue elements of a loss of function, while maintaining 
the gain of function mechanism, or if its presence exacerbates ALS-like features. 
Mice from this cross were maintained and sampled by me in collaboration with Dr. 
Philip McGoldrick. Data of SOD1 protein levels and dismutase activity are presented 
in this section. Motor neuron counts, muscle force and EDL motor unit number from 
the same colony were measured by Dr. Philip McGoldrick (data not published). 
The six genotypes generated from this cross plus a TgSOD1G93A(H) control were used in 
the experiments described in this section. All genotypes are listed in Table 4.6. 
Transgenic allele Sod1D83G allele Nomenclature  
Non-transgenic Wild-type (Sod1+/+) Wild-type 
d +/+Non-transgenic Sod1+/D83G Sod1+/D83G 
Non-transgenic Sod1D83G/D83G Sod1D83G/D83G 
SOD1WT transgenic Wild-type (Sod1+/+) TgSOD1WT 
SOD1WT transgenic Sod1+/D83G TgWTSod1+/D83G 
SOD1WT transgenic Sod1D83G/D83G TgWTSod1D83G/D83G 
SOD1G93A(H) transgenic Wild-type (Sod1+/+) TgSOD1G93A(H) 
Table 4.6 Experimental genotypes for Sod1D83G X TgSOD1WT characterisation. 
4.3.3.1 Ratio of Sod1D83G X TgSOD1WT 
Pervious data showed that Sod1D83G mice ratios, significantly differ from expected 
Mendelian ratios (Joyce et al., 2014). The number of offspring of the 6 potential 
genotypic ratios from the Sod1D83G X TgSOD1WT cross (Figure 2.2) was monitored from 
6 trios (two females and one male). The observed ratios were significantly different 
from the expected ratios χ2(5) = 14.97 p = 0.0105. Results are summarised in Table 4.7.  
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Genotype Number of 
animals 
Observed 
ratios 
Expected 
ratios 
Wild-type 25 0.173 0.125 
Sod1+/D83G 37 0.256 0.25 
Sod1D83G/D83G 6 0.041 0.125 
TgSOD1WT 25 0.173 0.125 
TgWTSod1+/D83G 38 0.263 0.25 
TgWTSod1D83G/D83G 6 0.090 0.125 
Total 144 1 1 
Table 4.7 Observed ratios of offspring from Sod1D83G X TgSOD1WT cross. The omnibus χ2 showed 
that observed ratios differ significantly from expected ratios. 
4.3.3.2 SOD1 protein levels of Sod1D83G X TgSOD1WT progeny at 15 weeks 
SOD1 protein levels of transgenic and non-transgenic animals, generated from the 
Sod1D83G X TgSOD1WT cross, were evaluated by western blot (section 2.6.4.2) using 
brain homogenate of 15-week old mice. Since these transgenic animals generally have a 
level of SOD1 protein that is about five-fold of wild-type mice, transgenic and non-
transgenic genotypes were assessed in separate blots and compared among each other. 
A control experiment was performed to show the difference in SOD1 protein between 
transgenic and wild-type non-transgenic animals. Values were compared using one-way 
ANOVA. 
The control experiment confirmed that SOD1 protein levels of TgSOD1WT 
(464 % ± 29.5 %) and TgSOD1G93A(H) (498 % ± 19.9 %) animals were significantly 
higher compare to SOD1 levels of wild-type mice (100 % ± 5.3 %), see Figure 4.8 (a) 
and Figure 4.9 (a). 
As expected SOD1 protein levels of non-transgenic homozygous and heterozygous 
mice were significantly reduced compared to wild-type littermates. In particular SOD1 
protein in Sod1D83G/D83G mice was reduced down to 21.8 % ± 1.4 % of wild-type 
littermates (100 % ± 1.6 %), while Sod1+/D83G mice retained 70.7 % ± 5.1 % of SOD1 
protein compared to wild-type (Figure 4.8 (c) and Figure 4.9 (c)). 
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Instead SOD1 protein levels of the 3 transgenic genotypes were all similar among each 
other. In particular SOD1 protein levels of TgWTSod1+/D83G mice were 101.3 % ± 0.9 % 
compare to SOD1 protein levels of TgSOD1WT (100 % ± 2.4 %) animals, while 
TgWTSod1D83G/D83G SOD1 protein levels (90.9 % ± 4 %) were slightly reduced but not 
significantly different from TgSOD1WTanimals, see Figure 4.8 (e) and Figure 4.9 (e). 
4.3.3.3 SOD1 enzymatic activity of Sod1D83G X TgSOD1WT progeny at 15 
weeks 
SOD1 enzymatic activity of transgenic and non-transgenic animals, generated from the 
Sod1D83G X TgSOD1WT cross, was measured by activity gel assays (section 2.6.4.4) using 
brain homogenate of 15-week old mice. As for SOD1 protein levels, SOD1 activity is 
much higher in transgenic animals compared to wild-type; therefore dismutase activity 
of transgenic and non-transgenic genotypes was assessed in separate gel assays. A 
control experiment showed the difference in SOD1 dismutase activity between 
transgenic and wild-type non-transgenic animals, see Figure 4.8 (b) and Figure 4.9 (b). 
Values were compared using one-way ANOVA. 
SOD1 activity of TgSOD1WT (479.6 % ± 64.8 %) and TgSOD1G93A(H) 
(532.4 % ± 96.2 %) animals was significantly higher compare to dismutase activity of 
wild-type mice (100 % ± 6.2 %), see Figure 4.8 (b) and Figure 4.9 (b). As found in 
previous experiments, SOD1 activity of non-transgenic Sod1D83G homozygous and 
heterozygous mice was significantly reduced compared to wild-type littermates. 
Specifically Sod1D83G/D83G mice did not have any SOD1 activity (0.0% ± 0.0 %) 
compared to wild-type littermates (100 % ± 8 %), while Sod1+/D83G mice retained 
49.9 % ± 4 % of SOD1 activity compared to normal (Figure 4.8 (d) and Figure 4.9 (d)). 
Conversely, there was no significant difference among SOD1 activity of transgenic 
animals. SOD1 activity of TgWTSod1+/D83G mice was 124 % ± 11.6 % compared to 
TgSOD1WT (100 % ± 10.9 %) littermates and TgWTSod1D83G/D83G SOD1 activity was 
134.5 % ± 4.1 % of TgSOD1WT, see Figure 4.8 (f) and Figure 4.9 (f). 
The SOD1 activity bands detected from brain homogenates of TgSOD1G93A(H), 
TgSOD1WT, TgWTSod1+/D83G and TgWTSod1D83G/D83G mice migrated faster compared to 
bands of wild-type and Sod1D83G mice. Gel electrophoresis was carried out in native 
conditions, therefore the electrophoretic mobility of the proteins depended only on 
their charge-to-mass ratio and physical shape. Of note in these assays it was not 
possible to use native ladder markers to detect the size of the SOD1 activity bands. 
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Figure 4.8 SOD1 western blots and activity gel assays of Sod1D83G X TgSOD1WT offspring at 15 
weeks of age. (a) Western blot and (b) activity gel assay of wild-type (WT), TgSOD1WT and 
TgSOD1G93A(H) animals. (c) Western blot and (d) activity gel assay of non-transgenic offspring: Sod1D83G 
homozygous, heterozygous and wild-type littermates. (e) Western blot and (f) activity gel assay of 
transgenic offspring: TgWTSod1+/D83G, TgWTSod1D83G/D83G and TgSOD1WT; n = 3 per genotype. 20 µg of 
protein for western blot and 30 µg of protein for activity assay were added per well. In activity gel assays 
SOD1 bands from TgSOD1G93A(H), TgSOD1WT, TgWTSod1+/D83G and TgWTSod1D83G/D83G mice migrate faster 
compared to SOD1 bands from wild-type and Sod1D83G mice. 
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Figure 4.9 Quantification of SOD1 protein levels and activity of Sod1D83G X TgSOD1WT offspring 
at 15 weeks of age. (a) SOD1 protein levels and (b) activity of wild-type (WT), TgSOD1WT and 
TgSOD1G93A(H) animals. (c) SOD1 protein levels and (d) activity of non-transgenic offspring: Sod1D83G 
homozygous, heterozygous and wild-type littermates. (e) SOD1 protein levels and (f) activity of 
transgenic offspring: TgWTSod1+/D83G, TgWTSod1D83G/D83G and TgSOD1WT. Values represent the 
mean ± SEM from 3 independent experiments, expressed as % of wild-type (a, b, c and d) or % of 
TgSOD1WT (e and f). SOD1 protein levels are normalised for β-actin. For all measurements p < 0.001 = 
***; p < 0.01 = **; p < 0.05 = *, n = 3 per genotype per experiment. 
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4.4 Conclusions 
Transgenic mouse models overexpressing either wild-type or mutant human SOD1 
have been largely employed in the study of ALS (Joyce et al., 2011). In particular mice 
overexpressing the mutant human SOD1 gene recapitulate many characteristics of 
human ALS and have been crucial in our understanding of this disease. However, they 
are not a close genetic representation of human ALS, as they overexpress the human 
SOD1 protein at high levels, alongside the endogenous mouse SOD1 protein (Figure 
4.10). Also Sod1 knockout models have been key in SOD1-ALS research. These mice 
have a slow progressive axonopathy and a range of ALS-like phenotypes but do not 
develop motor neuron degeneration therefore they are not a model of human ALS 
(Figure 4.10). Sod1D83G is the first mouse model described to date that carries the 
equivalent of a human pathogenic mutation in the mouse Sod1 gene expressed at 
endogenous levels (Joyce et al., 2014; Millecamps et al., 2010), and in this mouse line 
the mutant SOD1 protein is endogenous and not overexpressed (Figure 4.10). 
Investigation of the Sod1D83G line demonstrated that mutations in the mouse 
endogenous Sod1 gene model some human ALS features, which are different from the 
characteristics modelled by mice overexpressing human mutant SOD1 transgenes, 
making Sod1D83G a useful tool to study new aspects of ALS. 
 
Figure 4.10 Types of mouse model used in ALS research. Transgenic mouse models of ALS express 
endogenous mouse Sod1 gene (mouse chromosome 16) and overexpress the human mutant SOD1 gene; 
Sod1 knockout models lack the endogenous Sod1 gene; Sod1D83G mouse carries a mutation in the 
endogenous Sod1 gene. Mutant human SOD1 gene (mSOD1); mutant mouse Sod1 gene (mSod1). 
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Characterisation of the Sod1D83G line showed that homozygous Sod1D83G animals 
develop a distal axonopathy and have progressive loss of upper and lower motor 
neurons. This motor neuron degeneration appears to stop in early adulthood, does not 
lead to paralysis and is likely caused by a toxic gain of function mechanism as occurs in 
fALS patients. Heterozygous mice do not have motor neuron loss, at least up until one 
year of age, probably because the dose of mutant SOD1 protein is not sufficient to 
cause degeneration or because wild-type SOD1 has a protective effect. Both 
homozygous and heterozygous mice develop a series of other ALS related phenotypes 
(Joyce et al., 2014). 
Data presented in this chapter highlighted some interesting features of this mouse 
model. Morphological examination of the EDL muscle showed that at 52 weeks of age 
Sod1D83G/D83G animals have a significantly higher percentage of denervated NMJs 
compared to littermates. Also, the total number of NMJs counted is significantly 
smaller compared to the other genotypes, probably because some neuromuscular 
endplates are no longer detectable from muscle sections. Suggesting that the 
degeneration process occurs between 15 and 52 weeks of age. Since in Sod1D83G/D83G 
motor neuron degeneration occurs between 6 and 15 weeks and does not progress 
further with age (Joyce et al., 2014); taken together these findings point to the 
hypothesis that the loss of EDL neuromuscular junction detected in these mice is a 
peripheral neuropathy that is not caused by motor neuron death.  
Investigation of SOD1 protein by western blot showed a dose-dependent decrease of 
SOD1 in homozygous and heterozygous animals, which does not change with age. 
Sod1D83G/D83G mice have a reduction in SOD1 protein to approximately 10 % of wild-
type, while Sod1+/D83G retain about 70 % of SOD1 protein. Analysis of the mRNA levels 
revealed that these SOD1 protein reductions are not caused by allele-specific 
differences in transcription (Joyce et al., 2014), but more likely are the result of mutant 
SOD1 instability and degeneration. Indeed, the D83 residue was predicted to 
coordinate zinc and therefore be crucial for SOD1 stability, see Figure 1.4 (Choi et al., 
2011; Krishnan et al., 2006; Nordlund et al., 2009); moreover mutant SOD1 was 
shown to have a decreased half-life compare to wild-type protein and consequently 
degenerate faster (Kabuta et al., 2006). The low SOD1 protein detected in Sod1D83G/D83G 
mice might explain why the motor neuron loss does not progress with age in these 
animals. It is known from SOD1 transgenic mouse models that there is a positive 
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correlation between toxicity and SOD1 dose. Therefore it is possible to speculate that 
the low SOD1 protein level detected in homozygous animals is sufficient to trigger 
motor neuron denegation but not at the same levels seen in SOD1-ALS patients. 
Activity gel analysis showed that SOD1 dismutase activity in 15 and 60-week old 
Sod1D83G/D83G is approximately 1 % of wild-type animals, while Sod1+/D83G retain about 
50 % of SOD1 activity, similarly to SOD1-fALS patients (section 3.3.1) and to Sod1 
knockout mice (section 3.3.2 and Figure 4.5 (b)). Interestingly homozygous Sod1D83G 
animals share commonalities with Sod1-/- mice (discussed in section 7.1.4), the most 
striking example is the development of a progressive peripheral motor neuropathy. 
This shared phenotype, may be caused by a loss of dismutase function mechanism, 
which might increase the vulnerability of motor axons to oxidative stress (Fischer et al., 
2004) or simply be the result of a lack of a yet unknown SOD1 function. Of note the 
SOD1 protein activity bands detected from brain homogenates of mice carrying either 
the human wild-type or mutant SOD1 G93A transgene, migrated faster in the gel 
compared to the bands from mouse wild-type and mutant D83G samples. This 
difference in migration pattern in native conditions may be explained by diverse 
biochemical and biophysical characteristics of the human and mouse SOD1 proteins. 
Studies carried out in SOD1 transgenic mouse models and ALS patients led to the 
concept that ALS is a “dying back” disorder, meaning that in the disease muscle 
denervation occurs prior to motor neuron cell body death (Fischer et al., 2004; Murray 
et al., 2010). Thus suggesting that a gain of toxic function can contribute to the 
peripheral neuropathy seen in Sod1D83G/D83G animals. However, data presented here and 
findings from other SOD1 mouse models point to the hypothesis that axonal and 
neuron body degeneration are separate events, which may be regulated by different 
genes. The Sod1D83G/D83G mouse may be a good system in which it is possible to dissect 
the early stages of the human ALS and separate the effects of a mutant SOD1 toxic 
gain of function from a loss of function.  
To try and investigate the gain and loss of function mechanisms, Sod1D83G animals were 
crossed with Sod1 knockout and TgSOD1WT mice. To date only SOD1 protein levels 
and activity have been measured from the offspring of these crosses. Data on motor 
neuron counts, muscle force and EDL motor unit survival have not yet been analysed. 
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SOD1 protein levels of the compound heterozygous animals Sod1-/D83G, produced from 
the cross with the Sod1 knockout line, are significantly reduced compared to Sod1+/D83G 
and also compared to Sod1D83G/D83G littermates, while SOD1 activity is absent. 
Investigation of spinal cord and muscles of these animals will tell if the Sod1D83G 
phenotype is dose-dependent and whether one mutant D83G allele is sufficient to 
cause motor neuron degeneration. Moreover it will shed some light on the causes of 
the peripheral axonopathy and the motor neuron loss seen in Sod1D83G/D83G animals. 
Indeed, if a gain of function mechanism is present, the Sod1-/D83G phenotype should be 
less severe than the one of Sod1D83G/D83G mice. 
SOD1 protein levels and activity measured from offspring of the Sod1D83G X 
TgSOD1WT confirmed previous results from Sod1D83G animals and showed five-fold 
increase in protein level and SOD1 activity in transgenic animals compared to wild-
type. Investigation of motor neurons of transgenic offspring will tell if the presence of 
a human wild-type SOD1 protein has a protective effect and rescues the loss of motor 
neurons seen in homozygous Sod1D83G animals or if its exacerbates ALS phenotypes. 
The present work on the Sod1D83G model together with further analysis will hopefully 
give new insights on the contribution of both central neuronal loss and peripheral 
neuronal dysfunction in SOD1-ALS. 
4.5 Summary 
 Sod1D83G/D83G mice develop a distal progressive motor axonopathy between 15 
and 52 weeks of age 
 SOD1 protein levels are reduced to ~65 % in Sod1+/D83G and to ~10 % in 
Sod1D83G/D83G compared to wild-type littermates both at 15 and 60 weeks of age 
 SOD1 dismutase activity is reduced to 50 % in Sod1+/D83G and it is almost 
absent in Sod1D83G/D83G compared to wild-type littermates both at 15 and 60 
weeks of age 
 SOD1 protein levels of Sod1-/D83G mice are significantly reduced compared to 
Sod1+/D83G and Sod1D83G/D83G littermates 
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 SOD1 activity of Sod1-/D83G mice is almost absent and significantly reduced 
compared to Sod1+/D83G littermates 
 TgSOD1WT, TgWTSod1+/D83G and TgWTSod1D83G/D83G have similar SOD1 protein 
levels and activity which are significantly increased compared to wild-type 
littermates  
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Chapter 5 Characterisation of SOD1 proteins 
5.1 Introduction 
5.1.1 Possible prion-like mechanism for SOD1 protein 
SOD1 displays prion-like properties both in vitro and in vivo, as happens for proteins 
causative of other neurodegenerative diseases such as Parkinson’s and Alzheimer’s 
disease (Marciniuk et al., 2013). Proteins that have prion-like properties are able to 
sequester the wild-type form of the protein, seed its aggregation or misfolding, and act 
as transmissible agents between cells (Bunton-Stasyshyn et al., 2014; Polymenidou and 
Cleveland, 2012), Figure 5.1.  
 
Figure 5.1 Possible prion-like mechanism for SOD1 protein. (a) Misfolded SOD1 within a cell 
could (b) sequester and misfold wild-type SOD1 and eventually producing aggregates. (c) If secreted and 
taken up by neighbouring cells misfolded SOD1/aggregated SOD1 could (d) cause a chain reaction of 
misfolding, aggregate formation and transmission in a prion-like manner. 
Indeed, SOD1 protein can form aggregates, which are a well-known hallmarks of 
SOD1-fALS, and have been found also in sALS cases (Bosco et al., 2010; Forsberg et 
al., 2010; Grad and Cashman, 2014). Moreover SOD1 has been shown to seed its own 
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aggregation in vitro and to transmit in human and mouse cell lines and recently also in 
SOD1-fALS mouse models (Ayers et al., 2014; Chia et al., 2010; Furukawa et al., 2013; 
Münch et al., 2011; Weisberg et al., 2012). These findings are in accordance with the 
fact that ALS has a focal start and is a non-cell autonomous disease (Ilieva et al., 2009), 
and point to the hypothesis that mutant forms of the SOD1 proteins are the toxic 
spices causative of SOD1-ALS. Indeed non-amyloid SOD1 inclusions are found in 
SOD1-fALS MNs (Kato et al., 1996, 1997, 2000; Kerman et al., 2010), and there is a 
correlation between disease phenotype and aggregation pathology in SOD1-fALS mice 
(Turner et al., 2003; Wang et al., 2002a, 2002b, 2005a). Furthermore investigation of 
aggregate toxicity in cell culture models has yielded evidence suggesting that increasing 
the level of soluble SOD1 increases toxicity, while increasing recruitment of mutant 
SOD1 into insoluble inclusions decreased toxicity (Brotherton et al., 2013; Weisberg et 
al., 2012). 
5.1.1.1 SOD1 aggregation in vitro  
In vitro Thioflavin-T (ThT) assays, measuring protein aggregation propensity, 
demonstrated that both wild-type and mutant human SOD1 recombinant proteins can 
spontaneously aggregate, seed aggregation of themselves (self-seeding) and of each 
other (cross-seeding), in an autocatalytic manner (Chia et al., 2010). The lag time of 
fibrillization both for self-seeded and cross-seeded reactions was shorter compared to 
spontaneous seeding (Chia et al., 2010). Further, spinal cord homogenates from 
TgSOD1G93A(H) mice were shown to successfully self-seed and cross-seed aggregation in 
vitro with recombinant wild-type and mutant SOD1 proteins (Chia et al., 2010). Of note 
the seeding of SOD1 amyloid fibrilis occurred at acidic pH and in the presence of a 
chaotrophic and a misfolding agent (Bunton-Stasyshyn et al., 2014; Chia et al., 2010). 
Finally self-seeding and cross-seeding with recombinant proteins were shown to 
produce aggregate species with structural properties similar to aggregates found in 
SOD1-fALS (Hwang et al., 2010).  
5.1.1.2 SOD1 transmission in vitro 
Cells experiments showed that mutant SOD1 was secreted extracellularly in exosomes 
from primary astrocytes and neuronal-like stable cell lines (Basso et al., 2013; Grad and 
Cashman, 2014). Moreover, mutant SOD1 protein was detected in medium from 
primary cultures of spinal cord and of astrocytes from SOD1-ALS transgenic mice 
(Basso et al., 2013; Urushitani et al., 2006). Interestingly astrocytes derived from 
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SOD1-fALS mice showed increased secretion of SOD1 in exosomes compared to 
mice overexpressing the wild-type human SOD1 protein and these exosomes resulted 
toxic to primary cultures (Basso et al., 2013). 
Internalisation of recombinant mutant and wild-type SOD1 proteins also occurred in 
cell models, either via macropinocytosis in neuronal-like stable cell lines (Grad and 
Cashman, 2014; Münch et al., 2011; Sundaramoorthy et al., 2013), or via exosome 
internalisation in primary mouse spinal cord cultures and neuronal-like cell lines (Basso 
et al., 2013; Grad and Cashman, 2014). 
Investigations carried out using a mouse neuroblastoma-derived cell line confirmed in 
vitro results showing that once internalised, aggregates of recombinant mutant SOD1 
could self-seed aggregations of stable mutant SOD1 protein, even after the exogenous 
seeds were no longer present in the cells (Münch et al., 2011). Further aggregated and 
non-aggregated recombinant mutant SOD1 could cross-seed the wild-type form of the 
protein, which could also be self-seeded by aggregated recombinant wild-type SOD1 
(Bunton-Stasyshyn et al., 2014; Sundaramoorthy et al., 2013).  
In a human cell line, exogenously applied recombinant mutant SOD1 (both aggregated 
and non-aggregated) and aggregated wild-type SOD1 caused aggregation of 
endogenous SOD1, but also activated ER stress and apoptotic cell death 
(Sundaramoorthy et al., 2013), demonstrating ALS relevant toxicity related to self-
seeded and cross-seeded reactions. Of note self-seeding aggregation of endogenous 
SOD1 was reported in stable cell lines and could be blocked by immune-depletion of 
misfolded SOD1 or by knocking down the SOD1 gene (Grad and Cashman, 2014; 
Grad et al., 2011). 
5.1.1.3 SOD1 transmission in vivo 
In a recent study Ayers and colleagues investigated the prion-like transmissibility of 
mutant SOD1 and motor neuron disease pathology in vivo. Spinal cord homogenates 
from TgSOD1G93A(H) mice were injected in spinal cords of different SOD1 transgenic 
mice. After injection motor neuron disease was induced in and otherwise unaffected 
transgenic animals expressing low level of mutant SOD1 G85R (TgSOD1G85R). 
Interestingly when spinal cord homogenate from induced mice was used to inoculate 
new animals, as happened in prion models, the disease onset of recipient mice was 
early compared to the first passage animals. Also one-third of the TgSOD1G85R animals 
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inoculated with homogenates from TgSOD1WT animals developed degeneration of 
motor neurons. Of note self-seeding experiments carried out by the same group in 
other transgenic mice did not change the phenotype of these animals. There are 
therefore evidence suggesting that mutant SOD1 and motor neuron degeneration may 
be transmitted with a prion-like mechanism but is still unclear if misfolded SOD1 is 
required and sufficient for this to happen (Ayers et al., 2014). 
5.1.2 Human and mouse SOD1 proteins 
Human and mouse SOD1 proteins share a similar structure and are 84 % identical in 
amino acid sequence (Seetharaman et al., 2010). Both mouse and human SOD1 
function as a dimer and accomplish the same function of scavenging superoxide 
radicals from the body. In SOD1 transgenic mouse models the wild-type or mutant 
human SOD1 protein is overexpressed together with the endogenous mouse SOD1 
protein. The presence of SOD1 aggregates in these animals and the possible 
pathogenic role for misfolded SOD1 highlighted the importance of investigating the 
interaction between human and mouse SOD1. Cell culture and mouse model 
experiments showed that when co-expressed with human SOD1 mutants the 
endogenous mouse SOD1 does not co-aggregate (Wang, 2003). However, when 
mutant human SOD1 and wild-type human SOD1 are co-expressed the wild-type form 
of the protein co-aggregates with the pathogenic variant (Prudencio et al., 2009c; 
Seetharaman et al., 2010). Further a recent study on a mouse line carrying the G86R 
mutation (equivalent of human G85R) in the endogenous mouse Sod1 gene 
demonstrated that raising levels of wild-type human SOD1 does not affect disease in 
these animals (Audet et al., 2010). A subsequent study by Qualls and colleagues using 
cell culture models, showed that misfolded mouse SOD1 G86R interacts readily with 
mouse wild-type SOD1 protein and poorly with human wild-type SOD1 (Qualls et al., 
2013). 
5.2 Aim 
Mutant and wild-type human SOD1 recombinant proteins are known to spontaneously 
aggregate, self-seed and cross seed in vitro (Chia et al., 2010). Furthermore, both human 
and mouse SOD1 proteins are found in aggregates in SOD1 transgenic mouse models, 
however, it is still unclear whether the mouse and the human variants can co-aggregate 
in vitro and in vivo.  
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In order to investigate possible interactions between the human and the mouse SOD1, 
the aggregation propensity of human and mouse SOD1 recombinant proteins was 
examined in vitro. In particular human and mouse SOD1 recombinant proteins were 
produced using an E. coli system and purified by affinity chromatography. The purity of 
the preparations was then assessed by measuring protein quantity via western blot and 
coomassie blue. All SOD1 recombinant proteins were characterised by investigating 
their secondary structure with CD, focusing on the possible differences between 
human and mouse structure. Further, two preliminary experiments were carried out to 
investigate whether the mouse SOD1 recombinant proteins can spontaneously seed 
aggregation in vitro as happen for human SOD1.  
As part of a bigger project to study whether SOD1 can act in a prion-like way seeding 
aggregations (Appendix 8.6), mouse spinal cord homogenates were analysed by 
polyacrylamide gel electrophoresis to confirm the presence of SOD1 and possibly 
detect misfolded forms of the protein.  
5.3 Results 
5.3.1 SOD1 recombinant proteins 
To investigate the aggregation propensity of mouse and human SOD1 protein and its 
capacity to co-aggregate, eight SOD1 protein variants were produced, purified and 
characterised. Preliminary experiments were then carried out to study SOD1 protein 
aggregation. 
5.3.1.1 Production and purification of recombinant proteins 
Five human SOD1 and three mouse SOD1 recombinant proteins (Table 5.1) were 
produced using a prokaryotic expression system: E. coli BL21 (DE3), as in (Chia et al., 
2010). The cDNA of the eight SOD1 variants employed in this study had been 
previously cloned by Dr Chia Ruth into pET28a expression vectors downstream of a 
sequence encoding a string of six histidines, so that the SOD1 protein produced would 
be His-tagged. Expression of the SOD1 protein was based on an IPTG induction 
system see sections 2.6.1 and Appendix 8.1. 
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Species Variants 
Human 
Wild-type 
G93A 
D83G 
I113T 
D101G 
Mouse 
Wild-type 
G93A 
D83G 
Table 5.1 Human and mouse SOD1 recombinant proteins produced.  
 
A protein scale preparation from 9 litre culture was carried out for each SOD1 variant. 
E. coli strains transformed with plasmids carrying the SOD1 cDNAs of interest were 
grown as described in section 2.6.1. Once the desired cell density was reached, SOD1 
protein expression was induced using IPTG. Samples of SOD1 protein preparations 
pre-IPTG and post-IPTG treatment were collected and tested by coomassie blue to 
confirm induction (see example for human SOD1 wild-type in Figure 5.2). Prior to 
purification SOD1 proteins were extracted and solubilised as described in 2.6.1.1.  
Affinity chromatography purification was carried out using a Ni-NTA column on an 
ÄKTA pure machine. The soluble fraction from the crude cell extract of each 
preparation was loaded on the Ni-NTA column to remove the contaminating proteins 
from the His-SOD1 protein. After overnight on-column refolding (Figure 5.3 (a)) the 
His-SOD1 protein was eluted (Figure 5.3 (b)), dialysed and incubated with thrombin to 
cleave the His-tag. All SOD1 variants were separated by polyacrylamide gel 
electrophoresis and stained using coomassie blue to confirm cleavage (see example for 
human SOD1 wild-type Figure 5.4). The free His-tag was removed by a second Ni-
NTA affinity chromatography (Figure 5.5) and the SOD1 protein preparation was 
collected and dialysed against storage buffer, see 2.6.1.2. Prior to experiments, all 
SOD1 proteins were loaded with copper and zinc by subsequent dialysis to ensure 
acquisition of their full enzymatic activity see 2.6.1.2. 
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The amount of SOD1 protein produced varied between 20 and 130 mg depending on 
the protein preparation. While the final concentrations of the recombinant proteins 
ranged between 0.5 and 2 mg / ml per SOD1 variant. Protein concentration was a 
crucial parameter for characterisation and aggregation experiments, it was therefore 
carefully calculated using three different methods: absorbance, DC protein assay and 
coomassie blue staining compared to a sample of known concentration, (section 2.6.3 
and 2.6.4.1). Results obtained were consistent among the three methods.  
The images presented in this section are representative of the human wild-type SOD1 
protein, the same procedure was carried out for all other variants. 
 
Figure 5.2 Bacterial growth for human wild-type SOD1 protein pre and post IPTG induction. 
From the left ladder (L); His-tagged human SOD1 wild-type protein (Hu WT un-cleaved); non-His-
tagged variant (Hu WT cleaved); human SOD1 wild-type bacterial growth before IPTG induction (Hu 
WT un-induced); human SOD1 wild-type bacterial growth after IPTG induction (Hu WT induced). 
Approximately 15 µg of protein were loaded on each well. 
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Figure 5.3 Human wild-type SOD1 protein first Ni-NTA affinity chromatography. (a) Human 
wild-type SOD1 protein preparation solubilised in a chaotrope buffer was loaded on the column causing 
an increased in the UV (blue line). During this process the His-tagged SOD1 bound to the column while 
the contaminating proteins flushed through. The His-SOD1 protein was then allowed to refold 
overnight on column over a gradient of 0 to 100 % of a non chaotropic buffer (buffer B; green line), 
causing the UV to drop to zero. (b) The His-SOD1 protein was eluted from the column over a reducing 
gradient of buffer B and an increased concentration of an imidazole buffer, to displace the His-tag from 
nickel co-ordination. The UV peak on the graph correspond to the His-SOD1 protein elution. Due to 
the presence of imidazole UV does not plateau at zero but approximately at 600 mAU. The brown line 
indicates the conductivity of the buffer. 
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Figure 5.4 Human wild-type SOD1 protein before and after His-tag cleavage. The His-tagged 
human SOD1 wild-type protein (Hu WT un-cleaved) has a higher molecular weight compared to the 
non-His-tagged variant (Hu WT cleaved) therefore migrates slower on the gel. (Hu WT) purified and 
metal loaded recombinant human wild-type SOD1 protein; (L) ladder. Approximately 15 µg of protein 
were loaded on each well. 
 
Figure 5.5 Human wild-type SOD1 protein second Ni-NTA affinity chromatography. The human 
wild-type SOD1 protein was loaded on the column and eluted over an increasing gradient of imidazole 
buffer (buffer E), the peak in the UV correspond to the non-His-tagged SOD1 protein. Of note due to 
the presence of imidazole mAU do not plateau at zero. The brown line indicates the conductivity of the 
buffer. 
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5.3.1.2 Sodium dodecyl sulphate - polyacrylamide gel electrophoresis of 
mouse and human purified SOD1 recombinant proteins 
To confirm that the recombinant proteins produced were mouse or human SOD1 
variants and that the preparations were not contaminated by other proteins, all samples 
were separated by SDS-PAGE and tested by western blot and coomassie blue staining. 
Western blot analysis using a commercial polyclonal antibody (SOD-100) that detects 
both mouse and human SOD1, confirmed that the metal loaded recombinant proteins 
produced were SOD1 variants. Both human and mouse SOD1 proteins migrated as a 
monomer with a molecular weight of approximately 16 kDa, see Figure 5.6. 
 
Figure 5.6 Western blot of purified human and mouse SOD1 recombinant proteins. From the left 
ladder (L); human wild-type SOD1 (Hu WT); mouse-wild-type SOD1 (Mo WT); human G93A SOD1 
(Hu G93A); mouse G93A SOD1 (Mo G93A); human D83G SOD1 (Hu D83G); mouse D83G SOD1 
(Mo D83G); human I113T SOD1 (Hu I113T) and human D101G SOD1 (Hu D101G). SOD1 migrated 
as a monomer with a molecular weight of about 16 kDa; 20 µg of protein were loaded per well.  
To test the purity of the SOD1 protein preparations, metal loaded samples were 
separated by SDS-PAGE gel and stained by coomassie blue. As in the western blot, a 
single band of approximately 16 kDa was visible in all samples indicating that the only 
protein present in the preparations was SOD1, Figure 5.7. Both wild-type and mutant 
mouse SOD1 proteins migrated slightly faster than human wild-type SOD1. While 
most of human SOD1 mutants migrated as human wild-type SOD1 with the exception 
of human SOD1 G93A, see Figure 5.7. This difference in migration pattern might be 
due to the difference in metal binding capacity among these SOD1 variants.  
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Figure 5.7 Coomassie blue of purified human and mouse SOD1 recombinant proteins. From the 
left ladder (L); human wild-type SOD1 (Hu WT); mouse-wild-type SOD1 (Mo WT); human G93A 
SOD1 (Hu G93A); mouse G93A SOD1 (Mo G93A); human D83G SOD1 (Hu D83G); mouse D83G 
SOD1 (Mo D83G); human I113T SOD1 (Hu I113T) and human D101G SOD1 (Hu D101G). SOD1 
migrated as a monomer with a molecular weight of about 16 kDa. 20 µg of protein were loaded per well. 
5.3.2 SOD1 recombinant proteins structural profile with circular dichroism  
In order to confirm that the SOD1 recombinant proteins produced were correctly 
folded their secondary structure was investigate by circular dichroism (CD), a form of 
spectroscopy that measures the differential interaction of circularly polarised light with 
proteins in solution (Beychok, 1966). To examine proteins’ secondary structure CD is 
typically measured at a UV interval of 190-250 nm (far-UV). Three possible protein 
conformations are identifiable by the CD spectrum at a far-UV: α-helix, β-sheet and 
random coil.  
Purified SOD1 proteins stored in 20 mM Tris-HCl at pH 7.5, were dialysed in a 
20 mM phosphate buffer at pH 7.5. Tris-HCl indeed absorbs highly in the UV 
wavelength of interest and might interfere with a protein CD spectrum. Each 
recombinant protein was measured for its CD at a far-UV over a series of 10 
accumulations (Figure 5.8 and Figure 5.9). The CD spectra obtained for all the SOD1 
variants, showed a negative peak at approximately 208 nm, with the exception of 
mouse wild-type and mouse G93A SOD1. In particular the CD spectra of human 
SOD1 variants were all very similar among each other and resembled of proteins 
containing β-sheet conformation, as published by Chia and colleagues in 2010 (Figure 
5.8 (a)). Further the CD spectra of mouse SOD1 variants were similar, however, the 
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mouse G93A SOD1 showed a deviation of the negative peak to 200 nm compared to 
the other 2 mouse SOD1 variants, which indicates of an increase in random coil 
conformation (Figure 5.8 (b)). Interestingly when comparing the CD spectra of 
homologous human and mouse SOD1 recombinant proteins (SOD1 wild-type, D83G 
and G93A), the negative peak of the mouse SOD1 variants were always slightly shifted 
towards 200 nm compared to the human forms (Figure 5.9). These results taken 
together indicate that the SOD1 proteins examined have a β-sheet conformation, 
which is consistent with previous SOD1 structural and conformational studies (Chia et 
al., 2010; Getzoff et al., 1989; Khare et al., 2004; Rakhit and Chakrabartty, 2006; Tainer 
et al., 1982). 
 
Figure 5.8 CD spectra of human and mouse SOD1 recombinant proteins. CD spectra were 
measured at a wavelength interval of 190 to 250 nm. (a) Wild-type and mutants human SOD1 
recombinant proteins; (b) wild-type and mutants mouse SOD1 recombinant proteins All SOD1 
recombinant proteins, except mouse G93A SOD1 have a comparable CD spectra resembling of proteins 
containing β-sheet conformation. Mouse G93A SOD1 CD spectrum is the only one resembling a 
random coil confirmation. 
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Figure 5.9 CD spectra comparison between human and mouse SOD1 recombinant proteins. CD 
spectra were measured at a wavelength interval of 190 to 250 nm. (a) SOD1 wild-type human and mouse 
proteins; (b) SOD1 human and mouse D83G proteins; (c) SOD1 human and mouse G93A proteins. All 
mouse SOD1 recombinant proteins, have a CD spectra slightly shifted towards the far-UV compared to 
the human variants, resembling a random coil confirmation. 
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5.3.3 Kinetics of spontaneous fibrillization of mouse and human SOD1 
recombinant proteins  
In order to study the kinetics of human and mouse SOD1 fibrillization, some 
preliminary fibrillization assays for spontaneous reactions were carried out using the 
SOD1 recombinant proteins produced. 
For all SOD1 variants, fibrillization was carried using a protein concentration of 20 µM 
in a solution at pH 3.0 in mild denaturing conditions (0.5 GuHCl) similar to what 
described in Chia et al., 2010. Spontaneous fibril formation of SOD1 proteins was 
monitored by following the change in fluorescence of Thioflavin-T (section 2.6.6). The 
fibrillization lag time of the proteins was calculated using the equation described in 
2.6.6. In all the figures fibril formation is reported as % of maximum ThT relative 
fluorescence units (RFU) shown as a function of time (in hours).  
To optimise experimental conditions, two preliminary assays were conducted, testing 
the spontaneous fibrillization for all 8 SOD1 variant over 6 repetitions. In the first 
experiment ThT fluorescence was measured over a period of 250 hours. Formation of 
fibrils occurred evenly among the 6 sample repeats only for human wild-type SOD1 
(Figure 5.10) and mouse and human D83G SOD1 proteins (Figure 5.11). The lag time 
of human wild-type SOD1 was of 125 hours, which is very short compared to 
previously published data where the same recombinant protein was tested under 
similar conditions (Chia et al., 2010). While fibril formation for both human and mouse 
D83G SOD1 occurred at approximately 200 hours, only 50 hours before the 
conclusion of the experiment.  
Since human and mouse D83G SOD1 fibrillization seemed to start only at 200 hours, 
in the second experiment ThT fluorescence was measured over a period of 450 hours. 
In this case fibril formation occurred evenly among the 6 sample repeats for mouse 
wild-type SOD1 (Figure 5.12) and human D83G SOD1 (Figure 5.13). The lag time of 
mouse wild-type SOD1 was of approximately 225 hours. While similarly to the 
previous experiment fibril formation for human D83G SOD1 occurred at 200 hours. 
These results are preliminary, and more experiments are necessary to optimise the 
fibrillization assay. However, these first analysis confirmed that human SOD1 
recombinant proteins can spontaneously form fibrils in vitro and suggest that also 
mouse SOD1 recombinant proteins can spontaneously fibrillize under similar 
conditions. 
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Figure 5.10 Spontaneous fibrillization of SOD1 human wild-type recombinant protein. Data 
shown are average values from 6 replicates (± SEM) from an independent assay. SOD1 human wild-type 
recombinant protein (SOD1 Hu WT). 
 
Figure 5.11 Spontaneous fibrillization of SOD1 human and mouse D83G recombinant proteins. 
Data shown are average values from 6 replicates (± SEM) from an independent assay. SOD1 human 
D83G recombinant protein (SOD1 Hu D83G); SOD1 mouse D83G recombinant protein (SOD1 Mo 
D83G). 
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Figure 5.12 Spontaneous fibrillization of SOD1 mouse wild-type recombinant protein. Data 
shown are average values from 6 replicates (± SEM) from an independent assay. SOD1 mouse wild-type 
recombinant protein (SOD1 Mo WT). 
 
Figure 5.13 Spontaneous fibrillization of SOD1 human D83G recombinant protein over 450 
hours. Data shown are average values from 6 replicates (± SEM) from an independent assay. SOD1 
human D83G recombinant protein (SOD1 Hu D83G). 
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5.3.4  SOD1 transmission project  
As part of the transmission project (Appendix 8.6) mouse spinal cord homogenates 
used to inoculate TgSOD1G93A(H) animals were separated by SDS-PAGE and the SOD1 
protein was detected by western and native blot.  
The inoculum tested by SDS-PAGE were 1 % spinal cord homogenates of Sod1-/-, 
TgSOD1G93A(H) and TgSOD1WT mice in PBS, plus a wild-type controls prepared in the 
same manner. 
5.3.4.1 Western blot analysis  
Western blot analysis (section 2.6.4.2) carried out using a commercial polyclonal 
antibody against SOD1 protein (SOD-100) confirms that SOD1 was absent in Sod1-/- 
homogenates and that it was overexpressed in TgSOD1G93A(H) and TgSOD1WT samples 
compared to wild-type control (Figure 5.14). 
 
Figure 5.14 Western blot of spinal cord homogenates. SOD1 protein is overexpressed in transgenic 
samples and absent in the Sod1 knockout sample. Ladder (L); wild-type (WT) control. 20 µg of protein 
per well. 
5.3.4.2 Native blot analysis 
Native blot analysis was carried as described in section 2.6.4.3 using three different 
antibodies. A commercial polyclonal antibody against SOD1 protein (SOD-100), and 
two conformation specific SOD1 antibodies: SEDI (SOD1 exposed dimer interface) 
(Rakhit et al., 2007) and USOD (unfolded SOD1) (Kerman et al., 2010). In particular 
these two antibodies were shown to detect misfolded SOD1 by immunohistochemistry 
and immunoprecipitation, but accordingly to published date they were never employed 
in native blot analysis.  
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Native blot probed using USOD and SEDI failed to reveal misfolded SOD1 bands in 
any of the samples, probably because these two antibodies are not suitable for the 
detection of SOD1 protein in blots (Figure 5.15 (a) and (b)). Though, the native blot 
probed using SOD1-100 antibody confirmed the result seen in the western blot 
analysis, that SOD1 protein was absent in the Sod1-/- homogenate and it was 
overexpressed in TgSOD1G93A(H) and TgSOD1WT samples compared to wild-type 
control. Interestingly in non-denaturing and non-reducing conditions mouse wild-type 
SOD1 protein appears to migrate slower compared to the human SOD1 variants 
(Figure 5.15 (c)). All bands identified by the SOD1-100 antibody had a molecular 
weight bigger than 20 kDa, suggesting that the SOD1 proteins detected are not in the 
monomeric form. Of note these native blots have been purposely overexposed to 
reveal possible bands corresponding to misfolded SOD1. 
 
Figure 5.15 Native blot of spinal cord homogenates. (a), (b) SOD1 protein is not detected by USOD 
and SEDI antibodies. (c) SOD1 is overexpressed in transgenic samples and absent in the Sod1 knockout 
sample, mouse wild-type SOD1 (WT) migrates slower compared to human SOD1 variants 
(TgSOD1G93A(H) and TgSOD1WT); all SOD1 products detected have a higher molecular weight than 
monomeric SOD1 (16 kDa). 30 µg of protein per well. 
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5.4 Conclusions 
5.4.1 Comparison between SOD1 human and mouse proteins  
Data presented in this chapter showed that it is possible to produce and purify both 
human and mouse SOD1 recombinant proteins from an E. coli system. Western blot 
analysis established that the proteins produced were SOD1. While coomassie blue 
staining confirmed the purity of all the preparations and also showed the presence of a 
different migrations pattern among SOD1 variants, suggesting a diverse metal binding 
capacity between human and mouse SOD1 and also among human SOD1 variants. 
Characterisation of the SOD1 protein folding state by CD showed the presence of β-
sheet conformations in most of the SOD1 variants. The CD spectra of human SOD1 
proteins appeared very similar among each other as describe in Chia et al., 2010. Also 
mouse SOD1 CD spectra seemed comparable among each other with the exception of 
SOD1 mouse G93A, which resembled of a random coil conformation. Comparison 
between SOD1 wild-type human and mouse proteins and SOD1 human and mouse 
carrying the same mutations, revealed that the mouse CD spectra is always deviated 
slightly toward 200 nm, possibly indicating an increase in random coil conformation.  
Preliminary fibrillization experiments showed that both SOD1 human wild-type and 
mutant D83G recombinant proteins can spontaneously form fibrils in vitro under non 
physiological conditions, as indicated in literature (Chia et al., 2010). However, in this 
first analysis, differently from what was published by Chia and colleagues, the lag time 
of human wild-type SOD1 (Figure 5.10) was shorter compare to the lag time of the 
human SOD1 D83G mutant (Figure 5.11 and Figure 5.13), (Chia et al., 2010). 
Furthermore the experiments presented in this section showed that SOD1 mouse wild-
type and mutant D83G proteins could form fibrils in vitro under the same conditions 
used for the human variants. Specifically the lag time of the SOD1 mouse wild-type 
protein was shorter compare to the lag time of the mouse D83G mutant. Of note the 
lag time of human wild-type SOD1 protein was shorter compare to the lag time of the 
homologous mouse SOD1. While in the case of the D83G mutation the human variant 
had a slightly longer lag time compare to the mouse variant. 
Further investigation are necessary to optimise the experimental procedure to conduct 
fibrillization assays, but it is possible to conclude that both human and mouse SOD1 
recombinant proteins can spontaneously seed in vitro under non physiological 
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conditions. Supporting the idea that the ability to fibrilize is a generic and intrinsic 
property of the SOD1 proteins conserved among species. 
Results from native blots of mouse spinal cord indicated that the wild-type mouse 
SOD1 protein migrates slower compared to the wild-type and mutant G93A human 
SOD1 in non-reducing and non-denaturing conditions, possibly suggesting 
conformational and charge differences between the human and the mouse SOD1 
proteins. 
5.4.2 Future work 
5.4.2.1 Further mouse SOD1 proteins characterisation 
Other experiments can be done in order to further characterise the mouse SOD1 
proteins produced, as was extensively done for the human SOD1 variants (Rakhit and 
Chakrabartty, 2006; Valentine et al., 2005). For example the conformational and the 
aggregation state of the proteins could be investigated by analytical ultracentrifugation; 
their stability could be examined by differential scanning fluorimetry and their activity 
could be assessed by gel assays.  
5.4.2.2 Kinetics of mouse and human SOD1 proteins 
In order to optimise the fibrillization assay for SOD1 recombinant proteins it will be 
necessary to investigate a matrix of different experimental conditions. Important 
parameters that could be changed in order to potentiate fibril formations are: pH, 
temperature, experimental time and denaturant concentration. For example it was 
shown that apo-wild-type SOD1 proteins could form ThT-binding structures under a 
more physiological condition (pH 7.0), with very long periods of time (approximately 
5100 hours) (Banci et al., 2008). 
Once optimised fibrillization assays can be used to investigate self-seeding and cross 
seeding aggregation of mouse and human SOD1 proteins. Cross-seeding experiments 
will be crucial to determine whether mouse and human SOD1 variant have the ability 
to co-aggregate in vitro. Moreover, answering this question will be relevant to 
understand the results from the transmission project and the D83G project where 
human and mouse SOD1 proteins coexist and might interact within a living biological 
system. 
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5.5 Summary 
 Eight SOD1 human and mouse recombinant proteins were produced and 
purified 
 Purity and correct folding state were confirmed for all SOD1 recombinant 
proteins  
 All mouse SOD1 and human SOD1 G93A recombinant proteins migrate 
slightly faster compare to other human SOD1 recombinant variants including 
wild-type  
 The CD spectra of mouse SOD1 recombinant proteins always deviated to 
200 nm compared to the homologous human SOD1 recombinant proteins  
 Mouse SOD1 wild-type and D83G recombinant proteins can spontaneously 
form fibrils in vitro 
 In non-reducing and non-denaturant conditions mouse SOD1 wild-type 
migrates slower compared to human SOD1 wild-type and G93A mutant 
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Chapter 6 Galahad mouse 
6.1 Introduction 
Mouse models carrying genetic mutations have been extensively employed in 
neuroscience research since they often present pathologies that mimic the human 
disease state, and they are able to perform behavioural tasks and respond to drugs in a 
comparable way to humans (Acevedo-Arozena et al., 2008; Oliver and Davies, 2012). 
Two complementary strategies are typically applied to generate mouse models: the gene 
driven approach and the phenotype driven approach. In the gene driven approach the 
genome is manipulated to create genetically modified animals starting from a known 
gene, while in the phenotype driven approach mice carrying random mutations are 
screened for abnormal phenotypes (Acevedo-Arozena et al., 2008). Of note mice may 
also have mutations that occur naturally, examples of spontaneous mouse models of 
motor neuron degeneration are: the SOD/Ei mouse carrying a spontaneous mutation 
in the endogenous mouse Sod1 gene (Luche et al., 1997) and the motor neuron 
degeneration mouse (mnd) (Bertamini et al., 2002). 
The gene driven approach employing homologous recombination in embryonic stem 
cells has been extensively used to create knockout mice modelling human diseases and 
for the study of the disruption of specific genes in the whole organism. However, in 
nature many disorders are not caused by complete loss of gene function, but more 
likely they are the consequence of more subtle changes such as: protein structure 
modifications, binding affinity disruption, changes in expression or activity levels and 
more. In the phenotype driven approach N-ethyl-N-nitrosurea (ENU) chemical 
mutagenesis is used to generate point mutations in mice giving rise to a range of subtle 
mutant effects that model the diversity and complexity of human diseases, providing 
the tools to analyse compound genotypes and identify new pathways, genes or function 
involved in pathological mechanisms (Acevedo-Arozena et al., 2008; Justice et al., 
1999; Oliver and Davies, 2012).  
6.1.1 ENU mutagenesis and the phenotype driven approach 
In the last 20 years ENU mutagenesis screenings in conjunction with large-scale 
phenotype-driven approaches have been used to identify mouse models of human 
disorders and also to investigate new genes and pathways involved in complex disease 
pathologies (Acevedo-Arozena et al., 2008). 
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6.1.1.1 ENU properties 
ENU is a mutagen that since its discovery in 1979 has been largely employed to induce 
random point mutations in mouse (Russell et al., 1979). In particular when injected in 
mice ENU can transfer its ethyl group to oxygen or nitrogen radicals of 
deoxyribonucleotides causing random single base pair substitutions in the DNA during 
replication, in a dose-dependent manner, if not removed by DNA repair mechanisms 
(Justice et al., 1999; O’Neill, 2000). ENU preferentially modifies A/T base pairs, 
causing some amino acid changes to be more frequent than others (Table 6.1), 
nevertheless this limitation has not yet prevented the identification of new mutant 
models (Acevedo-Arozena et al., 2008; Justice et al., 1999).  
Base pair change   % 
A/T → T/A transversions 44 
A/T → G/C transitions 38 
G/C → A/T transitions 8 
G/C → C/G transversions 3 
A/T → C/G transitions 5 
G/C → T/A transitions 2 
Table 6.1 ENU base pair substitution frequency. ENU induced point mutations exhibit a preference 
towards specific nucleotide substitutions (Justice et al., 1999). 
6.1.1.2 ENU administration and breeding strategies 
Typically ENU is administrated to male mice as a sequence of two or three 
intraperitoneal injections at a dose of approximately 80-100 mg/kg. The dosage and 
the number of injections vary according to the mouse strain employed. It has been 
estimated that an optimal dose protocol should produce a mutation every 1-1.5 Mb, 
consequently the mutation rate of each gene varies depending on its size (Acevedo-
Arozena et al., 2008).  
ENU mutagenesis is used to carry out various types of screenings; different strategies 
and breeding schemes are applied depending on the chosen approach (genotype or 
phenotype driven), the allelic characteristics (recessive or dominant) and the strains 
required for subsequent genetic mapping (Acevedo-Arozena et al., 2008; Brown and 
Nolan, 1998). For example in a screen for dominant genome-wide mutations, ENU is 
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injected in male mice, causing random base-pair substitution preferentially in the 
spermatogonial stem cells. Mutagenized males are then mated with wild-type females 
and their progeny is screened for aberrant phenotypes through behavioural and 
physiological tests, followed by analysis of specific features of interest (Acevedo-
Arozena et al., 2008; Justice et al., 1999) (Appendix 8.5 and Figure 8.1). Furthermore 
ENU can be used to undertake sensitised screens to identify modifying loci that 
interact with specific mutations, and investigate new genetic pathways. In these screens 
ENU mutagenized male mice are crossed with females that are on a different genetic 
background and are mutant for a disease of interest. Different breeding strategies are 
employed depending on the nature of the mutant model, and the progeny are screened 
for aberrant phenotypes (Acevedo-Arozena et al., 2008). Of note in modifier screens 
analysis of the phenotype is crucial but also very challenging. Indeed animals that are 
not ENU mutant also present disease characteristics of the original model, thus it is 
essential to determine a baseline disease associate-phenotype and variation for the non-
mutagenized population in order to determine a suitable phenotyping strategy for the 
modifier screen (Acevedo-Arozena et al., 2008). 
Sensitised screens have been successfully employed in invertebrate models such as the 
fly Drosophila melanogaster , the nematode Caenorhabditis elegans and the zebrafish Danio 
rerio (St Johnston, 2002). Indeed the first pioneer screen using mutagenesis in a 
multicellular organism was carried out in Drosophila melanogaster and lead to the 
identification of 15 loci that when mutated alter the segmental pattern of the larva 
(Nüsslein-Volhard and Wieschaus, 1980). Since then many other sensitised chemical 
mutagenesis screens in lower organisms have provided models of neurological 
mutations related to human disease (Bach et al., 2003; Bonini and Fortini, 2003; 
Driscoll and Gerstbrein, 2003) and more recently this sensitised genetic systems have 
been developed also in mouse (Rubio-Aliaga et al., 2007). Using mouse models for 
sensitised screens is expensive, but to date mice are still the best model organism for 
the study of mammalian gene function and complex neurodegenerative disorders in the 
context of the whole organism. Indeed mice can be easily genetic manipulated and 
bred. Furthermore the complete genome is known for many inbred lines; therefore 
mutagenesis screens are a great tool for systematically generate new mutants. Also, 
mice complex behaviour makes them an effective model for human neurological 
disorders, hence sensitised screen, by producing a wide range of mutations, can not 
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only identify new mutants but also help elucidate intricate neurological pathways 
(Oliver and Davies, 2005). 
6.1.1.3 Mapping and cloning  
Once an ENU mutant is selected inheritance tests and positional cloning techniques 
are applied to isolate and identify the causative mutation of the new phenotype 
(Acevedo-Arozena et al., 2008; Oliver and Davies, 2012). The mutation is only 
inherited from the ENU mutagenized parent. Initial mapping commonly uses 
heterozygosity to detect areas of linkage, which is assisted by having two different 
inbred backgrounds for the parents. For inheritance testing in dominant screens if on 
the G0 (mutagenized generation and wild-type cross) animals have different 
backgrounds the ENU mutants of the G1 (first generation after mutagenesis) are 
backcrossed to the non-mutagenized strained of the G0, and the G2 (second 
generation after mutagenesis) is used for mapping. Conversely, if the G0 animals have 
the same background, it is not possible to test inheritance in the G2 but two other 
mating with a different inbred strain are required before positional cloning (Acevedo-
Arozena et al., 2008). While for recessive screens, regardless of the background of the 
G0, G2 mice are either intercrossed or mated to the original G1 ENU mutagenized 
parent, recessive mutations can be detected in the resultant G3 progeny. 
Causative mutations can be identified by genome mapping of a number of affected 
mice using single nucleotide polymorphisms (SNPs) as markers, in order to identify 
areas of linkage, followed by a candidate gene approach. Detecting newly induced 
causal variants in a forward genetic screen using these techniques is expensive and time 
consuming however, this process can now be accelerated using next-generation 
sequencing technologies which allow affordable whole-genome sequencing (Boles et 
al., 2009; Sun et al., 2012).  
6.1.2 A sensitised screen for modifiers in SOD1G93A low copy mice 
A sensitised screen focused on the identification of new genetic loci interacting with 
the mutant SOD1 gene was carried out as part of the Harwell ENU mutagenesis 
programme. BALB/c male mice were treated with a sequence of two 100 mg / kg 
ENU intraperitoneal injections. Mutagenized BALB/c males were then mated with 
hemizygous human SOD1G93A transgenic low copy females (TgSOD1G93A(L)/+) on a 
C57BL/6J background (see breeding scheme in Figure 6.1). SOD1 transgenic animals 
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from the G1 underwent a phenotyping analysis starting at 12 weeks of age and were 
compared to a non-mutagenized population of TgSOD1G93A(L)/+ on a hybrid 
C57BL/6J-BALB/c background (Acevedo-Arozena et al., 2011). Specifically every 2 
weeks transgenic G1 mice were tested using the SHIRPA protocol, and measures of 
weight, and grip-strength were taken. During this screen several mice were identified as 
phenodeviant of the SOD1G93A transgenic low copy line, but inheritance tests 
confirmed transmission of the ENU induced phenotype only from one male mouse, 
named Galahad. This animal developed paralysis at 27 weeks of age, showing an early 
disease onset compared to the non-mutagenized population, where the average age of 
paralysis is 35.6 weeks (Figure 6.2) (Acevedo-Arozena et al., 2011). Sperm samples 
from the affected G1 male mouse were collected to allow further breeding and in vitro 
fertilisation (IVF) (Thornton et al., 1999).  
A first IVF was carried out in Harwell soon after the identification of the Galahad 
mouse. Phenotyping of 32 G2 mice carrying the SOD1G93A low copy transgene 
confirmed the presence of an early paralysis onset in some of them, but it was not 
possible to identify any other phenotype. An initial genetic mapping on 9 animals that 
reached paralysis before 33 weeks of age suggested 3 possible regions of interest, 
however in order to confirm these areas of linkage a bigger number of G2 animals and 
a more in depth phenotyping approach will be necessary.  
 
Figure 6.1 Modifier screen in SOD1G93A low copy mice. In the G0 (mutagenized generation) ENU 
mutagenized BALB/c male mice were crossed with C57BL/6J hemizygous SOD1G93A low copy females. 
Transgenic animals of the G1 (first generation after mutagenesis) progeny were phenotypically screened 
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for modifications of the transgenic phenotypes. One phenodeviant mouse with an early paralysis onset 
was identified, named Galahad.  
6.1.3 The SOD1G93A low copy phenotype 
Transgenic human SOD1G93A low copy mice (Tg(SOD1*G93A)dl1Gur) carry 
approximately eight to ten copies of the human SOD1G93A transgene. This mouse line, 
here referred as TgSOD1G93A(L), derives from a deletion in the transgene array of the 
Jackson Laboratory SOD1G93A high copy (http://jaxmice.jax.org/strain/002299.html). 
TgSOD1G93A(L) are considered a model for human ALS, indeed these mice present 
progressive motor neuron loss, accumulations of mutant SOD1 in both spinal cord 
and brain and develop paralysis between 24 and 34 weeks of age that results in 
premature death (Acevedo-Arozena et al., 2011; Alexander et al., 2004; Teuling et al., 
2008). Compared to SOD1G93A high copy TgSOD1G93A(L) animals have a slow 
progressive pathology that make them invaluable for understanding early-stage disease 
mechanisms and testing therapies. Acevedo-Arozena and collegues carried out a 
comphrensive phenotypic analysis of the TgSOD1G93A(L) mice investigating the effects 
of five different genetic backgrounds on lifespan, motor neuron, muscle function and 
pathology (Acevedo-Arozena et al., 2011). Findings relevant to the present study are 
reported below. 
6.1.3.1 Effects of genetic background on time to end stage in 
TgSOD1G93A(L) mice 
The average time to end stage was assessed for TgSOD1G93A(L) animals on a C57BL/6J 
and on a hybrid C57BL/6J-BALB/c background. The humane endpoint was defined 
as loss of 20 % bodyweight, first sign of hind limb paralysis or loss of righting reflex. 
On both backgrounds approximately 92 % of mice were culled for leg paralysis, while 
the remaining 8 % was culled due to substantial weight loss. When on C57BL/6J 
background TgSOD1G93A(L) mice had an average time to endpoint of 37.8 weeks, while 
on a hybrid C57BL/6J-BALB/c background the average survival was of 35.6 weeks 
(Figure 6.2 and Table 6.2). The difference between the average survival of the two 
backgrounds was statistically non-significant. Interestingly gender was shown to affect 
survival on the C57BL/6J-BALB/c background with females reaching end point 
significantly later compared to males, while it had no effect on the C57BL/6J 
background (Table 6.2) (Acevedo-Arozena et al., 2011). 
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Figure 6.2 Representative distribution of TgSOD1G93A(L) mice survival on different genetic 
backgrounds. Mean average survival (µ) of TgSOD1G93A(L) mice on a C57BL/6J background (blue) and 
on a hybrid C57BL/6J-BALB/c background (black). The area of the two curves that fall between 2 
standard deviations (σ) of the mean, μ - 2σ and μ + 2σ, represent 95 % of the values. 
 Survival (weeks) 
Genetic background  Females Males Total 
C57BL/6J 37.5 38.1 37.8 
C57BL/6J-BALB/c 37.6 32.6 35.6 
Table 6.2 Average survival of TgSOD1G93A(L) mice on different genetic backgrounds. Survival was 
calculated on at least 6 animals per category. For the C57BL/6J-BALB/c survival was significantly 
different between genders (p = 0.001) (Acevedo-Arozena et al., 2011).  
6.1.3.2 Grip-strength analysis of C57BL/6J TgSOD1G93A(L) mice  
Grip-strength analysis of TgSOD1G93A(L) mice on a C57BL/6J background revealed that 
females were significantly different compared to gender matched wild-type littermates 
starting at 24 weeks of age (Figure 6.3 (a)) while males showed a difference from 28 
weeks of age (Figure 6.3 (b)). Interestingly at 30 and 32 weeks of age there was a 
significant difference in grip-strength between TgSOD1G93A(L) males and females, and 
the males appeared to be more severely affected (30 weeks: p = 0.020; 32 weeks 
p < 0.001) (Acevedo-Arozena et al., 2011).  
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Figure 6.3 Grip-strength analysis of C57BL/6J TgSOD1G93A(L) mice. (a) Male grip-strength. N = 5 
per genotype, except for week 20 where only four wild-type males were assessed. A significant difference 
was detected from 24 weeks of age (ANOVA; 28 weeks: p = 0.005; 30 and 32 weeks: p < 0.001). (b) 
Female grip-strength. N = 5 per genotype, except for week 20 where only two TgSOD1G93A(L) females 
were assessed. A significant difference was detected from 24 weeks of age (ANOVA; 24 weeks: 
p = 0.006; 26 weeks: p = 0.073; 28 weeks: p = 0.007; 30 weeks: p = 0.001; 32 weeks: p = 0.003). The 
graphs shows the average grip-strength ± SEM per genotype and time point (Acevedo-Arozena et al., 
2011). 
6.2 Aim  
The present work aimed to investigate the progeny of the ENU mutagenized Galahad 
mouse in order to try and identify possible modifying locus/loci interacting with the 
SOD1 G93A mutation. 
In particular the G2 and the G3 generation were phenotypically characterised to 
confirm the abnormal phenotype of the founder and a cross with TgSOD1G93A(H) 
animals was set up to try exacerbate the Galahad phenotype. Moreover a quantitative 
trait locus (QTL) approach was applied to identify regions where the mutation might 
lay.  
6.3 Results 
In this chapter all mice generated from the Galahad founder are named Galahad 
whether they carry or not the ENU mutation.  
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6.3.1 Phenotypic characterisation of the G2 Galahad progeny 
In order to phenotypically characterize the G2 Galahad progeny, and possibly identify 
other distinctive features of the ENU mutagenized animals, the following measure of 
disease progression were investigated: survival, weight and grip-strength. 
6.3.1.1 Galahad breeding strategy 
The Galahad mouse was identified during an ENU sensitised screen at the MRC 
Mammalian Genetics Unit of Harwell, and it was generated by a cross between a 
BALB/c mutagenized male and a C57BL/6J hemizygous TgSOD1G93A(L) female (see 
G0 and G1 in Figure 6.4). The Galahad mouse was found to have an early paralysis 
onset at 27 weeks of age compare to the average described for a TgSOD1G93A(L) line on 
the same hybrid C57BL/6J-BALB/c background, which was of 35.6 weeks (Figure 6.2) 
(Acevedo-Arozena et al., 2011). To recover the Galahad phenotype and characterise the 
second generation of animals after mutagenesis, three IVFs were carried out at MRC 
Harwell, using the sperm of the G1 Galahad founder and oocytes from wild-type 
C57BL/6J females. Mice of the G2 progeny were then, genotyped, phenotyped and 
their DNA was used for positional cloning studies (see G2 in Figure 6.4).  
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Figure 6.4 Galahad breeding scheme. In the G0 ENU mutagenized BALB/c males were crossed 
with C57BL/6J hemizygous SOD1G93A low copy females. Transgenic animals of the G1 were 
phenotypically screened for modifications of the transgenic phenotypes. One phenodeviant mouse with 
an early paralysis onset was identified, named Galahad. IVFs were carried out using the sperm of the 
Galahad mouse and wild-type C57BL/6J females. Mice from the G2 were then genotyped for the 
SOD1G93A transgene, phenotypically characterised and their DNA was used for mapping. 
6.3.1.2 Galahad G2 genotype and ratios 
A total of 142 animals were generated from the three Galahad IVFs. G2 mice were 
genotyped for the presence of the human SOD1G93A transgene as described in section 
2.5.2.1. Ratios and numbers of SOD1G93A transgenic (TgG93A(L)Galahad), and non-
transgenic (NTgGalahad) animals are reported in Table 6.3. The observed ratios were 
not significantly different from the expected ratios χ2(1) = 2.208 p = 0.131 for 
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inheritance of the low copy SOD1 transgene. Of note 50 % of the TgG93A(L)Galahad and 
50 % of the NTgGalahad should also carry the ENU mutation of the founder. 
Genotype Number of animals Observed 
ratios 
Expected 
ratios 
 Females  Males Total    
NTgGalahad 34 28 62 0.44 0.5 
TgG93A(L)Galahad 40 40 80 0.56 0.5 
Total 74 68 142 1 1 
Table 6.3 TgSOD1G93A genotype ratios of Galahad G2 mice. The omnibus χ2 showed that observed 
ratios do not differ from expected ratios. 
6.3.1.3 Survival of TgG93A(L)Galahad mice 
In this study the humane endpoint for the Galahad line was defined as first paralysis 
onset, loss of 20 % bodyweight and loss of righting reflex.  
Fifty TgG93A(L)Galahad mice were employed in survival analysis, among them 64 % were 
culled due to development of hind limb paralysis while the remaining 36 % reached the 
humane end point because of loss of 20 % bodyweight. Of note no NTgGalahad 
animals reached the humane endpoint within the timescale of the TgG93A(L)Galahad 
littermates, suggesting that the ENU mutation alone does not have an effect on 
survival. The survival distribution of TgG93A(L)Galahad mice was investigated to try and 
understand if it was possible to distinguish between two populations: one carrying only 
the SOD1G93A low copy mutation and a phenodeviant population with an early paralysis 
onset, carrying both the SOD1G93A low copy and the ENU mutation of the founder. 
The Shapiro-Wilk normality test gave a p value of p = 0.848, accepting the null 
hypothesis that the data are normally distributed. However, when a graphical 
assessment of normality was carried out using a quantile-quantile (QQ) plot, it was 
observed that the sample quantiles matched the theoretical quantiles only at the median 
and the extremes, suggesting a bimodal distribution of the data (Figure 6.5). A further 
investigation using the EM algorithm of the R mixtools package (Benaglia et al., 2009), 
confirmed that the survival frequency distribution of TgG93A(L)Galahad mice was a 
continuous curve with two different peaks (black dotted line Figure 6.6) compatible 
with a mixture of two normal distributions. One curve with a mean (µ) and a standard 
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deviation (σ) of µ = 32.05; σ = 2.4 weeks, and the other with µ = 37.3; σ = 2.97 weeks 
that most likely represent respectively the population of SOD1G93A low copy mice 
carrying the Galahad founder ENU mutation (mTgG93A(L)Galahad) and the SOD1G93A low 
copy population (TgSOD1G93A(L)) (Figure 6.6). Since it is known that gender affects 
survival in TgSOD1G93A(L) mice on a hybrid C57BL/6J-BALB/c background (Acevedo-
Arozena et al., 2011), the survival frequency of TgG93A(L)Galahad males and females was 
plotted separately, to see if it was still possible to distinguish between two normal 
distributions. In the case of the males two normal distributions were identified one 
with µ = 32.1; σ = 2.5 weeks and the other with µ = 35.8; σ = 3.3 weeks (Figure 6.7 
(a)). While in the case of the females only one normal curve was identified with 
µ = 37.5; σ = 3.1 weeks, while the other curve appeared as a distribution with a 
positive kurtosis (Figure 6.7 (b)); a bigger sample number will be needed to separate the 
two populations. 
 
Figure 6.5 Quantile-quantile plot of TgG93A(L)Galahad mice survival. Survival data of males and 
females are analysed together. The y axis represents the observed values (Sample quantiles), n = 50. The 
x axis represents the predicted values (Theoretical quantiles) which are equally spaced quantiles of a 
normal distribution that has the same mean and standard deviation of the sample dataset. The dots 
indicate each predicated value matched by rank with the corresponding observed value. If the data are 
sampled from a normal distribution the dots are expected to line up to the line of identity (black line). In 
this case the dots line up only at the median and the extremes of the line of identity, showing two kinks 
(red dotted line), characteristic of a bimodal distribution. 
187 
 
 
Figure 6.6 TgG93A(L)Galahad mice survival bimodal distribution. The survival frequency of the 
TgG93A(L)Galahad mice, n = 50, is represented by the histograms. The sample distribution, (black dotted 
line) shows two peaks compatible with two normal distributions. One with a mean of µ = 32.05 (red 
line) corresponding to the mTgG93A(L)Galahad population, and one with a mean of µ = 37.3 (green line) 
corresponding the TgSOD1G93A(L) population. 
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Figure 6.7 TgG93A(L)Galahad males and females survival bimodal distribution. (a) The survival 
frequency of the TgG93A(L)Galahad male mice, n = 26, is represented by the histograms. The sample 
distribution, (black dotted line) shows two peaks compatible with two normal distributions. One with a 
mean of µ = 32.1; σ = 2.5; (red line) corresponding to the mTgG93A(L)Galahad population, and one with a 
mean of µ = 35.8; σ = 3.3; (green line) corresponding the TgSOD1G93A(L) population. (b) The survival 
frequency of the TgG93A(L)Galahad female mice, n = 24, is represented by the histograms. The sample 
distribution, (black dotted line), seems to be compatible with two normal distributions. However, the 
first curve, corresponding to the mTgG93A(L)Galahad population, is not normally distributed (red line) and 
has µ = 32.4; σ = 0.1, the second curve is a normal distribution with µ = 37.5; σ = 3.1; (green line) 
corresponding the TgSOD1G93A(L) population. A bigger n number is needed to distinguish between the 
two populations. 
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6.3.1.4 Definition of two transgenic populations for phenotypic analysis  
In order to analyse weight and grip-strength data of the G2 Galahad progeny, and try to 
identify other phenotypes characteristic of SOD1G93A transgenic ENU mutagenized 
animals, it was crucial to determine which of the transgenic G2 mice to score 
mTgG93A(L)Galahad, and which mice to score TgSOD1G93A(L). Since the survival 
distribution of the transgenic Galahad population is continuous and the two normal 
curves describing it greatly overlap (Figure 6.6), for the phenotypic analysis it was 
defined that: all the mice with survival greater than the mean of the mTgG93A(L)Galahad 
curve plus two standard deviations (µ + 2σ = 36.8) were classified as TgSOD1G93A(L) 
(Figure 6.8 (a)); whereas animals with survival smaller than the mean of the 
TgSOD1G93A(L) curve minus two standard deviations (µ - 2σ = 31.36) were classified as 
mTgG93A(L)Galahad (Figure 6.8 (b)). Hence theoretically only 2.1 % of the TgSOD1G93A(L) 
animals were included in the mTgG93A(L)Galahad population and vice versa only 2.1 % of 
the mTgG93A(L)Galahad mice were included in the TgSOD1G93A(L) population. A total of 7 
animals were defined a mTgG93A(L)Galahad and 25 mice were defined as TgSOD1G93A(L). 
All animals with a time to end point between 31.36 and 36.85 weeks of age were 
excluded from the phenotypical analysis, since it was impossible to statistically 
categorise them into one of the two populations. 
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Figure 6.8 Definition of TgSOD1G93A(L) and mTgG93A(L)Galahad populations for phenotypic 
analysis. (a) All TgSOD1G93A(L) mice that had a survival equal or greater than the mean of the 
mTgG93A(L)Galahad curve plus 2 standard deviations (µ + 2σ = 36.85 weeks) were considered for the 
phenotypic analysis (grey area). Only 2.1 % of the mTgG93A(L)Galahad data might be included in the non-
mutagenized population during analysis (right tail of the red curve). (b) All mTgG93A(L)Galahad mice that 
had a survival equal or smaller than the mean of the TgSOD1G93A(L) curve minus 2 standard deviations 
(µ + 2σ = 31.36 weeks) were considered for the phenotypic analysis (grey area). Only 2.1 % of the 
TgSOD1G93A(L) data might be included in the mutagenized population during analysis (left tail of the 
green curve). 
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6.3.1.5  Correlation between transgene copy number and survival 
There is a positive correlation between the copy number of the SOD1 G93A transgene 
array and the phenotype of the mice (Alexander et al., 2004). To verify whether the 
copy number of G2 TgG93A(L)Galahad mice might influence their survival, a correlation 
was calculated between the copy number and the survival of 21 animals. 
A quantitative real time PCR (qPCR) was carried out as described in section 2.5.4. The 
data presented in Figure 6.9 proves the existence of a significant correlation between 
these two parameters: p = 0.01. The negative r of the correlation test (r = -0.5731) 
confirmed that with a decrease in copy number, there was an increase in survival. 
Finally the r2 (r2 = 0.328) showed that 32.8 % of variance was shared between the two 
variables. However, the copy number of animals that died before 31.36 weeks seemed 
to be quite variable (Figure 6.9, below dotted line), a bigger number of 
mTgG93A(L)Galahad animals will be needed to verify if there is correlation with copy 
number within this population.  
 
Figure 6.9 Correlation between copy number and survival in G2 TgG93A(L)Galahad mice. The r2 
(r2 = 0.328) confirmed that 32.8 % of variance is shared between the copy number and survival. Indeed 
a reduced copy number corresponds to an increase in survival. N = 21; r = -0.5731, p = 0.01. 
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6.3.1.6 Galahad G2 body weight analysis  
To investigate if the presence of the Galahad mutation together with the SOD1G93A low 
copy transgene could cause body weight deficits, weight measures of mTgG93A(L)Galahad 
mice were examined in comparison to TgSOD1G93A(L) and NTgGalahad littermates. 
Weight was assessed weekly as described in section 2.3.2.2. A one-way analysis of 
variance (ANOVA) with Bonferroni post-hoc test was used to evaluate the difference 
in body weight between the 3 genotypes from 24 to 27 weeks of age. The analysis was 
carried out combining the results from the two sexes and for male mice. Of note the 
number of mTgG93A(L)Galahad females was too small to be able to conduct a female only 
analysis. To minimise gender variation and also size variation that might occur due to 
the hybrid background all weight measures of each individual were normalised to its 
maximum bodyweight.  
For the whole cohort the overall ANOVA was significant at 26 weeks (p = 0.007) and 
27 weeks of age (p < 0.001). Similarly for the males the overall ANOVA was significant 
at 26 weeks (p = 0.005) and 27 weeks of age (p = 0.009). In both analysis the pair-wise 
comparison found that mTgG93A(L)Galahad animals were significantly different from 
TgSOD1G93A(L) and NTgGalahad littermates at 26 and 27 weeks of age. No difference 
was found between TgSOD1G93A(L) and NTgGalahad mice (Table 6.4 and Figure 6.10). 
 Weeks mTgG93A(L)Galahad 
vs 
TgSOD1G93A(L) 
mTgG93A(L)Galahad 
vs 
NTgGalahad 
TgSOD1G93A(L) 
vs 
NTgGalahad 
Males and 
females 
24 p = 1 p = 1 p = 1 
25 p = 0.180 p = 0.313 p = 1 
26 p = 0.005  ** p = 0.037  * p = 1 
27 p < 0.001  *** p = 0.001  *** p = 1 
Males 
24 p = 1 p = 1 p = 1 
25 p = 0.213 p = 0.361 p = 1 
26 p = 0.008  ** p = 0.013  * p = 1 
27 p = 0.027  * p = 0.014  * p = 1 
Table 6.4 Galahad G2 mice normalised body weight pair-wise comparisons. Results of Bonferroni 
post-hoc analysis between the three genotypes, for the whole cohort and males only. Significant p-values 
are indicated with (*) p ≤ 0.05; (**) p ≤ 0.01; (***) p ≤ 0.001. 
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Figure 6.10 Normalised body weight of G2 Galahad mice. (a) Male and female normalised body 
weight. At least 7 animals per genotype were assessed. mTgG93A(L)Galahad mice are significantly different 
from TgSOD1G93A(L) and NTgGalahad littermates at 26 and 27 weeks of age. (b) Male normalised body 
weight. At least 6 animals per genotype were assessed. Also for males only by 26 weeks of age 
mTgG93A(L)Galahad mice are significantly different from TgSOD1G93A(L) and NTgGalahad littermates. The 
graphs represent the average normalised weight ± SEM per genotype and time point. (*) indicates the 
significant differences between the two transgenic genotypes: mTgG93A(L)Galahad and TgSOD1G93A(L), 
other significant results are reported in Table 6.4. 
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6.3.1.7 Galahad G2 grip-strength analysis 
To gain more details on the disease progression of the Galahad line, grip-strength was 
assessed weekly for mTgG93A(L)Galahad, TgSOD1G93A(L) and NTgGalahad littermates, as 
described in section 2.3.2.3. A one-way ANOVA with Bonferroni post-hoc test was 
used to evaluate the difference in grip-strength between the 3 genotypes from 23 to 28 
weeks of age. Since it is known that gender has an effect on the grip-strength of 
TgSOD1G93A(L) animals (see above), the analysis was carried out both combining the 
results from the two sexes and for male mice. As for the weight, also for grip-strength 
the n number of the mTgG93A(L)Galahad females was too small to allow a female only 
investigation. To minimise variations each grip-strength measure was corrected for the 
corresponding body weight. 
For the whole cohort the overall ANOVA was significant at all weeks tested: 23 weeks 
(p = 0.006); 24 weeks (p = 0.04), 25 weeks (p = 0.014); 26 weeks (p = 0.021), 27 weeks 
(p = 0.012) and 28 weeks (p = 0.001). While for the males the overall ANOVA was 
significant at 23 week (p = 0.017), 27 weeks (p = 0.037) and 28 weeks of age 
(p = 0.003). In the whole cohort analysis, the pair-wise comparison found that 
mTgG93A(L)Galahad animals were significantly different from TgSOD1G93A(L) at 23, 25, 26, 
27 and 28 weeks of age, while they differ significantly from NTgGalahad littermates 
only at 27 and 28 weeks of age. No difference was found between TgSOD1G93A(L) and 
NTgGalahad mice (Figure 6.11 (a) and Table 6.5). When only male mice were 
investigated a significant difference was found between mTgG93A(L)Galahad and 
TgSOD1G93A(L) littermates at 27 and 28 weeks of age. mTgG93A(L)Galahad were also 
significantly different form NTgGalahad mice at 28 weeks of age. Of note at 23 weeks 
of age the grip-strength of NTgGalahad animals appeared significantly reduced 
compared to TgSOD1G93A(L) littermates, however a difference was detected only for the 
first time point examined, suggesting that there is not a real variance between the two 
groups (Figure 6.11 (b) and Table 6.5). 
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 Weeks mTgG93A(L)Galahad 
vs 
TgSOD1G93A(L) 
mTgG93A(L)Galahad 
vs 
NTgGalahad 
TgSOD1G93A(L) 
vs 
NTgGalahad 
Males and 
females 
23 p = 0.011  * p = 0.433 p = 0.7 
24 p = 0.064 p = 0.747 p = 0.207 
25 p = 0.012  * p = 0.057 p = 1 
26 p = 0.024  * p = 0.541 p = 0.207 
27 p = 0.012  * p = 0.024  * p = 1 
28 p = 0.001  *** p = 0.001  *** p = 1 
Males 
23 p = 0.058 p = 1 p = 0.036  * 
24 p = 0.819 p = 1 p = 1 
25 p = 0.163 p = 1 p = 0.869 
26 p = 0.581 p = 1 p = 0.483 
27 p = 0.041  * p = 0.151 p = 1 
28 p = 0.003  ** p = 0.012  * p = 1 
Table 6.5 Galahad G2 mice normalised grip-strength pair-wise comparison. Results of Bonferroni 
post-hoc analysis between the three genotypes, for the whole cohort and males only. Significant p-values 
are indicated with (*) p ≤ 0.05; (**) p ≤ 0.01; (***) p ≤ 0.001. 
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Figure 6.11 Normalised grip-strength of G2 Galahad mice (a) Males and females’ normalised grip-
strength. At least 6 animals per genotype were assessed for every time point. mTgG93A(L)Galahad mice are 
significantly different from TgSOD1G93A(L) littermates at all-time points except 24 weeks, and they are 
significantly different from NTgGalahad mice at 27 and 28 weeks of age. (b) Males normalised body 
weight. At least 5 animals per genotype were assessed for every time point. mTgG93A(L)Galahad mice are 
significantly different from TgSOD1G93A(L) littermates at 27 and 28 weeks, and they are significantly 
different from NTgGalahad mice at 28 weeks of age. There is also a significant difference between 
NTgGalahad and TgSOD1G93A(L)  at 23 weeks. The graphs represent the average grip-strength normalised 
by weight ± SEM per genotype and time point. (*) indicates the significant differences between the two 
transgenic genotype: mTgG93A(L)Galahad and TgSOD1G93A(L), the other significant difference are noted in 
Table 6.5. 
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6.3.2 Phenotypic characterisation of the G3 Galahad progeny 
A first genome-wide scan (GWS) carried out at MRC Harwell on G2 SOD1G93A(L) 
transgenic Galahad mice that reached paralysis before 33 weeks of age, suggested 3 
potential areas of linkage for the ENU mutation, located in in chromosomes 1, 3 and 
10. In order to see if the selected regions were of interest and if it was possible to 
refine their map position, it was necessary to carry out additional backcrossing 
followed by a phenotypical investigation and genetic mapping of the new progenies. 
6.3.2.1 Galahad G2 breeding strategy 
G2 SOD1G93A(L) transgenic Galahad animals were genotyped for markers specific for the 
3 regions of interest, which were polymorphic between BALB/c and C57BL/6J 
background strains (see section 2.5.3). Since the Galahad founder (hybrid C57BL/6J-
BALB/c) was backcrossed to C57BL/6J mice and the ENU mutation must within 
DNA from the inbred strain used for chemical mutagenesis (BALB/c), G2 mice that 
were heterozygous in one or more of the 3 regions of interest were selected for further 
backcrosses. Twelve G2 TgG93A(L)Galahad mice, 7 females and 5 males were backcrossed 
with C57BL/6J mice in 9 crosses. Females that were heterozygous for the same 
regions were crossed in trio matings. 
6.3.2.2 Galahad G3 genotype and ratios 
A total of 132 animals were generated from the 9 crosses. Interestingly the number of 
males produced was considerably higher than the number of females, respectively 80 
and 48. The observed sex ratios were indeed significantly different from the expected 
χ2(1) = 8.00 p = 0.0047.  
Only G3 females were kept and genotyped for the presence of the human SOD1G93A 
transgene as described in section 2.5.2.1. Among them 22 were TgG93A(L)Galahad and 26 
were NTgGalahad, in this case the observed ratios between transgenic and non-
transgenic females was not significantly different from the expected: χ2(1) = 0.333 
p = 0.564. 
6.3.2.3 Survival of G3 TgG93A(L)Galahad mice 
Because of the low number of TgG93A(L)Galahad females it was not possible to 
statistically investigate if the survival data could fit a bimodal curve, as it was done for 
the G2 progeny. Hence, the same parameters applied for the G2 mice were used to 
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define which of the SOD1G93A(L) transgenic G3 females were mTgG93A(L)Galahad and 
which were TgSOD1G93A(L) (Figure 6.8). Five female mice reached the humane end 
point before 31.36 weeks and were defined as mTgG93A(L)Galahad, and 9 mice reached 
the humane endpoint after 36.85 weeks and were defined as TgSOD1G93A(L). 
Interestingly all mTgG93A(L)Galahad were culled due to substantial weight loss. Of note 
among all the transgenic SOD1G93A(L) females only 13.6 % reached the humane end 
point because of paralysis while the remaining 86.4 % were culled due to weight loss.  
The five mTgG93A(L)Galahad females from the G3 progeny were genotyped for the 3 
regions of interest selected by the MRC Harwell GWS, their genotype together with 
the genotype of the corresponding G2 parents are reported in Table 6.6. 
Cross G Sex Survival 
(weeks) 
Chr 1 
20 Mb 
Chr 1  
59 Mb 
Chr 3     
58 Mb 
Chr 3  
108 Mb 
Chr 10 
105 Mb 
1 G2 f 36.3 B/B B/B B/B B/B B/C 
G2 f 36.3 B/B B/B B/B B/B B/C 
G3 f 28.7 B/B B/B B/B B/B B/C 
2 G2 f 38.7 B/C B/C B/B B/B B/B 
G2 f 38.1 B/C B/C B/B B/B B/B 
G3 f 27.14 B/C B/C B/B B/B B/B 
3 G2 f 39.6 B/B B/B B/C B/C B/C 
G2 f 38 B/B B/B B/C B/C B/C 
G3 f 30.7 B/B B/B B/B B/B B/B 
G3 f 31.3 B/B B/B B/B B/C B/B 
4 G2 m 34.2 B/C B/C B/C B/C B/B 
G3 f 31.1 B/B B/B B/B B/C B/B 
Table 6.6 Haplotype of the G3 mTgG93A(L)Galahad females and G2 parents. Four crosses produced 
mTgG93A(L)Galahad females. Column (Cross) indicates the cross number, column (G) indicates the 
generation: parental generation (G2) and progeny generation (G3). Five SNPs were employed for the 
genotype of the 3 interesting regions, they are labelled by chromosome (chr) location. Regions of 
heterozygosity between C57BL/6J and BALB/c are indicated in yellow (B/C) while regions on 
homozygosity (both alleles C57BL/6J), are indicated in grey (B/B). Of note even though the G3 animals 
reached the humane end point before 31.36 weeks of age, none of the parents died within that period. 
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6.3.2.4 Galahad G3 body weight analysis 
To investigate whether the significant difference in bodyweight detected in G2 
mTgG93A(L)Galahad mice compared to littermates was presented also in the G3 progeny; 
body weight of G3 mTgG93A(L)Galahad, TgSOD1G93A(L) and NTgGalahad was assessed 
weekly (see 2.3.2.2). Analysis was carried out using a one-way ANOVA with 
Bonferroni post-hoc correction, from 24 to 27 weeks of age. All weight measures of 
each individual were normalised for its maximum bodyweight.  
The overall ANOVA was significant only at 27 weeks (p < 0.0001), and the pair-wise 
comparison found that mTgG93A(L)Galahad animals were significantly different from 
TgSOD1G93A(L) and NTgGalahad littermates at 27 weeks of age while no difference was 
found between TgSOD1G93A(L) and NTgGalahad mice (Table 6.7 and Figure 6.12) 
Weeks 
mTgG93A(L)Galahad 
vs 
TgSOD1G93A(L) 
mTgG93A(L)Galahad 
vs 
NTgGalahad 
TgSOD1G93A(L) 
vs 
NTgGalahad 
   24 p = 0.569 p = 0.241 p = 1 
   25 p = 1 p = 1 p = 1 
   26 p = 1 p = 0.594 p = 0.790 
   27 p = 0.001  *** p < 0.001  *** p = 1 
Table 6.7 Galahad G3 normalised weight pair-wise comparisons. Results of Bonferroni post-hoc 
analysis between the three genotypes, for females only. Significant p-values are indicated with (*) 
p ≤ 0.05; (**) p ≤ 0.01; (***) p ≤ 0.001. 
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Figure 6.12 Normalised body weight of G3 Galahad females. At least 5 animals per genotype were 
assessed for every time point. mTgG93A(L)Galahad mice are significantly different from TgSOD1G93A(L) and 
NTgGalahad littermates at 27 weeks of age. The graphs represent the average normalised weight ± SEM 
per genotype and time point. (*) indicates the significant differences between the two transgenic 
genotype: mTgG93A(L)Galahad and TgSOD1G93A(L), other significant results are reported in Table 6.7. 
6.3.3 NTgGalahad X TgSOD1G93A(H) cross 
Preliminary results of a second GWS carried out on the IVF1 G2 progeny, suggested 
two potential regions of linkage in chromosome 1 and 7 (data not shown). Considering 
the difficulties in the identification of this new ENU mutation, NTgGalahad animals 
carrying the potential areas of linkage were crossed with TgSOD1G93A(H) mice, to 
investigate whether it was possible to exacerbate the Galahad phenotype by having 
more copies of the human SOD1G93A transgene. 
In particular G2 NTgGalahad animals were genotyped for markers specific for the 2 
regions of interest, which were polymorphic between BALB/c and C57BL/6J 
background strains (as described section 2.5.3). Eight NTgGalahad females carrying 
one or more regions of interest were then crossed with TgSOD1G93A(H) males. A total of 
52 animals were generated: 28 females and 24 males, the observed sex ratios were not 
significantly different from the expected χ2(1) = 0.308 p = 0.5791. Among 52 mice, 24 
were non-transgenic for SOD1G93A(H) (NTgGalahad), 23 were transgenic 
(TgG93A(H)Galahad) and 5 died for other causes and were not genotyped. From these 
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mice the observed ratios between transgenic and non-transgenic animals was not 
significantly different from the expected: χ2(1) = 0.021 p = 0.884.  
The average survival for TgSOD1G93A(H) animals on a C57BL/6J background is of 19.5 
weeks of age (data from Dr. Rosie Bunton-Stasyshyn), so far 16 TgG93A(H)Galahad mice 
reached the humane end point with an average survival of 20 weeks. A bigger sample 
number will be necessary to statistically investigate if it possible to distinguish between 
a non-mutagenized and an ENU-mutagenized population, and determine whether the 
ENU mutation can worsen the phenotype of TgSOD1G93A(H) mice. 
6.3.4 Genetic mapping  
The breeding strategy applied to generate the Galahad line was based on the cross 
between two different inbred strains: BALB/c (ENU-mutagenized) and C57BL/6J. 
Animals from inbred strains are as genetically alike as possible, being homozygous at 
virtually all of their loci. Therefore when the Galahad founder was backcrossed to the 
non-mutagenized paternal strain (C57BL/6J), the G2 progeny produced were obligate 
heterozygous (BALB/c-C57BL/6J) at the mutation affected locus/loci. Furthermore 
recombination events and the presence of C57BL/6J homozygosity excluded unlinked 
areas.  
6.3.4.1  Genome wide scan 
To try to identify the Galahad mutation the DNAs of 28 G2 TgG93A(L)Galahad animals 
that died between 26 and 39.6 weeks of age were sent for GWS. The 19 mouse 
autosomal chromosomes were genotyped for 1358 polymorphic SNPs markers, that 
were uniformly distributed at a density of approximately three SNPs every 5 Mb 
intervals across the genome. The genome coverage by chromosome is reported in 
Figure 6.13. Of note the marker position is expressed in centimorgan (cM) a unit of 
linkage that represent the genetic distance between two loci determined by 
recombination frequency. The genetic distance does not always correspond to the 
physical distance expressed in base pair, since recombination rate is not constant along 
the length of the chromosomes.  
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Figure 6.13 SNPs genome coverage. The image shows the coverage density in Mb for every 
autosomal chromosome. This SNP array provided a medium density genome coverage.  
6.3.4.2 QTL analysis 
A quantitative trait locus (QTL) analysis was carried out to try and link the phenotypic 
data (survival) and genotypic data (SNP markers) in an attempt to identify the new 
modifier mutation/s. 
In particular a single QTL genome scan analysis was performed in R using the method 
of maximum likelihood via the EM algorithm (Lander and Botstein, 1989). Briefly the 
hidden Markov model was used to calculate QTL genotype probability and correct for 
missing values, using a step size of 1 cM. For each marker, a logarithm of the odds 
(LOD) score was calculated, which is an estimation of the probability that the 
difference seen between homozygous and heterozygous individuals in a specific locus 
is linked to the phenotype tested; details of the genotype data per chromosome per 
mouse are shown in Figure 6.14.  
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The results of the QTL analysis are presented in Figure 6.15 as a plot of the LOD 
score against the chromosomal map position. Results of the top LOD score obtained 
for each chromosome are listed in Table 6.8. Of note for the purpose of this analysis a 
threshold of significance for the LOD score was not calculated, the significance 
depends on a series of factors, such as species, genome length and recombination, and 
requires complex algorithms. Instead the 3 highest LOD scores obtained for 
chromosome 6, 12 and 18 were graphically investigated. 
 
Figure 6.14 Genotype data for the G2 Galahad mice. Regions of homozygosity (red), regions of 
heterozygosity (blue), and missing data (white) plotted for each G2 mouse for every chromosome.  
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Figure 6.15 LOD scores for Galahad G2 progeny. Logarithm of the likelihood odds ratio (LOD) 
score curves along the genome (minus the X chromosome). The positions of the markers are shown as 
black lines on each chromosome. A significance threshold has not been calculated for this data set, 
however it was possible to identify 3 peaks: on chromosome 6, 12 and 18. 
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Chr Position 
(cM) 
Marker LOD 
1 12.19 c1.loc9 0.419 
2 131.99 rs4223511 0.288 
3 154.84 rs13477506 0.441 
4 26.96 rs13477617 0.384 
5 34.91 rs13459085 0.6308 
6 16.06 rs13478641 1.438 
7 22.23 c7.loc18 1.060 
8 106.80 gnf08.108.032 0.353 
9 121.91 rs13459114 0.859 
10 4.96 rs6185923 0.658 
11 77.55 c11.loc74 0.411 
12 117.72 rs3692361 1.814 
13 99.09 c14.loc91 1.321 
14 92.09 c14.loc84 0.804 
15 74.85 rs8259436 0.735 
16 87.49 rs4214396 0.866 
17 94.13 rs3706382 0.318 
18 79.94 rs3720876 1.955 
19 53.44 rs13483682 1.095 
Table 6.8 Top LOD score marker per chromosome. The markers with the highest LOD score values 
per chromosome (Chr) are shown with relative position in cM.  
The three most significant markers identified by QTL analysis were located on 
chromosomes 6, 12 and 18. To further investigate these three SNPs the genotypes of 
each animal were plotted against the corresponding survival values and the 
heterozygosity and homozygosity regions of each mouse were plotted for the 
corresponding chromosome (Figure 6.16, Figure 6.17 and Figure 6.18). This graphic 
analysis suggested that regions located in chromosome 6 and 18 were possible areas of 
linkage since the majority of animals that reached an early time to end point presented 
areas of heterozygosity along the chromosomes in contrast to mice that displayed a 
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longer survival (Figure 6.16 (a), Figure 6.18 (a)). Furthermore on the top hit markers 
the mean of the heterozygous animals was significantly lower compared to the 
homozygous: p = 0.005 for chromosome 6 top hit marker and p = 0.001 for 
chromosome 18 top hit marker (Figure 6.16 (b), Figure 6.18 (b)). Instead chromosome 
12 appeared to be a false positive, indeed the majority of animals were homozygous for 
C57BL/6J along the whole chromosome (Figure 6.17(a)), and on the top hit marker 
the mean of the heterozygous animals was higher compared to one of the homozygous 
(Figure 6.17 (b)). Plots showing the regions of homozygosity and heterozygosity with 
recombination events, for all mice per each chromosome are presented in Appendix 
8.7. 
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Figure 6.16 Chromosome 6. (a) Genotype and recombination events per mouse along chromosome 6. 
(b) Maximum LOD score marker for chromosome 6 (LOD = 1.438). Each animal is plotted for the 
genotype (homozygous or heterozygous, x axis) and survival (y axis). The bars indicate the average 
survival time for animals that are heterozygous (green) and homozygous (red) in that position. 
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Figure 6.17 Chromosome 12. (a) Genotype and recombination events per mouse along chromosome 
12. (b) Maximum LOD score marker for chromosome 12 (LOD = 1.814). Each animal is plotted for its 
genotype (homozygous or heterozygous, x axis) and survival (y axis). The bars indicate the average 
survival time for animals that are heterozygous (green) and homozygous (red) in that position. In this 
case the high LOD score is a false positive. 
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Figure 6.18 Chromosome 18. (a) Genotype and recombination events per mouse along chromosome 
18. (b) Maximum LOD score marker for chromosome 18 (LOD = 1.955). Each animal is plotted for the 
genotype (homozygous or heterozygous, x axis) and survival (y axis). The bars indicate the average 
survival time for animals that are heterozygous (green) and homozygous (red) in that position. 
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6.4 Conclusions 
6.4.1 Concluding remarks on Galahad mice 
The aim of the work presented in this chapter was to phenotypically characterise the 
progeny of the ENU mutagenized Galahad mouse and identify possible modifying 
locus/loci interacting with the SOD1 G93A mutation. 
The results from the behavioural screen provided valuable data towards the 
characterisation of the Galahad mice. 
Investigation of the survival phenotype of the second generation of Galahad after 
mutagenesis, confirmed the presence of an early onset phenotype in a subset of 
TgG93A(L)Galahad mice. Analysis of transgenic SOD1G93A(L) survival distribution showed 
that it was possible to discern between two normal populations, allowing the 
identification of statistical criteria to classify the TgG93A(L)Galahad mice as ENU 
mutagenized (mTgG93A(L)Galahad) or non-mutagenized (TgSOD1G93A(L)). 
A correlation between survival and the number of SOD1 G93A transgene copies was 
found in TgG93A(L)Galahad animals. However, a measure of copy number should not be 
applied as a strategy to identify mTgG93A(L)Galahad within the transgenic Galahad 
population, since the copy number of the mice with the smallest survival appeared to 
be extremely variable.  
A significant reduction in body weight was detected in mTgG93A(L)Galahad mice 
compared to TgSOD1G93A(L) and NTgGalahad littermates from 26 weeks of age. Of 
note, even if not significant, a reduction in mTgG93A(L)Galahad body weight was visible 
already at 25 weeks. This was true both when the males and females were analysed 
together and for males alone. However, a body weight reduction a few weeks before 
death is expected in mice carrying several copies of the human SOD1 G93A transgene. 
A significant and progressive reduction in grip-strength was found in mTgG93A(L)Galahad 
compared to TgSOD1G93A(L) littermates, starting at 25 weeks of age when males and 
females were assessed together and from 27 weeks in males only. Interestingly in the 
whole cohort there was a significant difference between the two transgenic populations 
already at 23 weeks of age, suggesting that the impairment in grip-strength might start 
even earlier in mTgG93A(L)Galahad animals. Further analysis at earlier time points will be 
needed to confirm this hypothesis, however if true, grip-strength analysis could be 
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employed as a strategy to identify mTgG93A(L)Galahad mice within the transgenic 
population. mTgG93A(L)Galahad showed a reduction in grip-strength also in comparison 
to NTgGalahad animals, from 27 weeks of age in the mixed gender group and from 28 
weeks in males. Of note a significant difference in grip-strength was detected also in 
NTgGalahad animals compare to TgSOD1G93A(L) littermates at a single time point of 23 
weeks of age. In the literature wild-type animals show difference in grip-strength 
compared to TgSOD1G93A(L) from 24 weeks of age (Acevedo-Arozena et al., 2011). 
Grip-strength investigation on a bigger number of animals will clarify whether this is a 
random difference or if this might be due to presence of ENU mutagenized animals 
within the NTgGalahad group that may display a subtle phenotype in reduction of grip-
strength.  
Analyses of body weight of Galahad G3 female mice confirmed the same pattern seen 
in the G2 generation. Indeed the body weight of mTgG93A(L)Galahad mice was 
significantly reduced at 27 weeks of age compared to littermates. Interestingly all these 
animals were culled due to loss of body weight and none of them reached paralysis. 
This might be an effect of the backcross to the C57BL/6J background as it was shown 
that SOD1 G93A transgenic mice display a milder phenotype when on a C57BL/6J 
background compare to others strains (Acevedo-Arozena et al., 2011; Heiman-
Patterson et al., 2005). However, the G2 mice that generated the G3 progeny were 
chosen on the basis of a GWS carried out on a small number of animals and is 
important to note that the QTL analysis presented in this work excluded those areas as 
possible regions of linkage. Furthermore none of the G2 parental animals reached the 
humane end point early enough to be considered mTgG93A(L)Galahad, therefore there is 
the possibility that none of the transgenic animals of the G3 generation that were 
analysed were carrying the ENU mutation/s of interest.  
So far a cross between the G2 NTgGalahad and TgSOD1G93A(H) mice did not exacerbate 
the phenotype of the progeny compared to the parental TgSOD1G93A(H)  animals. This 
might be simply because a bigger number of samples is needed, or because the animals 
selected on the base of a previous GWS were not carrying the ENU mutation of the 
founder. Alternatively no difference in survival can be detected because the presence of 
the high copy SOD1G93A transgene causes such a severe phenotype that the ENU 
mutation if present gives rise only to subtle charges. 
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The QTL analysis carried out on the G2 progeny suggested two main regions of 
linkage, one located in chromosome 6 and one located in chromosome 18. The fact 
that the exact location of these regions is still unclear suggests that the effect of the 
Galahad ENU mutation on the SOD1G93A(L) phenotype might be caused either by a 
dominant mutation with low penetrance or by a more than one mutations.  
6.4.2 Future work 
6.4.2.1 Further phenotypic characterisation 
To further phenotypically characterise the Galahad line it would be necessary to 
generate a bigger number of animals both for the G2 and the G3 generation. This 
should allow the investigation of survival, weight and grip-strength of males and 
females separately, to see if the gender has effect as happens in TgSOD1G93A(L) mice 
when in a hybrid background (Acevedo-Arozena et al., 2011). Analysis of the grip-
strength from an earlier time point should also reveal if this measure can be employed 
as a strategy to select ENU mutagenized animals. 
The G3 mice that have been investigated should be genotyped for the new areas of 
linkage identified by the QTL analysis, in order to further investigate the reasons for 
the differences detected in the sex ratios and the high percentage of animals reaching 
the humane end point because of weight loss and not paralysis.   
6.4.2.2 Further QTL analysis and next-generation sequencing  
For the QTL analysis it will be crucial to increase the number of animals in the analysis 
to better identify the locus/loci that are related to the early onset of the founder. It will 
be also important to calculate the threshold for the LOD score based on the data to 
see if there are significant QTLs. Furthermore the whole genome of the Galahad 
founder has now been sequenced using next-generation sequencing technology. These 
new sequence data together with the result of the QTL analysis will possibly allow the 
identification of candidate modifier genes of the SOD1G93A(L) phenotype. 
6.4.2.3 Pathology investigation 
During this study, spinal cord, brain, TA and EDL samples have been collected from a 
large number of Galahad animals. It will be very interesting to carry out experiments 
such as motor neuron counts in the spinal cords, and neuromuscular junction counting 
to investigate the pathology of this line.  
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6.5 Summary 
 Survival data from the transgenic SOD1G93A(L) G2 progeny can fit two normal 
distributions  
 From the transgenic SOD1G93A(L) G2 progeny it was possible to define statistical 
criteria to classify Galahad transgenic SOD1G93A(L) mice as ENU mutagenized or 
non-mutagenized 
 There is a correlation between SOD1G93A(L) copy number and survival in the G2 
progeny  
 G2 mTgG93A(L)Galahad mice have a reduction in body weight compared to 
littermates starting at 26 weeks of age  
 G2 mTgG93A(L)Galahad mice appear to have early grip-strength impairment, that 
might be help to distinguish them from the TgSOD1G93A(L) population 
 In the G3 progeny Galahad transgenic SOD1G93A(L) animals that have a short 
survival all reach a humane end point because of substantial weight loss 
 The QTL analysis suggests two areas of linkage, on chromosomes 6 and 18 
 Chromosome 12 appears to have an area of linkage but is a false positive 
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Chapter 7 Discussion 
The work described in this thesis has focused on the characterisation of the role that 
the SOD1 protein plays in ALS, investigating the human and the mouse variants in vivo 
and in vitro. In particular a meta-analysis was carried out on the literature to review 
measures of SOD1 activity from SOD1-fALS patients and the phenotype of Sod1 
knockout animals, aiming to understand if a loss of SOD1 function could play a role in 
disease. Further the phenotype of a novel mouse model, Sod1D83G, carrying a point 
mutation in the endogenous mouse Sod1 gene was investigated. Then the Sod1D83G 
mouse was crossed with Sod1 knockout mice and mice overexpressing the human wild-
type SOD1 to see if it was possible to dissect elements of a loss of function (the 
peripheral axonopathy) and aspects of a gain of function (the central body 
degeneration). Recombinant SOD1 proteins were produced, purified and characterised 
and preliminary spontaneous aggregation experiments were conducted, to try to 
investigate human-mouse SOD1 protein interactions. Finally the phenotype of the 
progeny of the Galahad ENU mutagenized mouse was examined and a QTL analysis 
was carried out in order to try to identify possible modifying locus/loci interacting with 
the SOD1 G93A mutation. 
7.1 Gain and loss of function could coexist in SOD1-ALS 
When in 1993 mutations in the SOD1 gene were identified as causative of fALS, it was 
thought that the absence of functional SOD1 could increase oxidative stress, causing 
neurodegeneration (Smith et al., 1991; Stadtman, 1992; Stadtman and Berlett, 1997). 
Indeed patients showed oxidative stress markers in tissues and reduction of SOD1 
activity in blood (Deng et al., 1993; Fitzmaurice et al., 1996; Rosen et al., 1993; Shaw et 
al., 1995). However, subsequent findings carried out in SOD1-fALS mouse models 
soon dismissed the idea that SOD1-ALS could arise from a loss of SOD1 function 
demonstrating that the disease is caused by a toxic gain of function (Bruijn et al., 1998). 
Only in recent years, a number of studies investigating Sod1 knockout and SOD1 
transgenic mice reopened the possibility that a loss of SOD1 function could play a role 
in SOD1-ALS (Saccon et al., 2013). Loss and gain of function mechanisms are already 
known to coexist in other neurodegenerative diseases such as Huntington’s disease and 
Parkinson’s disease (Winklhofer et al., 2008; Zuccato et al., 2010) and have been both 
hypothesised to contribute to TDP-43-ALS and FUS-ALS (Lagier-Tourenne and 
Cleveland, 2009; Petkova et al., 2005). 
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7.1.1 Reduction of SOD1 activity in SOD1-fALS patients 
In the present work published data was analysed from patients carrying SOD1-fALS 
mutations and it was found that on average the overall SOD1 activity is reduced to 
approximately 50 % (Figure 3.1). However, we did not find any description of ALS 
patients with complete loss of SOD1 activity, not even when SOD1 mutations were 
present in homozygosity. Moreover from human genetic studies no evidence was 
found suggesting that SOD1 loss of function alone causes ALS. Of note none of the 
160 mutations linked to SOD1-ALS generate an effectively null allele, reflecting the 
situation of Sod1-/- mice. Indeed there are no truncation mutations in the N-terminal of 
the SOD1 protein (Figure 1.5). The only described SOD1 mutation that might be a 
null is a frameshift in exon 2 predicting a protein of 35 amino acid, but segregation 
data are unclear therefore no assumption can be made (Hu et al., 2012). 
7.1.2 SOD1 loss of function worsens the phenotype of transgenic mouse 
models pointing to a neuroprotective role for SOD1 activity 
Although data from transgenic mouse models of SOD1-fALS show that ALS arises 
from a toxic gain of function, some experiments also point to the possibility that a loss 
of SOD1 activity might worsen the disease phenotype of these animals. 
As reviewed in 3.3.3.3 selective excision of mutant SOD1 from microglia and 
astrocytes improves the phenotype of transgenic SOD1 mouse models, producing a 
greater amelioration when the SOD1 mutation is dismutase inactive (Ilieva et al., 2009; 
Wang et al., 2011b). Further knockdown of mutant SOD1 from Schwann cells worsens 
the disease progression of enzymatically active SOD1 mutants and ameliorates disease 
from dismutase inactive SOD1 mutants (Kiernan et al., 2011; Lobsiger et al., 2009; 
Wang et al., 2012). These results suggest that, in addition to the gain of function, 
microglia cells and astrocytes of dismutase active mutant SOD1 mice have a 
neuroprotective effect on the disease, thanks to the presence of residual SOD1 activity. 
7.1.3 Sod1 knockout mice have specific cell-type sensitivities and share 
characteristics with ALS 
Sod1 knockout mice do not develop motor neuron loss and therefore are not a model 
of ALS, but they are considered a model of chronic oxidative stress. These mice are 
indeed the most useful tool to investigate the effects of the absence of SOD1 protein 
in vivo.  
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The meta-analysis carried out in the present work shows that although Sod1-/- mice do 
not develop MN degeneration, they present several ALS-related phenotypes. For 
example, these mice are characterised by a progressive distal axonopathy (Murray et al., 
2010) and their motor neurons are preferentially affected and susceptible to injuries 
compared to sensory neurons (Pupillo et al., 2012). Furthermore they develop other 
phenotypes such as increased susceptibility to APP-induced neurodegeneration, or 
progressive loss of auditory ganglion neurons and retinal cells, that emphasise the 
importance of SOD1 in neurodegeneration. 
Interestingly also heterozygous knockout animals present an increased neuronal loss 
and susceptibility to injury. Confirming that in mice a 50 % reduction in SOD1 activity, 
as in SOD1-fALS patients, has direct consequences on neuronal survival and increases 
predisposition to neurodegeneration. This is different from other human disease data 
involving loss of enzyme activity, where usually 50 % loss of activity is not sufficient to 
cause disease related phenotypes (Mitchell et al., 2011). 
7.1.4 Sod1D83G a novel mouse model to investigate axonal and neuronal body 
degeneration  
We have recently published a paper describing the characterisation of a novel mouse 
model carrying an ENU-induced point mutation in the mouse Sod1 gene, which is 
identical to a human fALS causative mutation (Joyce et al., 2014; Millecamps et al., 
2010). 
Since the Sod1D83G mouse mutation is within the endogenous mouse Sod1 gene, it 
overcomes one of the limitations of the transgenic mouse model of SOD-ALS: the 
overexpression of mutant human SOD1, which is known to affect various features of 
the disease phenotype and pathology (Jaarsma et al., 2000; Jonsson et al., 2006b). 
Analysis of the Sod1D83G mouse has shown that homozygous Sod1D83G/D83G mice develop 
both upper and lower motor neuron degeneration, modelling the situation in humans, 
but with a different profile than in mice carrying a human mutant SOD1 transgene 
array. Indeed, although the degeneration of motor neurons in Sod1D83G/D83G animals is 
progressive, LMN death appears to stop in early adulthood and mice do not become 
paralysed. Since MN degeneration is never reported in Sod1-/- animals (Table 7.1) we 
believe that the MN loss phenotype in these mice arises from the same toxic gain of 
function seen in patients (Fischer et al., 2011; Flood et al., 1999). The fact that MN loss 
in Sod1D83G/D83G does not progress to paralysis could be explained by the fact that the 
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SOD1 protein in these mice is present at a reduced level, ~10 % compared to wild-
type (Figure 4.4 and Figure 4.5). Since SOD1 expression levels show a dose-dependent 
toxicity in other fALS models (Acevedo-Arozena et al., 2011; Jonsson et al., 2006b), 
this dose of SOD1 protein in Sod1D83G/D83G mice may be sufficient to cause some degree 
of MN degeneration but not at the same levels seen in SOD1-fALS mouse models or 
in patients. Such low levels of SOD1 protein could be explained by the location of the 
D83G mutation. The D83 is one of the four residues implicated in the zinc binding 
(Figure 1.4) (Valentine et al., 2005), and its mutation is predicted to disrupt the metal 
binding site of the SOD1 dimer causing it to become instable and more likely to 
monomerise (Choi et al., 2011; Krishnan et al., 2006; Nordlund et al., 2009). Of note 
Sod1+/D83G heterozygous do not develop LMN loss up to one year of age, this might be 
because the presence of a wild-type SOD1 allele has a protective effect. Alternatively 
Sod1+/D83G heterozygotes mice might develop MN loss later in life, given that the dose 
of mutant SOD1 protein is known to correlate with the progression of ALS-like 
phenotypes (Acevedo-Arozena et al., 2011). 
Investigation of the innervation pattern of endplate NMJs presented in Chapter 4 
(Figure 4.2 and Figure 4.3) shows that Sod1D83G/D83G animals develop a severe peripheral 
neuropathy between 15 and 52 weeks of age, similar to the one described for Sod1-/- 
mice. This result is also confirmed by physiological analysis of motor unit survival 
(Joyce et al., 2014). Interestingly analysis of SOD1 protein levels and activity revealed 
that in Sod1D83G/D83G the SOD1 dismutase activity is only 1 % of the wild-type animals 
(Figure 4.5). These findings together with details, gathered in Table 7.1 show that 
Sod1D83G/D83G mice mimic several characteristics of the Sod1-/- animals suggesting that 
the peripheral neuropathy present in this novel mouse may be due to a loss of SOD1 
function, potentially leading to oxidative stress and consequently to an increased 
vulnerability of motor neuron axons. Another indication that SOD1 loss of function 
plays a role in the pathology of SOD-ALS comes from the analysis of the 
mitochondrial membrane potentials of embryonic MN cultures of Sod1+/D83G and 
Sod1+/- mice, which are both hyperpolarised, suggesting that mitochondria 
abnormalities can be caused by loss of dismutase activity (Joyce et al., 2014).  
Although ALS has been proposed to be a ‘dying back’ disorder because NMJ 
denervation appeared to precede motor neuron cell body death (Bilsland et al., 2008; 
Duchen et al., 2003). Data on the Sod1D83G mouse presented in this thesis and in Joyce 
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et al., 2014 suggest that axonal and neuronal cell body degeneration may be two 
separate events. Experiments carried out in SOD1 G93A transgenic mouse models 
where the BCL2-associated X protein (Bax) is ablated support this hypothesis. In these 
animals indeed Bax deficiency protects MN cell bodies from degeneration without 
altering muscle denervation and mice survival, compared to normal SOD1 G93A 
transgenic animals (Gould et al., 2006). 
Overall, our data suggest that Sod1D83G/D83G mice model early stages of human ALS, and 
are a good system in which is possible to separate the effects of central neuronal loss 
from the peripheral distal neuropathy. 
Phenotype  Sod1-/- Sod1D83G/D83G 
Weight loss Reduced from 20 weeks 
(Larkin et al., 2011) 
Reduced from 4 weeks  
Rotarod Reduced from 36 weeks 
(Flood et al., 1999)  
Reduced from 23 weeks 
Grip-strength  Reduced from 52 weeks 
(Fischer and Glass, 2010) 
Reduced from 6 weeks 
Motor unit number  Reduced from 15 weeks 
(data from our group) 
Reduced from 52 weeks 
NMJ innervation Denervation from 16 weeks 
(data from our group) 
Denervation at 52 weeks  
Development of HCC 56 % females, 79 % males 
(Elchuri et al., 2005) 
78 % females, 91 % males 
Survival Reduced to ~86 weeks 
(Elchuri et al., 2005) Reduced to ~86 weeks 
MN loss No MN loss                   
(data from our group) 
MN loss occurs from 15 
weeks 
Table 7.1 Comparison between Sod1-/- and Sod1D83G/D83G animals. Data refer to Sod1-/- and 
Sod1D83G/D83G mice on a C57BL/6J background. 
7.1.5 Separation of gain of function and loss of function phenotypes in the 
SOD1D83G mouse model  
As explained above the work described in this thesis suggests that mice carrying a 
D83G mutation in the Sod1 gene develop phenotypes typical of gain and loss of SOD1 
function, in the absence of protein overexpression. To confirm that motor neuron loss 
and distal neuropathy arise respectively from a gain of function and loss of function of 
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SOD1, we have crossed Sod1D83G mice with Sod1-/- and TgSOD1WT mice to examine the 
effects of varying SOD1 activity on these phenotypes. 
Our preliminary findings seem to confirm that the distal neuropathy in Sod1D83G/D83G 
mice was due to a loss of SOD1 function. Indeed Sod1-/D83G mice show a reduction in 
TA force similar to Sod1D83G/D83G animals, but no lower motor neuron loss was detected 
in contrast to the 20 % loss of lower motor neurons seen in Sod1D83G/D83G mice 
(courtesy of Dr Philip McGoldrick). Data presented in Chapter 4 show that SOD1 
protein levels in the compound heterozygous animals Sod1-/D83G are significantly 
reduced compared to Sod1+/D83G and also compared to Sod1D83G/D83G littermates, but are 
not absent as in Sod1-/-mice (Figure 4.4 and Figure 4.5). Taken together these results 
suggest that the distal neuropathy seen in Sod1D83G/D83G mice occurs independently of 
motor neuron loss, which is dependent on the dose of SOD1 protein and occurs due 
to a toxic gain of function of mutant SOD1. As mention before dose-dependent 
toxicity of mutant SOD1 has been reported for other transgenic mice overexpressing 
mutant SOD1 (Acevedo-Arozena et al., 2011; Deng et al., 2006; McGoldrick et al., 
2013). 
The cross between Sod1D83G and TgSOD1WT mice further confirmed that the distal 
axonopathy of Sod1D83G/D83G mice was due to a loss of SOD1 function. Indeed TA force 
data show that the distal neuropathy of Sod1D83G/D83G mice and of Sod1-/- mice can be 
completely rescued by the presence of human wild-type SOD1 (courtesy of Dr Philip 
McGoldrick). These results are consistent with previously published reports in which 
central nervous system specific expression of SOD1 could rescue distal neuropathy in 
Sod1-/- mice (Flood et al., 1999). 
Analysis of SOD1 protein levels and activity of the transgenic progeny generated from 
the cross between Sod1D83G and TgSOD1WT mice, confirms as expected the presence of 
a high level of SOD1 and dismutase activity (Figure 4.8 and Figure 4.9). Data from 
double transgenic mutant mice overexpressing the wild-type human SOD1 together 
with the mutant protein, have been shown to accelerate ALS-like phenotypes (Deng et 
al., 2006). Crucially our TgWTSod1D83G/D83G mice have not shown any exacerbation of the 
mutant SOD1-mediated phenotypes. This might be because the human wild-type 
SOD1 and the mutant mouse SOD1 D83G fail to interact (Sakellariou et al., 2014). 
Alternatively it may be because wild-type SOD1 only exacerbates mutant SOD1 
toxicity in a transgenic line showing high expression of mutant SOD1 (Deng et al., 
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2006). If the latter is true it may suggest that a threshold limit of mutant SOD1 
expression is needed for the manifestation of ALS-like phenotypes. Most probably this 
limit is not reached in Sod1D83G/D83G mice, since SOD1 protein level is 10 % of wild-type 
and only a non-progressive motor neuron degeneration is present in these mice. In vitro 
experiments using mouse and human recombinant SOD1 proteins described in 
Chapter 5 could elucidate whether mouse and human SOD1 proteins can interact, and 
if there is a threshold under which cross-seeding of two SOD1 variants does not occur 
(Chia et al., 2010). 
Preliminary data from these crosses seems to confirm that motor neuron degeneration 
in Sod1D83G/D83G mice is due to a gain of function of mutant SOD1 while the peripheral 
axonopathy is the result of a loss of SOD1 function.  
Although the role of SOD1 loss of function still needs to be investigated and it is 
insufficient to provoke motor neuron degeneration, the data presented in this thesis 
suggest that it is crucial for normal motor neuron function. Interestingly many new 
roles for the SOD1 protein are emerging and understanding them might help to 
elucidate the roles that an absence of SOD1 protein may play in the pathogenesis of 
SOD1-ALS. 
7.1.6 Co-existence of a SOD1 gain and loss of function in ALS 
Superoxide clearance is the best known function of SOD1 and its loss of function 
causes oxidative stress. SOD1 has also been demonstrated to be a target of oxidisation 
in transgenic SOD1-fALS mice (Andrus et al., 1998). Additionally following oxidative 
stress, SOD1 oxidation and glutathionylation, increase the propensity of the dimer to 
dissociate and become misfolded (Ezzi et al., 2007; Khare et al., 2004; Rakhit et al., 
2004; Wilcox et al., 2009). All these findings together with the work presented in this 
thesis support our hypothesis, previously published, of a potential co-operation of 
SOD1 loss of function and gain of function in ALS pathogenesis (Saccon et al., 2013). 
Confirming that a vicious circle can be postulated in which oxidized SOD1 has 
increased propensity to misfold, causing seeding and aggregation of SOD1 and 
determining a reduction of dismutase activity, which therefore feeds more potential 
oxidative stress to the beginning of the loop (Figure 3.2). Evidence from recent 
findings suggest that this mechanism can be relevant not only to SOD1-fALS but also 
to sporadic cases (Bosco et al., 2010; Forsberg et al., 2010) and to non SOD1-ALS; 
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indeed misfolding of SOD1 was shown to be induced by both TDP-43 and FUS 
mislocalisation (Pokrishevsky et al., 2012). 
7.2 Human and mouse SOD1 proteins in ALS 
Mutant SOD1 proteins have been intensively investigated in the study of ALS, but the 
mechanism through which they exert toxicity is still unknown (Bruijn et al., 2004; 
Seetharaman et al., 2009). Over the years a number of transgenic mouse models 
recapitulating the features of human SOD-ALS have been generated, introducing the 
human SOD1 gene into mice. In all of these mouse models of SOD1-fALS it is 
possible to detect accumulation of mutant SOD1, as happen in patients, leading to the 
concept that SOD1-ALS is a protein misfolding disorder. This feature together with 
the focality of the clinical onset and the regional spreading of neurodegeneration 
pointed to the idea that ALS spreads through a prion-like mechanism (Grad et al., 
2015; Lee and Kim, 2015). Such mechanism of seeded aggregation and spread of 
pathology have been demonstrated both in vivo and in vitro for many neurodegenerative 
diseases such as Alzheimer disease and Parkinson’s disease (Marciniuk et al., 2013). 
Genetic mutation is not the only way through which SOD1 can misfold and aggregate. 
Indeed post-translational modification and aberrant oxidation of wild-type SOD1 have 
been shown to drive aggregation in vivo (Casoni et al., 2005; Rakhit et al., 2004), and 
human wild-type SOD1 has been found to co-aggregate with mutant SOD1 variants in 
cell cultures. This discovery underlined the importance that in SOD1-fALS transgenic 
mouse models the mutant human and the mouse wild-type SOD1 protein coexist, and 
to interpret mouse SOD1-ALS research it is crucial to understand whether the human 
and the mouse SOD1 variants interact. 
7.2.1 In vivo interaction of human and mouse SOD1 proteins  
Evidence from previous studies suggest that there is no interaction between mouse and 
human SOD1 in mouse models of SOD1-fALS. When human wild-type SOD1 protein 
was overexpressed in a mutant mouse carrying a several copies of the G86R mutation 
in the mouse Sod1, no effect was detected on the motor phenotype or survival of the 
G86R mouse line, and the mouse and the human variants were not co-aggregating 
(Audet et al., 2010; Ripps et al., 1995). Further in SOD1-fALS mouse models 
endogenous mouse SOD1 has previously been reported as having little or no effect on 
the phenotype (Bruijn et al., 1998; Deng et al., 2006) and wild-type mouse SOD1 is 
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usually absent from mutant human SOD1 aggregates (Bruijn et al., 1998; Deng et al., 
2006; Jonsson et al., 2004). 
Results presented in this thesis show that the presence of the D83G mutant mouse 
SOD1 protein at endogenous levels does not exacerbate the phenotype of TgSOD1WT 
mice. Although, the presence of the overexpressed wild-type SOD1 protein rescues the 
phenotype of the Sod1D83G/D83G mice. In accordance with previous findings these data 
suggests that there is no interaction between the human and the mouse SOD1 protein, 
and the rescue of the D83G phenotype appears to occur in a dose-dependent manner, 
where high levels of wild-type SOD1 are present. Indeed in double transgenic mice in 
which an exacerbation of the phenotype is seen, the amount of wild-type human 
SOD1 has a dose-dependent effect, with higher levels of expression resulting in more 
profound exacerbation of the phenotype (Prudencio et al., 2010) 
The work presented in this thesis show that when SOD1 enzymatic activity is 
measured from mouse brain homogenates, using non-denaturing and non-reducing 
conditions the human wild-type and human G93A SOD1 transgenic proteins migrate 
faster in the gel, compared to the wild-type and D83G mutant mouse SOD1 variants 
(Figure 4.4, Figure 4.6Figure 4.7, Figure 4.8). In general transgenic human SOD1 animals 
display high levels of activity and the signal detected in activity gel assays is 
considerably more intense compared to that of wild-type or Sod1D83G mice. Thus in 
TgWTSod1D83G/D83G and TgWTSod1+/D83G mice it is not possible to distinguish between the 
human transgenic SOD1 protein and the mouse D83G SOD1, due to the intensity of 
the transgenic SOD1 signal. Further the native blot in Chapter 5 comparing SOD1 
protein from brain homogenates of wild-type, Sod1-/-, TgSOD1WT and TgSOD1G93A(H) 
mice using a commercial antibody against SOD1, confirms that the human SOD1 
transgenic protein migrates faster than the mouse SOD1.  
Unfortunately in native gels it is difficult to determine the size of the protein products 
since their electrophoretic mobility depends only on the charge-to-mass ratio and on 
the physical shape of the protein. Moreover in activity gel experiments it is not possible 
to stain the gel in order to identify the ladder. Besides these limitations it is possible to 
say that the protein products detected using activity gel assays corresponded to dimeric 
SOD1 proteins, or other functional SOD1 forms, but not to monomeric SOD1. 
Indeed monomeric SOD1 is not active and therefore undetectable by activity assays. 
Additionally in the native blot shown in Figure 5.15 (c) the minimum sized SOD1 
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bands electrophoresed higher on the gel than expected for SOD1 monomers. Further 
experiments measuring SOD1 activity and protein levels under native conditions from 
human and mouse brain samples could help clarify whether this difference in protein 
migration is due to species specific SOD1 protein charge or conformation, or if the 
fast migration pattern seen in transgenic SOD1-fALS is a consequence of protein 
overexpression. 
The hypothesis that these differences in migration pattern are due to diverse 
biochemical and biophysical characteristics of the human and mouse SOD1 protein is 
supported by several publications. Indeed, wild-type human SOD1, but not wild-type 
mouse SOD1, was found to co-aggregate with mutant human SOD1 (Prudencio et al., 
2010) while wild-type mouse SOD1, but not wild-type human SOD1, co-aggregates 
with mutant mouse SOD1 (Qualls et al., 2013). Further experiments carried out in cells 
by Grad and colleagues showed that residue tryptophan 32 is crucial for the conversion 
of human wild-type SOD1 to a misfolded form; but that mouse SOD1 possesses a 
serine residue at position 32, which is unable to participate in misfolding reactions with 
human wild-type SOD1 (Grad et al., 2011, 2015). These results taken together suggest 
that there are limited interactions between human and mouse SOD1 and that the 
tryptophan at residue 32 is implicated in species specific interaction limiting the co-
aggregation of human and mouse SOD1. 
7.2.2 In vitro interactions of human and mouse SOD1 recombinant proteins 
To further investigate human and mouse SOD1 interactions, and their role in ALS we 
produced and characterised recombinant human and mouse SOD1 proteins, and 
carried out preliminary spontaneous aggregation experiments. It has already been 
demonstrated that human mutant and wild-type SOD1 proteins can form aggregates in 
vitro. Aggregation can occur either by self-seeding or by cross-seeding with other pre-
formed aggregates, or with SOD1-fALS transgenic mice spinal cord homogenates 
(Chia et al., 2010). In Chapter 5 it is shown that human and mouse SOD1 protein 
share similar conformation characteristics of their secondary structure, this is expected 
since they are 84 % identical in amino acid sequence (Seetharaman et al., 2010). 
Interestingly when proteins were electrophoresed in denaturing and reducing 
conditions and stained by coomassie blue, the mouse SOD1 variants appeared to 
migrate slightly faster compared to the majority of the human variants (Figure 5.7). We 
hypothesise that this difference in migration might be due to a difference in metal 
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binding capacity among the SOD1 variants. Our preliminary experiments also show 
that the wild-type and mutant D83G human and mouse recombinant proteins that we 
produced can aggregate in vitro. Further cross-seeding experiments can be conducted to 
investigate whether the human and the mouse protein can co-aggregate in vitro and will 
help us to understand if the conversion of wild-type SOD1 by misfolded templates is a 
sequence or structure dependent process subject to species specific barriers. 
7.3 The importance of investigating SOD1 modifiers  
In ALS research transgenic SOD1-fALS mouse models have been extensively 
employed in the investigation of genetic modifiers of disease expression, that could 
potentially contribute to the susceptibility or neuroprotection of motor neuron 
degeneration (Heiman-Patterson et al., 2011). Both types of modifiers are quite 
valuable: suppressors can be used as targets for new drugs, and together with 
enhancers they might highlight new disease genes or pathways and lead to new 
therapeutic targets (Acevedo-Arozena et al., 2008). Modifiers can sometimes act both 
as enhancers and suppressors of different genes. For example, the ENU Legs-at-odd-
angles (Loa) mutation in Dync1h1 is known to act as an enhancer modifier in HD 
(Ravikumar et al., 2005) and as a suppressor in SOD1-ALS (Kieran et al., 2005). New 
interesting genes and pathways that may contribute to the disease have been mainly 
investigated by crossing transgenic SOD1-fALS mouse models with other mouse 
models expressing or lacking genes of interest (Oliver et al., 2011; Riboldi et al., 2011; 
Turner and Talbot, 2008). At MRC Harwell ENU mutagenesis, which can create a 
range of mutations from loss to gain of function, has been employed in combination 
with transgenic SOD1 G93A low copy mice to find possible new modifiers of SOD1-
ALS. One mouse with reduced survival was identified: the Galahad mouse. In the 
present work the survival, weight and grip-strength of the G2 progeny generated from 
the Galahad founder were investigated. The results of this study confirmed that the 
only phenodeviant feature of these animals compared to SOD1 G93A low copy mice 
is a subtle reduction in survival. Indeed as shown in Figure 6.8 the average survival for 
the mTgG93A(L)Galahad population is of 32.05 weeks while the average survival for the 
TgSOD1G93A(L) population is of 36.85 weeks. Such subtle difference in survival makes 
the analysis of behavioural data very difficult for two reasons. First the normal 
distribution of the two populations greatly overlap therefore, the majority of the 
animals, 31 out of 50, could not be included in the statistical analysis of the weight and 
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the grip-strength. Second because we could identify whether a mouse was 
mTgG93A(L)Galahad or not only at the time of end stage, it was not possible to carry out 
more accurate behavioural experiments since it would have been too costly to 
investigate all transgenic Galahad mice at the same time. Nevertheless, the results of the 
phenotypic analysis presented here suggests that it might be possible to select 
phenodeviant animals on the basis of their grip-strength, a few weeks before symptoms 
onset. Furthermore a genome scan investigation followed by a QTL analysis helped 
identifying a few regions of linkage where a possible mutation/s may be located. QTL 
analysis has already produced good results in the identification of important loci in 
SOD1-ALS. Indeed genome scan investigations have revealed the presence of modifier 
loci in chromosome 13 for SOD1-G86R mice and in chromosome 17 for SOD1-
G93A mice (Kunst et al., 2000; Sher et al., 2014). However, to date next-generation 
sequencing technology is a fast an affordable approach in the identification of newly 
induced causal variants that might be favoured over QTL analysis in ENU sensitised 
screens. 
As mentioned above genetic modifiers are important in the investigation of 
therapeutics for ALS. However, several reports showed that many therapeutic 
modifiers of mouse ALS did not translate successfully into patients (Perrin, 2014; 
Turner and Talbot, 2008). Indeed when working with SOD1-ALS mouse models it is 
crucial to take into consideration some experimental design guidelines to help ensure a 
standardisation of interpretation. It is therefore important to control for parameters 
such as background effect, a copy number and gender (Perrin, 2014; Turner and 
Talbot, 2008).  
7.4 Conclusions 
The work presented in this thesis proposes that loss of SOD1 function might play a 
modulating role in SOD-fALS, and shows that the Sod1D83G mice represent a good 
mouse model in which is possible to dissect elements of a gain of function and of a 
loss of function mechanism. Further characterisation of SOD1 protein in vivo and in 
vitro suggests that although the mouse and the human SOD1 proteins are capable of 
forming spontaneous aggregates, their conformational differences may prevent them 
from interacting in mouse models. Finally using ENU mutagenesis and QTL analysis 
two regions of linkage have been identified where might lie a possible modifying 
locus/loci interacting with the SOD1 G93A mutation. 
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SOD1 research has significantly contribute to broad our understanding of ALS 
however, in the last ten years several new causative genes have been identified, such as 
TDP-43, FUS, and C9orf72, providing new unforeseen insights into the pathogenesis of 
this disease. For example mutations in the RNA binding proteins TDP-43 and FUS 
exert toxicity through abnormal RNA metabolism or processing (Sreedharan et al., 
2008; Vance et al., 2009), while C9orf72 repeat expansion is hypothesized to drive 
repeat-associated non-ATG (RAN) translation that results in toxic peptides (Mackenzie 
et al., 2014; Mizielinska and Isaacs, 2014). All these mechanisms seem not to be 
implicated in SOD1-ALS suggesting that this disease cannot be explained solely by 
studying mutations in the SOD1 gene. Nevertheless several evidence point to the 
hypothesis that SOD1 might be implicated in the pathogenic mechanism of other 
causative ALS genes and vice versa. For example, as discussed in Chapter 3 mutant 
TDP-43 and FUS, and wild-type TDP-43, but not wild-type FUS can trigger 
misfolding of wild-type SOD1 in neural cells (Pokrishevsky et al., 2012). Moreover 
SOD1-immunoreactive inclusions were detectable in the spinal cords of fALS patients 
with and without SOD1 mutations (Forsberg et al., 2010). Recent reports also 
suggested that SOD1 mutations share similar toxic mechanisms with other ALS 
causative gene mutations. For instance motor protein kinesin 14 (KIF14) and an 
oxidative stress-related catalase CAT were commonly upregulated in transcripts from 
iPSCs derived from patients with C9orf72 expansion and SOD1 A4V mutation 
(Kiskinis et al., 2014). Of note SOD1 has also been suggested to work as a RNA 
binding protein similarly to TDP-43 and FUS (Chen et al., 2014; Lu et al., 2007; 
Volkening et al., 2009). 
Since nearly all ALS associated mutants target motor neurons, it is possible that 
multiple causative gene products share the same targets. Therefore investigating 
SOD1-fALS models can help elucidate important mechanism relative not only to 
SOD1-fALS but also to ALS in general. SOD1 mouse models are the best established 
models of ALS and in the last 30 years they helped elucidate disease mechanism and 
treatments (Ittner et al., 2015). The research carried out in the present work shows how 
studying novel mouse models of SOD1-fALS gives us new insights on disease and also 
reassess concepts of ALS pathology mechanism. Indeed the investigation of the 
Sod1D83G mouse described in Chapter 4, together with other findings, discredited the 
hypothesis that ALS is a dying back disorder, suggesting that the axonal and neuronal 
body degeneration, typical of ALS, may be two separate events possibly modulated by 
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different sets of genes. Further, the preliminary data on SOD1 recombinant proteins, 
reported in Chapter 5 confirmed that not only human SOD1 but also mouse SOD1 
variants can spontaneously aggregate in vitro, contributing to the current notion that 
SOD1 can propagate in a prion-like manner. A similar mechanism has been proposed 
also for TDP-43 and other neurodegenerative diseases, suggesting once again that 
studying SOD1-ALS might give important contributions not only to ALS but also to 
the broader field of neurodegenerative diseases. Additionally exploring human-mouse 
SOD1 interaction in the context of SOD1-fALS mouse models will help interpret 
SOD1 transgenic mouse models pathology data and their translation into clinical trials. 
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Chapter 8 Appendices 
8.1 Appendix 1 Table of SOD1 transgenic mice 
Transgenic SOD1 mouse lines are reported in Table 8.1. Rows are arranged by the 
location of the mutation used. All figures are for hemizygous mice unless specified. 
The protein level and dismutase activity reported were assayed from spinal cord, unless 
specified. 
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Mutation Promoter Tg 
copy 
number 
Protein level 
(fold 
increase to 
endogenous 
SOD1 level) 
SOD1 
activity 
(fold 
difference 
to non-
transgenic) 
Onset 
(weeks) 
Survival 
(weeks) 
Notes  References  
Wild-type hSOD1 7 50; 24 fold in 
(Jonsson et 
al., 2006b) 
8.6 36 
(hom) 
52 
(hom) 
 (Graffmo et 
al., 2013; 
Gurney et al., 
1994; Jonsson 
et al., 2006b) 
A4V hSOD1 ~5 nr ~1.4 None   (Gurney et al., 
1994) 
G37R (line 106) hSOD1 nr 4.2 brain; 5.3 
spinal cord 
7.2 22-30 25-29  (Wong et al., 
1995) 
G37R (line 29) hSOD1 nr 4 brain; 5 
spinal cord 
7 24-32   (Wong et al., 
1995) 
G37R (line 42) hSOD1 nr 8 brain; 10.5 
spinal cord 
14.5 14-16   (Wong et al., 
1995) 
G37R (line 9) hSOD1 nr 5.4 brain 6.2 
spinal cord 
9 20-24   (Wong et al., 
1995) 
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Mutation Promoter Tg 
copy 
number 
Protein level 
(fold 
increase to 
endogenous 
SOD1 level) 
SOD1 
activity 
(fold 
difference 
to non-
transgenic) 
Onset 
(weeks) 
Survival 
(weeks) 
Notes  References  
G37R Neurofilament 
light chain 
promoter 
nr 4.3 (line 
3156) and 2.8 
(line 4012) 
nr None 
until 1.5 
years  
None 
until 1.5 
years 
Neuron specific 
expression, two lines 
reported  
(Pramatarova 
et al., 2001) 
G37R (see notes) Mouse prion 
promoter 
nr nq nq 28-36 
(hom) 
1 or 2 
weeks 
after 
onest 
Co-integration of SOD1 
transgene with construct 
encoding wild-type 
human presenilin 1 
(hPS1) with PrP 
promoter) 
(Wang et al., 
2005a) 
G37R (floxed) nr nr nq nr 26-30 37-48  (Boillée et al., 
2006) 
G37R and G93A  
(see notes) 
Chicken skillet 
muscle αsk 
actin 
1-8   32-40  Two mutants (G37R and 
G93A, plus the WT) 
created, results do not 
specify which mutant.  
(Wong and 
Martin, 2010) 
H46R hSOD1 nr nr nr 22-26 4 weeks 
after 
onset 
 (Nagai, 2000) 
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Mutation Promoter Tg 
copy 
number 
Protein level 
(fold 
increase to 
endogenous 
SOD1 level) 
SOD1 
activity 
(fold 
difference 
to non-
transgenic) 
Onset 
(weeks) 
Survival 
(weeks) 
Notes  References  
H46R hSOD1 nr nr nr 20 24  (Chang-Hong 
et al., 2005) 
H46R/H48Q     
(line 139) 
hSOD1 nr nq 1 nr 17-26  (Wang et al., 
2002b) 
H46R/H48Q     
(line 58) 
hSOD1 nr nq nr nr 12-47  (Wang, 2003; 
Wang et al., 
2002b) 
H46R/H48Q/ 
H63G/H120G    
(line 121) 
hSOD1 nr nq nr nr Over 69 
weeks 
Experimental mutations 
to disrupt copper binding 
(Wang, 2003) 
H46R/H48Q/ 
H63G/H120G    
(line 125) 
hSOD1 nr nq 1 nr 39-52 Experimental mutations 
to disrupt copper binding 
(Wang, 2003) 
H46R/H48Q/ 
H63G/H120G    
(line 187) 
hSOD1 nr nq nr nr 35-48 Experimental mutations 
to disrupt copper binding 
(Wang, 2003) 
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Mutation Promoter Tg 
copy 
number 
Protein level 
(fold 
increase to 
endogenous 
SOD1 level) 
SOD1 
activity 
(fold 
difference 
to non-
transgenic) 
Onset 
(weeks) 
Survival 
(weeks) 
Notes  References  
E77X hSOD1 nq nr nr None Normal Experiential to see if 
truncated proteins can 
cause disease (RNA 
barely detectable) 
(Deng et al., 
2008) 
L84V hSOD1 nr nr nr 22-26 26  (Kato, 2001; 
Tobisawa et 
al., 2003) 
G85R (line 148) hSOD1 nr 1 1 33 35  (Bruijn et al., 
1997) 
G85R (line 74) hSOD1 nr 0.2 nr 51-61 2 weeks 
after 
onset 
 (Bruijn et al., 
1997) 
G85R Thy1.2  nq nq None 
up to 87 
weeks 
nr Bicistronic expression of 
SOD1 and EGFP in 
postnatal motor neurons 
(Lino et al., 
2002) 
G85R (floxed) nr nr 1.5 1 44 50 LoxP flanked trangene (Wang et al., 
2009c) 
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Mutation Promoter Tg 
copy 
number 
Protein level 
(fold 
increase to 
endogenous 
SOD1 level) 
SOD1 
activity 
(fold 
difference 
to non-
transgenic) 
Onset 
(weeks) 
Survival 
(weeks) 
Notes  References  
G85R (YFP fusion 
line 641) 
nr  nr nr 36 
(hom) 
  (Wang et al., 
2009a) 
G83R (mouse) nr nr nr 1 13-17 13-17  (Pramatarova 
et al., 2001; 
Ripps et al., 
1995) 
G86R (mouse)    
(line 2) 
Mouse GFAP nq nq  None 
up until 
70 
weeks 
 Astrocyte specific 
expression 
(Gong et al., 
2000) 
G86R (mouse)    
(line 29) 
Mouse GFAP 10 nq  None 
up until 
70 
weeks 
 Astrocyte specific 
expression 
(Gong et al., 
2000) 
D90A (line 134) nr nr nr ~6-9 50 
(hom) 
58 
(hom) 
 (Jonsson et 
al., 2006a) 
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Mutation Promoter Tg 
copy 
number 
Protein level 
(fold 
increase to 
endogenous 
SOD1 level) 
SOD1 
activity 
(fold 
difference 
to non-
transgenic) 
Onset 
(weeks) 
Survival 
(weeks) 
Notes  References  
K91X (stop) hSOD1 nq nr nr None  Normal  Experiential to see if 
truncated proteins can 
cause disease (RNA 
barely detectable) 
(Deng et al., 
2008) 
G93A (line G1) hSOD1 18 nr ~4 12-16 20  (Gurney et al., 
1994) 
G93A (line G20) hSOD1 1.7 nr ~1.6 nr 49  (Dal Canto 
and Gurney, 
1995; Gurney 
et al., 1994) 
G93A (line G1H) hSOD1 25 17 <4; as 8.9 in 
(Wang et al., 
2008) 
13 19.4 High transgene copy 
number derived from G1 
(Chiu et al., 
1995; Tu et 
al., 1996) 
G93A (line G1del) hSOD1 8 nr nr 28 36 Low transgene copy 
derived form G1line 
(Gurney, 
1997; Zhang 
et al., 1997) 
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Mutation Promoter Tg 
copy 
number 
Protein level 
(fold 
increase to 
endogenous 
SOD1 level) 
SOD1 
activity 
(fold 
difference 
to non-
transgenic) 
Onset 
(weeks) 
Survival 
(weeks) 
Notes  References  
G93A Rat myosin 
light chain 
(MLC1) 
nr nq nq Muscle 
atrophy 
from 4 
weeks 
nr Muscle specific  (Dobrowolny 
et al., 2008) 
G93A (T1xT3)     
(see notes) 
Thy1.2 nr   77-104 84-104 Compound hemizygous 
T1 and T3 transgene. 
Postnatal motor neurons 
specific 
(Jaarsma et 
al., 2008) 
G93A (line T1) Thy1.2 nr   None Normal  Postnatal motor neurons 
specific 
(Jaarsma et 
al., 2008) 
G93A (line T3) Thy1.2 nr nq  None 
(54-104 
for 
hom) 
62-104 
(hom) 
Postnatal motor neurons 
specific 
(Jaarsma et 
al., 2008) 
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Mutation Promoter Tg 
copy 
number 
Protein level 
(fold 
increase to 
endogenous 
SOD1 level) 
SOD1 
activity 
(fold 
difference 
to non-
transgenic) 
Onset 
(weeks) 
Survival 
(weeks) 
Notes  References  
G93A (with 
luciferase reporter) 
BiTetO     None Over 64 
weeks  
BiTetO (bicistronic 
tetracycline-repressible 
transactivator) promoter 
expressing a SOD1-
G93A and luciferase 
transgene. WT line also 
made 
(Wang et al., 
2008) 
G93A MLC1f/3f      Skeletal muscle specific.  (Dobrowolny 
et al., 2008) 
G93A TRE    None  Bidirectional 
tetracycline/doxycycline 
response (TRE) 
transgene 
(Bao-Cutrona 
and Moral, 
2009) 
I113T nr nr nr nr 52 nr  (Kikugawa, 
2000) 
T116X (stop) hSOD1 nr nr nr 2 weeks 
before 
survival 
43 
(hom) 
Experiential to see if 
truncated proteins can 
cause disease 
(Deng et al., 
2008) 
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Mutation Promoter Tg 
copy 
number 
Protein level 
(fold 
increase to 
endogenous 
SOD1 level) 
SOD1 
activity 
(fold 
difference 
to non-
transgenic) 
Onset 
(weeks) 
Survival 
(weeks) 
Notes  References  
L126delTT          
(see notes) 
nr nr nr nr None   Mouse created to model 
ALS but resultant 
phenotype was due to 
insertional disruption of 
the single stranded DNA 
binding protein 1 
(Nishioka et 
al., 2005) 
L126delTT (line D1) hSOD1 1 nr nr None    (Watanabe et 
al., 2005) 
L126delTT (line D2) hSOD1 5  1 63 (34 
for 
hom) 
68 (36 
for 
home) 
 (Watanabe et 
al., 2005) 
L126delTT-FLAG 
(line DF2) 
hSOD1 3 nr nr None  FLAG tagged SOD1 (Watanabe et 
al., 2005) 
L126delTT-FLAG 
(line DF7) 
hSOD1 4 nq 1 49 (17 
for 
hom) 
53 (18 
for 
hom) 
FLAG tagged SOD1 (Watanabe et 
al., 2005) 
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Mutation Promoter Tg 
copy 
number 
Protein level 
(fold 
increase to 
endogenous 
SOD1 level) 
SOD1 
activity 
(fold 
difference 
to non-
transgenic) 
Onset 
(weeks) 
Survival 
(weeks) 
Notes  References  
L126Z (stop) hSOD1 nr 0-0.5 nr 30-39 nq SOD1 locus with 
engineered fusion exon 
3,4 and 5 
(Wang et al., 
2005b) 
L126Z (stop) nr nr 0-1 nr 48 51  (Deng et al., 
2006) 
SOD1G127insTGGG 
(line 716) 
nr 19 0.45-0.97 1 7-10 
weeks 
before 
survival 
(hom) 
64 (36 
for 
hom) 
 (Jonsson et 
al., 2004) 
SOD1G127insTGGG 
(line 832) 
nr 28 nr nr nr 30 (18 
for 
hom) 
 (Jonsson et 
al., 2004) 
Table 8.1 Transgenic mice expressing mutant or wild-type SOD1. Transgene (Tg); homozygous (hom); not reported (nr); measured but not quantified (nq). 
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8.2 Appendix 2 Vector and constructs 
The open reading frame (ORF) sequence of the human wild-type SOD1 cDNA was 
determined by sequencing an ‘in house’ plasmid stock, pSP64 Poly(A)Vector, 
containing SOD1 insert. This insert sequence was compared to available sequence 
(accession No.: NM_000454) from the Nucleotide Database on NCBI 
(http://www.ncbi.nlm.nih.gov). Using this as template, site directed mutagenesis was 
performed to generate constructs for other mutants, human G93A, human D101G. 
Constructs were cloned into the pET28 expression vector (Novagen), downstream of 
the T7 promoter between the NdeI and XhoI restriction sites. The SOD1 expression 
was based on IPTG induction of the T7 RNA polymerase (T7 RNAP). Once 
expressed T7 RNAP drove the expression of SOD1 at the IPTG inducible T7 
promoter, located upstream of the cloned SOD1 cDNA. The constructs were cloned 
such that a thrombin cleavage site was created between the protein and the N-
terminally added His-tag. Mutant constructs were generated by Dr. David Emery 
(University of Bristol), Dr Ruth Chia and Julian Pietrzyk (Institute of Neurology, 
University College London).  
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8.3 Appendix 3 Ni-NTA column recharged protocol 
After 6 uses the resin of Ni-NTA columns needs to be recharged with nickel ions. The 
protocol consists in a series of washed with different buffers, see Table 8.2 
Buffer 
Volume 
(column/volume) 
6 M GuHCl, 0.2 M acetic acid in ddH2O 2 
ddH2O 5 
2 % SDS in ddH2O 3 
25 % ethanol in ddH2O 1 
50 % ethanol in ddH2O 1 
75 % ethanol in ddH2O 1 
100 % ethanol  5 
75 % ethanol in ddH2O 1 
50 % ethanol in ddH2O 1 
25 % ethanol in ddH2O 1 
ddH2O 5 
100 mM NiSO4 in ddH2O 2 
ddH2O 2 
6 M GuHCl, 0.2 M acetic acid in ddH2O 2 
ddH2O 2 
20 % ethanol in ddH2O 2 
Table 8.2 Ni-NTA resin recharge protocol. 
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8.4 Appendix 4 Sod1-/- other neuronal and extra-neuronal 
phenotypes  
8.4.1 Sod1-/- non-motor neuronal phenotypes  
Hearing deficit with loss of ganglion neurons  
Keithley and colleagues found that at 12 months of age all Sod1-/- mice developed a 
hearing loss with an increased auditory threshold. This phenotype was accompanied by 
a decrease in ganglion cell density at 7 months (Keithley et al., 2005). 
Progressive retinal degeneration and age related macular degeneration (AMD)  
Sod1-/- mice developed a progressive retinal degeneration with manifestation of necrotic 
cells, and decreasing of wave amplitudes, similarly to AMD patients (Hashizume et al., 
2008). Furthermore they displayed other human AMD features, such as overtime 
build-up of drusen (extracellular accumulations in Bruch's membrane of the eye) 
detectable in over 85% of eyes by 10 months of age. At 12 months Bruch’s membrane 
was strikingly thickened and 15 months old mice showed a choroidal 
neovascularization. Drusen number could also be increase in young animals by 
exposure to light (Imamura et al., 2006). 
Blood-brain-barrier disruption and increased lethality following focal cerebral 
ischemia  
Sod1-/- mice were shown to be susceptible to ischemic brain damage. Mortality 24 hours 
after ischemic insult occurred in 100 % of Sod1-/- animals, compared to 11 % of wild-
type littermates, with evidence of early and severe blood-brain-barrier (BBB) disruption 
(Kondo et al., 1997). Also, BBB disruption following noxious stimuli was increased in 
homozygous Sod1 knockout mice (Kim et al., 2003).  
Increased damage following brain trauma 
Superoxide is known to be produced in vulnerable regions after traumatic brain injury, 
for example in the dentate gyrus or in cortex. Indeed Sod1-/- mice experiencing 
traumatic brain developed increased lesion volume and levels of apoptotic cell death 
compared to wild-type controls (Lewén et al., 2000). In accordance, previous data 
showed a protective role of SOD1 overexpression after brain injury (Mikawa et al., 
1996).  
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Increased susceptibility to neurodegeneration 
Murakami et al. crossed Sod1-/- mice with mice overexpressing the amyloid precursor 
protein (APP). The double mutant progeny obtained showed significantly increased 
memory loss, tau phosphorylation, Aβ oligomerisation and plaque formation, pointing 
to a modulation role of neurodegeneration progression for SOD1 (Murakami et al., 
2011). Furthermore it was shown that Sod1 mRNA binds the Fragile X Mental 
Retardation Protein (FMRP), increasing translation of SOD1 protein. Thus, SOD1 
protein levels were reduced in Fmrp1 knockout mice suggesting that this reduction 
played a role in the physiopathology of Fragile X syndrome (Bechara et al., 2009). 
8.4.2 Sod1-/- extra-neuronal phenotypes  
Decreased survival, hepatocellular carcinoma 
Survival of Sod1-/- mice was significantly decreased compared to wild-type littermates 
(20.8 months versus 29.8 months for controls) due to increased incidence of 
hepatocellular carcinoma (HCC). Tumour nodules and hepatocyte injury were found 
on 70 % of end stage Sod1-/- animals on a C57BL/6J background; which is proven to 
be protective against development of HCC (Elchuri et al., 2005; Takahashi et al 2002). 
Preferential development of HCC in these mice might occur because of the high 
amount of ROS that are constantly generated in the liver, due to lack of SOD1 activity. 
Indeed clinical studies carried out in patients with different stages of HCC showed a 
strong correlation between low levels of SOD and the severity of HCC (Casaril et al., 
1994; Liaw et al., 1997). Furthermore HCC patient’s data demonstrated a positive 
correlation between SOD1 activity in tumours and post-surgery survival time (Lin et 
al., 2001).  
Impaired endothelial-dependent relaxation 
Sod1-/- mice developed increased myogenic tone, augmented vasoconstrictor response 
and impaired endothelium-dependent relaxation in large arteries and microvessels 
(Didion et al., 2002). These phenotypes might occur due to increased levels of 
superoxide that rapidly inactivates nitric oxide, which is released by endothelial cells 
and induces vasodilatation (Fukai and Ushio-Fukai, 2011). This is in accordance with 
previous observations that ROS play an important role in in endothelial cell 
dysfunction, which can be rescued by SOD1 (Niwa et al., 2000) and prevented by 
SOD1 overexpression (Iadecola et al., 1999). 
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Skin thinning and osteoporosis 
Sod1-/- mice have atrophic skin morphology at 4 months of age, accompanied by 
degeneration of collagen and elastic fibres and reduction of skin hydroxyproline. 
Vitamin C derivate treatment were shown to ameliorate these conditions regenerating 
collagen and elastin (Murakami et al., 2009). 
In vivo and in vitro studies demonstrate that Sod1-/- mice have a number of key features 
of human bone aging such as: decreased bone density and cortical areas (typical signs 
of osteopenia), loss of bone volume and quality (involving a significant reduction in 
enzymatic collagen cross-linking) resulting in bone fragility. Vitamin C treatment 
reduced bone loss, leading to normalization of bone strength (Nojiri et al., 2011). 
Infertility 
Fertility of Sod1-/- males was described as normal. However, Sod1-/- sperm suffered 
from oxidative damage during in-vitro fertilization (Tsunoda et al., 2012). Only in some 
studies fertility of Sod1-/- females was reported as decreased due to ovarian defects (Ho 
et al., 1998; Matzuk et al., 1998). 
8.5 Appendix 5 Identification of the Sod1D83G mouse model by ENU 
mutagenesis 
ENU mutagenesis is a powerful technique largely used to generate mouse models of 
human disease. In particular ENU is a chemical that that when injected in mice induces 
random point mutations in the DNA in a dose dependent manner (approximately one 
mutation every 1-1.5 Mb). To produce animals carrying a point mutation in specific 
genes male mice are treated with ENU, which selectively kills spermatogonial cells. 
After a period of sterility spermatogonial cells of mutagenized animals repopulate and 
each of them express an assortment of point mutations along the genome. Treated 
males are then mated with wild-type females, the sperm from their offspring is stored 
while tissue is used to screen for mutations in the gene of interest (Acevedo-Arozena et 
al., 2008; Quwailid et al., 2004). To identify the Sod1D83G model genomic DNA from 
Harwell ENU-induced mutagenesis archive of over 10000 mice was screened for 
mutations in the Sod1 gene (Joyce et al., 2014).  
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Figure 8.1 Sod1D83G identification: ENU mutagenized mice breeding scheme. 
8.6 Appendix 6 Transmission project 
To investigate if SOD1 can seed aggregation in mouse model in a prion-like manner, 
transgenic mice overexpressing human SOD1 were intracerebrally inoculated with 
tissue homogenates of mutant human SOD1 spices, or with control homogenates or a 
vehicle only control to asses misfolded SOD1 aggregate pathology. 
To evaluate SOD1 self-seeded aggregation potential, spinal cord homogenates of 
TgSOD1G93A(H) mice were inoculated in animals of the same line. While, to assess cross-
seeded aggregation potential, spinal cord homogenates of TgSOD1G93A(H) mice, and 
homogenates of motor cortex human SOD1-fALS carrying the I113T and the D101G 
mutations were inoculated in TgSOD1WT mice. 
All animals employed for this project were bred on to a Sod1-/- background, to avoid 
the possible interaction between the human SOD1 proteins and the endogenous 
mouse SOD1 protein. 
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8.7 Appendix 7 Galahad project 
Plots showing the genotype and recombination events along the different chromosome 
for all the G2 animals employed in the QTL analysis are reported below in Figure 8.2. 
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Figure 8.2 Genotype and recombination events per mouse along the 19 autosomal 
chromosomes. Animals are listed in crescent order of survival from top to bottom. Chromosomes 6 
and 18 appears to be the most interesting. 
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Mutations in the gene superoxide dismutase 1 (SOD1) are causative for familial forms of the neurodegenerative disease
amyotrophic lateral sclerosis. When the first SOD1 mutations were identified they were postulated to give rise to amyotrophic
lateral sclerosis through a loss of function mechanism, but experimental data soon showed that the disease arises from a—still
unknown—toxic gain of function, and the possibility that loss of function plays a role in amyotrophic lateral sclerosis patho-
genesis was abandoned. Although loss of function is not causative for amyotrophic lateral sclerosis, here we re-examine two
decades of evidence regarding whether loss of function may play a modifying role in SOD1–amyotrophic lateral sclerosis.
From analysing published data from patients with SOD1–amyotrophic lateral sclerosis, we find a marked loss of SOD1
enzyme activity arising from almost all mutations. We continue to examine functional data from all Sod1 knockout mice and
we find obvious detrimental effects within the nervous system with, interestingly, some specificity for the motor system. Here,
we bring together historical and recent experimental findings to conclude that there is a possibility that SOD1 loss of function
may play a modifying role in amyotrophic lateral sclerosis. This likelihood has implications for some current therapies aimed
at knocking down the level of mutant protein in patients with SOD1–amyotrophic lateral sclerosis. Finally, the wide-ranging
phenotypes that result from loss of function indicate that SOD1 gene sequences should be screened in diseases other than
amyotrophic lateral sclerosis.
Keywords: amyotrophic lateral sclerosis; motor neuron disease; superoxide dismutase 1; loss of function
Abbreviations: ALS = amyotrophic lateral sclerosis; tgSOD1 = SOD1 transgenic mice
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder
characterized by the progressive loss of upper and lower motor
neurons. Its clinical course is relentlessly progressive and typically
causes death within 3 to 5 years of onset, mostly due to respira-
tory failure (Haverkamp et al., 1995). Similar to other major
neurodegenerative disorders, such as Alzheimer’s disease and
Parkinson’s disease, ALS is typically sporadic, but 5–10% of
cases have an autosomal dominant pattern of transmission and
are termed ‘familial’ (Rothstein, 2009). In 1993 the first causative
mutations were found within the gene encoding the enzyme,
superoxide dismutase 1 (SOD1) (Deng et al., 1993; Rosen
et al., 1993). Since then, over 155 SOD1 mutations have been
described (although pathogenicity has not been shown for all of
these changes) and these mutations account for up to 20% of
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familial ALS cases (Fig. 1) and 3% of sporadic ALS cases (Pasinelli
and Brown, 2006; Acevedo-Arozena et al., 2011; Andersen and Al
Chalabi, 2011).
SOD1 is ubiquitously expressed and highly conserved across
species (Fridovich, 1995). The gene is composed of five exons
encoding a 153 amino acid metalloenzyme, also referred to as
Cu/Zn superoxide dismutase. The protein localizes to the cyto-
plasm, nucleus, lysosomes and intermembrane space of
mitochondria (Chang et al., 1988; Keller et al., 1991; Crapo
et al., 1992; Sturtz et al., 2001). It binds copper and zinc ions
and forms a homodimer whose main known function is as a dis-
mutase removing dangerous superoxide radicals by metabolizing
them to molecular oxygen and hydrogen peroxide, thus providing
a defence against oxygen toxicity. Recently, SOD1 has been found
to be critical for repressing respiration and directing energy
metabolism through integrating responses to O2, glucose and
Figure 1 Diagram of human SOD1 mutations, variants and activity in the current literature. The amino acid sequence of SOD1 is
shown, with the location of introns (A). One hundred and fifty-five SOD1 mutations described in patients with ALS are annotated; data
are taken from the ALS online database (ALSoD, http://alsod.iop.kcl.ac.uk, January 2013) and additional literature. Note that only
variations that are predicted to affect the amino acid sequence of the protein have been included. Pathogenicity has not been shown
for all mutations. Mutations listed on ALSoD, InsAexon2 and E133del are the same as mutations V29insA and E133delGAA, re-
spectively, and so have not been annotated separately. Similarly, we believe the mutation D125TT to be L126delTT and mutation
E133insTT to be E132inTT. Information about highlighted structural elements was from Wang et al. (2006). Additional references are
Pramatarova et al. (1995) and Kobayashi et al. (2012). †Locations where two nucleotide changes results in the same amino acid
substitution; Mutations which result in a frameshift and premature stop codon. (B) Diagram of human SOD1 mutations and overall
enzyme activity measured in red blood cells, fibroblast and lymphoblast cell lines. Measurements from patients carrying 48 SOD1-
familial ALS mutations between 1993 and December 2012; original references are cited in Supplementary Table 1. All measures fall
below 100% normal activity. Three mutations found in homozygous individuals are shown on the right hand side of the figure. Red
circles show measures of intrinsic activity where these are known. We note that all mutations shown here are familial, not sporadic, and
have supporting data indicating they are ALS causative (Supplementary Table 1). Where more than one publication shows overall
activity for an individual mutation the value from the report with the highest sample size has been plotted. Refer to supporting
references for details. Het = heterozygous; Hom = homozygous.
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superoxide levels (through casein kinase signalling); this role is
independent of its function in oxidative stress (Reddi and
Culotta, 2013). Other described functions are nitration of proteins
(Beckman et al., 1993), copper buffering (Culotta et al., 1997),
phosphate activation (Wang et al., 1996), zinc homeostasis (Wei
et al., 2001), thiol oxidation, and immunomodulation—modula-
tion of SOD1 activity may differentially affect the NO-dependent
microbicidal activity and release of cytokines by activated macro-
phages (Marikovsky et al., 2003). Further, SOD1 is produced at
high levels that have not yet been explained by known functions,
therefore, it may well play other roles both neuron-specific and
generally (Reddi and Culotta, 2013).
The finding of loss of dismutase activity in patients with ALS
and the distribution of ALS-causative mutations spread throughout
the SOD1 gene initially suggested loss of function as a mechanism
(Deng et al., 1993; Rosen et al., 1993). However, evidence for a
gain of function mechanism was quick to follow from analysis of
mutant SOD1 transgenic (tgSOD1) mouse models. The first of
these, tgSOD1G93A, carries an ALS-causative point mutation
resulting in a glycine to alanine substitution at residue 93
(Gurney et al., 1994). Currently there are more than 12 different
published human mutant SOD1 transgenic strains (Joyce et al.,
2011) and most of them (including tgSOD1G93A) have increased
dismutase activity because they greatly overexpress transgenic
mutant human SOD1 in addition to endogenous mouse SOD1
and they develop a progressive adult-onset motor phenotype,
accompanied by a striking loss of lower motor neurons.
Thus a loss of function mechanism became less favoured com-
pared with gain of function because: (i) in humans, a lack of
correlation was found between SOD1 dismutase activity and
aggressiveness of clinical phenotypes (Ratovitski et al., 1999);
(ii) in mice, a lack of overt ALS-like phenotype was found in
Sod1 null (Sod1/) animals, the first of which was published
by Reaume et al. (1996); whereas (iii) transgenic mouse models
over-expressing mutant human SOD1 have increased SOD1 activ-
ity and a loss of motor neurons that models human ALS.
The death knell for loss of function came in a seminal study
published by the Cleveland laboratory (Bruijn et al., 1998) who
analysed survival time in mice carrying a mutant SOD1 transgene
(tgSOD1G85R) on a normal mouse background (i.e. with two
copies of the endogenous mouse Sod1 gene) compared with the
same transgene on a Sod1/ background. They found no
change in survival of the mice, thus concluding that survival was
entirely due to a gain of function mechanism, and independent of
mouse SOD1 loss of function. These findings essentially ended the
debate for a role of loss of function as a contributor to SOD1-
familial ALS (Bruijn et al., 1998).
SOD1 mutations remained the only known cause of ‘classical’
ALS until causative mutations in the gene TARDBP were found
(Sreedharan et al., 2008), and therefore have been studied exten-
sively in a variety of animal and cellular models (Ilieva et al.,
2009). The causative gain of function is indisputable and several
mechanisms by which this occurs have been proposed and com-
prehensively reviewed (Turner and Talbot, 2008; Ilieva et al.,
2009; Rothstein, 2009). However, in recent years a number
of laboratories have further investigated Sod1 knockout mice,
examining their neuromuscular involvement and non-neurological
features. Data from these investigations and recent experiments
using transgenic SOD1 overexpressing mice have pointed to the
possibility of a modifying role played by loss of dismutase activity
on familial ALS disease course.
Here we review what is known about SOD1 loss of function
and the evidence to suggest it may play a role in ALS pathogenesis
after all, possibly through increased susceptibility to neurodegen-
eration. It is important and timely to consider these data because
they are relevant to current therapeutic strategies to reduce the
level of mutant familial ALS-SOD1 in heterozygous individuals.
Such strategies could provide badly needed approaches to ameli-
orating the ALS phenotype, but clearly SOD1 loss has effects on
both neuronal and non-nervous system tissues. SOD1 loss of func-
tion data also strongly suggest that SOD1 should be screened in
disorders other than ALS.
SOD1 dismutase activity is
greatly reduced in patients
with SOD1-familial
amyotrophic lateral sclerosis
Dismutase activity is the best characterized function of SOD1. Two
other dismutases, encoded by separate genes, have been identi-
fied in mammals: SOD2 (Mn-SOD), which has manganese (Mn)
as a cofactor and localizes to the mitochondrial matrix (Fridovich,
1986; Zelko et al., 2002) and SOD3 (Fe-SOD), which exists as a
homotetramer and is mainly extracellular (Marklund et al., 1982).
The existence of three enzymes with dismutase activity may com-
plicate measures of SOD1 activity alone.
Box 1 Methods of measuring SOD1 dismutase activity
Activity
assay:
A sample is collected from the tissue of interest, such as
red blood cells. Xanthine–xanthine oxidase is added
to the sample to generate superoxide anions (O2 ),
and then a chromagen is used as an indicator of O2
production. In the presence of SOD, O2 concentrations
are reduced, resulting in decreased colorimetric signal.
However, all three SOD isoforms contribute to the ac-
tivity measured, and so SOD1 activity is obtained in-
directly by subtracting SOD2 and SOD3 activity from
total SOD activity. This is achieved by running a
parallel assay with the addition of potassium cyanide
which preferentially inhibits SOD1 (Roe et al., 1988).
Gel
assay:
Proteins from the tissue of interest are separated by elec-
trophoresis in a native gel which is subsequently
stained using a solution of nitro blue tetrazolium and
riboflavin. Riboflavin is a source of O2 when exposed
to light. The superoxide anions interact with nitro blue
tetrazolium, reducing the yellow tetrazolium within the
gel to a blue precipitate. This reduction reaction stains
the gel blue; however, SOD inhibits this reaction, re-
sulting in colourless bands where SOD is present. As
the intensity of these bands is relative to the amount of
SOD present, quantification can be inferred by measur-
ing the intensity of the bands at the correct molecular
weight using digital software (Weydert and Cullen,
2010).
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In patients with ALS, SOD1 activity has most commonly been
measured using two methods, generally either (i) the ‘activity
assay’ which measures total dismutase activity of all three enzymes
and then subtracts SOD2 and SOD3 activity, to leave only SOD1
activity; or (ii) the ‘gel assay’ in which the three enzymes
are separated by electrophoresis and then dismutase activity is
measured within the band of the correct size for the SOD1
dimer (Box 1).
Intrinsic and overall SOD1
activity
The dismutase activity of SOD1 can be measured in two ways
depending on whether the focus is on (i) the ‘intrinsic’ SOD1
activity, which reflects the enzymatic efficiency of the protein
and is obtained by measuring the activity of recombinant SOD1
protein normalized to its quantity; or (ii) the ‘overall’ activity
within a tissue sample, which may be affected by various factors
in the cellular environment (as described below), and is obtained
by normalizing dismutase activity to the quantity of tissue. This
last measure has generally been used with patients with familial
ALS, and is a reflection of the amount of activity present in a
biological context.
Intrinsic activity influences the overall activity, but is only one of
the determinants; the others being any factor that affects the
quantity, biological availability and functionality of SOD1.
Amongst these are SOD1 messenger RNA half-life, SOD1 protein
half-life, correct folding of SOD1, Cuþ2 -loading of SOD1 and other
post-translational modifications (Wilcox et al., 2009). In general,
the ‘overall’ activity is an unbiased measure that takes into ac-
count known and unknown influences on SOD1 enzyme activity.
Measurements are generally expressed relative to normal control
samples.
Overall SOD1 activity is
reduced in human amyotrophic
lateral sclerosis samples
Intrinsic SOD1 activity has been measured in at least eight mutant
proteins, giving diverse results ranging from 0–150% of human
wild-type SOD1 activity. Correlation between these values and
clinical aspects of the disease was assessed and did not show
significant links (Borchelt et al., 1994; Ratovitski et al., 1999).
However, overall SOD1 activity has most commonly been mea-
sured in red blood cells, fibroblasts and lymphoblastoid cell lines
derived from patients carrying at least 48 different mutations, and
has proved to be more homogeneous than measures of intrinsic
activity. We have searched reports of SOD1 activity from 1993 to
2012 in patients with SOD1–familial ALS and found that the
majority of 48 tested mutations all have a reduction of overall
activity. The average loss of activity is notable and averages
58% (17, SD) of normal values (Fig. 1). These results are of
strikingly consistency given the variability arising from different
laboratories performing the measurements and the naturally
occurring variation in activity documented in blood samples (de
Lustig et al., 1993; Borchelt et al., 1994; Robberecht et al., 1994).
Overall SOD1 activity is normal or only slightly reduced in two
mutations: the D90A in both homozygous and heterozygous pa-
tients, and the L117V in heterozygotes; although measurement
from a homozygous patient showed a reduction of 67% SOD1
activity compared with control subjects (Andersen et al., 1995;
Synofzik et al., 2012). Both these mutations are atypical, for
example (i) SOD1 misfolding is not detected in cells derived
from patients carrying these mutations (see below for association
between SOD1 misfolding and SOD1 activity); (ii) the disease
allele is homozygous in the majority of patients with D90A ALS
and in one of four reported patients with L117V ALS; (iii) pene-
trance in heterozygotes is low; and (iv) disease progression is
unusually slow (Synofzik et al., 2012). Possibly these mutants
have a slightly increased propensity to aggregate that is sufficient
to start the disease process, although with reduced frequency, in
the CNS, but is not enough to determine misfolding and loss of
dismutase activity in the periphery.
Of note is the non-correspondence between the overall patient
activity and the intrinsic activity; for example, the SOD1G37R
mutant has 150% intrinsic activity but only 40% overall activity
compared with normal control subjects. Given that the intrinsic
activity is only one of the determinants of the overall activity,
other factors, such as the stability of mutant SOD1 protein,
have been investigated to try to account for this loss of activity.
Different mutant SOD1 proteins have been shown to have a
variable half-life, but this is consistently reduced compared to the
wild-type form (Sato et al., 2005). Calculations combining the
measurement of intrinsic activity and half-life of six SOD1-familial
ALS mutant proteins predicted that the overall activity would have
been only 50% of normal levels (Borchelt et al., 1994). Other
studies and Fig. 1 are in accord with this finding (Deng et al.,
1993; Birve et al., 2010). Further, most measures of SOD1 activity
from patients with ALS have been taken in red blood cells, and we
note that these cells have no active protein synthesis and are on
average 60 days old, making the system particularly responsive
to detecting protein half-life changes (Broom et al., 2008).
Nevertheless, when tested in post-mortem brain and spinal cord,
SOD1 activity was found to be reduced to levels similar to those
measured in red blood cells (Bowling et al., 1993; Rosen et al.,
1994; Watanabe et al., 1997; Browne et al., 1998; Jonsson et al.,
2004), and when activity in red blood cells and CNS was
compared in the same subset of patients, results were strikingly
concordant (Rosen et al., 1994).
Is SOD1 dismutase activity
reduction exacerbated in
motor neurons?
SOD1 activity has not been specifically measured in motor neu-
rons and other affected cell types from SOD1–familial ALS post-
mortem material, owing to technical difficulties in conducting
these assays on limited micro-dissected material. The level of
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activity reduction in these cell types is therefore unknown; how-
ever, there is evidence that the dismutase activity reduction may
be enhanced in motor neurons.
RNA
SOD1 messenger RNA was shown to form tissue-specific com-
plexes with ribonucleoproteins from brain and spinal cord and
these interactions prolong its half-life in these tissues. However,
complex formation appears to be impaired when SOD1 messenger
RNA carries ALS-causing mutations, therefore potentially reducing
the half-life of mutant SOD1 messenger RNA preferentially in CNS
of patients with SOD1-familial ALS (Ge et al., 2006).
Aggregation
Indirect evidence indicates that SOD1 aggregation reduces dismu-
tase activity. For example, data from cell experiments in which
SOD1G93A and amyloid-b were co-expressed, suggesting that ag-
gregation results in reduction of SOD1 activity (Yoon et al., 2009).
Further, two transgenic mouse lines over-expressing human wild-
type-SOD1 at a high level and at 2-fold this level, were analysed
for aggregation and SOD1 activity. In liver and muscle samples,
aggregation was not found to be present, SOD1 protein levels
were increased, as expected, 2-fold and SOD1 activity increased
accordingly. However, in spinal cord and brain, where SOD1
aggregation was clearly found, protein levels had a similar increase
as in muscle and liver, but importantly SOD1 activity did not show
an increase, strongly suggesting a link between protein aggrega-
tion and activity (Graffmo et al., 2013). Furthermore, even if
SOD1 retains enzymatic activity in aggregates, it may not
accomplish the same functions as when correctly targeted to the
appropriate cell compartments. SOD1 misfolding and aggregation
are a hallmark of SOD1-familial ALS and have been extensively
documented in SOD1-familial ALS (Jonsson et al., 2008) and wild-
type SOD1 has also been shown to be present in spinal cord
aggregates of both patients with familial ALS (Jonsson et al.,
2004) and SOD1 mouse models (Deng et al., 2006; Wang
et al., 2009a; Prudencio et al., 2010), thus making a dominant
negative loss of function plausible. The recent finding of SOD1
aggregation in cases with sporadic ALS (Bosco et al., 2010;
Forsberg et al., 2010) makes this mechanism potentially relevant
also to sporadic disease.
Oxidative stress
Lastly, oxidative stress induces SOD1 to monomerize as an inter-
mediate step to aggregate formation and it is known that SOD1
does not have dismutase activity in this form (Khare et al., 2004;
Rakhit et al., 2004; Ezzi et al., 2007; Wilcox et al., 2009). Motor
neurons are known to be particularly susceptible to oxidative stress
(Barber and Shaw, 2010) making this process potentially more
pronounced in these cell types.
The tissue-specific changes in SOD1 messenger RNA half-life
and the effect of SOD1 aggregation and monomerization on
dismutase activity, raise the possibility that SOD1 activity in the
affected neurons may be lower than that measured from blood.
How SOD1 activity in blood relates to that in spinal cord motor
neurons is a critical issue that remains to be addressed.
In summary, SOD1 overall activity is consistently reduced in
blood samples of patients with SOD1–familial ALS, likely owing
to changes in protein activity and alterations in mutant protein
half-life. Further, there is an additional possible tissue-specific
dismutase activity reduction in neurons.
Sod1/ mice have
neuromuscular, neuronal and
extra-neuronal phenotypes
An approach to elucidating the effect of SOD1 loss of function is
to assess the phenotype of Sod1 null (Sod1/) mice.
Homozygous Sod1 null mice have been used to analyse the role
of SOD1 in ALS, and for other purposes such as studying oxide
radical-mediated toxicity in reproduction and development (Huang
et al., 1997; Matzuk et al., 1998). To date five Sod1 knockout
mouse lines have been published: Sod1tm1Cpe (Reaume et al.,
1996); Sod1tm1Cje (Huang et al., 1997); Sod1tm1Leb (Matzuk
et al., 1998); Sod1tm1Ysh (Ho et al., 1998); and Sod1tm1Dkd
(Yoshida et al., 2000). All were obtained by targeted deletion of
different regions of the Sod1 gene, ranging from a single exon to
the entire genomic sequence. For all five lines, no SOD1 protein is
detectable in homozygous null mice and SOD1 activity is absent or
very low [which may represent the background of the enzyme
assay or might be caused by an endogenous superoxide dismutase
activity supplied by an alternative scavenging enzyme (Reaume
et al., 1996)].
Deletion of different portions of the same gene may result in
different phenotypes, but the five Sod1 knockout strains have
been compared in a number of studies and are strikingly similar
(Huang et al., 1997; Kondo et al., 1997; Kostrominova, 2010). For
example, skeletal muscles of three different Sod1 null strains were
compared and all developed accelerated age-related muscle
denervation (Kostrominova, 2010). Genetic background may also
influence phenotypes, however the majority of the studies
discussed here, have been carried out on Sod1/ mice on a
congenic C57BL/6 background, making results from different
laboratories comparable.
When Sod1/ mice were first generated, a key issue was
whether they developed motor neuron degeneration. The first
analysis, from Reaume et al. (1996), found no reduction in
motor neuron number at 4 months of age, but an increase in
small neurons and astrocytes in spinal cord ventral horns.
Subsequent studies confirmed the lack of motor neuron loss at
6, 9 and 17 months (Flood et al., 1999) and lack of vacuolation
or chromatolysis, key features of ALS, at 4 and 18 months (Fischer
et al., 2012). Microgliosis and ubiquitinated protein accumulation
in motor neurons were ruled out, but mild astrocytosis was found
at 4 and 18 months (Fischer et al., 2012). Evaluation of lumbar
ventral roots confirmed no loss in motor neuron number, but
interestingly axonal diameter was reduced at 6 and 19 months
and evidence of degenerating and regenerating axons was seen
in the ventral L3 root at the latter time point (Flood et al., 1999),
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although another study did not see these results when analysing
the L4 root (Fischer et al., 2012).
Although Sod1 null mice do not develop overt motor neuron
degeneration, there is now a considerable literature, summarized
below and described in more detail in the Supplementary material,
showing that compared with wild-type controls, these mice have
a wide range of phenotypes, including several relevant to ALS,
such as a slowly progressive motor deficit that manifests from
early adulthood and likely involves defects in large motor axons.
Sod1 null mice develop an adult-onset
progressive motor axonopathy
Behavioural data
Sod1 null animals appear indistinguishable from littermates at birth
through to weaning (Reaume et al., 1996). Weight reduces with
age compared with wild-type littermates (Jang et al., 2010; Larkin
et al., 2011) and voluntary wheel running diminishes, which is a
sensitive test for early locomotor defects (Muller et al., 2006). At 9
months of age Rotarod performance and stride-length worsen
(Flood et al., 1999; Muller et al., 2006), although spontaneous
locomotion is normal, thus changes in motivation are not likely to
contribute to these results (Flood et al., 1999; Muller et al., 2006).
At 1 year of age, Sod1/ mice also have a deficit in grip-
strength, and tremors (Fischer and Glass, 2010)—hallmarks of
neuromuscular disorders in mice (Muller et al., 2006).
Neurophysiological data
Direct neurophysiological measurement of the response to stimu-
lation of nerve and muscle eliminates behavioural/motivational
variability from the outcome. Such studies showed Sod1 null
mice have a reduction in muscle strength suggesting a progressive
deficit in innervation (Larkin et al., 2011). Motor unit number is
reduced at 3 months, with progressive loss with age (Shefner
et al., 1999). Complex repetitive discharges found on needle
examination indicate a deficit in the terminal part of the motor
axon (Shefner et al., 1999). Measures of nerve conduction vel-
ocity and latency analysis on sensory and mixed nerves, show a
reduction only where a motor component is present, compatible
with a deficit in the largest motor axons (Flood et al., 1999). Thus
neurophysiological investigations show clear muscle denervation
and deficits in motor axons and functional motor units in Sod1
null mice.
Axonal damage and early involvement of neuromuscular
junctions
Denervation in Sod1/ mice has been documented by neuro-
muscular junction analysis of both fast and slow twitch muscles
(Flood et al., 1999; Fischer et al., 2011, 2012; Larkin et al., 2011).
Denervation progresses with age, maintaining a more aggressive
pattern in fast-twitch rather than slow-twitch muscles (Jang et al.,
2010; Fischer et al., 2012). Thus SOD1 is required for mainten-
ance of motor axons and their terminals (Fischer et al. (2011) and
without this protein, fast-twitch motor units are lost preferentially,
as is also observed in patients with ALS and mouse models
of familial ALS (Dengler et al., 1990; Pun et al., 2006). The
involvement of neuromuscular junctions as an early pathological
target has been extensively documented in mouse models of
SOD1–familial ALS (Murray et al., 2010) and was shown to pre-
cede motor neuron cell body loss in early disease in a patient with
ALS (Fischer et al., 2004).
Muscle pathology is secondary to denervation
Muscle mass is progressively lost (Muller et al., 2006; Jang et al.,
2010; Larkin et al., 2011) but has not been reported for organs
such as liver, heart or kidney (Muller et al., 2006). Angular muscle
fibres, indicating denervation, are present by 2 months of age
(Flood et al., 1999) and by later time points a massive reduction
in fibre number occurs, preferentially affecting type 2b fibres (fast
glycolytic type innervated by large motor neurons), along with an
increase in angular fibres (Reaume et al., 1996; Larkin et al.,
2011). This muscle profile also occurs in mouse models of familial
ALS–SOD1 (Kennel et al., 1996; Frey et al., 2000) and is typical of
the neurogenic changes that initially affect larger motor neurons,
suggesting that muscle pathology is secondary to axonal events.
Confirmation of muscle pathology being secondary to axonal
damage and denervation was obtained by crossing Sod1/
mice with transgenic mice expressing Sod1 in the CNS but not
in muscle. In double mutant progeny, muscle pathology was fully
rescued despite the absence of SOD1 in muscle (Flood et al.,
1999). Further, in Sod1/ mice, measurements of steady state
redox potential of glutathione (which is routinely used as indicator
of the intracellular redox state) in tibial nerve and gastrocnemius
muscle showed a selective involvement of the nerve at 4 months,
again indicating the primary involvement of the axon (Fischer
et al., 2012). Thus muscle changes in Sod1/ mice are second-
ary to denervation; they are non-specific and also present in
muscle biopsies from patients with ALS (Baloh et al., 2007a).
Sod1/ motor neurons show increased
vulnerability to stress
SOD1 activity is important for motor neuron survival after injury as
shown by facial axotomy of Sod1 null mice which resulted in a
significant increase in motor neuron loss compared with wild-type
controls. This is interesting when considering the potential role for
injury and trauma in ALS (Pupillo et al., 2012; Yip and Malaspina,
2012).
Selective susceptibility to damage of the motor system
An important feature of ALS is the selective involvement of motor
neurons and their related circuits, and indeed the phenotypes
induced by lack of SOD1 in mice preferentially affect motor neu-
rons. Sod1/ mice have no significant deficits in somatosensory
behaviour (Flood et al., 1999). Further, neurophysiology testing
showed preferential motor involvement in Sod1/ mice and,
on histopathological examination, L3 dorsal roots at 19 months
are normal in contrast to the ventral roots, which have signs of
degeneration/regeneration (Flood et al., 1999). Finally, analysis of
Sod1 null epidermal nerves, which are the most distal tracts of the
sensory axons, showed no abnormality, in contrast to their
severely affected motor counterparts, the neuromuscular junctions
(Fischer et al., 2012).
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Loss of SOD1 affects mitochondrial function
Sod1/ mice lack superoxide scavenging function in the cytosol
and mitochondrial intermembrane space, which contain O2 gen-
erated by complex III (Muller et al., 2004). Sod1 null mitochondria
release significantly increased amounts of O2 and therefore
increased oxidative stress in these compartments was hypothesized
to account for the neuromuscular phenotype of the mice (Jang
et al., 2010). Fischer et al. (2011) demonstrated that mitochon-
drial density is reduced in Sod1/ axons and, remarkably, they
reversed this loss and the neuromuscular phenotype, by replacing
SOD1 selectively in the mitochondrial intermembrane space of
these mice.
Mitochondrial dysfunction is associated with ALS (Faes and
Callewaert, 2011) and mitochondria are important for distal
axonal maintenance (Baloh et al., 2007b; Cassereau et al.,
2011). Furthermore, mitochondrial transport abnormalities are
described in tgSOD1-ALS mouse models (De Vos et al., 2007).
Also, abnormal mitochondrial accumulations have been described
in lower motor neurons and proximal axons from patients with
ALS, post-mortem (Sasaki et al., 2009). Thus it seems likely that
damage to mitochondria through raised levels of free radicals may
have a significant effect on distal axons of motor neurons.
In summary Sod1/ mice appear normal up to the age of
weaning, after which they develop a slowly progressive motor-
neuronopathy that involves primarily the motor neuron axons
and neuromuscular junctions and is accompanied by significant
secondary denervation pathology in muscles (Supplementary
Fig. 1). Sensory involvement is negligible. Although no motor
neuron loss has been documented, these are more vulnerable
to damage in Sod1/ mice.
Other neuronal and extra-neuronal Sod1
null phenotypes
In addition to deficits in the motor system, Sod1 null mice develop
a range of other disorders including: progressive neuronal hearing
loss; progressive retinal degeneration; greatly increased suscepti-
bility to cerebral ischaemia and brain trauma. Most importantly for
studies of ALS, these mice have an increased susceptibility to neu-
rodegeneration, for example, when crossed to a mouse model of
Alzheimer’s disease (Supplementary Box 1).
Extra neuronal phenotypes are also striking, in particular the
well-known susceptibility to hepatocellular carcinoma, a feature
that also manifests in the human population; there is a positive
correlation between SOD1 activity and postoperative hepatocellu-
lar carcinoma survival time, as well as low levels of SOD1 and
severity of hepatocellular carcinoma (Elchuri et al., 2005;
Takahashi et al., 2002; Casaril et al., 1994; Liaw et al., 1997;
Lin et al., 2001). Other non-neuronal features include impaired
endothelial-dependent relaxation, thinning of the skin, osteopor-
osis and female infertility (Supplementary Box 1).
These remarkably wide-ranging phenotypes are perhaps not sur-
prising in an animal that is missing such an important enzyme, but
the tissue specificity partly points to effects in tissues with a high
production of free radicals, such as the nervous system and liver.
Further, the progressive nature of most of these phenotypes is strik-
ing and may be relevant to the mechanism of SOD1–familial ALS,
both in terms of deficits increasing with age and in terms of targeting
of many of the deficits to neuronal tissues.
A SOD1 activity of 50% is
not sufficient for normal
neuronal function
Sod1+ / mice have abnormal phenotypes including
within the motor system
Sod1 null mice are invaluable for investigating in vivo conse-
quences of SOD1 loss of function, and may provide clues for
the effects of reduced enzyme activity in ALS. However, the
100% loss of enzyme activity is a different setting from the aver-
age 57% reduction in patients with ALS. Thus, although Sod1 null
mice clearly indicate a susceptibility of specific tissues to the
effects of a loss of SOD1 function, any discussion in the context
of ALS must look at phenotypes that arise in Sod1+ / animals
(Supplementary Fig. 1) that retain 50% SOD1 activity (Reaume
et al., 1996) and so mimic the physiological levels described in
patients with SOD1–familial ALS. Although Sod1+/ mice clearly
do not develop an ALS-like syndrome, a wide range of studies
show that Sod1+ / mice have abnormal phenotypes involving
progressive cellular damage and deficits in reaction to injury and
toxic stimuli. Here we consider how these may have implications
for human ALS.
Sod1+ / motor neurons are more susceptible to cell
death after axon injury
Sod1+ / mice suffer significantly more motor neuron loss in
response to facial nerve axotomy than wild-type mice. This
result is intermediate between Sod1/ and control mice, sug-
gesting a dose dependence of this effect and demonstrating that
50% SOD1 activity is not sufficient for a normal function of motor
neurons in response to injury (Reaume et al., 1996).
Facial nerve axotomy was also performed on copper chaperone
for SOD1 null mice (Ccs/), that retain only 20% of SOD1
activity, owing to the lack of this crucial protein for delivery of
copper to SOD1 (Box 2). Motor neuron survival was significantly
reduced in Ccs/ mice (Subramaniam et al., 2002). This result,
BOX 2 Ccs/ null mice model SOD1 partial loss of
activity
Another mouse model that is relevant to studying the effects of
reduced SOD1 activity is the ‘copper chaperone for SOD1’ (Ccs)
null mouse. Copper chaperones shuttle copper, which is toxic for
cells in its free form, to intracellular target proteins. CCS delivers
copper to SOD1 by direct protein–protein interaction and is
required for full activation of SOD1 (Culotta et al., 1997, 1999).
Mice lacking CCS (Ccs/) were generated by gene targeting and
retain only 20% of normal SOD1 activity; CCS-independent copper
loading into SOD1 probably accounts for the remaining activity.
Although the dismutase activity is impaired, there is no difference
in the levels of SOD1 protein among wild-type, Ccs+ / and
Ccs/ littermates (Wong et al., 2000).
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and the similar result from Sod1+ / mice, is important in light of
the potential role for injury and trauma as a trigger in ALS patho-
genesis (Pupillo et al., 2012; Yip and Malaspina, 2012).
Spontaneous denervation, motor neuron sensitivity and
reduction in mitochondrial numbers are not significant
in Sod1+/ mice but all show trends
Although Sod1+ / mice have been less studied than null animals,
there have been comprehensive investigations of denervation in
these mice (Fischer et al., 2011, 2012). At 18 months, 80% of
tibialis anterior muscle (neuromuscular junctions) were innervated
in Sod1+ / compared with 92% in controls (Fischer et al., 2011).
This result did not reach statistical significance, but this trend was
repeated in a following study (Fischer et al., 2012). Currently,
there is no evidence for spontaneous denervation in Sod1+ /
mice. Experiments were conducted up to the time-point of 18
months, the maximum limit when investigating Sod1/ mice—
which develop and die of liver cancer at this stage—but could be
extremely informative at later time-points for the Sod1+ / mice.
Whether increased sample size or a later time-point would show a
significant result, remains to be determined.
Glutamate toxicity is enhanced in Sod1+ / mice
Glutamate toxicity is implicated in disease in patients with ALS and
in animal models (Ilieva et al., 2009). The role of SOD1 in neur-
onal sensitivity to glutamate toxicity was assessed in vivo by
intrastriatal injection of N-methyl-D-aspartic acid and kainite glu-
tamate receptor agonists. Sod1+ / mice were more susceptible to
the neurotoxic effects of both stimuli and had reduced glutamic
acid decarboxylase and choline acetyltransferase activities com-
pared with controls (Schwartz et al., 1998). Thus SOD1 partial
loss of function could play a role in facilitating damage from
glutamate toxicity, which may have relevance to ALS.
Increased susceptibility to cerebral ischaemia in Sod1+ /
 mice
Sod1+ / mice have decreased survival after induced focal cerebral
ischaemia, along with increased early blood–brain barrier disrup-
tion and increased infarct volume causing brain swelling. Apoptotic
neuronal death is also increased demonstrating enhanced ischae-
mia–reperfusion injury (Kondo et al., 1997). Intriguingly, an im-
portant mechanism involved in ischaemia–reperfusion injury is
glutamate excitotoxicity, which as discussed above, is postulated
to play a role in ALS pathogenesis (Beal, 1992).
We note that blood–brain barrier alterations are found in
tgSOD1-ALS mouse models and that indirect evidence of disrup-
tion, such as increased cerebrospinal fluid (CSF) albumin/plasma
albumin ratios, has been documented in patients with ALS
(Leonardi et al., 1984; Apostolski et al., 1991).
Increased memory deficits and plaque formation in an
Alzheimer’s disease model on a Sod1+ / background
Overexpression in mice of the APP gene carrying the Swedish
mutation causes behavioural deficits and plaque formation and
thus models Alzheimer’s disease (Bodendorf et al., 2002). When
this mutation is expressed on a Sod1+ / background, it results in
increased deficits in behavioural tests used to assess memory and
in increased senile plaque formation, thus showing that lack of
50% of SOD1 activity does indeed increase the development of
a neurodegenerative phenotype in vivo.
Ganglion neuron loss is increased with ageing in Sod1+/
 mice
A 50% reduction in SOD1 activity results in reduced neuronal
survival in vivo with respect to ganglion cell density, although
this does not cause an apparent hearing deficit (Keithley et al.,
2005).
DNA methylation is reduced in Sod1+/ mice
The effects of reduced mouse SOD1 activity could be relevant to
ALS because DNA methyltransferases, the enzymes involved in
DNA methylation, and 5-methylcytosine, the end-product of
DNA methylation, were found to be upregulated in human ALS,
suggesting that aberrant regulation of DNA methylation is part of
the pathobiology of ALS (Chestnut et al., 2011). DNA methylation
was significantly reduced at 2 months of age in Sod1+ / mice,
although this study focused on prostate tissue (Bhusari et al.,
2010).
Sod1+ / mice exhibit a contractile vascular phenotype
with ageing
High levels of superoxide play a major role in contractile vascular
dysfunction and loss of a single copy of Sod1 is enough to
increase vascular superoxide levels and produce vascular contract-
ile dysfunction with ageing (Didion et al., 2006).
Loss of mouse SOD1 activity to 50% of normal levels
does not cause death of motor neurons but may be
relevant to human SOD1–familial amyotrophic lateral
sclerosis
Sod1+ / mice show an increased loss of specific neuronal sub-
types with ageing and an increased susceptibility to injury and
toxic stimuli. These results are relevant to SOD1-familial ALS
given the similarity of enzyme activity levels between patients
with SOD1-familial ALS and Sod1+ / models. The vulnerability
shown in motor neurons after injury, the susceptibility of neurons
to glutamate toxicity, and the blood–brain barrier alterations seen
in these mice are significant elements since they are mechanisms
and alterations postulated to be involved in ALS pathogenesis.
Overall Sod1/ and Sod1+ / animals do not recapitulate
mouse ALS, but they have a wide range of phenotypes that are
both related to ALS directly (for example, denervation, increased
susceptibility to glutamate toxicity, increased susceptibility to
axonal damage) and more generally to neuronal degeneration
(for example, loss of ganglion and retinal cells) and therefore
this raises the question of a contribution of SOD1 loss of function
to disease. A further point to consider is that although several
transgenic mice carrying SOD1 mutations have motor neuron de-
generation and characteristics of human ALS, other mouse strains
with well-characterized pathogenic mutations in different ‘ALS
genes’ (for example, TARDBP) have phenotypes less clearly rem-
iniscent of the human disease (Joyce et al., 2011). Thus it remains
debatable as to how a mouse–ALS syndrome might manifest, and
so considering all phenotypes that develop in the CNS of these
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models is essential for understanding how ALS mutations cause
disease.
SOD1 activity and its influence
on SOD1–familial amyotrophic
lateral sclerosis mouse models
SOD1 loss of function does not
influence survival of transgenic SOD1
disease models
The possibility that SOD1 loss of function contributes to ALS
pathogenesis has been investigated by analysing the double
mutant progeny of Sod1/ or of Ccs/ mice crossed to three
tgSOD1-ALS lines overexpressing the human mutations, G93A,
G37R and G85R. These crosses produce double mutant mice in
which either the transgenic human mutant protein is the only
SOD1 present (in the case of Sod1/ crosses) or both the en-
dogenous and transgenically expressed SOD1 are mostly inactive
due to the Ccs/ background.
As both G93A and G37R mutant SOD1 retain dismutase activity
(Fig. 1) they are not informative for the effect of SOD1 dismutase
loss of function when on a Sod1 null background. Further, trans-
genes often form multiple copy concatamers and indeed both
the tgSOD1G93A and the tgSOD1G37R lines have an increase of
46-fold of mouse SOD1 activity, compared with non-transgenic
control mice (Bruijn et al., 1997; Subramaniam et al., 2002; Deng
et al., 2006). As a result, even on a Ccs/ background, these
two transgenic lines still have SOD1 activity levels comparable
with those of non-transgenic wild-type mice and so are not
useful for examining the effects of SOD1 loss of function on dis-
ease course (Subramaniam et al., 2002).
However, two experiments do examine the effect of mouse
SOD1 loss of function on the disease developed by tgSOD1-ALS
mouse models. These assess progeny from crosses of Sod1/
and Ccs/ with tgSOD1G85R, a human ALS mutation that has
no detectable intrinsic activity (Borchelt et al., 1994; Bruijn et al.,
1997). Activity is predicted to fall to 0% when crossed with
Sod1/ (Bruijn et al., 1998) and shown to be 20% when crossed
with Ccs/, as expected, given the residual SOD1 activity of the
Ccs/ line (Subramaniam et al., 2002).
The tgSOD1G85R line shows clinical signs of disease between 8–
10 months of age, which aggressively progress to paralysis within
a few weeks (Bruijn et al., 1997). The disease onset is much later
than many other tgSOD1-ALS mouse models, this is appropriate
for evaluating any potential modifying effect of SOD1 loss of
function. Crosses to both Sod1/ (n = 5 double mutant progeny)
and Ccs/ (n = 10 double mutant progeny) did not show signifi-
cant effects on lifespan (Bruijn et al., 1997; Subramaniam et al.,
2002).
Both of these studies resulted in seminal papers that have been
extremely important to the field and have answered critical ques-
tions about SOD1 gain of function in ALS. However, neither paper
answered the separate question about whether loss of function
modifies ALS, presumably and quite reasonably because that
was not the focus of the papers. Both studies were performed
using a cohort size too small to detect potential subtle changes
[n = 5 in Bruijn et al. (1997) and n = 10 in Subramaniam et al.
(2002)] and the sex of the mice analysed was not reported, al-
though it is clear that in both humans and mouse, gender plays a
role in ALS natural history (Acevedo-Arozena et al., 2011; Joyce
et al., 2011). Furthermore, neither study evaluated the age of
disease onset or performed behavioural analysis therefore not ad-
dressing the possibility that SOD1 loss of function may have an
impact on onset and disease course. Lastly, both studies lack a
quantitative pathology analysis: Bruijn et al. (1997) noted n = 2 for
axonal count in the L5 ventral roots, and Subramaniam et al.
(2002) perform a qualitative analysis only, at end-stage, therefore
missing any potential modifier effect occurring during the disease
process.
Thus while it remains unclear if SOD1 loss of function modifies
important disease characteristics such as age of onset or progres-
sion, it appears not to affect lifespan. The lack of effect on survival
in the absence of mouse SOD1 activity is an important result be-
cause it shows that life expectancy in this line is determined
uniquely by mutant SOD1. It has been also speculated that the
lack of an effect on lifespan is due to the insufficient levels of
endogenous SOD1 to counteract the oxidative stress present in
the tgSOD1G85R mice, and because the tgSOD1G85R mice die
before developing a significant oxidative stress-mediated motor
axonopathy (Wang et al., 2012). With respect to onset and dis-
ease course, a larger cohort would be required to note differences,
particularly if they are subtle.
SOD1 activity may influence disease
course of transgenic SOD1 disease
models
While the effect of mouse SOD1 activity on disease onset and
progression of tgSOD1-ALS models is unclear from the crosses
to Sod1 null mice, there are other experimental data indicating
that SOD1 activity may play a role in modifying SOD1-
familial ALS.
SOD1 overexpression and influence
on disease
The effect of overexpression of wild-type human SOD1 on disease
course has been tested by crossing mutant tgSOD1-ALS animals
with transgenic mice overexpressing wild-type human SOD1
(tgSOD1-WT). Double mutant progeny carry both the wild-type
and mutant human SOD1 transgenes, with two copies of the en-
dogenous mouse Sod1 in the genetic background (Bruijn et al.,
1998; Jaarsma et al., 2000; Fukada et al., 2001; Deng et al.,
2006; Wang et al., 2009a, b; Prudencio et al., 2010). Generally,
a worsening of both age of onset and survival have been reported,
compared with single mutant tgSOD1-ALS littermates. However,
we note that tgSOD1-WT mice spontaneously develop motor
neuron and axon loss and have misfolded SOD1 accumulations
(Jaarsma et al., 2000) and develop an ALS-like disease when
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expression is further increased (Graffmo et al., 2013), making the
results of these crosses hard to interpret.
Of note, transgenic mice over-expressing CCS have also been
generated and crossed to different tgSOD1 lines, and results have
ranged from no effect to a significant worsening of the phenotype.
However, CCS over-expression was shown to have biological effects
in the absence of SOD1 enzymatic activation and also to have an
influence on the reduced state of SOD1, making these results not
helpful for dissecting the role of dismutase activity on disease
(Proescher et al., 2008; Son et al., 2009; Graffmo et al., 2013).
Tissue specific expression and
inactivation of mutant SOD1 points to a
modifying role for dismutase activity
To address questions regarding the cell-autonomy of SOD1-famil-
ial ALS, investigators have used Cre-loxP technology to condition-
ally eliminate mutant SOD1 expression in different cell lineages or
used specific promoters to overexpress mutant SOD1 in selected
cell types. Analysis of their results is beyond our scope here, but
generally demonstrates a central role for neurons in the determin-
ation of age of onset and disease progression in SOD1-familial
ALS, and has also pointed to a role for other cell types, such as
astrocytes and microglia in influencing the course of the disease
(Ilieva et al., 2009).
Cre-loxP experiments were conducted using two mutant tgSOD1
lines: conditional tgSOD1G37R, which retains intrinsic dismutase ac-
tivity, and conditional tgSOD1G85R, which lacks activity. Neuronal
excision experiments in both lines showed a beneficial effect on dis-
ease onset and survival. Interestingly, for consideration of the effects
of dismutase activity, significant differences were found between the
conditional tgSOD1G37R and conditional tgSOD1G85R lines after
mutant SOD1 excision from microglia and from astrocytes.
A more profound amelioration was observed with the
tgSOD1G85R line in both experiments, with an effect on early
disease with microglia excision and also on disease onset with
excision in astrocytes; neither result occurred in the tgSOD1G37R
experiments (Ilieva et al., 2009; Wang et al., 2009b, 2011). A
possible explanation for these divergent results has been proposed
to lie in differences in dismutase activity (Wang et al., 2012). If in
addition to the toxic gain of function effects, tgSOD1G37R has
neuroprotective effects in microglia and astrocytes due to its en-
zymatic activity, then a knockdown of tgSOD1G37R expression
would have less ameliorative effects on the disease course than
knockdown of the inactive SOD1G85R (Wang et al., 2009b, 2011).
In support of a modifying effect of SOD1 dismutase activity are
findings obtained with the excision of tgSOD1G37R from Schwann
cells. Excision from the tgSOD1G37R made the disease progression
in the mice more severe. Lobsiger et al. (2009) proposed that
SOD1G37R activity in Schwann cell had a neuroprotective effect.
Conversely, excision of the inactive SOD1G85R caused a delay in
disease onset, an increased survival and an amelioration of path-
ology (Wang et al., 2012). Furthermore, increasing SOD1G93A ex-
pression specifically in Schwann cells of the tgSOD1G93A mouse
had a beneficial effect on disease (Turner et al., 2010).
In conclusion, the experimental data overall point to a protective
role of SOD1 dismutase activity, at least in some cell types, on
non-cell autonomous degeneration and disease in SOD1–ALS.
Conclusions
SOD1 loss of function models share
many commonalities with amyotrophic
lateral sclerosis indicating specific
cell-type sensitivities
SOD1 loss of function was initially thought to play a role in ALS
due to the discovery of disease-causing mutations in the SOD1
gene and due to the well-established link between oxidative stress
and neurodegeneration (Smith et al., 1991; Stadtman 1992;
Stadtman and Berlett, 1997). Indeed free radical damage has
been shown in CSF, serum and urine from patients with ALS
(Smith et al., 1998; Simpson et al., 2004; Mitsumoto et al.,
2008) and proteins, lipids and DNA were shown to have elevated
oxidative damage in ALS post-mortem material (Shaw et al.,
1995; Fitzmaurice et al., 1996; Shibata et al., 2001). As SOD1-
familial ALS undoubtedly arises primarily from SOD1 toxic gain of
function, the loss of dismutase activity may play a modifying role.
The most useful tools to study this possibility in vivo have been
the Sod1/ mice. These mice are a model of chronic oxidative
stress, but do not develop a disease that models human ALS.
Long term studies of Sod1/ mice show striking features
related to ALS. Notably, these mice develop a progressive distal
motor axonopathy and ALS has indeed been postulated to start by
affecting the distal portions of the neurons including neuromuscu-
lar junctions and axons (Murray et al., 2010). The most affected
motor units in Sod1/ mice are fast-twitch, which is in accord-
ance with observations in ALS models (Frey et al., 2000). Motor
neurons in Sod1 null mice have an increased susceptibility to injury
and importantly, stimuli such as trauma, could play a role in initi-
ating ALS (Pupillo et al., 2012) where humans, even if carrying
disease-causing mutations, are healthy for decades. Further, in
Sod1/ mice, motor neurons are preferentially affected com-
pared to sensory neurons, recapitulating the selectivity observed
clinically and pathologically in ALS.
The neuromuscular phenotype in Sod1 null mice has been
demonstrated to be caused by the lack of SOD1 in the mitochon-
drial intermembrane space and a related decrease in axonal mito-
chondrial density (Fischer et al., 2011). The involvement of
mitochondria in ALS and other forms of motor neuron disease
such as spinal muscular atrophy, has been shown in animal and
cellular models and indirectly in post-mortem material (Baloh
et al., 2007b; De Vos et al., 2007; Acsadi et al., 2009; Sasaki
et al., 2009; Wen et al., 2010; Faes and Callewaert, 2011). As
described, Sod1/ mice have other phenotypes that underline
the importance of this gene in neuronal ageing and in neurode-
generation. Among these are the spontaneous progressive loss of
retinal cells and auditory ganglion neurons, the increased suscep-
tibility to APP induced neurodegeneration and the increased
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susceptibility to apoptotic cell death following brain trauma and
ischaemic injury.
SOD1 activity is greatly reduced in
human SOD1-familial amyotrophic
lateral sclerosis
SOD1 activity is generally reduced to approximately half of normal
in patients with SOD1-familial ALS, as measured in red blood cells,
lymphoblastoid cells and fibroblasts (Fig. 1). Indirect evidence
raises the possibility that a more severe reduction could occur in
susceptible tissues and cell types, owing to reduced mutant SOD1
messenger RNA half-life in the CNS and due to possible effects of
SOD1 protein misfolding and aggregation on activity.
Data from other human diseases involving loss of enzyme ac-
tivity shows many of these are recessive and heterozygotes are
generally unaffected (Mitchell et al., 2011). However, this is
clearly not the case in the Sod1+ / mouse; these animals have
increased neuronal loss and increased susceptibility to injury.
Further, the stimuli to which these mice are more susceptible are
motor neuron axonal damage and glutamate toxicity, both closely
related to ALS pathogenesis. In addition, the blood–brain barrier is
more permeable following injury in these mice; indirect evidence
of a similar state has also been described in patients with ALS and
in mouse models of ALS. Exacerbation of neurodegenerative
phenotypes in an Alzheimer’s disease mouse model when on a
Sod1+ / background also indicates a potential predisposition to
neurodegeneration of mice with a 50% reduction in SOD1 activ-
ity. Lastly, as Sod1+ / mice show a spontaneous loss of spiral
ganglion cells this confirms that decreased dismutase activity has
direct consequences on neuronal survival.
A human SOD1 loss of function
phenotype?
Although both Sod1/ and Sod1+ / mice develop characteris-
tics that have obvious relevance to ALS, we have found no data
from human genetic analyses to suggest that SOD1 loss of func-
tion alone causes the human disease. 4155 mutations in SOD1
have been described (Fig. 1), but there have been no truncation
mutations occurring in the N-terminal part of SOD1 that would
generate an effectively null allele (i.e. due to reduced expression
from nonsense mediated decay of the messenger RNA or from
inactivity of just a short stretch of N-terminal amino acids). We
note a frameshift in exon 2 generating a predicted 35 amino acid
protein that might be a null, has been reported in a family with
ALS, but data regarding segregation are unclear making conclu-
sions uncertain (Hu et al., 2012).
Further, we could find no description of patients with full loss of
SOD1 activity, even when SOD1 mutations are found in homo-
zygosity. Of the six homozygous SOD1 mutations (L84F, N86S,
D90A, L117V, L126S and G27delGGACCA) described, activities
for four (D90A, L117V, L126S and G27delGGACCA) have been
measured and vary between 25% and 93% of normal levels
(Andersen et al., 1995; Boukaftane et al., 1998; Hayward et al.,
1998; Kato et al., 2001; Zinman et al., 2009; Synofzik et al.,
2012). Of note, a patient with a CCS homozygous mutation has
been described with SOD1 activity of 25% of normal. This
patient showed a complex neurodevelopmental phenotype; how-
ever, this is attributed to a mutation in SLC33A1 and not a loss of
SOD1 function (Huppke et al., 2012).
SOD1 gain and loss of function could
complement each other in amyotrophic
lateral sclerosis pathogenesis
A reduction in SOD1 activity is not causative for ALS (which is
certainly what the mouse data show), however, it may modify
disease, as suggested by results from the mouse cross experiments
described above. It seems likely such modifying effects would
come through an increased susceptibility to neurodegeneration
either directly through, for example, the increased susceptibility
to axonal damage seen in Sod1+ / mice, or indirectly through,
for example, effects on respiration in high energy consumers such
as motor neurons—note the recent finding that SOD1 is a critical
focus for integrating O2, glucose and superoxide levels, through
casein kinase signalling, to repress respiration and directing energy
metabolism, and that this role is independent of its function in
oxidative stress (Reddi and Culotta, 2013). Thus SOD1 loss of
function will likely have effects on cellular metabolism and, fur-
ther, as it is still unclear why this enzyme is produced at such high
levels, SOD1 may well have other as yet unknown roles in neur-
onal function.
Loss and gain of function mechanisms coexist in other neuro-
degenerative diseases as shown in models of Huntington’s disease
(Zuccato et al., 2010), Parkinson’s disease (Winklhofer et al.,
2008) and spinocerebellar ataxia 1 (Lim et al., 2008; Crespo-
Barreto et al., 2010). Indeed both loss and gain of function
have been hypothesized to contribute to pathogenesis in ALS
caused by TARDBP and FUS mutations (Lagier-Tourenne and
Cleveland, 2009; Guo et al., 2011).
SOD1 has a crucial role in superoxide clearance and its loss of
function generates an increased state of oxidative stress. In a
tgSOD1-ALS mouse model, SOD1 is itself a major target of oxi-
dization (Andrus et al., 1998) and SOD1 oxidation and glutathio-
nylation, which occurs in response to oxidative stress, both
increase the propensity of the dimer to dissociate and become
misfolded (Khare et al., 2004; Rakhit et al., 2004; Ezzi et al.,
2007; Wilcox et al., 2009).
These findings set the scene for a potential co-operation of
SOD1 loss and gain of function in ALS pathogenesis. Indeed, a
vicious circle can be hypothesized in which oxidized SOD1 has an
increased propensity to misfold, causing seeding and aggregation
of SOD1 and resulting in a reduction of dismutase activity, which
therefore feeds more potential oxidative stress to the start of the
loop (Fig. 2). We note that the strong link between SOD1 mis-
folding and its loss of function (see above) make the two effects
very difficult to assess independently.
A number of recent findings have underlined how such a mech-
anism could be relevant not only to SOD1-familial ALS, but also
to sporadic cases. Hyperoxidized and misfolded SOD1 have been
demonstrated in sporadic ALS cases (Bosco et al., 2010; Forsberg
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et al., 2010; Guareschi et al., 2012) and misfolding of SOD1 was
shown to be induced by both TDP43 and FUS mislocalization
(Pokrishevsky et al., 2012), events that occur in the majority of
sporadic patients with ALS (Maekawa et al., 2009; Deng et al.,
2010; Matsuoka et al., 2011). Recent studies demonstrating that
SOD1 aggregation can be seeded in vitro from mouse
tgSOD1G93A spinal cord material (Chia et al., 2010), and ‘trans-
mitted’ between cells (Munch et al., 2011) extend the potential
role for these pathogenic mechanisms to the clinical and patho-
logical ‘spread’ of ALS (Ravits et al., 2007; Pokrishevsky et al.,
2012). Of note, SOD1 was also found to be oxidized in
Alzheimer’s disease and Parkinson’s disease (Choi et al., 2005).
In fact, it is possible to speculate that the absence of SOD1 in
the loss of function mouse model omits one of the most important
targets of oxidative stress in ALS—that is, SOD1 itself—leaving the
pathogenic cascade incomplete.
Finally, we note the lack of studies addressing the expression of
the SOD1 trans allele in SOD1–familial ALS and the possibility that
this plays a role in modifying the disease. Indeed, a 50 base pair
deletion in the promoter region of SOD1 has been described to
influence SOD1 expression and there have been attempts to cor-
relate this with clinical characteristics in sporadic ALS, although so
far results have not been replicated (Broom et al., 2008). To our
knowledge no studies analyse the SOD1 trans-allele in SOD1–
familial ALS cases for the presence of this variant or other factors
influencing the expression of the trans-allele.
Implications of SOD1 loss of function
for current therapeutic approaches for
amyotrophic lateral sclerosis and other
diseases
Therapies are being developed for ALS and other neurodegenera-
tive disease caused by dominant mutations, which entail knock-
down of the mutant allele RNA (Smith et al., 2006; Kordasiewicz
et al., 2012; Lu and Yang 2012). This approach is showing prom-
ise for Huntington’s disease; a recent report has shown suppres-
sion of huntingtin in Huntington’s disease mouse models and in
the non-human primate brain, and a 75% suppression of hunting-
tin throughout the CNS appears to be well tolerated (Kordasiewicz
et al., 2012).
A number of analogous strategies have been tested for SOD1
(Ralph et al., 2005; Raoul et al., 2005; Saito et al., 2005; Smith
et al., 2006; Wang et al., 2010; Towne et al., 2011; Wright et al.,
2012) and have shown very encouraging results. Excitingly, a phase
1 clinical trial has been conducted in SOD1-ALS (Fratta, 2013; Miller
et al., 2013) using antisense oligonucleotides that silence both
mutant and wild-type SOD1, that were previously shown to be
effective in a transgenic SOD1-ALS rat model (Smith et al., 2006).
The main aim of this study, the first of its kind, was to assess safety
and so the treatment was undertaken for periods too brief to obtain a
biological effect on SOD1 levels, so although the regime is reported
Figure 2 The cycle of SOD1 loss of function, schematic representation of a potential co-operation between SOD1 loss and gain of
function in SOD1–familial ALS pathogenesis. SOD1 loss of function (LOF) increases levels of oxidative stress, which through glutathio-
nylation and oxidation, can facilitate the monomerisation of dimeric SOD1. Once monomerized, SOD1 is more prone to become
misfolded, oligomerized and aggregated. The monomerization of previously active dimeric SOD1 and the recruitment of SOD1 into
aggregates further enhance the loss of function, feeding back to the beginning of the loop. In this way the gain of function (GOF) effects
of misfolded, oligomerized and aggregated SOD1, which are known to cause motor neuron degeneration, are amplified by the loss of
function circle. Mutant SOD1 (mutSOD1) has both a direct effect on reduction of SOD1 activity and induces SOD1 misfolding and
aggregation. Mislocalisation of both TDP43 and FUS result in misfolding of SOD1. ER = endoplasmic reticulum; MN = motor neuron.
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to be well-tolerated, it remains to be determined whether SOD1
downregulation causes unwanted effects.
The Sod1 knockout mouse data presented here are important
for these types of studies in illustrating the need to understand the
full implications of such strategies. These are not only neuronal;
for example, the reason most Sod1 null (and a small percentage of
Sod1+ /) mice die is liver cancer. Thus particular attention must
be paid to delivery routes, protein levels and distribution.
We note that the null mice lack Sod1 completely, from the
earliest time in development, and no appropriate model appears
to be available currently for evaluating the effects of long-term
endogenous Sod1 knockdown from adulthood. The preclinical
trials with RNA interference technologies used tgSOD1-ALS
adult models to investigate SOD1 reduction on a very early
onset and fast progressing disease, but did not study potential
long term effects (Raoul et al., 2005; Smith et al., 2006).
Experiments using conditional Sod1 alleles would help clarify the
situation. A hopeful note for ALS from the Huntington’s disease
study is that transient knockdown ameliorates disease for an ex-
tended period (Kordasiewicz et al., 2012).
The data from Sod1+ / animals indicate that in patients with
SOD1–ALS there may be a case for epidemiological studies of the
known phenotypes that arise with a 50% enzyme loss; for ex-
ample, is there a greater incidence of cardiovascular disease and
stroke in families with SOD1–familial ALS? Do these families have
an increased incidence of liver cancer or, protection from tumours
such as lung cancer, given that the majority of human lung adeno-
carcinomas express SOD1 at higher than normal levels (Somwar
et al., 2011).
Finally, knowledge of the effects of SOD1 loss of activity clearly
indicates that this gene should be screened in cohorts with dis-
eases such as hereditary distal motor neuropathies, age-related
macular degeneration and progressive hearing loss, because both
homozygous and heterozygous loss of function are compatible
with life, at least in mice, but have abnormal phenotypes.
Acknowledgements
We thank Dr Peter Joyce and Dr Abraham Acevedo-Arozena for
comments and Mr Ray Young for graphics.
Funding
P.F is funded by Medical Research Council / Motor Neuron
Disease Association Lady Edith Wolfson Fellowship. R.S. and
E.M.C.F. are funded by the UK Motor Neuron Disease
Association. R.K.A.B.-S., E.M.C.F. are funded by the UK Medical
Research Council and the Thierry Latran Foundation.
Supplementary material
Supplementary material is available at Brain online.
References
Acevedo-Arozena A, Kalmar B, Essa S, Ricketts T, Joyce P, Kent R, et al.
A comprehensive assessment of the SOD1G93A low-copy transgenic
mouse, which models human amyotrophic lateral sclerosis. Dis Model
Mech 2011; 4: 686–700.
Acsadi G, Lee I, Li X, Khaidakov M, Pecinova A, Parker GC, et al.
Mitochondrial dysfunction in a neural cell model of spinal muscular
atrophy. J Neurosci Res 2009; 87: 2748–56.
Andersen PM, Al Chalabi A. Clinical genetics of amyotrophic lateral
sclerosis: what do we really know? Nat Rev Neurol 2011; 7: 603–15.
Andersen PM, Nilsson P, Ala-Hurula V, Keranen ML, Tarvainen I,
Haltia T, et al. Amyotrophic lateral sclerosis associated with homozy-
gosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat
Genet 1995; 10: 61–6.
Andrus PK, Fleck TJ, Gurney ME, Hall ED. Protein oxidative damage in a
transgenic mouse model of familial amyotrophic lateral sclerosis.
J Neurochem 1998; 71: 2041–8.
Apostolski S, Nikolic J, Bugarski-Prokopljevic C, Miletic V, Pavlovic S,
Filipovic S. Serum and CSF immunological findings in ALS. Acta
Neurol Scand 1991; 83: 96–8.
Baloh RH, Rakowicz W, Gardner R, Pestronk A. Frequent atrophic
groups with mixed-type myofibers is distinctive to motor neuron
syndromes. Muscle Nerve 2007a; 36: 107–10.
Baloh RH, Schmidt RE, Pestronk A, Milbrandt J. Altered axonal
mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth
disease from mitofusin 2 mutations. J Neurosci 2007b; 27: 422–30.
Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron
injury and therapeutic target. Free Radic Biol Med 2010; 48: 629–41.
Beal MF. Role of excitotoxicity in human neurological disease. Curr Opin
Neurobiol 1992; 2: 657–62.
Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and per-
oxynitrite. Nature 1993; 364: 584.
Bhusari SS, Dobosy JR, Fu V, Almassi N, Oberley T, Jarrard DF.
Superoxide dismutase 1 knockdown induces oxidative stress and
DNA methylation loss in the prostate. Epigenetics 2010; 5: 402–9.
Birve A, Neuwirth C, Weber M, Marklund SL, Nilsson AC, Jonsson PA,
et al. A novel SOD1 splice site mutation associated with familial ALS
revealed by SOD activity analysis. Hum Mol Genet 2010; 19: 4201–6.
Bodendorf U, Danner S, Fischer F, Stefani M, Sturchler-Pierrat C,
Wiederhold KH, et al. Expression of human beta-secretase in the
mouse brain increases the steady-state level of beta-amyloid.
J Neurochem 2002; 80: 799–806.
Borchelt DR, Lee MK, Slunt HS, Guarnieri M, Xu ZS, Wong PC, et al.
Superoxide dismutase 1 with mutations linked to familial amyotrophic
lateral sclerosis possesses significant activity. Proc Natl Acad Sci USA
1994; 91: 8292–6.
Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P,
et al. Wild-type and mutant SOD1 share an aberrant conformation
and a common pathogenic pathway in ALS. Nat Neurosci 2010; 13:
1396–403.
Boukaftane Y, Khoris J, Moulard B, Salachas F, Meininger V,
Malafosse A, et al. Identification of six novel SOD1 gene mutations
in familial amyotrophic lateral sclerosis. Can J Neurol Sci 1998; 25:
192–6.
Bowling AC, Schulz JB, Brown RH Jr., Beal MF. Superoxide dismutase
activity, oxidative damage, and mitochondrial energy metabolism in
familial and sporadic amyotrophic lateral sclerosis. J Neurochem
1993; 61: 2322–5.
Broom WJ, Greenway M, Sadri-Vakili G, Russ C, Auwarter KE, Glajch KE,
et al. 50bp deletion in the promoter for superoxide dismutase 1
(SOD1) reduces SOD1 expression in vitro and may correlate with
increased age of onset of sporadic amyotrophic lateral sclerosis.
Amyotroph Lateral Scler 2008; 9: 229–37.
Browne SE, Bowling AC, Baik MJ, Gurney M, Brown RH Jr., Beal MF.
Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral
sclerosis. J Neurochem 1998; 71: 281–7.
2354 | Brain 2013: 136; 2342–2358 R. A. Saccon et al.
by guest on January 30, 2015
D
ow
nloaded from
 
Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG,
et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes
and promotes rapidly progressive disease with SOD1-containing inclu-
sions. Neuron 1997; 18: 327–38.
Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD,
Ohama E, et al. Aggregation and motor neuron toxicity of an ALS-
linked SOD1 mutant independent from wild-type SOD1. Science
1998; 281: 1851–4.
Casaril M, Corso F, Bassi A, Capra F, Gabrielli GB, Stanzial AM, et al.
Decreased activity of scavenger enzymes in human hepatocellular car-
cinoma, but not in liver metastases. International Journal of Clinical
and Laboratory research 1994; 24: 94–97.
Cassereau J, Chevrollier A, Gueguen N, Desquiret V, Verny C, Nicolas G,
et al. Mitochondrial dysfunction and pathophysiology of Charcot-
Marie-Tooth disease involving GDAP1 mutations. Exp Neurol 2011;
227: 31–41.
Chang LY, Slot JW, Geuze HJ, Crapo JD. Molecular immunocytochem-
istry of the CuZn superoxide dismutase in rat hepatocytes. J Cell Biol
1988; 107: 2169–79.
Chestnut BA, Chang Q, Price A, Lesuisse C, Wong M, Martin LJ.
Epigenetic regulation of motor neuron cell death through DNA methy-
lation. J Neurosci 2011; 31: 16619–36.
Chia R, Tattum MH, Jones S, Collinge J, Fisher EM, Jackson GS.
Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils,
suggesting a propagative cell death mechanism in amyotrophic lateral
sclerosis. PLoS One 2010; 5: e10627.
Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L. Oxidative
modifications and aggregation of Cu,Zn-superoxide dismutase asso-
ciated with Alzheimer and Parkinson diseases. J Biol Chem 2005;
280: 11648–55.
Crapo JD, Oury T, Rabouille C, Slot JW, Chang LY. Copper,zinc super-
oxide dismutase is primarily a cytosolic protein in human cells. Proc
Natl Acad Sci USA 1992; 89: 10405–9.
Crespo-Barreto J, Fryer JD, Shaw CA, Orr HT, Zoghbi HY. Partial loss
of ataxin–1 function contributes to transcriptional dysregulation in
spinocerebellar ataxia type 1 pathogenesis. PLoS Genet 2010; 6:
e1001021.
Culotta VC, Klomp LW, Strain J, Casareno RL, Krems B, Gitlin JD. The
copper chaperone for superoxide dismutase. J Biol Chem 1997; 272:
23469–72.
Culotta VC, Lin SJ, Schmidt P, Klomp LW, Casareno RL, Gitlin J.
Intracellular pathways of copper trafficking in yeast and humans.
Adv Exp Med Biol 1999; 448: 247–54.
de Lustig ES, Serra JA, Kohan S, Canziani GA, Famulari AL,
Dominguez RO. Copper-zinc superoxide dismutase activity in red
blood cells and serum in demented patients and in aging. J Neurol
Sci 1993; 115: 18–25.
De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau KF,
et al. Familial amyotrophic lateral sclerosis-linked SOD1 mutants per-
turb fast axonal transport to reduce axonal mitochondria content.
Hum Mol Genet 2007; 16: 2720–8.
Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, et al.
Amyotrophic lateral sclerosis and structural defects in Cu,Zn super-
oxide dismutase. Science 1993; 261: 1047–51.
Deng HX, Shi Y, Furukawa Y, Zhai H, Fu R, Liu E, et al. Conversion to
the amyotrophic lateral sclerosis phenotype is associated with intermo-
lecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl
Acad Sci USA 2006; 103: 7142–7.
Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, et al. FUS-
immunoreactive inclusions are a common feature in sporadic and
non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol 2010;
67: 739–48.
Dengler R, Konstanzer A, Kuther G, Hesse S, Wolf W, Struppler A.
Amyotrophic lateral sclerosis: macro-EMG and twitch forces of single
motor units. Muscle Nerve 1990; 13: 545–50.
Didion SP, Kinzenbaw DA, Schrader LI, Faraci FM. Heterozygous CuZn
superoxide dismutase deficiency produces a vascular phenotype with
aging. Hypertension 2006; 48: 1072–9.
Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson RL, Van Remmen H,
et al. CuZnSOD deficiency leads to persistent and widespread oxida-
tive damage and hepatocarcinogenesis later in life. Oncogene 2005;
24: 367–380.
Ezzi SA, Urushitani M, Julien JP. Wild-type superoxide dismutase acquires
binding and toxic properties of ALS-linked mutant forms through oxi-
dation. J Neurochem 2007; 102: 170–8.
Faes L, Callewaert G. Mitochondrial dysfunction in familial amyotrophic
lateral sclerosis. J Bioenerg Biomembr 2011; 43: 587–92.
Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-
Sanchez A, et al. Amyotrophic lateral sclerosis is a distal axonopathy:
evidence in mice and man. Exp Neurol 2004; 185: 232–40.
Fischer LR, Glass JD. Oxidative stress induced by loss of Cu,Zn-
superoxide dismutase (SOD1) or superoxide-generating herbicides
causes axonal degeneration in mouse DRG cultures. Acta
Neuropathol 2010; 119: 249–59.
Fischer LR, Igoudjil A, Magrane´ J, Li Y, Hansen JM, Manfredi G, et al.
SOD1 targeted to the mitochondrial intermembrane space prevents
motor neuropathy in the Sod1 knockout mouse. Brain 2011; 134:
196–209.
Fischer LR, Li Y, Asress SA, Jones DP, Glass JD. Absence of SOD1 leads
to oxidative stress in peripheral nerve and causes a progressive distal
motor axonopathy. Exp Neurol 2012; 233: 163–71.
Fitzmaurice PS, Shaw IC, Kleiner HE, Miller RT, Monks TJ, Lau SS, et al.
Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle
Nerve 1996; 19: 797–8.
Flood DG, Reaume AG, Gruner JA, Hoffman EK, Hirsch JD, Lin YG, et al.
Hindlimb motor neurons require Cu/Zn superoxide dismutase for
maintenance of neuromuscular junctions. Am J Pathol 1999; 155:
663–72.
Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS,
Hultdin M, et al. Novel antibodies reveal inclusions containing non-
native SOD1 in sporadic ALS patients. PLoS One 2010; 5: e11552.
Fratta P. Antisense makes sense for ALS. Lancet Neurol 2013; 12:
416–417.
Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. Early
and selective loss of neuromuscular synapse subtypes with low sprout-
ing competence in motoneuron diseases. J Neurosci 2000; 20:
2534–42.
Fridovich I. Biological effects of the superoxide radical. Arch Biochem
Biophys 1986; 247: 1–11.
Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev
Biochem 1995; 64: 97–112.
Fukada K, Nagano S, Satoh M, Tohyama C, Nakanishi T, Shimizu A,
et al. Stabilization of mutant Cu/Zn superoxide dismutase (SOD1)
protein by coexpressed wild SOD1 protein accelerates the disease pro-
gression in familial amyotrophic lateral sclerosis mice. Eur J Neurosci
2001; 14: 2032–6.
Ge WW, Leystra-Lantz C, Sanelli TR, McLean J, Wen W, Strong W,
et al. Neuronal tissue-specific ribonucleoprotein complex formation
on SOD1 mRNA: alterations by ALS SOD1 mutations. Neurobiol Dis
2006; 23: 342–50.
Graffmo KS, Forsberg K, Bergh J, Birve A, Zetterstrom P, Andersen P,
et al. Expression of wild-type human superoxide dismutase-1 in mice
causes amyotrophic lateral sclerosis. Human Mol Genet 2013; 22:
51–60.
Guareschi S, Cova E, Cereda C, Ceroni M, Donetti E, Bosco DA, et al.
An over-oxidized form of superoxide dismutase found in spor-
adic amyotrophic lateral sclerosis with bulbar onset shares a toxic
mechanism with mutant SOD1. Proc Natl Acad Sci USA 2012; 109:
5074–9.
Guo W, Chen Y, Zhou X, Kar A, Ray P, Chen X, et al. An ALS-associated
mutation affecting TDP-43 enhances protein aggregation, fibril
formation and neurotoxicity. Nat Struct Mol Biol 2011; 18: 822–30.
Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY,
Alexander DD, et al. Motor neuron degeneration in mice that express
a human Cu,Zn superoxide dismutase mutation. Science 1994; 264:
1772–5.
SOD1 loss of function in ALS Brain 2013: 136; 2342–2358 | 2355
by guest on January 30, 2015
D
ow
nloaded from
 
Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral
sclerosis in a database population. Validation of a scoring system and
a model for survival prediction. Brain 1995; 118: 707–19.
Hayward C, Brock DJH, Minns RA, Swingler RJ. Homozygosity for
Asn86Ser mutation in the CuZn superoxide dismutase gene produces
a severe clinical phenotype in a juvenile onset case of familial
amyotrophic lateral sclerosis. J Med Genet 1998; 35: 174.
Ho YS, Gargano M, Cao J, Bronson RT, Heimler I, Hutz RJ. Reduced
fertility in female mice lacking copper-zinc superoxide dismutase. J Biol
Chem 1998; 273: 7765–9.
Hu J, Chen K, Ni B, Li L, Chen G, Shi S. A novel SOD1 mutation in
amyotrophic lateral sclerosis with a distinct clinical phenotype.
Amyotroph Lateral Scler 2012; 13: 149–54.
Huang TT, Yasunami M, Carlson EJ, Gillespie AM, Reaume AG,
Hoffman EK, et al. Superoxide-mediated cytotoxicity in superoxide
dismutase-deficient fetal fibroblasts. Arch Biochem Biophys 1997;
344: 424–32.
Huppke P, Brendel C, Korenke GC, Marquardt I, Donsante A, Yi L, et al.
Molecular and biochemical characterization of a unique mutation in
CCS, the human copper chaperone to superoxide dismutase. Hum
Mutat 2012; 33: 1207–15.
Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity
in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009; 187:
761–72.
Jaarsma D, Haasdijk ED, Grashorn JA, Hawkins R, van Duijn W,
Verspaget HW, et al. Human Cu/Zn superoxide dismutase (SOD1)
overexpression in mice causes mitochondrial vacuolization, axonal
degeneration, and premature motoneuron death and accelerates
motoneuron disease in mice expressing a familial amyotrophic lateral
sclerosis mutant SOD1. Neurobiol Dis 2000; 7: 623–43.
Jang YC, Lustgarten MS, Liu Y, Muller FL, Bhattacharya A, Liang H,
et al. Increased superoxide in vivo accelerates age-associated muscle
atrophy through mitochondrial dysfunction and neuromuscular
junction degeneration. FASEB J 2010; 24: 1376–90.
Jonsson PA, Bergemalm D, Andersen PM, Gredal O, Brannstrom T,
Marklund SL. Inclusions of amyotrophic lateral sclerosis-linked super-
oxide dismutase in ventral horns, liver, and kidney. Ann Neurol 2008;
63: 671–5.
Jonsson PA, Ernhill K, Andersen PM, Bergemalm D, Brannstrom T,
Gredal O, et al. Minute quantities of misfolded mutant superoxide dis-
mutase-1 cause amyotrophic lateral sclerosis. Brain 2004; 127: 73–88.
Joyce PI, Fratta P, Fisher EM, Acevedo-Arozena A. SOD1 and TDP-43
animal models of amyotrophic lateral sclerosis: recent advances in
understanding disease toward the development of clinical treatments.
Mamm Genome 2011; 22: 420–48.
Kato M, Aoki M, Ohta M, Nagai M, Ishizaki F, Nakamura S, et al.
Marked reduction of the Cu/Zn superoxide dismutase polypeptide in
a case of familial amyotrophic lateral sclerosis with the homozygous
mutation. Neurosci Lett 2001; 312: 165–8.
Keithley EM, Canto C, Zheng QY, Wang X, Fischel-Ghodsian N,
Johnson KR. Cu/Zn superoxide dismutase and age-related hearing
loss. Hear Res 2005; 209: 76–85.
Keller GA, Warner TG, Steimer KS, Hallewell RA. Cu,Zn superoxide
dismutase is a peroxisomal enzyme in human fibroblasts and hepa-
toma cells. Proc Natl Acad Sci USA 1991; 88: 7381–5.
Kennel PF, Finiels F, Revah F, Mallet J. Neuromuscular function impair-
ment is not caused by motor neurone loss in FALS mice: an electro-
myographic study. Neuroreport 1996; 7: 1427–31.
Khare SD, Caplow M, Dokholyan NV. The rate and equilibrium constants
for a multistep reaction sequence for the aggregation of superoxide
dismutase in amyotrophic lateral sclerosis. Proc Natl Acad Sci USA
2004; 101: 15094–9.
Kobayashi J, Kuroda M, Kawata A, Mochizuki Y, Mizutani T, Komori T,
et al. Novel G37V mutation of SOD1 gene in autopsied patient with
familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012;
13: 570–72.
Kondo T, Reaume AG, Huang TT, Carlson E, Murakami K, Chen SF,
et al. Reduction of CuZn-superoxide dismutase activity exacerbates
neuronal cell injury and edema formation after transient focal cerebral
ischemia. J Neurosci 1997; 17: 4180–9.
Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM,
Pytel KA, et al. Sustained therapeutic reversal of Huntington’s disease
by transient repression of huntingtin synthesis. Neuron 2012; 74:
1031–44.
Kostrominova TY. Advanced age-related denervation and fiber-type
grouping in skeletal muscle of SOD1 knockout mice. Free Radic Biol
Med 2010; 49: 1582–93.
Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-
43. Cell 2009; 136: 1001–4.
Larkin LM, Davis CS, Sims-Robinson C, Kostrominova TY, Remmen HV,
Richardson A, et al. Skeletal muscle weakness due to deficiency of CuZn-
superoxide dismutase is associated with loss of functional innervation.
Am J Physiol Regul Integr Comp Physiol 2011; 301: R1400–7.
Leonardi A, Abbruzzese G, Arata L, Cocito L, Vische M. Cerebrospinal
fluid (CSF) findings in amyotrophic lateral sclerosis. J Neurol 1984; 231:
75–8.
Liaw KY, Lee PH, Wu FC, Tsai JS, Lin-Shiau SY. Zinc, copper, and super-
oxide dismutase in hepatocellular carcinoma. Am J Gastroenterol 1997;
92: 2260–2263.
Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE,
et al. Opposing effects of polyglutamine expansion on native protein
complexes contribute to SCA1. Nature 2008; 452: 713–8.
Lin MT, Wang MY, Liaw KY, Lee PH, Chien SF, Tsai JS, et al. Superoxide
dismutase in hepatocellular carcinoma affects patient prognosis.
Hepatogastroenterology 2001; 48: 1102–1105.
Lobsiger CS, Boillee S, McAlonis-Downes M, Khan AM, Feltri ML,
Yamanaka K, et al. Schwann cells expressing dismutase active
mutant SOD1 unexpectedly slow disease progression in ALS mice.
Proc Natl Acad Sci USA 2009; 106: 4465–70.
Lu XH, Yang XW. "Huntingtin Holiday": Progress toward an antisense
therapy for Huntington’s disease. Neuron 2012; 74: 964–6.
Maekawa S, Leigh PN, King A, Jones E, Steele JC, Bodi I, et al. TDP-43 is
consistently co-localized with ubiquitinated inclusions in sporadic and
Guam amyotrophic lateral sclerosis but not in familial amyotrophic
lateral sclerosis with and without SOD1 mutations. Neuropathology
2009; 29: 672–83.
Marikovsky M, Ziv V, Nevo N, Harris-Cerruti C, Mahler O. Cu/Zn super-
oxide dismutase plays important role in immune response. J Immunol
2003; 170: 2993–3001.
Marklund SL, Holme E, Hellner L. Superoxide dismutase in extracellular
fluids. Clin Chim Acta 1982; 126: 41–51.
Matsuoka T, Fujii N, Kondo A, Iwaki A, Hokonohara T, Honda H, et al. An
autopsied case of sporadic adult-onset amyotrophic lateral sclerosis with
FUS-positive basophilic inclusions. Neuropathology 2011; 31: 71–6.
Matzuk MM, Dionne L, Guo Q, Kumar TR, Lebovitz RM. Ovarian func-
tion in superoxide dismutase 1 and 2 knockout mice. Endocrinology
1998; 139: 4008–11.
Miller T, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. A
Phase I, randomised, first-in-human study of an antisense oligonucleo-
tide directed against SOD1 delivered intrathecally in SOD1–familial
ALS patients. Lancet Neurol 2013; 12: 435–442.
Mitchell JJ, Trakadis YJ, Scriver CR. Phenylalanine hydroxylase deficiency.
Genet Med 2011; 13: 697–707.
Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al.
Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler
2008; 9: 177–83.
Muller FL, Liu Y, Van Remmen H. Complex III releases superoxide to
both sides of the inner mitochondrial membrane. J Biol Chem 2004;
279: 49064–73.
Muller FL, Song W, Liu Y, Chaudhuri A, Pieke-Dahl S, Strong R, et al.
Absence of CuZn superoxide dismutase leads to elevated oxidative
stress and acceleration of age-dependent skeletal muscle atrophy.
Free Radic Biol Med 2006; 40: 1993–2004.
Munch C, O’Brien J, Bertolotti A. Prion-like propagation of mutant
superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad
Sci USA 2011; 108: 3548–53.
2356 | Brain 2013: 136; 2342–2358 R. A. Saccon et al.
by guest on January 30, 2015
D
ow
nloaded from
 
Murray LM, Talbot K, Gillingwater TH. Review: neuromuscular synaptic
vulnerability in motor neurone disease: amyotrophic lateral sclerosis
and spinal muscular atrophy. Neuropathol Appl Neurobiol 2010; 36:
133–56.
Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis:
insights from genetics. Nat Rev Neurosci 2006; 7: 710–23.
Pokrishevsky E, Grad LI, Yousefi M, Wang J, Mackenzie IR,
Cashman NR. Aberrant localization of FUS and TDP43 is associated
with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS One
2012; 7: e35050.
Pramatarova A, Figlewicz DA, Krizus A, Han FY, Ceballos-Picot I,
Nicole A, et al. Identification of new mutations in the Cu/Zn super-
oxide dismutase gene of patients with familial amyotrophic lateral
sclerosis. Am J Genet 1995; 56: 592–6.
Proescher JB, Son M, Elliott JL, Culotta VC. Biological effects of CCS in
the absence of SOD1 enzyme activation: implications for disease in a
mouse model for ALS. Hum Mol Genet 2008; 17: 1728–37.
Prudencio M, Durazo A, Whitelegge JP, Borchelt DR. An examination
of wild-type SOD1 in modulating the toxicity and aggregation of
ALS-associated mutant SOD1. Hum Mol Genet 2010; 19: 4774–89.
Pun S, Santos AF, Saxena S, Xu L, Caroni P. Selective vulnerability and
pruning of phasic motoneuron axons in motoneuron disease alleviated
by CNTF. Nat Neurosci 2006; 9: 408–19.
Pupillo E, Messina P, Logroscino G, Zoccolella S, Chio A, Calvo A, et al.
Trauma and amyotrophic lateral sclerosis: a case-control study from a
population-based registry. Eur J Neurol 2012; 19: 1509–17.
Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR,
Chakrabartty A. Monomeric Cu,Zn-superoxide dismutase is a
common misfolding intermediate in the oxidation models of sporadic
and familial amyotrophic lateral sclerosis. J Biol Chem 2004; 279:
15499–504.
Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, et al.
Silencing mutant SOD1 using RNAi protects against neurodegenera-
tion and extends survival in an ALS model. Nat Med 2005; 11:
429–33.
Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, et al.
Lentiviral-mediated silencing of SOD1 through RNA interference
retards disease onset and progression in a mouse model of ALS. Nat
Med 2005; 11: 423–8.
Ratovitski T, Corson LB, Strain J, Wong P, Cleveland DW, Culotta VC,
et al. Variation in the biochemical/biophysical properties of mutant
superoxide dismutase 1 enzymes and the rate of disease progression
in familial amyotrophic lateral sclerosis kindreds. Hum Mol Genet
1999; 8: 1451–60.
Ravits J, Laurie P, Fan Y, Moore DH. Implications of ALS focality: rostral-
caudal distribution of lower motor neuron loss postmortem. Neurology
2007; 68: 1576–82.
Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF,
et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice
develop normally but exhibit enhanced cell death after axonal injury.
Nat Genet 1996; 13: 43–7.
Reddi AR, Culotta VC. SOD1 integrates signals from oxygen and glucose
to repress respiration. Cell 2013; 152: 224–35.
Robberecht W, Sapp P, Viaene MK, Rosen D, McKenna-Yasek D, Haines J,
et al. Cu/Zn superoxide dismutase activity in familial and sporadic amyo-
trophic lateral sclerosis. J Neurochem 1994; 62: 384–7.
Roe JA, Butler A, Scholler DM, Valentine JS, Marky L, Breslauer KJ.
Differential scanning calorimetry of Cu,Zn-superoxide dismutase, the
apoprotein, and its zinc-substituted derivatives. Biochemistry 1988; 27:
950–8.
Rosen DR, Bowling AC, Patterson D, Usdin TB, Sapp P, Mezey E, et al. A
frequent ala 4 to val superoxide dismutase-1 mutation is associated
with a rapidly progressive familial amyotrophic lateral sclerosis. Hum
Mol Genet 1994; 3: 981–7.
Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A,
et al. Mutations in Cu/Zn superoxide dismutase gene are
associated with familial amyotrophic lateral sclerosis. Nature 1993;
362: 59–62.
Rothstein JD. Current hypotheses for the underlying biology of amyo-
trophic lateral sclerosis. Ann Neurol 2009; 65 (Suppl 1): S3–9.
Saito Y, Yokota T, Mitani T, Ito K, Anzai M, Miyagishi M, et al.
Transgenic small interfering RNA halts amyotrophic lateral sclerosis in
a mouse model. J Biol Chem 2005; 280: 42826–30.
Sasaki S, Aoki M, Nagai M, Kobayashi M, Itoyama Y. Mitochondrial
alterations in transgenic mice with an H46R mutant Cu/Zn superoxide
dismutase gene. J Neuropathol Exp Neurol 2009; 68: 365–73.
Sato T, Nakanishi T, Yamamoto Y, Andersen PM, Ogawa Y, Fukada K,
et al. Rapid disease progression correlates with instability of mutant
SOD1 in familial ALS. Neurology 2005; 65: 1954–7.
Schwartz PJ, Reaume A, Scott R, Coyle JT. Effects of over- and under-
expression of Cu,Zn-superoxide dismutase on the toxicity of glu-
tamate analogs in transgenic mouse striatum. Brain Res 1998; 789:
32–39.
Shaw PJ, Ince PG, Falkous G, Mantle D. Oxidative damage to protein in
sporadic motor neuron disease spinal cord. Ann Neurol 1995; 38:
691–5.
Shefner JM, Reaume AG, Flood DG, Scott RW, Kowall NW, Ferrante RJ,
et al. Mice lacking cytosolic copper/zinc superoxide dismutase dis-
play a distinctive motor axonopathy. Neurology 1999; 53: 1239–46.
Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, et al.
Morphological evidence for lipid peroxidation and protein glycoxida-
tion in spinal cords from sporadic amyotrophic lateral sclerosis patients.
Brain Res 2001; 917: 97–104.
Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH. Increased lipid
peroxidation in sera of ALS patients: a potential biomarker of disease
burden. Neurology 2004; 62: 1758–65.
Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER,
Floyd RA, et al. Excess brain protein oxidation and enzyme dysfunction
in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA
1991; 88: 10540–3.
Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G,
et al. Antisense oligonucleotide therapy for neurodegenerative disease.
J Clin Invest 2006; 116: 2290–6.
Smith RG, Henry YK, Mattson MP, Appel SH. Presence of 4-hydroxy-
nonenal in cerebrospinal fluid of patients with sporadic amyotrophic
lateral sclerosis. Ann Neurol 1998; 44: 696–9.
Somwar R, Erdjument-Bromage H, Larsson E, Shum D, Lockwood WW,
Yang G, et al. Superoxide dismutase 1 (SOD1) is a target for a small
molecule identified in a screen for inhibitors of the growth of lung
adenocarcinoma cell lines. Proc Natl Acad Sci USA 2011; 108:
16375–80.
Son M, Fu Q, Puttaparthi K, Matthews CM, Elliott JL. Redox suscepti-
bility of SOD1 mutants is associated with the differential response to
CCS over-expression in vivo. Neurobiol Dis 2009; 34: 155–62.
Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-
43 mutations in familial and sporadic amyotrophic lateral sclerosis.
Science 2008; 319: 1668–72.
Stadtman ER. Protein oxidation and aging. Science 1992; 257: 1220–4.
Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in
aging and disease. Chem Res Toxicol 1997; 10: 485–94.
Sturtz LA, Diekert K, Jensen LT, Lill R, Culotta VC. A fraction of yeast
Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to
the intermembrane space of mitochondria. A physiological role for
SOD1 in guarding against mitochondrial oxidative damage. J Biol
Chem 2001; 276: 38084–9.
Subramaniam JR, Lyons WE, Liu J, Bartnikas TB, Rothstein J, Price DL,
et al. Mutant SOD1 causes motor neuron disease independent of
copper chaperone-mediated copper loading. Nat Neurosci 2002; 5:
301–7.
Synofzik M, Ronchi D, Keskin I, Basak AN, Wilhelm C, Gobbi C, et al.
Mutant superoxide dismutase-1 indistinguishable from wild-type
causes ALS. Hum Mol Genet 2012; 21: 3568–74.
Takahashi M, Dinse GE, Foley JF, Hardisty JF, Maronpot RR.
Comparative prevalence, multiplicity, and progression of spontaneous
and vinyl carbamate-induced liver lesions in five strains of male mice.
Toxicol Pathology 2002; 30: 599–605.
SOD1 loss of function in ALS Brain 2013: 136; 2342–2358 | 2357
by guest on January 30, 2015
D
ow
nloaded from
 
Towne C, Setola V, Schneider BL, Aebischer P. Neuroprotection by gene
therapy targeting mutant SOD1 in individual pools of motor neurons
does not translate into therapeutic benefit in fALS mice. Mol Ther
2011; 19: 274–83.
Turner BJ, Ackerley S, Davies KE, Talbot K. Dismutase-competent SOD1
mutant accumulation in myelinating Schwann cells is not detrimental
to normal or transgenic ALS model mice. Hum Mol Genet 2010; 19:
815–24.
Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent
models of mutant SOD1-mediated familial ALS. Prog Neurobiol
2008; 85: 94–134.
Wang J, Xu G, Borchelt DR. Mapping superoxide dismutase 1 domains
of non-native interaction: roles of intra- and intermolecular disulfide
bonding in aggregation. J Neurochem 2006; 96: 1277–88.
Wang L, Deng HX, Grisotti G, Zhai H, Siddique T, Roos RP. Wild-type
SOD1 overexpression accelerates disease onset of a G85R SOD1
mouse. Hum Mol Genet 2009a; 18: 1642–51.
Wang L, Grisotti G, Roos RP. Mutant SOD1 knockdown in all cell types
ameliorates disease in G85R SOD1 mice with a limited additional
effect over knockdown restricted to motor neurons. J Neurochem
2010; 113: 166–74.
Wang L, Gutmann DH, Roos RP. Astrocyte loss of mutant SOD1 delays
ALS disease onset and progression in G85R transgenic mice. Hum Mol
Genet 2011; 20: 286–93.
Wang L, Pytel P, Feltri ML, Wrabetz L, Roos RP. Selective knockdown of
mutant SOD1 in Schwann cells ameliorates disease in G85R mutant
SOD1 transgenic mice. Neurobiol Dis 2012; 48: 52–7.
Wang L, Sharma K, Grisotti G, Roos RP. The effect of mutant
SOD1 dismutase activity on non-cell autonomous degeneration
in familial amyotrophic lateral sclerosis. Neurobiol Dis 2009b; 35:
234–0.
Wang X, Culotta VC, Klee CB. Superoxide dismutase protects calcineurin
from inactivation. Nature 1996; 383: 434–7.
Watanabe Y, Kuno N, Kono Y, Nanba E, Ohama E, Nakashima K, et al.
Absence of the mutant SOD1 in familial amyotrophic lateral sclerosis
(FALS) with two base pair deletion in the SOD1 gene. Acta Neurol
Scand 1997; 95: 167–72.
Wei JP, Srinivasan C, Han H, Valentine JS, Gralla EB. Evidence for a novel
role of copper-zinc superoxide dismutase in zinc metabolism. J Biol
Chem 2001; 276: 44798–803.
Wen HL, Lin YT, Ting CH, Lin-Chao S, Li H, Hsieh-Li HM. Stathmin, a
microtubule-destabilizing protein, is dysregulated in spinal muscular
atrophy. Hum Mol Genet 2010; 19: 1766–78.
Weydert CJ, Cullen JJ. Measurement of superoxide dismutase, catalase
and glutathione peroxidase in cultured cells and tissue. Nat Protoc
2010; 5: 51–66.
Wilcox KC, Zhou L, Jordon JK, Huang Y, Yu Y, Redler RL, et al. Modifica-
tions of superoxide dismutase (SOD1) in human erythrocytes: a possible
role in amyotrophic lateral sclerosis. J Biol Chem 2009; 284: 13940–7.
Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding:
gain- and loss-of-function in neurodegenerative diseases. EMBO J
2008; 27: 336–49.
Wong PC, Waggoner D, Subramaniam JR, Tessarollo L, Bartnikas TB,
Culotta VC, et al. Copper chaperone for superoxide dismutase is
essential to activate mammalian Cu/Zn superoxide dismutase. Proc
Natl Acad Sci USA 2000; 97: 2886–91.
Wright PD, Wightman N, Huang M, Weiss A, Sapp PC, Cuny GD, et al.
A high-throughput screen to identify inhibitors of SOD1 transcription.
Front Biosci (Elite Ed) 2012; 4: 2801–8.
Yip PK, Malaspina A. Spinal cord trauma and the molecular point of no
return. Mol Neurodegener 2012; 7: 6.
Yoon EJ, Park HJ, Kim GY, Cho HM, Choi JH, Park HY, et al. Intracellular
amyloid beta interacts with SOD1 and impairs the enzymatic activity
of SOD1: implications for the pathogenesis of amyotrophic lateral
sclerosis. Exp Mol Med 2009; 41: 611–7.
Yoshida T, Maulik N, Engelman RM, Ho YS, Das DK. Targeted disruption
of the mouse Sod I gene makes the hearts vulnerable to ischemic
reperfusion injury. Circ Res 2000; 86: 264–9.
Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a
comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and
EC-SOD (SOD3) gene structures, evolution, and expression. Free
Radic Biol Med 2002; 33: 337–49.
Zinman L, Liu HN, Sato C, Wakutani Y, Marvelle AF, Moreno D, et al.
A mechanism for low penetrance in an ALS family with a novel SOD1
deletion. Neurology 2009; 72: 1153–9.
Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential
therapeutical targets in Huntington’s disease. Physiol Rev 2010; 90:
905–81.
2358 | Brain 2013: 136; 2342–2358 R. A. Saccon et al.
by guest on January 30, 2015
D
ow
nloaded from
 
OR I G INA L ART I C L E
A novel SOD1-ALS mutation separates central
and peripheral effects of mutant SOD1 toxicity
Peter I. Joyce1, Philip Mcgoldrick2,†, Rachele A. Saccon2,†, William Weber3,†,
Pietro Fratta2, Steven J. West4, Ning Zhu4, Sarah Carter1, Vinaya Phatak1,
Michelle Stewart1, Michelle Simon1, Saumya Kumar1, Ines Heise1,
Virginie Bros-Facer2, James Dick2, Silvia Corrochano1, Macdonnell J. Stanford3,
Tu Vinh Luong5, Patrick M. Nolan1, Timothy Meyer6, Sebastian Brandner2,
David L.H. Bennett4, P. Hande Ozdinler3, Linda Greensmith2,*,
Elizabeth M.C. Fisher2,*, and Abraham Acevedo-Arozena1,*
1MRC Mammalian Genetics Unit, Harwell, Oxfordshire OX11 0RD, UK, 2MRC Centre for Neuromuscular Disease,
UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK, 3Department of Neurology, Northwestern
University, Feinberg School of Medicine, Chicago, IL 60611, USA, 4Nufﬁeld Department of Clinical Neurosciences,
University of Oxford, Oxford OX3 9DU, UK, 5Department of Cellular Pathology, Royal Free LondonNHS Foundation
Trust, Pond Street, London NW3 2QG, UK, and 6UCL Cancer Institute, Paul O’Gorman Building, 72 Huntley Street,
London WC1E 6BT, UK
*To whom correspondence should be addressed at: Medical Research Council Mammalian Genetics Unit, Harwell, Oxfordshire OX11 0RD, UK.
Email: a.acevedo@har.mrc.ac.uk (A.A.-A.); Institute of Neurology and MRC Centre for Neuromuscular Disease, UCL, Queen Square, London WC1N 3BG, UK.
Email: e.ﬁsher@prion.ucl.ac.uk (E.M.C.F.); Institute of Neurology and MRC Centre for Neuromuscular Disease, UCL, Queen Square, London WC1N 3BG, UK.
Email: l.greensmith@ucl.ac.uk (L.G.)
Abstract
Transgenicmousemodels expressingmutant superoxide dismutase 1 (SOD1) have been critical in furthering our understanding of
amyotrophic lateral sclerosis (ALS). However, such models generally overexpress the mutant protein, which may give rise to
phenotypes not directly relevant to the disorder. Here, we have analysed a novel mousemodel that has a pointmutation in the
endogenousmouse Sod1 gene; thismutation is identical to a pathological change in human familial ALS (fALS) which results in
a D83G change in SOD1 protein. Homozgous Sod1D83G/D83G mice develop progressive degeneration of lower (LMN) and upper
motor neurons, likely due to the same unknown toxic gain of function as occurs in human fALS cases, but intriguingly LMN cell
death appears to stop in early adulthood and themice do not become paralyzed. The D83 residue coordinates zinc binding, and
the D83G mutation results in loss of dismutase activity and SOD1 protein instability. As a result, Sod1D83G/D83G mice also
phenocopy the distal axonopathy and hepatocellular carcinoma found in Sod1 null mice (Sod1−/−). These unique mice allow us
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to further our understanding of ALS by separating the centralmotor neuron body degeneration and the peripheral effects froma
fALS mutation expressed at endogenous levels.
Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegen-
erative disease characterized by a loss of upper and lower motor
neurons (LMNs), which causes muscle weakness, paralysis and
ultimately death, typically within 3–5 years of disease onset.
Approximately 10% of ALS cases have a clear family history
(fALS), caused by mutations in speciﬁc genes, usually with a
dominant pattern of inheritance (1–3). Mutations in superoxide
dismutase 1 (SOD1) account for 10–20% of fALS cases (although
pathogenicity has not be demonstrated for all these changes),
and to date >155 mutations have been identiﬁed throughout all
ﬁve exons of the SOD1 gene, >95% of which are dominant (4).
SOD1 is a 153 amino acid metalloenzyme (also called Cu/Zn
SOD1) that forms a homodimer whose main known function is
to remove superoxide radicals through creating molecular oxy-
gen and hydrogen peroxide, although other functions are
known (5). Mutant SOD1 takes on a toxic gain of unknown func-
tion in SOD1-fALS, causing many cellular abnormalities that
ultimately result in death of motor neurons (6). Recent research
has identiﬁed misfolded wild-type (WT) SOD1 in non-SOD1-
fALS and in ‘sporadic’ ALS suggesting that it may also play a
role in the pathogenesis of these ALS cases (7–10).
SOD1 is highly conserved across species (11) and >12 different
transgenic mouse models have been created that overexpress
mutant forms of human SOD1 (6,12,13) and in one case mouse
Sod1 (14). The majority of these mice recapitulate many charac-
teristics of ALS, including progressive motor deﬁcits, hindlimb
paralysis, motor neuron degeneration and early death (6,12,13).
A mouse strain carrying a spontaneous point mutation in
mouse Sod1 has been previously described (15), although the
equivalent mutation in humans has not been identiﬁed as
pathogenic.
However, concerns remain regarding the translation of
these models to human SOD1-fALS—particularly because
SOD1 is generally overexpressed in transgenics and such raised
expression levels affect the pathology of these animals (6,12).
For example, the most widely used model of SOD1-fALS, the
high-copy SOD1G93A transgenic, carries ∼24 copies of the
mutant human SOD1 gene, expresses SOD1 protein at ∼17-fold
over the endogenous level, and has greatly accelerated disease
compared with SOD1G93Adl mice, a strain derived from the
SOD1G93A founder line but with lower levels of SOD1 protein be-
cause of a deletion in the transgene array (∼8–10 copies of
SOD1G93A gene, 8-fold SOD1 protein expression over WT)
(16–18). As well as raised levels of mutant SOD1 affecting
phenotype, increased levels of WT SOD1 also give rise to neuro-
degeneration—overexpression of WT human SOD1 at levels
comparable with that found in SOD1G93A transgenics results in
an ALS-like syndrome with progressive loss of spinal motor
neurons and premature death (19). Thus SOD1 ‘dose’ is clearly
important for determining phenotype—and as well as overex-
pression, reduced expression also gives rise to neuronal and
non-neuronal phenotypes in heterozygous and homozygous
SOD1 knockout mice (reviewed in 4).
Mutations in SOD1-ALS cause a toxic gain of function, which
leads to motor neuron degeneration. However, curiously, the
majority of studies that have analysed dismutase activity of
SOD1-fALS patient samples show that SOD1 dismutase activity
is reduced to an average of ∼58% of normal levels (reviewed in 4).
SOD1 transgenic models overexpress mutant SOD1 and also
express two copies of endogenous mouse Sod1, so dismutase ac-
tivity is not reduced in these animals. Therefore, although SOD1
transgenics clearly model the SOD1 toxic gain-of-function lead-
ing to motor neuron degeneration, they do not generally model
the possible effects on ALS pathogenesis of a reduction in dismu-
tase activity, as observed in the majority of SOD1-fALS patient
samples.
The effects of SOD1 loss of function on motor neurons have
been recently readdressed through the study of Sod1−/− mice
(20,21), which suffer from a severe progressive denervation of
hindlimb muscles, leading to striking motor phenotypes (20).
Importantly however, several reports show that aged Sod1−/−
mice do not develop motor neuron degeneration at any age
(20,22,23). Thus, SOD1 activity is critical in maintaining innerv-
ation of neuromuscular junctions, but its removal does not result
in motor neuron cell body loss.
In order to create the genetically closest model of SOD1 ALS
to date, and to investigate the effects of a SOD1 mutation at
endogenous expression levels, we identiﬁed a mutant line that
carries an N-ethyl-N-nitrosourea (ENU)-induced point mutation
in the mouse Sod1 gene. Fortuitously, this mutation is identical
to the nucleotide change found in human SOD1 D83G dominant
fALS cases (24). In a D83G SOD1-fALS family, four of the ﬁve af-
fected individuals had a rapid disease duration (range: 6–12
months), whilst one family member had a long disease duration
(151 months). Two of the affected SOD1 D83G family members
whowere clinically examined in detail ﬁrst presentedwith symp-
toms of LMN deﬁcits, which were followed with upper motor
neuron (UMN) symptoms (24).
Results
Identiﬁcation of an ENU-induced point mutation
in the mouse Sod1 gene
To identify mouse lines carrying the equivalent of human ALS
causative pathogenic mutations, we screened for mutations in
Sod1 using genomic DNA from an ENU-induced mutagenesis
archive containing over 10 000 mice (25,26). We identiﬁed a
mouse mutant carrying an adenosine-to-guanine missense mu-
tation resulting in a D83G substitution (Supplementary Material,
Fig. S1). Importantly, the same point mutation (A–G) gives rise to
dominant D83G SOD1-fALS (24).
For all subsequent studies, female andmalemice carrying the
Sod1D83G mutation were assessed on a C57BL/6J genetic back-
ground, backcrossed at least four generations and then inter-
crossed. Homozygous Sod1D83G/D83G mice were not produced in
Mendelian ratios from Sod1+/D83G intercrosses (in total: 167 WT,
362 Sod1+/D83G, 101 Sod1D83G/D83G) (Supplementary Material,
Table S1).
Upper and LMNs die in Sod1D83G/D83G mice
Since degeneration of both LMN and UMNs is the deﬁning hall-
mark of ALS and occurs in fALS patients carrying the D83Gmuta-
tion (24), we ﬁrst examined the survival of LMN and UMNs. The
number of LMN in the sciatic motor pool in lumbar spinal cord
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was assessed at 6, 15 and 52 weeks of age. At 6 weeks, we found
no loss of motor neurons in heterozygous Sod1+/D83G or homozy-
gous Sod1D83G/D83G mice (WT 483 ± 12 LMN; Sod1+/D83G 481 ± 10
LMN; Sod1D83G/D83G 495 ± 8 LMN; n ≥ 5 per genotype). However,
by 15 weeks there was a 23% reduction in the number of LMNs
in Sod1D83G/D83Gmice only (359 ± 9 LMN) comparedwithWT litter-
mates (442 ± 11 LMN; P < 0.001) (Fig. 1A and B), and this remained
stable at 52 weeks (Fig. 1B). Thus, homozygous Sod1D83G/D83Gmice
develop signiﬁcant LMN degeneration between 6 and 15weeks of
age, which does not progress.
Figure 1. The Sod1D83Gmutation causes LMN andUMNdegeneration. (A) Representative images of lumbar spinal cord ventral horn sections stained for Nissl fromWTand
15-week-old Sod1D83G/D83Gmice; sciatic pool ofmotor neurons depicted in inset image. Scale bars:main 200 μm, inset 100 μm. (B) LMNnumbers at 6, 15 and 52weeks of age
in female littermates. At 6 weeks of age counts are comparable, but by 15 weeks of age in Sod1D83G/D83G have a 23% loss of LMNs (359 ± 9) compared with WT littermates
(469 ± 11) and Sod1+/D83G (477 ± 11). Motor neuron survival of Sod1D83G/D83G mice (353 ± 9) at 52 weeks is not signiﬁcantly reduced compared with that at 15 weeks (359 ± 9;
P = 0.47). n≥ 5 animals per group (*P < 0.001). (C) Representative images of ventral horn of lumbar spinal cord from 15- to 52-week-old mice stained for IBA-1 (green), GFAP
(red) and Nissl (blue). Immunoreactivity for micro- and astrogliosis is increased in 15-week-old Sod1D83G/D83G mice, and yet further in 52-week-old Sod1D83G/D83G mice
compared with WT littermates. Scale bar is 20 μm. (D) CTIP2 expression is detected in the striatum, in layer VI, and is restricted to CSMN within layer V of the motor
cortex. (E) CSMN survival of female mice at 15 and 29 weeks of age. CSMNs are reduced in Sod1D83G/D83G mice at 29 weeks (49.7 ± 2.4) compared with WT littermates
(64.1 ± 2.8). CSMNs within layer V were averaged across three slides per animal; n = 5 per group. Scale bar is 50 μm. Numbers represent the mean ± SEM (*P < 0.01).
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Reactive gliosis of both astrocytes andmicroglia is observed in
ALS patients and mouse models. In Sod1D83G/D83G mice, lumbar
spinal cord sections from 15-week-old mice showed striking as-
trogliosis (GFAP) andmicrogliosis (IBA1), which increased further
at 52weeks of age (Fig. 1C). Sod1+/D83Gmice did not showelevation
in reactive gliosis compared with WT littermates (Fig. 1C).
To investigate UMNs in Sod1D83G/D83G mice, we examined the
survival of corticospinal motor neurons (CSMNs) at 15 and 29
weeks of age (Fig. 1D and E). Although Nissl staining of the cere-
bral cortex did not reveal obvious abnormalities in Sod1D83G/D83G
mice at either age (Supplementary Material, Figure S2A), analysis
of Cry-mu, a selective marker of CSMNs in layer V of the
motor cortex (27), revealed signs of cellular degeneration in
Sod1D83G/D83G mice at 29 weeks (Supplementary Material,
Figure S2B). This was supported by staining for the molecular
marker chicken ovalbumin upstream promoter transcription
factor-interacting protein 2 (CTIP2), a transcription factor
expressed by CSMN in layer V of the motor cortex and a subset
of layer VI neurons (27) (Fig. 1D). CTIP2 expression helps distin-
guish between a possible reduction in molecular marker expres-
sion and cellular degeneration, and is restricted to the nucleus,
allowing for reliable quantitative analysis.
CSMN numbers were comparable betweenWT, Sod1+/D83G and
Sod1D83G/D83G littermates at 15 weeks of age (WT 70 ± 4; Sod1+/D83G
67 ± 5; Sod1D83G/D83G 65 ± 5) (Fig. 1E), but reduced by 22% at 29
weeks in Sod1D83G/D83G mice (WT 64 ± 6; Sod1+/D83G 64 ± 4;
Sod1D83G/D83G 50 ± 5; P < 0.05) (Fig. 1D and E). This degeneration
was restricted to CSMNs since analysis of callosal projection
neurons (CPNs), which are developmentally closely related to
CSMN but less vulnerable in ALS, showed that staining with
CPN-speciﬁc markers LIM domain only four (LMO4) and special
AT-rich sequence-binding protein 2 (SATB2), did not differ be-
tween WT and Sod1D83G/D83G littermates, at either age (Supple-
mentary Material, Fig. S2C and D). These results therefore
suggest a selective and progressive CSMN degeneration (UMN)
within the cortical component of motor neuron circuitry, which
is likely to affect the motor capability of Sod1D83G/D83G mice.
Analysis of functional motor units reveals a distal
motor neuropathy in Sod1D83G/D83G mice
In view of the MN degeneration observed in Sod1D83G/D83G mice,
we next determined the number of functional motor neurons
that innervated the extensor digitorum longus (EDL) hindlimb
muscle by physiological analysis of motor unit survival
(MUNE). We found no differences in EDL motor unit survival
across genotypes at 15 weeks of age, suggesting that the loss of
LMN cell bodies detected at this age is restricted to populations
of motor neurons that innervate hindlimb muscles other than
EDL. Indeed, EDL has been previously shown to be less vulnerable
to disease in transgenic SOD1models (28). However, by 52 weeks
of age, we observed a signiﬁcant reduction in the number of
motor units in EDL muscles of Sod1D83G/D83G mice compared
with WT littermates (P < 0.001; Fig. 2A and B). Comparison be-
tween WT and Sod1+/D83G littermates did not reveal any signiﬁ-
cant differences in EDL motor units at 15, 52 or 96 weeks of age
(Fig. 2A).
Morphological analysis of the innervation pattern of endplate
neuromuscular junctions (NMJ) of the EDL muscle conﬁrmed the
distal progressive denervation occurring between 15 and 52
weeks of age in Sod1D83G/D83G mice (Fig. 2C–E). In agreement
with the MUNE analysis, no signiﬁcant differences in denervated
EDL endplateNMJwere observed between anyof the genotypes at
15weeks of age (Fig. 2E). However, by 52weeksof age, a signiﬁcantly
different proportion of endplate NMJ in Sod1D83G/D83G EDL is de-
nervated (WT 2.6 ± 0.9; Sod1+/D83G 2.6 ± 1.1; Sod1D83G/D83G
14.8 ± 2.8; P < 0.001) (Fig. 2E). Since no additional LMNbody degen-
eration occurs between 15 and 52 weeks of age in Sod1D83G/D83G
mice, the progressive denervation and loss of EDL motor units
are likely a peripheral neuropathy that is not the result of
motor neuron death.
Sod1D83G/D83G mice display progressive motor
and behavioural deﬁcits
We next examined whether the loss of motor neurons and
progressive denervation in Sod1D83G/D83G mice was reﬂected in
deﬁcits in motor function. Longitudinal phenotypic character-
ization of WT, Sod1+/D83G and Sod1D83G/D83G littermates showed
motor function of Sod1D83G/D83Gmice deteriorates progressively
with age, and these mice develop tremors, gait abnormalities
and become severely kyphotic (Supplementary Material,
Video S1).
We found a reduction in body weight of Sod1D83G/D83G from
4weeks of age compared withWT littermates (females, P = 0.001;
males, P = 0.034) (Fig. 3A; Supplementary Material, Fig. S3A). To
evaluate the weight differences between littermates, the relative
levels of lean and fat mass were determined using Echo MRI (29).
Fifty-two-week-old male and female Sod1D83G/D83G mice showed
signiﬁcantly less fat mass compared with sex-matched WT
littermates, while there were no differences observed between
WT and Sod1+/D83G littermates at 6, 35, 52 or 88 weeks of age
(Fig. 3B; Supplementary Material, Fig. S3B).
To assess motor function, we examined grip strength and
performance on an accelerating rotarod, starting at 6 and
7 weeks of age, respectively. We observed reduced grip strength
in female and male Sod1D83G/D83G mice from 6 weeks of age
(females, P ≤ 0.002; males, P < 0.05), but not in Sod1+/D83G mice
(Fig. 3C; Supplementary Material, Fig. S3C). Female Sod1D83G/D83G
mice displayed earlier deﬁcits in accelerating rotarod compared
with males (23 weeks versus 67 weeks) (Fig. 3D; Supplementary
Material, Fig. S3D).
We also examined the performance of WT, Sod1+/D83G and
Sod1D83G/D83G littermates using a modiﬁed SHIRPA analysis,
which comprises of a battery of simple phenotypic tests with
an emphasis on neurological function (30,31). Three traits dif-
fered between genotypes: the presence and progression of tre-
mors, pelvic elevation and the ability to walk down a vertical
wire grate (negative geotaxis) (Table 1).
We found subtle behavioural deﬁcits in heterozygous
Sod1+/D83G animals when examining the performance of mice
on an in-cage wheel running system (32). A similar system has
previously been used to identify presymptomatic motor abnor-
malities in SOD1G93A transgenic mice (33). WT and Sod1+/D83G
littermates were assessed at 44 and 88 weeks of age by recording
activity over 7 days. Sod1+/D83G animals exhibited a signiﬁcant
deﬁcit in nightly total distance travelled compared with WT lit-
termates (P < 0.05), which declined further with age (Fig. 3E). In
addition, while WT mice at 88 weeks of age showed an increase
in the duration for each running bout (duration per run) when
compared with 44 weeks of age, 88-week-old Sod1+/D83G mice
showed a reduction in duration. Sod1+/D83G mice also displayed
a reduction in the duration per running bout at 44 and 88
weeks of age compared with WT littermates (Fig. 3F). Thus,
Sod1+/D83G mice present with subtle yet progressive deﬁcits in
motor function in the home cage, showing that the deleterious
effects of the SOD1 D83Gmutation are not restricted to homozy-
gous mice.
4 | Human Molecular Genetics
 at U
niversity College London on January 30, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
Sod1D83G/D83G mice lose muscle force with age
To gain a detailed understanding of the effect of the Sod1D83Gmu-
tation on motor neuron and muscle function, we undertook a
physiological analysis of the tibialis anterior (TA) and EDL hind-
limb muscles of female WT, Sod1+/D83G and Sod1D83G/D83G
littermates at 15 and 52 weeks age. We also assessed Sod1+/D83G
mice at 96 weeks of age.
TAmuscle of 15-week-old Sod1D83G/D83Gmicewas signiﬁcantly
weaker than in WT littermates (P = 0.02), and muscle force de-
clined further at 52 weeks of age (Fig. 4A and B). This may reﬂect
Figure 2. MUNE and endplate NMJ analysis from EDL muscle. (A and B) Surviving motor units for the EDL, which are reduced in 52-week-old Sod1D83G/D83G mice (21 ± 1)
comparedwithWT littermates (39 ± 0.4). (B) Representative traces from (A); each twitch trace recording is a singlemotor unit. Numbers represent themean ± SEM, at least
nine legs were assessed per group. (C–E) Percentage of denervated endplate NMJ from EDL muscle at 15 and 52 weeks of age. Motor endplates are identiﬁed via
α-bungarotoxin staining (red). Axons are revealed via neuroﬁlament and SV2 (green). Representative images of (C) innervated and (D) denervated NMJ endplates. (E)
Quantitative analysis of the percentage of denervated EDL endplate NMJ (denervated NMJ/total NMJ counted × 100) from all three genotypes at 15 weeks of age reveal
no signiﬁcant differences between any of the genotypes. By 52 weeks of age, a signiﬁcant difference in the percentage of denervated endplate NMJ appear between
Sod1D83G/D83G and the other two genotypes (WT and Sod1+/D83G). At 15 weeks of age, at least 700 NMJ endplates were counted per genotype. At 52 weeks of age, at least
465 NMJ endplates were counted per genotype. Percentage of denervated endplate NMJ at 52 weeks: WT: 2.6 ± 0.9; Sod1+/D83G: 2.6 ± 1.1; Sod1D83G/D83G: 14.8 ± 2.8.
***P < 0.001. Scale bar is 20 μm.
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the LMN degeneration detected in the spinal cord at this stage
(Fig. 1B). However, as observed with motor unit survival and
NMJ innervation, no deﬁcit in EDL muscle force was detected in
Sod1D83G/D83G mice at 15 weeks, conﬁrming that this muscle is
less vulnerable to the effects of mutant SOD1 than other hind-
limb fast twitch muscles. However, by 52 weeks, EDL muscle
force in Sod1D83G/D83G mice was signiﬁcantly reduced by ∼35%
compared with WT (P < 0.001; Fig. 4C and D). Therefore, TA and
EDL muscles undergo a progressive loss in muscle strength in
Sod1D83G/D83G animals between 15 and 52 weeks of age, at a time
when there is no progression in the death of LMN. In addition, as
with SOD1 transgenic mouse models, the TA is affected earlier
than EDL (28).
TA and EDL are fast twitchmuscles that normally fatigue rap-
idly when repeatedly stimulated. Changes in the fatigue charac-
teristics of fast twitch muscles are a typical feature of disease in
Figure 3. Bodymass, behavioural andmotor deﬁcits in female Sod1D83G/D83Gmice. (A) Weights recorded weekly from 4 weeks of age to the humane endpoint; cohort sizes
for (A,C andD) started as 11WT, 13 Sod1+/D83G, 11 Sod1D83G/D83G; due to the death ofmicewith age, at least ﬁvemicewere assessed per genotype at later time points.Weight
is reduced in Sod1D83G/D83Gmice from 4weeks of age (P = 0.001). (B) Echo MRI assessment of lean and fat mass for mice at 6, 35, 52 and 88 weeks of age. Fatmass is reduced
and lean mass increased in 52-week-old Sod1D83G/D83G mice by comparison with WT littermates (*P≤ 0.001). (C) Grip strength recorded monthly from 6 weeks of age to
humane endpoint. Grip strength is reduced in Sod1D83/D83G mice (P ≤ 0.002 from 6 weeks). (D) Rotarod recorded monthly from 7 weeks of age to humane endpoint.
Rotarod performance is reduced in Sod1D83G/D83G mice (P < 0.05 from 23 weeks). (E and F) Wheel running activity over 7 days from 44- and 88-week-old singly housed
female WT and Sod1+/D83G littermates. The distance run (E) is shorter in 44-week-old Sod1+/D83G mice compared with WT (P < 0.01), while the distance run (E) and
duration per run (F) both deteriorate with age in Sod1+/D83G mice (44 versus 88 weeks) compared with WT littermates (P < 0.05). n = 7 per genotype per time point.
Numbers shown represent the mean ± SEM.
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Table 1. Semi-quantitative-modiﬁed SHIRPA phenotypic analysis of WT (Sod1+/+), Sod1+/D83G and Sod1D83G/D83G littermates
Genotype Sample size Mild tremors Severe tremors Reduced pelvic
elevation
Negative geotaxis
Onset (weeks) % Onset (weeks) % Onset (weeks) % Onset (weeks) %
Sod1+/+ ♂ 12 96 17 – – 88 33 60 42
Sod1+/D83G ♂ 15 94 13 – – 86 20 69 60
Sod1D83G/D83G ♂ 11 20 100 62 82 39 100 29 100
Sod1+/+ ♀ 13 98 15 – – 86 46 90 8
Sod1+/D83G ♀ 14 96 36 – – 78 71 – –
Sod1D83G/D83G ♀ 12 22 100 67 58 32 100 49 75
Onset values are themean age at onset, inweeks, formice presenting each phenotype. Percentage represents the proportion ofmice per line presenting each phenotype at
least twice during their lifetime.
Figure 4. Functional deﬁcits in muscle function in female Sod1D83G/D83Gmice. (A) TA tetanic muscle force for mice at 15, 52 and 88 weeks of age; 15-week-old Sod1D83G/D83G
TA tetanicmuscle force (93 g ± 4 g) is reduced comparedwithWT littermates (140 ± 8 g) and deteriorates further at 52 weeks of age (77 ± 4 g). (B) Representative traces of TA
tetanic tension fromWT and Sod1D83G/D83Gmice. (C) EDL tetanic muscle force: 52-week-old Sod1D83G/D83G EDL tetanic muscle force (29 ± 1 g) is reduced compared withWT
littermates (43 ± 2 g). (D) Representative traces of EDL tetanic tension fromWT and Sod1D83G/D83Gmice. (E) FI of EDLmuscle for mice at 15, 52 and 88 weeks of age. FI of 52-
week-old Sod1D83G/D83G mice (0.32 ± 0.03) is increased compared with WT littermates (0.24 ± 0.03). (F) Representative fatigue traces from WT, and Sod1D83G/D83G mice,
produced by repeated stimulation of the EDL muscle for 180 s. Each line in the trace represents a single tetanic tension; line length is proportional to force produced
(see Materials and Methods). *P < 0.05, **P < 0.001.
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SOD1 transgenic mouse models (34) and so we undertook a fa-
tigue test of EDL muscles in Sod1D83G/D83Gmice (Fig. 4E and F).
The force measured at the beginning of a 3 min period of stimu-
lation was compared with that at the end of the test to produce a
Fatigue Index (FI), ameasure of the fatigability of themuscle. The
results highlight the progressive deterioration of EDL in these
mice, so that at 15 weeks, the FI of EDL in Sod1D83G/D83G mice is
no different fromWT, but by 52 weeks of age, EDL FI is increased
by 30% in Sod1D83G/D83Gmice compared with WT (P = 0.04) (Fig. 4E
and F). Comparison between WT and Sod1+/D83G littermate mice
did not reveal any signiﬁcant differences in TA or EDL muscle
function at 15, 52 or 96 weeks of age (Fig. 4).
Sod1D83G/D83G mice have ALS-like changes in the
histochemical phenotype of fast twitch muscles
To further characterize the effect of the Sod1D83G mutation on
muscle physiology, we examined the oxidative capacity of the
muscle ﬁbres in the TA and EDL muscles, by staining for the oxi-
dative enzyme succinate dehydrogenase (SDH) at 15 and 52weeks
of age. Even at 15 weeks of age, Sod1D83G/D83G TA muscle show a
clear change in thehistochemical properties of theirmuscleﬁbres
(Supplementary Material, Fig. S4A and B). Fast twitch muscles,
such as the TA and EDL, normally contain a large proportion of
glycolytic ﬁbres that stain only lightly for SDH activity, a marker
of oxidative ﬁbres. However, in the TA of Sod1D83G/D83G mice at
15 weeks of age, grouping of intensely stained type I slow oxida-
tive muscle ﬁbres was observed and by 52 weeks almost all of the
muscle ﬁbres in the TA of Sod1D83G/D83G mice stain intensely for
SDH, indicating an oxidative phenotype that is more characteris-
tic of slow twitch, type I muscle ﬁbres (Supplementary Material,
Fig. S4A). EDLmuscles of 15-week-old Sod1D83G/D83Gmice, had a simi-
lar SDH staining pattern to WT littermates, but by 52 weeks, there
was a marked increase in the proportion of intensely stained, likely
type I muscle ﬁbres (Supplementary Material, Fig. S4B). These re-
sults once again indicate that in mice expressing mutant SOD1,
EDLmuscles are affected later in the disease than other hindlimb
muscles such as the TA.
Sod1D83G/D83G mice have selective sensory deﬁcits
Although ALS is predominantly a motor neuron disorder, a sub-
set of ALS patients and SOD1G93A transgenicmice develop deﬁcits
in the sensory system (35,36). Thus, we performed behavioural
sensory phenotypic analyses with four sensory tests on female
mice at 22 weeks of age (n≥ 10 per group): (i) cold plate (noxious
cold stimulus), (ii) Randall Sellito test of mechanosensation
(withdrawal to a high-threshold ramp mechanical stimulus),
(iii) Von Frey (low threshold mechanical stimulus), (iv) Har-
greaves method (noxious heat stimulus) (Fig. 5A–D). Interest-
ingly, Sod1D83G/D83G mice have signiﬁcant sensory deﬁcits in
response to both a low threshold mechanical stimulus (von
Frey; P < 0.05) (Fig. 5C) and a noxious heat stimulus (Hargreaves
method; P < 0.01) (Fig. 5D) but no deﬁcit toward a noxious cold
stimulus (cold plate) (Fig. 5A) or a high-threshold mechanical
stimulus (Randall Sellito) (Fig. 5B). These results suggest that dif-
ferent primary afferent populations have selective vulnerabilities
to the Sod1D83Gmutation, or theymay be a consequence of central
sensorimotor integration.
SOD1 D83G protein is dismutase inactive and at reduced
levels in Sod1D83G/D83G mice
The D83 residue coordinates zinc binding to SOD1, and is re-
quired for the correct folding of human SOD1 (37). Thus,mutating
the D83 residue is likely to interfere with the correct folding of
SOD1 and potentially affect SOD1 activity. We measured SOD1
dismutase activity from the brains of WT, Sod1+/D83G, and
Sod1D83G/D83G littermates, and found Sod1D83G/D83G mice showed
almost no SOD1 dismutase activity (1 ± 2%), whereas Sod1+/D83G
brain homogenates have 56 ± 7% (n = 3 per genotype) ofWT litter-
mate SOD1 activity (Fig. 6A and B).
To assess if the D83G mutation affects SOD1 protein stability,
we also measured protein levels of SOD1 in spinal cord fromWT,
Sod1+/D83G and Sod1D83G/D83G littermates. Intriguingly, SOD1 D83G
protein levels are 12% ± 0.4% in Sod1D83G/D83Gmice comparedwith
100% ± 9% in WT littermates, while in Sod1+/D83G mice SOD1 pro-
tein levels are intermediate at 70% ± 5% (n = 3 per genotype)
(Fig. 6C and D).
The reduction of mutant SOD1 D83G in the soluble fraction
might be due to an unfolding and sequestration to the insoluble
fraction. Therefore, we measured the level of SOD1 in the RIPA-
insoluble fractions from spinal cords of WT, Sod1+/D83G and
Sod1D83G/D83G littermates and found low levels of insoluble SOD1
in all genotypes, with a similar reduction in SOD1 D83G protein
levels in Sod1+/D83G and Sod1D83G/D83G mice as that observed in
the soluble fraction (Supplementary Material, Fig. S5A). Thus,
SOD1D83G protein does not accumulate in the insoluble fraction.
Wewere unable to identify misfolded SOD1 by immunopreci-
pitation using either the SEDI or USOD misfolded SOD1 anti-
bodies from Sod1+/D83G and Sod1D83G/D83G tissue extracts or
immunohistochemistry (Supplementary Material, Figs. S5B and
S6A), or detect overt inclusion pathology using p62 or ubiquitin
staining in Sod1+/D83G and Sod1D83G/D83G mice from spinal cord
and brain (Supplementary Material, Figs. S5C and S6B).
Figure 5. Behavioural sensory deﬁcits in female Sod1D83G/D83Gmice. No signiﬁcant
differences in cold nociceptive sensitivity (A, cold plate) or mechanical pressure
threshold (B, Randall Sellito) between genotypes. (C) von Frey: Sod1D83G/D83G
(1.22 g ± 0.10 g) display increased basal paw withdrawal threshold to von Frey
ﬁlaments compared with WT littermates (0.92 g ± 0.06 g). (D) Hargreaves:
Sod1D83G/D83G (14.3 s ± 2.1 s) display increased baseline heat withdrawal latency
compared with WT littermates (7.9 ± 1.0 s). Numbers shown represent the
mean ± SEM. At least 10 animals were assessed per genotype and time point
(*P < 0.05, **P < 0.01).
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To examine whether Sod1D83G mRNA is differentially regu-
lated from WT Sod1, we performed quantitative PCR of Sod1
mRNA isolated from brains of 9-week-old WT, Sod1+/D83G,
Sod1D83G/D83G littermates and did not observe a difference be-
tween genotypes (Supplementary Material, Fig. S7A). In addition,
we directly compared the relative levels of Sod1 WT and D83G
mRNA levels from the brains of 9-week-old Sod1+/D83G mice
using quantitative pyrosequencer analysis (see Materials and
Methods) and did not see a difference between the relative
expression levels of WT and mutant alleles (Supplementary
Material, Fig. S7B).
Sod1D83G/D83G have some phenotypes of Sod1 null mice
Since Sod1D83G/D83G mice are dismutase inactive (Fig. 6A and B),
they are likely to phenocopy at least some aspects of Sod1 null
mice (Sod1−/−). Sod1−/− mice develop a progressive peripheral
motor neuropathy, inwhichmotor axons retract fromneuromus-
cular junctions resulting inmuscle denervation (20,22). However,
unlike Sod1D83G/D83Gmice, there is no reported motor neuron loss
in Sod1−/− mice at any age (20,22,23). To verify that LMN loss in
Sod1D83G/D83Gmice is not due to a loss of SOD1 activity and to con-
ﬁrm that motor neuron survival is unaffected in Sod1−/−mice, we
compared LMN survival in female Sod1D83G/D83G and Sod1−/−mice
at 15 weeks of age; both genotypes were backcrossed to a C57BL/
6J background. In contrast to Sod1D83G/D83Gmice and in agreement
with all previous reports, Sod1−/−mice do not developmotor neu-
ron cell body loss and the survival ofmotor neurons in the sciatic
pool is similar in WT (484 ± 9 MN, n = 6) and Sod1−/−(489 ± 6 MN,
n = 5; P = 0.47) mice. Therefore, unlike Sod1−/− mice, Sod1D83G/D83G
mice have an additional toxic gain of function that causes the
degeneration of motor neuron cell bodies.
Lifespan is reduced in transgenic SOD1mice that overexpress
mutant SOD1 and in Sod1−/− mice. We set the humane endpoint
of life in Sod1D83G/D83G mice as either the time at which a loss of
20% of maximum bodyweight occurs or the onset of piloerection
(an involuntary erection of fur that is indicative of loss of health).
Themajority ofWT, Sod1+/D83G and Sod1D83G/D83G littermateswere
culled due to a loss of 20% bodyweight (∼70% of Sod1D83G/D83G
mice), while the rest (∼30%)were culled for the presence of piloer-
ection. The survival of Sod1D83G/D83Gmice is shortened compared
with Sod1+/D83G andWTmice (Table 2 and Fig. 7A). We also found
that male Sod1D83G/D83Gmice had a signiﬁcantly reduced lifespan
compared with female Sod1D83G/D83G mice (495 ± 22 days versus
588 ± 24 days; P = 0.024).
At autopsy, Sod1D83G/D83G mice had signiﬁcantly more liver
tumours than WT and Sod1+/D83G littermates (Table 2; P < 0.001).
Interestingly, it has previously been shown that Sod1−/− mice
also develop liver tumours, most likely as a result of an increase
in oxidative damage (38). Given that Sod1D83G/D83G mice are dis-
mutase inactive for SOD1 (Fig. 6A and B), it is likely that the loss
of SOD1 activity in these mice is the cause of liver tumours.
The identiﬁcation of liver tumours in Sod1D83G/D83Gmice led us
to examine end-stage male Sod1D83G/D83G mouse livers. Livers
from WT littermates had no pathology other than variable
perivenular lymphocytic inﬁltration (Fig. 7B). In Sod1D83G/D83G
mice, tumours occurred in the presence of otherwise pathologic-
ally normal and abnormal livers. In Figure 7C, there is a single,
well-circumscribed and well-differentiated hepatocellular
carcinoma occurring in a liver that is otherwise morphologically
Table 2. Incidence of hepatocarcinogenesis and average survival of Sod1D83G/D83G mice
Genotype No. of animals examined Average survival (days) No. of animalswith abnormal livera
Males Females Males Females Males Females
Sod1+/+ 9 11 710 ± 21 754 ± 22 1 (11%) 0 (0%)
Sod1+/D83G 15 13 696 ± 14 779 ± 15 2 (13%) 0 (0%)
Sod1D83G/D83G 11 9 495 ± 22 588 ± 24 10 (91%) 7 (78%)
aGross analysis of liver and presence of abnormal nodules.
Figure 6. SOD1D83G is dismutase inactive andunstably expressed. (A andB) SOD1
dismutase activity of brain homogenates from 65-week-old WT, Sod1+/D83G and
Sod1D83G/D83G littermates, assessed using a nitroblue treazolium (NBT) in-gel
assay. (A) Cleared areas indicate SOD activity. (B) Quantiﬁcation of SOD1
dismutase activity across the three genotypes shows Sod1+/D83G (56% ± 7%) and
Sod1D83G/D83G (1% ± 2%) homogenates have signiﬁcantly less activity than WT
(100% ± 17%) (*P = 0.002). (C and D) Immunoblot analysis of spinal cord soluble
fractions for SOD1 protein levels from 65-week-old mice showing reduced SOD1
protein levels in Sod1+/D83G (70% ± 5%) and Sod1D83G/D83G (12 ± 0.4%) extracts
compared with WT littermate extracts. Actin provides a protein loading
reference; SOD1 levels are normalized to actin (*P < 0.001). Numbers represent
the mean ± SEM. Values represent the average from three independent
experiments.
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normal. In contrast, another Sod1D83G/D83G liver demonstrated
multiple ill-deﬁned hepatocellular carcinomas and a well-cir-
cumscribed nodular lesion, composed of sheets of pleomorphic
tumour cells with vesicular nuclei and basophilic cytoplasm
compatible with a poorly differentiated hepatocellular carcin-
oma or cholangiocarcinoma (Fig. 7D). This liver also showed dif-
fuse nuclear anisocytosis, moderate parenchymal inﬂammation
and patchy fatty change (Fig. 7E). Hence, pathological analysis re-
veals that the hepatocellular carcinomas in Sod1D83G/D83G mice
occurred in the presence of bothmorphologically normal and ab-
normal livers.
Mitochondrial membrane potential defects in Sod1+/D83G
embryonic motor neurons
Mitochondrial dysfunctionhas been identiﬁed as one of the earli-
est defects in motor neurons of transgenic SOD1 mice and it has
been suggested that mitochondrial dysfunction may play a piv-
otal role in motor neuron degeneration in ALS (39). We therefore
analysed themitochondrialmembrane potential (Δψm) of embry-
onic motor neurons. Δψm is an indicator of mitochondrial ener-
getic state and can be measured using tetramethylrhodamine
methylester (TMRM) (40). Those from Sod1D83G/D83G (as previously
reported for Sod1−/−) did not survive for >72 h in culture and
therefore Δψm could only be examined in motor neurons from
WT and Sod1+/D83G littermates. We have previously shown that
Δψm in embryonic motor neurons from SOD1
G93A transgenic
mice is disrupted (41). In embryonic motor neurons of Sod1+/D83G
mice, Δψm was signiﬁcantly elevated compared with WT litter-
mates (Fig. 8; P < 0.001).
Since the Sod1+/D83Gmice have an∼45% reduction in SOD1 dis-
mutase activity, it was unclear whether the elevation in Δψm in
Sod1+/D83Gmotor neuronswas due to a loss of SOD1 dismutase ac-
tivity, or a gain of function of SOD1 D83G protein. We therefore
analysed the Δψm of embryonic motor neurons derived from
WTand Sod1+/− littermates and found that Sod1+/−motor neurons
also have elevated Δψm (Fig. 8). This indicates that the mitochon-
drial defects present in Sod1+/D83G motor neurons are likely
caused by a partial loss of SOD1 function.
Discussion
We have identiﬁed and characterized the ﬁrst mouse model car-
rying the equivalent of a human ALS pathogenic mutation in the
endogenous mouse Sod1 gene, and this mutation is identical to a
human fALS mutation (24). Since the mutation is within the en-
dogenous Sod1 gene, mutant SOD1 is not overexpressed. Here we
show that homozygous Sod1D83G/D83G mice develop upper and
LMN degeneration, unlike Sod1 null animals. This is therefore
likely due to a toxic gain of function of mutant SOD1—presum-
ably modelling that which causes motor neuron death in
human ALS cases.
We found ∼20% loss of UMN by 29 weeks of age in homozy-
gotes, but did not look at later time points and so do not know
if this phenotype progresses. Given the importance of mutant
SOD1 protein dose in accelerating the ALS-like phenotype (16),
it is possible heterozygotesmay developUMN loss later in life. Al-
ternatively, a copy of WT SOD1 might be protective; this remains
to be determined.
We showed 23% loss of LMN in the lumbar spinal cord of
homozygous Sod1D83G/D83G mutants by 15 weeks of age that re-
mained stable at 52 weeks of age. We speculate whether further
ageing, or a ‘second hit’ might be required to cause a more dra-
matic loss of LMN in this mouse mutant; however, this remains
to be determined. We note that a similar loss of MN in humans
is unlikely to cause sufﬁcient loss of motor function to prompt
a visit to a physician. Sod1+/D83G heterozygous mutants displayed
Figure 7. Lifespan of Sod1D83G/D83G mice and the presence of hepatocellular
carcinoma. (A) Survival of male and female WT, Sod1+/D83G and Sod1D83G/D83G
littermates to humane endpoint (see Materials and Methods). Sod1D83G/D83G
mice reach end-stage sooner than WT and Sod1+/D83G littermates (Table 2) and
male Sod1D83G/D83G mice (495 ± 22 days) reach end-stage earlier than females
(588 ± 24 days) (P = 0.024). (B–E) Hematoxylin and eosin (H&E) stained liver
sections from age-matched (B) WT and (C–E) end-stage Sod1D83G/D83G
mice. Livers from Sod1D83G/D83G mice contain well-deﬁned hepatocellular
carcinoma (C) within an otherwise morphologically normal liver. (D) A poorly
differentiated hepatocellular carcinoma or cholangiocarcinoma (E) within an
otherwise inﬂamed liver background. Scale bar for (B)–(D) is 100 μm, and for (E)
is 50 μm.
Figure 8.Mitochondrial potential in Sod1+/D83G and Sod1+/−motor neurons. Resting
Δψm, estimated using TMRM, from embryonic WT littermates, Sod1
+/D83G and
Sod1+/− motor neurons (WT, 100% ± 3.4%; Sod1+/D83G, 121% ± 1.9%; Sod1+/−,
126% ± 3.8%). Data are normalized to resting Δψm for WT littermates (100%) and
represent the mean ± SEM. Recordings taken from at least 75 cells from 2 or
more independent embryonic motor neuron cultures (*P < 0.001).
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no LMN loss up to 52weeks of age, either because the dose ofmu-
tant SOD1 was insufﬁcient or because WT SOD1 might have a
protective effect.
Our analyses of the Sod1D83G mouse mutant show that muta-
tion in the endogenous mouse Sod1 gene models critical features
of human ALS (U and LMN cell death), albeit with a different pro-
ﬁle than found in mice expressing human mutant SOD1 trans-
gene arrays. This corroborates earlier ﬁndings in which a
mutant genomic mouse Sod1 transgenic was used to model
human SOD1 G85R-fALS—‘Sod1 G86R’mice with ‘high transgene
expression’ had both U and LMN degeneration by 3–4 months of
age (14). Therefore, the endogenous mouse SOD1 D83Gmutation
is informative for determining why some U and LMN die in ALS
but removes any possible confounding effects of overexpression
observed in SOD1 transgenic mice. We note that we and others
have not observed MN cell body degeneration in Sod1−/− mice at
any stage, and therefore MN loss in Sod1D83G/D83G mice likely
arises from a toxic gain of function of the mutant SOD1 protein,
as in ALS (20–22).
The signiﬁcant reduction in SOD1 D83G protein is not due to
allele-speciﬁc differences at the transcriptional level, but the
dose-dependent decreases in SOD1 protein in heterozygous
and homozygous D83G mutant mice may result from instability
of mutant SOD1 and its subsequent degradation (42). It has been
previously reported that mutant SOD1 has decreased half-life
compared with WT SOD1 (42), and potentially the inability of
D83G SOD1 to coordinate zinc may contribute to its instability
(37,43,44).
Given that SOD1 expression levels in different transgenic
mouse models show dose-dependent toxicity (16,18), the low le-
vels of SOD1 D83G proteinmay only be sufﬁcient to causemoder-
ate motor neuron degeneration. The low SOD1 mutant protein
level (∼10% of WT in homozygotes) may be sufﬁcient to elicit a
degree of motor neuron degeneration but not the levels of loss
seen in ALS, and may at least partially explain why loss of
motor neurons within the sciatic motor pool appears not to pro-
gress between 15 and 52 weeks of age.
With respect to loss-of-function effects, which are of interest
because of the loss of dismutase activity in the majority of
human pathogenic SOD1-fALS mutations (average dismutase
activity in SOD1-fALS is ∼58% of normal (4)), we foundmitochon-
drial membrane potentials (Δψm) of both Sod1
+/D83G and Sod1+/−
embryonic MNs are hyperpolarized. Thus, SOD1 loss of dismu-
tase function to just 56% of WT (Sod1+/D83G level) contributes to
mitochondrial abnormalities. Distal axonopathy in Sod1−/− mice
can be rescued by expressing mitochondrial-targeted WT SOD1
(20); the relevance of this to ALS remains to be determined.
Sod1D83G/D83G mice develop a severe peripheral neuropathy
similar to that arising from the loss of function in Sod1−/− mice.
This peripheral neuropathy is likely driving the phenotypic de-
terioration from 15 weeks of age in Sod1D83G/D83G mice (Supple-
mentary Material, video S1), as no further LMN loss occurs after
that. As dismutase activity is only 1% of WT animals in the
SOD1 D83G homozygotes, this peripheral neuropathy may be
due to a loss of dismutase activity, potentially leading to in-
creased vulnerability of peripheral motor axons to oxidative
stress (45). It is also possible that the neuropathy develops be-
cause of a loss-of-unknown SOD1 function.
In at least one patient with diagnosed ALS who unexpectedly
died from other causes, NMJ degeneration was found to precede
motor neuron cell body death (45). Similarly, in transgenic
human mutant SOD1 mouse models (with normal dismutase le-
vels), NMJ degeneration leading to synaptic dysfunction precedes
motor neuron cell body death and behavioural motor deﬁcits
(45,46). These ﬁndings led to the concept of ALS as a “dying
back” disorder in which muscle denervation precedes the death
of the motor neuron cell body, and suggests that SOD1 gain of
function can also lead to NMJ degeneration—and potentially
also contributing to the distal neuropathy seen in Sod1D83G/D83G
mice.
Here our data, and that from other SOD1 mouse models, sug-
gests that the axonal andneuronal cell body degenerationmay be
separate events that could be modulated by different sets of
genes and/or environmental factors. In further support of this
hypothesis, ablation of Bax in the human G93A SOD1 transgenic
mousemodel leads to complete dissociation betweenmotor neu-
ron soma death and motor dysfunction via distal denervation
(47). While cell bodies are protected in Bax deﬁcient G93A SOD1
transgenic mice, the degree of NMJ denervation and overall sur-
vival is not altered compared with G93A transgenic mice alone.
Thus, Sod1D83G/D83G mice provide a novel model to test therapeu-
tics aimed at preserving NMJ as well as ameliorating the early
stages of motor neuron cell body degeneration.
Overall, these results suggest that Sod1D83G/D83Gmice not only
model the early stages of humanALS but are also able to separate
the effects of central neuronal death from the peripheral distal
neuropathy in a system in which the mutant gene is expressed
at endogenous levels.
The Sod1D83G model is the ﬁrst of its kind carrying a known
pathogenic point mutation in the mouse endogenous Sod1
gene, which is identical to a human fALSmutation. Homozygous
Sod1D83G/D83G mice develop a degree of UMN and LMN degener-
ation, as well as progressive motor dysfunction due to a distal
neuropathy, and hence model key aspects of the early stages of
ALS. The Sod1D83G model therefore provides a unique mamma-
lian system in which to assess the contribution of both central
neuronal loss and peripheral axonal dysfunction, which will fur-
ther our understanding of ALS.
Materials and Methods
Mice
Ethics statement: all experiments were performed under licence
from the UK Home Ofﬁce. WT, Sod1+/D83G and Sod1D83G/D83G mice
were initially on a C57BL/6J-C3H background and backcrossed at
least four generations to C57BL/6J. For all experiments, litter-
mates for all genotypes were used, produced by intercrossing
Sod1+/D83G mice. Experiments were performed blind to genotype
and lifespan was deﬁned as a loss of 20% of maximum body
weight or the presence of piloerection. Animals were assessed
daily and weighed at least biweekly.
Identiﬁcation of Sod1D83G mutation
The Harwell ENU-DNA archive (http://www.har.mrc.ac.uk/
services/dna_archive/) was screened with high-resolution melt-
ing analysis using the LightScanner platform (Idaho Technology
Inc., Salt Lake City, Utah, USA) (48). Coding sequence from exon 4
of Sod1 including ﬂanking (∼70 bp) splice sites was tested in DNA
derived from ∼10 000 F1 ENU mutagenized animals. Sod1 exon 4
was ampliﬁed with the following primers: SOD1_4F CATCCACT
CATACGTATTTGAC, SOD1_4R ACCATAAAGTCATGGGAAGG using
the lightscanner mastermix plus LC green (Idaho Technology
Inc.) and possible mutations analysed with Sanger sequencing
(GATC, Germany). We identiﬁed the chromosome 16 A90,224,
530G mutation, corresponding to the D83G amino acid change
in SOD1. The mouse line was rederived using sperm from the
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(C57BL/6J × C3H) F1 founder by in vitro fertilization. Genomic DNA
from the F1 founder carrying the Sod1 D83G mutation was deep
sequenced (see Supplementary Material, Materials and Methods
for details) to identify any other possible ENU-inducedmutations
linked to Sod1 on mouse chromosome 16. The closest ENU-in-
duced coding mutation was ∼46 Mb proximal to the Sod1 gene
and did not segregate with lifespan or weight abnormalities in
Sod1D83G/D83G mice.
Behavioural analysis
See Supplementary Material, Materials and Methods for a de-
scription of behavioural and Echo MRI analysis.
Physiological assessment of hindlimb muscle force,
motor units and fatigue index
Muscle force, motor unit number andmuscle fatigue characteris-
tics for female WT, Sod1+/D83G and Sod1D83G/D83G littermates
were examined at 15 and 52 weeks of age, and female WT and
Sod1+/D83G littermates also at 88 weeks of age, as described previ-
ously (49). Cohort sizes per time point were at 15 weeks: 5 WT,
5 Sod1+/D83G and 5 Sod1D83G/D83G animals; 52-weeks: 5 WT,
7 Sod1+/D83G and 6 Sod1D83G/D83G animals; 88 weeks: 5 WT, 7
Sod1+/D83G. Brieﬂy, micewere anaesthetized (4.5% chlorohydrate),
the distal tendons of the TA and EDL muscles in both hindlimbs
cut and attached to isometric force transducers (Dynamometer
UFI Devices, UK), and the sciatic nerves exposed and sectioned.
Isometric contractions were elicited by stimulating the nerve to
the TA or EDL muscles using squarewave pulses of 0.02 ms dur-
ation at supra-maximal intensity. The number of motor units in-
nervating the EDL muscle was determined by stimulating the
motor nerve with stimuli of increasing intensity, resulting in in-
cremental increases in twitch tension due to successive recruit-
ment of motor axons with increasing threshold. The number of
increments in twitch force was counted giving an estimate of
the number of functional motor units present in muscle. The
fatigue characteristics of EDL were examined by undertaking a
fatigue test in which the EDL muscle was repeatedly stimulated
at 40 Hz for 250 ms every second for 180 s. The resulting contrac-
tions were recorded on a pen recorder (Lectromed Multitrace 2)
producing a fatigue trace from which an FI, a measure of muscle
fatigability, can be determined by expressing the force at the end
of the test as a ratio of the force at the start: FI = Ft180/Ft0. Amuscle
that is completely fatigue resistant has an FI approaching 1.0.
Morphological assessment ofmuscle andneuronal tissue
For assessment of survival ofmotor neurons in the sciatic pool of
the lumbar spinal cord (16,18), animalswere perfusedwith saline
followed with 4% paraformaldehyde (PFA) ﬁxation. Spinal cords
were removed, postﬁxed in 4% PFA and cryopreserved in 30% su-
crose. Transverse sections (20 μm) of the lower L2–lower L6 lum-
bar region of ﬁxed spinal cords cut on a cryostat serially onto
glass slides and stained for Nissl (gallocyanin) (50). Nissl-stained
motor neurons in the sciatic pool in every third section of the L3–
L6 lumbar region, over 40 sections in total, were counted. Only
large, polygonal neurons with a distinguishable nucleus and nu-
cleolus and clearly identiﬁable Nissl structure were included in
the counts. This method avoids the possibility of counting the
same motor neuron in consecutive sections. At least ﬁve mice
were analysed from each experimental group per time point.
For assessment of CSMNs, brains were removed intact from
animals perfused as above, postﬁxed (4% PFA, overnight), and
stored in PBS with sodium azide (0.01%) at 4°C. Brains were sec-
tioned in 50 μm coronal planes and serially collected in 12-well
plates. Sections mounted on Superfrost Plus glass slides (VWR)
were stained for Nissl (cresyl violet). Antibodies used for assess-
ment of CSMNs: anti-CTIP2 (1 : 1000; Abcam), anti-Cry-mu
(1 : 500, Sigma), anti-Satb2 (1 : 1000; Abcam) and anti-LMO4 (1 :
500, Millipore). Sections for LMO4 were pretreated with 0.05%
trypsin EDTA at 37°C for 10 min, followed by washes in blocking
solution (0.5% BSA, 2% FBS, 0.1% Triton X-100 and 0.01% saponin,
0.02% sodium azide) and treatment with 50 m ammonium
chloride for 30 min. All sections were incubated with primary
antibodies in blocking solution overnight at 4°C. Appropriate
secondary antibodies (1 : 500 alkaline phosphatase conjugated,
Santa Cruz Biotechnology; 1 : 500 Cy3-conjugated, Millipore)
were applied. Sections with Cy3-conjugated antibodies were
stained with DAPI (1 : 5000 in PBS) for 5 min. Sections for CTIP2
were processed with Vector blue AP substrate kit (Vector Labora-
tories) according to manufacturer’s instructions. Sections were
analysed using a Nikon Eclipse TE2000-E ﬂuorescence micro-
scope equipped with Intensilight C-HGFI (Nikon). Epiﬂuorescent
images were acquired using Digital Sight DS-Qi1MC CCD camera
(Nikon). Three well-deﬁned sections spanning the motor cortex
(Bregma 0.86 mm, interaural 4.66 mm; Bregma 0.02 mm, inter-
aural 3.82 mm; Bregma −1.22 mm, interaural 2.58 mm) (51) were
used for quantitative analysis, as previously described (27,52).
Muscle histochemistry was performed on TA and EDLmuscle
sections by staining for the oxidative enzyme, as previously de-
scribed (53). Brieﬂy, serial cross-sections of fresh frozen TA and
EDL were cut on a cryostat at 12 μm, collected on glass slides
and stained for SDH activity to determine the oxidative capacity
of the muscle ﬁbres.
Neuromuscular junction quantiﬁcation
EDL muscles were dissected from mice of all three genotypes at
15 and 52 weeks of age. The numbers of whole EDL muscles ana-
lysed at 15 weeks of age: 7WT, 4 Sod1+/D83G and 8 Sod1D83G/D83G. At
52 weeks: 11 WT, 8 Sod1+/D83G and 8 Sod1D83G/D83G. Mice were per-
fused trans-cardial with saline solution and 4% PFA. Muscles
were postﬁxed in 4% PFA and cryopreserved in sucrose. Whole
EDL muscles were then embedded in OCT media (Tissue-Tek),
frozen on dry-ice and stored at −80°C. A Bright™ cryostat was
used to cut 20 µm longitudinal section of frozen EDL muscles
which were subsequently collected onto poly-lysine-coated
slides. Primary antibodies used: mouse monoclonal anti-synap-
tic vesicle (Developmental Studies Hybridoma Bank) Mouse
monoclonal anti-neuroﬁlament (165 kDa) (Developmental Stud-
ies Hybridoma Bank). M.O.M. biotinylated secondary antibody
(Vector Labs) was used following manufacturer instructions.
α-Bungarotxin-rhodamine was used to label postsynapsis and
sections mounted. Images were acquired on a confocal micro-
scope (Leica DFC 420C) and NMJ were manually counted.
Immunocytochemistry
See Supplementary Material, Materials and Methods for im-
munocytochemistry experiments.
qPCR, western blotting, dismutase activity and
immunoprecipitations
qPCR, western blotting, dismutase activity and immunoprecipi-
tation protocols are available in Supplementary Material, Materi-
als and Methods.
12 | Human Molecular Genetics
 at U
niversity College London on January 30, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
Embryonic motor neuron culture and mitochondrial
membrane potential
Motor neuron culture and measurement of mitochondrial mem-
brane potential are described in Supplementary Material, Materi-
als and Methods.
Statistical analysis
An ANOVA test was used to compare betweenWT, Sod1+/D83G and
Sod1D83G/D83Ggenotypes per time point followed by Bonferroni’s
multiple comparisons testing correction for weight, dismutase
activity, protein quantiﬁcation, Echo MRI analysis, grip strength,
rotarod, startle response and sensory analysis. Wheel running
behaviour was analysed using a repeated measures ANOVA.
Cox survival analysis was used to analyse SHIRPA and survival
data. TheMann–Whitney test was used to compare between gen-
otypes per time point or Sod1D83G/D83G cohorts across time points
for TA and EDLmaximummuscle force, survivingmotor units, FI
and motor neuron survival. Two-tailed tests were used in all in-
stances and signiﬁcance level was set at P < 0.05.
Supplementary Material
Supplementary Material is available at HMG online.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset 
neurodegenerative disease characterized by degeneration 
and death of upper and lower motor neurons (MNs). 
Patients typically suffer from progressive motor weak-
ness, which starts focally and spreads through the body 
leading to paralysis and ultimately death within a few 
years of diagnosis. Although usually sporadic (without a 
family history), approximately 10% of ALS cases are 
familial (fALS) and of those, ~20% are caused by muta-
tions in the gene superoxide dismutase 1 (SOD1) (Kiernan 
and others 2012). More than 160 mutations in SOD1 have 
been identified in ALS sufferers, the majority of which 
are missense point mutations resulting in a dominant 
mode of inheritance. At least 75 of SOD1’s 154 amino 
acids have been reported as mutated in ALS and their 
positions are scattered throughout the five exons of the 
gene (Saccon and others 2013).
SOD1 is highly conserved throughout evolution 
(Wang and others 2006), ubiquitously expressed and 
makes up 1-2% of the total soluble protein in the central 
nervous system (Pardo and others 1995). Its primary 
function is thought to be as a cytosolic and mitochondrial 
antioxidant enzyme, converting superoxide to molecular 
oxygen and hydrogen peroxide; however, in yeast at 
least, less than 1% of total SOD1 is required to carry out 
this canonical function (Corson and others 1998; Reddi 
and Culotta 2013) leaving the question open as to whether 
SOD1 plays other equally important role(s), which might 
account for its abundance.
Many lines of evidence have led to the conclusion that 
mutations in SOD1 cause ALS via an as yet unidentified 
gain of function, although it has been proposed that a loss 
of function may also play a secondary role in disease, at 
least in some cases (Saccon and others 2013). A great 
number of cellular mechanisms has been implicated as 
potentially involved in SOD1-fALS pathogenesis, how-
ever, distinguishing cause from effect and identifying the 
critical processes remains challenging (Redler and 
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Abstract
The canonical role of superoxide dismutase 1 (SOD1) is as an antioxidant enzyme protecting the cell from 
reactive oxygen species toxicity. SOD1 was also the first gene in which mutations were found to be causative for 
the neurodegenerative disease amyotrophic lateral sclerosis (ALS), more than 20 years ago. ALS is a relentless and 
incurable mid-life onset disease, which starts with a progressive paralysis and usually leads to death within 3 to 5 years 
of diagnosis; in the majority of cases, the intellect appears to remain intact while the motor system degenerates. It 
rapidly became clear that when mutated SOD1 takes on a toxic gain of function in ALS. However, this novel function 
remains unknown and many cellular systems have been implicated in disease. Now it seems that SOD1 may play a 
rather larger role in the cell than originally realized, including as a key modulator of glucose signaling (at least so far 
in yeast) and in RNA binding. Here, we consider some of the new findings for SOD1 in health and disease, which may 
shed light on how single amino acid changes at sites throughout this protein can cause devastating neurodegeneration 
in the mammalian motor system.
Keywords
amyotrophic lateral sclerosis, ALS, motor neuron, superoxide dismutase 1, SOD1
 at University College London on December 10, 2014nro.sagepub.comDownloaded from 
2 The Neuroscientist 
Dokholyan 2012). Here, we describe emerging themes in 
SOD1 biology that suggest this enzyme is involved in a 
widening array of cellular processes in both health and 
disease; this may shed new light on the pathogenesis of 
SOD1-ALS.
Transmission of SOD1
Some causative proteins for neurodegenerative diseases 
may have “prion-like” properties: the ability to sequester 
wildtype proteins and seed their aggregation or misfold-
ing, and to act as transmissible agents between cells 
(Polymenidou and Cleveland 2012) (Fig. 1). SOD1 dis-
plays prion-like properties in vitro and in cellular and 
now in animal models, which is particularly of interest 
for SOD1-fALS, given the focal start of ALS, the finding 
that motor neuron death is not cell-autonomous (e.g., see 
Ilieva and others 2009), and the implications for therapy 
to halt the spread of pathology. These findings are also 
important for a potential mechanism for spread, and pos-
sibly even pathogenesis in sporadic ALS (sALS), given 
the presence of aggregated SOD1 in sALS cases (Bosco 
and others 2010; Forsberg and others 2010; Grad and 
Cashman 2014).
SOD1 Seeded Aggregation In Vitro
In vitro assays measuring aggregation propensity show 
recombinant wildtype and ALS-mutant SOD1 can seed 
aggregation of themselves (self-seeding) and of each 
other (cross-seeding). Seeded amyloid fibrilization of 
SOD1 occurred at acidic pH and in the presence of a cha-
otrope (Chia and others 2010), and non-amyloid seeded 
fibrilization was seen at physiological pH (Hwang and 
others 2010). Spinal cord tissue homogenate from a 
SOD1G93A transgenic mouse (which models human ALS) 
was then shown to efficiently self- and cross-seed the 
amyloid fibrilization of recombinant wildtype and mutant 
SOD1 in vitro (Chia and others 2010). However, self- and 
cross-seeding does not, alone, indicate prion-like proper-
ties; the prion-like nature of a protein also comes from its 
ability to transmit between cells and indeed between 
organisms.
Transmission in Cell Models
Mutant SOD1 is found in medium from primary cultures 
of whole spinal cord and of astrocytes from SOD1-ALS 
transgenic mice (Basso and others 2013; Urushitani and 
Figure 1. Superoxide dismutase 1 (SOD1) may have prion-like properties. (A) Misfolded SOD1 within a cell could (B) sequester 
and misfold wildtype SOD1, ultimately producing aggregates, and (C) if secreted and taken up by neighboring cells could (D) 
cause a “chain reaction” of misfolding, aggregate formation, and transmission in a prion-like manner. The exact nature of this 
process—for example, the roles of monomers and aggregates—remains unknown.
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others 2006). Furthermore, mutant SOD1 is secreted in 
exosomes from primary astrocytes and neuronal-like sta-
ble cell lines, (Basso and others 2013; Grad and Cashman 
2014) (Fig. 2). Thus there is a mechanism for mutant 
SOD1 to get out of cells.
In terms of getting into cells, a range of recombinant 
forms of SOD1 (including wildtype and mutant, aggre-
gated and non-aggregated) are efficiently internalized by 
neuronal-like stable cell lines, via the non-selective 
mechanism, macropinocytosis (Grad and Cashman 2014; 
Münch and others 2011; Sundaramoorthy and others 
2013). Primary mouse spinal cord cultures and neuronal-
like cell lines also take in wildtype and mutant SOD1 via 
internalization of exosomes (Basso and others 2013; 
Grad and others 2014).
Once internalized, recombinant aggregated mutant 
SOD1 can self-seed aggregation of stably expressed 
mutant SOD1; this is sustained for up to 1 month and 
through multiple passages of a mouse neuroblastoma-
derived cell line, long after the exogenous seeds had 
apparently been cleared from the cells (Münch and others 
2011). Furthermore, recombinant mutant SOD1 (both 
aggregated and non-aggregated forms) can also cross-
seed endogenous wildtype SOD1—which can also be 
self-seeded by recombinant aggregated wildtype SOD1 
(Sundaramoorthy and others 2013).
Self-seeded aggregation of endogenous SOD1 by con-
ditioned medium has been shown in stable cell lines 
through multiple passages; this was blocked by both 
SOD1 knock-down and immuno-depletion of misfolded 
Figure 2. Mutant superoxide dismutase 1 (SOD1) may be transmitted from astrocytes to motor neurons, causing cell death. 
Mutant SOD1 is secreted in exosomes by astrocytes and may be taken in by motor neurons; propagation of misfolding may 
then proceed within the cell (see Fig. 1). Exposure of motor neurons to mutant SOD1 results in increased sodium channel 
permeability, induction of nitroxidative stress, hyperexcitability likely through dysregulation of AMPA receptors as well as sodium 
channel dysfunction and reduced viability.
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SOD1 in the medium (Grad and others 2011; Grad 
and Cashman 2014).
Transmission between Mouse Models
Recently, transmissibility of mutant SOD1 and motor 
neuron disease pathology between different transgenic 
mouse models appears to have been demonstrated. 
Spinal cord homogenates from SOD1G93A mice were 
injected into the spinal cords of different SOD1 trans-
genic models and motor neuron disease was induced in 
an otherwise unaffected transgenic animal expressing 
low levels of a different (SOD1 G85R) mutant SOD1 
protein (Ayers and others 2014). Remarkably, when tis-
sues from the induced mice were used to inoculate new 
SOD1G85R mice (“second passage homogenates”) dis-
ease onset was earlier in recipient animals, exactly as 
seen in prion disease models. Other data shows potential 
SOD1 “strains” akin to prion strains (Ayers and others 
2014). This article offers compelling data to indicate the 
physiological prion-like transmission of mutant SOD1 
and motor neuron disease pathology in vivo. Of note, 
one-third of the SOD1G85R mice inoculated with homog-
enates from wildtype SOD1 transgenic mice also devel-
oped the motor neuron degeneration phenotype, while 
self-seeding experiments in two other mutant SOD1 
transgenic lines failed to accelerate disease in these 
mice. Future work to identify whether a misfolded 
SOD1 species is both necessary and sufficient to induce 
disease, and to determine whether the phenomenon is 
applicable to other SOD1 variants will be needed.
Mutant SOD1 Expressing Glia Are 
Toxic to Motor Neurons
Data from transgenic mice with tissue specific/restricted 
expression of mutant SOD1 demonstrate that non-neuro-
nal cells are involved in the progression of disease-related 
phenotypes (reviewed in Ilieva and others 2009). In vitro 
experiments also clearly demonstrate the toxicity of 
mutant SOD1-expressing glia to motor neurons.
Astrocytes
Toxicity of astrocytes, to motor neurons has been dem-
onstrated by co-culture, and by the application of astro-
cyte conditioned medium (ACM) (Basso and others 
2013; Haidet-Phillips and others 2011; Meyer and oth-
ers 2014; Nagai and others 2007). Intriguingly, this 
interaction appears to be cell-type specific: mutant 
SOD1 expressing primary astrocytes reduced viability 
of both primary and embryonic stem cell-derived MNs 
in co-culture, but interneurons, GABAergic neurons, or 
dorsal root ganglion neurons were not affected. Mutant 
SOD1 fibroblasts, microglia, cortical neurons, or myo-
cytes were not toxic to co-cultured MNs (Nagai and 
others 2007).
Induction of nitroxidative stress and hyperexcitability 
has been proposed as a possible mode of astrocyte toxic-
ity to motor neurons: within 30 minutes of applying 
mutant SOD1 ACM, primary spinal MNs had increased 
excitability and increased sodium channel permeability; 
this exposure, followed by 4 days of culture with normal 
medium, was sufficient to cause ~50% MN death (Fritz 
and others 2013). ACM also produced an increase in 
intracellular nitroxidative stress in cultured MNs (Rojas 
and others 2014) (Fig. 2). Similarly, co-treatment with 
ACM and sodium channel blockers protected MNs from 
hyperexcitability, nitroxidative stress, and cell death, 
while antioxidants protected against nitroxidative stress 
and significantly improved MN survival, although their 
effect on sodium channel activity was not assessed (Fritz 
and others 2013; Rojas and others 2014). MNs co-cul-
tured with mutant SOD1 expressing astrocytes have been 
shown to have dysregulated AMPA receptor subunits and 
increased excitability (Van Damme and others 2007).
However, conversely, a separate study of mutant 
SOD1 transgenic mouse models found MNs with lowest 
basal excitability were the most vulnerable, and pharma-
cologically increasing MN activity reduced misfolded 
SOD1 pathology and markers of cellular stress while 
decreasing activity had the opposite, detrimental, effects 
(Saxena and others 2013).
The toxic factor released by astrocytes has not yet been 
identified and may well be/include mutant SOD1 because 
exosome depletion prevents ACM toxicity (Basso and 
others 2013). Interestingly, astrocytes from mutant TDP43 
transgenic mice, sALS and C9orf72 expansion patients 
have also been shown to cause MN toxicity by co-culture 
and by ACM (Haidet-Phillips and others 2011; Meyer and 
others 2014; Rojas and others 2014) suggesting some 
common toxic pathway in sALS and fALS.
Microglia
Activated microglia are thought to play an initially protec-
tive role in ALS, but then possibly become toxic due to 
increasing neuroinflammatory processes as disease 
advances (Lewis and others 2012). Microglia purified from 
mutant SOD1 mice are toxic to stem cell–derived human 
MNs and this toxicity appears to be dependent on prosta-
glandin signalling: activation of prostaglandin D2 (PGD2) 
receptor 1 (DP1) in wildtype mouse and human microglia 
prior to co-culture with MNs, induced significant MN tox-
icity. Conversely, pretreatment of mutant SOD1 mouse 
microglia with a pharmacological inactivator of DP1, or 
genetic ablation of DP1 expression, significantly attenuates 
toxicity to MNs (de Boer and others 2014).
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Expression of mutant SOD1 up-regulates PGD2 
receptor 1 (PTGDR) transcript levels in mouse and 
human microglia, and increases the release of PGD2 in 
rat microglia and astrocytes suggesting a possible interac-
tion between these glial cell types (Thonhoff and others 
2011). Nitroxidative stress may mediate microglial toxic-
ity to MNs; however, this appears to be specific to 
microglia prepared from symptomatic mutant SOD1 
expressing mice, so this effect is unlikely to be a primary 
cause of MN degeneration (Thonhoff and others 2011).
Protein Homeostasis
Unfolded Protein Response/Endoplasmic 
Reticulum Stress
The endoplasmic reticulum (ER) is a cellular compart-
ment in which post-translation protein processing, includ-
ing chaperone-assisted protein folding, is carried out. 
When the function of the ER is perturbed, ER stress acti-
vates two adaptive pathways: (1) the unfolded protein 
response (UPR) to refold misfolded proteins, and (2) 
ER-associated degradation (ERAD) to export misfolded 
proteins from the ER to the ubiquitin proteasome system 
(UPS) for degradation. Although ER stress pathways are 
initially protective responses, prolonged activation can 
lead to pro-apoptotic consequences.
The UPR has three main pathways (the activating tran-
scription factor 6 [ATF6], endoplasmic reticulum to 
nucleus signaling 1 (also known as inositol-requiring 
kinase 1) [IRE1], and eukaryotic translation initiation 
factor 2-α kinase 3 (also known as protein kinase RNA-
activated (PKR)-like ER kinase) [PERK] pathways) that 
are all activated in spinal MNs in SOD1-ALS mouse 
models (Walker and Atkin 2011). This activation appears 
to be an early, presymptomatic, event in SOD1G93A mice, 
with toxic consequences for the affected cells (Saxena 
and others 2009). Similarly, RNA profiles of MNs derived 
from a SOD1+/A4V fALS patient, show activation of ER 
stress and the UPR, compared with non-mutant isogenic 
controls (Kiskinis and others 2014).
Endoplasmic reticulum stress initially increases phos-
phorylation of eIF2α via PERK activation, which stalls 
protein synthesis (anti-apoptotic ER stress pathways). 
However, chronic ER stress activates GADD34 which 
dephosphorylates eIF2α, reinitiating protein translation 
in a pro-apoptotic pathway (Fig. 3). Blocking the dephos-
phorylation of p-eIF2α, increased survival of SOD1+/A4V 
MNs (Kiskinis and others 2014), and this could be due to 
stopping the pro-apoptotic action of GADD34. However, 
as the basal state of SOD1+/A4V MNs was of increased 
p-eIF2α these results are difficult to interpret.
Mutant SOD1G85R transgenic mice in which Perk is 
reduced (heterozygous knockout), have shortened disease 
duration and lifespan, perhaps because the UPR is over-
whelmed by misfolded mutant SOD1, whereas SOD1G85R 
transgenic mice in which the effect of PERK is increased 
by reduction of Gadd34 (heterozygous knockout), have 
an ameliorated disease and prolonged lifespan (Wang and 
others 2011; Wang and others 2014).
Mutant SOD1 has been implicated in the direct activa-
tion of ER stress through interaction with subunits of coa-
tomer coat protein II complex (COPII) in a transfected 
cell model and in mutant SOD1 transgenic mice as early 
as 10 days of age (Atkin and others 2014). COPII is 
essential for ER-Golgi transport, and expression of 
mutant SOD1 caused ER-Golgi transport disturbance 
before either the earliest markers for ER stress or aggre-
gate formation, implicating the interaction and its effect 
as an early upstream event in mutant SOD1 toxicity. 
Disrupting ER-Golgi transport in this way results in acti-
vation of ER stress responses (Fig. 4). In cellular models, 
co-expression of COPII subunits with mutant SOD1 sig-
nificantly reduced SOD1-induced apoptosis (Atkin and 
others, 2014).
SOD1 as an ER Stress Activating Zinc Sensor
Another recently proposed role for SOD1 is as a zinc sen-
sor, activating ER stress and up-regulating zinc transport-
ers by binding to Derlin1 in zinc-deficient conditions 
(Homma and others 2013). Derlin1 is an ERAD protein 
involved in export of misfolded proteins from the ER to 
the UPS. Under conditions of zinc depletion SOD1, 
which is a copper/zinc dependent enzyme, binds Derlin1 
at a normally hidden Derlin1 binding region, and the 
resulting dysfunction of both Derlin1 and the ERAD pro-
cess causes a build-up of misfolded protein in the ER and 
elicits ER stress (Fig. 5). ATF6, a transcription factor acti-
vated by ER stress, as well as up-regulating ER chaper-
ones, also promotes transcription of the zinc transporter 
ZIP14, which may act to restore intracellular zinc levels 
(Homma and others 2013).
SOD1 mutation in ALS may result in constitutive 
exposure of the Derlin1 binding region and chronic ER 
stress and ERAD dysfunction. Mutant SOD1 activates 
ER stress and the IRE1-ASK1 pro-apoptotic pathway in a 
Derlin1 binding-dependent manner (Nishitoh and others 
2008); further, of 132 ALS associated SOD1 mutations, 
124 co-immunoprecipitated with Derlin1 in transfected 
HEK cells (Fujisawa and others 2012). The mutants 
which did not co-precipitate with Derlin1 also failed to 
activate ER stress and were less toxic in cellular assays 
(Fujisawa and others 2012). In a SOD1G93A transgenic 
mouse model of ALS, knocking-out Ask1 improved sur-
vival and reduced MN death, showing that this pathway 
is also important in vivo, however, age at disease onset 
was unchanged (Nishitoh and others 2008).
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Motor neurons may have an increased basal level of 
ER stress as compared with other neuronal and non-neu-
ronal cell types; this difference might be a source of the 
selective vulnerability of MNs in ALS (Kiskinis and oth-
ers 2014) and might also make them more susceptible to 
perturbation of Derlin1 function by mutant SOD1.
Autophagy
The autophagy pathway for protein clearance has been 
implicated as dysfunctional in sALS and fALS patients 
(unidentified genotypes) and transgenic mouse models of 
SOD1-fALS (Hetz and others 2009, and reviewed in 
Song and others 2012). Pharmacological and genetic 
manipulation of autophagy pathways in SOD1-fALS 
mice and Caenorhabditis elegans models has resulted in 
conflicting findings suggesting both protective and toxic 
roles for autophagy (Hetz and others 2009; Li and others 
2013; Song and others 2012; Zhang and others 2011; 
Nassif and others 2014).
A direct role for mutant SOD1 in abnormal autoph-
agy is suggested as, when overexpressed in a neuronal-
like cell line, mutant SOD1 was found to co-precipitate 
with beclin 1 (BECN1), an autophagy activator, and 
with BCL2L1, a suppresser of BECN1 activity, whereas 
wildtype SOD1 only precipitated with BCL2L1 (Nassif 
and others 2014). The BECN1–BCL2L1 complex was 
weakened by co-expression with mutant SOD1, sug-
gesting mutant SOD1 may activate autophagy by releas-
ing BECN1 from the suppression of BCL2L1. However, 
Figure 3. Mutant superoxide dismutase 1 (SOD1) may cause chronic activation of endoplasmic reticulum (ER) stress. 
Acute anti-apoptotic and chronic pro-apoptotic ER stress pathways: (A) during acute activation of ER stress the three signal 
transduction pathways (the PERK, ATF6, and IRE1 pathways) mediate the unfolded protein response. PERK, ATF6, and IRE1 
proteins are associated with BiP (binding immunoglobulin protein). (B) However, if there is chronic activation of the ER stress 
PERK, ATF6, and IRE1 dissociate from BiP causing the activation of pro-apoptotic pathways. GADD34 is activated in the PERK 
pathway, promoting the dephosphorylation of p-elF2α and the reinitiation of protein synthesis. Chronic activation of ER stress, 
may mediate the unfolded protein response (UPR) and the ER-associated degradation (ERAD) mechanism.
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the effect of wildtype SOD1, or any other co-expressed 
protein, on the BECN1-BCL2L1 complex was not 
assessed, therefore it is not possible to attribute the 
effect specifically to mutant SOD1 rather than increased 
protein expression per se. The activation of autophagy 
by mutant SOD1 could also be a downstream conse-
quence of early effects on axonal transport and ER stress 
and ERAD (Hetz and others 2009; Zhang and others 
2007).
Other Emerging Roles for SOD1
Several causative “ALS genes” encode RNA binding 
proteins, and this has highlighted how disruption of 
processes involving RNA may play a primary role in the 
pathogenesis of the disease. Among these proteins, 
TDP43 and FUS are to date the most studied (Ling and 
others 2014; Nassif and others 2014). However, recent 
findings also point to a potential role of SOD1 in nucleic 
acid metabolism, as below.
SOD1 as a Transcription Factor
Although this is not their best characterized role, both 
TDP43 and FUS have been shown to act as transcription 
factors and, similarly, recent evidence has shown that 
SOD1 can regulate transcription in response to oxidative 
stress stimuli by moving into the nucleus and binding to 
Figure 4. Mutant superoxide dismutase 1 (SOD1) activates endoplasmic reticulum (ER) stress by disrupting ER-Golgi trafficking 
through binding to coatomer coat protein II complex (COPII). (A) In normal conditions, COPII transports normal and misfolded 
proteins from the ER to the Golgi (only misfolded proteins are show in the figure) but (B) when mutant SOD1 is present, it interacts 
with a COPII subunit disrupting ER-Golgi trafficking resulting in a buildup of misfolded proteins in the ER, leading to ER stress.
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promoters to regulate the expression of oxidative resis-
tance genes (Hu and others 2009; Tsang and others 2014).
SOD1 as an RNA Binding Protein
TDP43 (Transactive response DNA Binding protein 
43kDa) and FUS (Fused in Sarcoma) are involved in 
mRNA splicing, miRNA biogenesis, and mRNA stabili-
zation and transport (Ling and others 2014). Whilst evi-
dence of a role for SOD1 in the former two is still lacking, 
mutant SOD1 can bind mRNAs and play a role in their 
stabilization (Lu and others 2007; Lu and others 2009; 
Chen and others 2014). Wildtype SOD1 has further been 
shown to interact with TDP43, suggesting a potential 
common action in the regulation of specific RNA stabil-
ity (Volkening and others 2009).
Mutant SOD1 binds sequence elements within the 3′ 
UTR of VEGF (Vascular Endothelial Growth Factor) 
mRNA and forms complexes with other ribonucleopro-
teins such as TIAR and HuR. These interactions, which 
are specific to mutant SOD1, negatively affect levels of 
VEGF mRNA, which is a neuroprotective factor for 
motor neurons (Lu and others 2007; Lu and others 2009). 
Similarly, mutant SOD1 has been shown to bind the 3′ 
UTR of the neurofilament light chain (NFL) mRNA and 
negatively affect its stability. In an induce Pluripotential 
Stem Cell-derived cell model of ALS this reduction of 
NFL mRNA level mediates axonal degeneration, which 
could be a critical first step in ALS (Chen and others 
2014).
SOD1 as a Signaling Molecule
SOD1 and Cell Metabolic State Signaling. Using yeast and 
human cell lines Reddi and Culotta (2013) identified a 
new role in cellular metabolism for SOD1: to integrate 
signals from oxygen and glucose in order to repress res-
piration within cells. In the mechanism proposed SOD1 
binds the casein kinase gamma homologues Yck1p and 
Yck2p preventing their degradation via its enzymatic 
activity (Fig. 6). This results in repression of aerobic res-
piration and promotion of aerobic fermentation. Without 
SOD1, Yck1p and Yck2p are degraded, resulting in aero-
bic respiration. This finding gives insight into how rap-
idly proliferating cells may favor anaerobic glycolysis. 
Although effects in neurons remain to be determined the 
authors note the link between this signaling pathway and 
responses to hypoxia, a toxic state for motor neurons 
Figure 5. Superoxide dismutase 1 (SOD1) as an endoplasmic reticulum (ER) stress activating zinc sensor. (A) Under normal 
conditions wildtype SOD1 does not bind Derlin1, allowing export of misfolded proteins to the ubiquitin proteasome system 
(UPS). The three ER stress signal transducers PERK, ATF6, and IRE1 remain inactive and associated with binding immunoglobulin 
protein (BiP). (B) When mutant and/or in conditions of zinc depletion SOD1 assumes a mutant-like conformation exposing a 
binding site for Derlin1. The SOD1-Derlin1 interaction causes an accumulation of misfolded proteins which sequester BiP away 
from PERK, ATF6, and IRE1, activating the homeostatic ER stress response. Therefore, mutation of SOD1 in amyotrophic lateral 
sclerosis (ALS) may lead to constitutive Derlin1–SOD1 binding and ER stress activation.
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(Reddi and Culotta 2013). It is also interesting to note 
that a de novo mutation in casein kinase 1 gamma 3 
(CSNK1G3) was recently identified as a potential ALS 
risk factor (Chesi and others 2014) and, in a yeast screen 
YCK2, a homologue of the human casein kinase 1 gamma 
2, was identified as an enhancer of TDP43 toxicity (Kim 
and others 2014), offering hints that the putative interac-
tion between SOD1 and casein kinase 1 gamma could be 
relevant to ALS.
Conclusions and Outstanding 
Questions
In ALS, SOD1 takes on a toxic unknown gain of function. 
However, as with many proteins involved in neurodegen-
erative disease, it is still not clear what the normal func-
tions are for SOD1, and which cellular pathways rely on 
this protein. We know that it is abundant and ubiquitous, 
but protein levels appear to be far above what would be 
required solely for its role as an antioxidant in the cytosol.
New functions are now coming to light, and intrigu-
ingly—given the roles of other causative ALS genes—
SOD1 is involved in RNA metabolism, including acting 
as a nuclear transcription factor, and in metabolic signal-
ing. Almost certainly there is much more to be discovered 
about SOD1 function in the normal situation, as well as in 
ALS, where there are interesting links and converging 
themes involving excitotoxicity (AMPA receptors, 
sodium channel activation) and ER stress, as well as cell 
specific effects from astrocytes and microglia.
Study of these functions present new opportunities for 
badly needed therapeutics to modulate disease progres-
sion in SOD1-fALS, and possibly even sALS, perhaps in 
combination with anti-sense oligonucleotide therapies 
(Musarò 2013; Yang and others 2013). However, until we 
have a considerably better understanding of SOD1 func-
tions, much about this small protein remains enigmatic.
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